{"docstore/metadata": {"a0eaa9a5-aece-426b-8f20-580de8fb9f35": {"doc_hash": "76e194b2637b440a1b1cdf5698cae061524bb4d7a3b73dfc2ba71d268a3f7019"}, "bbd4baa4-ae84-4508-bfed-a7c2cb433d1a": {"doc_hash": "ceb5aada31c18041f13c6672171f942ebff98887eb584345a2153ad374b573a7", "ref_doc_id": "a0eaa9a5-aece-426b-8f20-580de8fb9f35"}, "f8f153ef-0f33-40c9-b07a-1edb5ddeacdc": {"doc_hash": "625afe6165ad917cc4d71ddaa73aebbe2cf0735957677afb7328bae70e6465ac", "ref_doc_id": "a0eaa9a5-aece-426b-8f20-580de8fb9f35"}, "8e69c8bc-27ca-4263-a3b9-21a66520c4bd": {"doc_hash": "1ad51b29a6ad4b874cf2837710b7df177a9fe68a34be3fd7222efe378ec1117f", "ref_doc_id": "a0eaa9a5-aece-426b-8f20-580de8fb9f35"}, "c837b524-37dd-4a8d-80f5-04f501ea5d94": {"doc_hash": "f2a2670cac0f60bab8da207404d6abd853d7a661f5c0fec9479d976c286352e3", "ref_doc_id": "a0eaa9a5-aece-426b-8f20-580de8fb9f35"}, "69becf14-6c0c-4e2c-962b-19f81cb59e48": {"doc_hash": "791f3e65dac3ee308a5982d84d58edfa785cce84dd1d8ed13cbac5f1c6681720", "ref_doc_id": "a0eaa9a5-aece-426b-8f20-580de8fb9f35"}, "e9751117-56d0-4930-95a8-de8a758fcec7": {"doc_hash": "e42fbaba11ab09422af23115558c18a95c7db074a6e44bc79e553e7483ddd2be", "ref_doc_id": "a0eaa9a5-aece-426b-8f20-580de8fb9f35"}, "34e6b0a0-591f-4efa-997a-a1923c8fad58": {"doc_hash": "5ad16e145e03603ed616981011fbcdb9946fabf3ea2683245345c89bde8440de", "ref_doc_id": "a0eaa9a5-aece-426b-8f20-580de8fb9f35"}, "ed0262b0-e314-429f-8eff-5b23a68c375a": {"doc_hash": "4e17421e51b78443c688653b298e8081f85f6d3045757e98b7b7a54e8701e08c", "ref_doc_id": "a0eaa9a5-aece-426b-8f20-580de8fb9f35"}, "82d970d1-55ff-47b1-991a-424227d2a819": {"doc_hash": "de85034f7deb387d4bb914d8a7e939474f3f46f34aa3bf047c9db4b167220b2c", "ref_doc_id": "a0eaa9a5-aece-426b-8f20-580de8fb9f35"}, "7fb4cb7f-3756-4de5-83f4-4c46edf5db68": {"doc_hash": "0562b419a5e0a5b1b657caee93f43a79dce663a960931d2be9e26a5571563cfd", "ref_doc_id": "a0eaa9a5-aece-426b-8f20-580de8fb9f35"}, "13098646-5b47-4002-8d99-d0f177e3eff8": {"doc_hash": "143091b52bbf3888674c75090c7631acc4ebde80adf2ef1b4c9904b3f6aff2c5", "ref_doc_id": "a0eaa9a5-aece-426b-8f20-580de8fb9f35"}, "dd1adc35-aa10-418c-a564-07dd8f0ff28f": {"doc_hash": "08284b50b09d4e0828264dabd568db1897321a16ca632bf529a82e3ddc29860f", "ref_doc_id": "a0eaa9a5-aece-426b-8f20-580de8fb9f35"}, "424f8406-2074-4a46-b943-c95f9a7d79e3": {"doc_hash": "59d239ec13e0fbb3c819dd44cbb44f8b64e5930b2f12111d122c59767ace03c3", "ref_doc_id": "a0eaa9a5-aece-426b-8f20-580de8fb9f35"}, "4a52ea30-c9bb-420f-a744-059010702fa2": {"doc_hash": "aa12c10812a5f305153d69b97a10c6e9baa1942fb83f8be2223d2cc3755166a6", "ref_doc_id": "a0eaa9a5-aece-426b-8f20-580de8fb9f35"}, "e1a669e6-7a0a-4bff-bf8a-09398503f04c": {"doc_hash": "9ce965522b9ab9e3559828abf8426c8e1bcc1056b4283fb40f75ae1c9258d366", "ref_doc_id": "a0eaa9a5-aece-426b-8f20-580de8fb9f35"}, "08d2fdaf-e724-4186-85cb-bcb1d36bc6d6": {"doc_hash": "97747ab5c4aa5cd4858f0cb8e9b8110e4b13acd73323aa027514c450ed6dcd88", "ref_doc_id": "a0eaa9a5-aece-426b-8f20-580de8fb9f35"}, "701d2f9e-cdd0-4984-9ee1-dc83c5eb2357": {"doc_hash": "2789a830034becc3b1235b4b76e42c98743aab324d900c9a9f108449074e2629", "ref_doc_id": "a0eaa9a5-aece-426b-8f20-580de8fb9f35"}, "267009fd-b62c-49da-ad26-725119870165": {"doc_hash": "6478e6575e28f9c4719084126ab3c5af2e5a6ec332b0ddfcf8b76a51f7870f04", "ref_doc_id": "a0eaa9a5-aece-426b-8f20-580de8fb9f35"}, "370b0028-229f-4784-9254-d7c7919356f1": {"doc_hash": "ba964cca80af22e0afa46b712875e71bfc41ce1469fad77457a23f545de0658d", "ref_doc_id": "a0eaa9a5-aece-426b-8f20-580de8fb9f35"}, "b7857807-c303-450e-a91d-a1063c15668b": {"doc_hash": "1fc5cd2ffc66e4c4d4b892652e33cb823a0689a1aa84de52920bf5053eb06c8a", "ref_doc_id": "a0eaa9a5-aece-426b-8f20-580de8fb9f35"}, "37406ad9-817c-43d4-aa71-f5cf3a6c0830": {"doc_hash": "2d6a600fe22c25865b245e2e2dbdf57ee8fe539bd5fbf52b5f264470366bc5cd", "ref_doc_id": "a0eaa9a5-aece-426b-8f20-580de8fb9f35"}, "79f04175-06e1-4be6-a6a5-87fe45e0a8d0": {"doc_hash": "b8bbc656f6cf3fbbfd4debc894e052dc5c29faaf7548827daed1fb4faa943a04", "ref_doc_id": "a0eaa9a5-aece-426b-8f20-580de8fb9f35"}, "7cf6ad74-5796-4e7b-a5db-a597641b605f": {"doc_hash": "8e981ec713cc20426637a2289dc03ad3375f0cbf59b7cf4cc1bbd0f7a455240d", "ref_doc_id": "a0eaa9a5-aece-426b-8f20-580de8fb9f35"}, "58f038fc-7646-4ea8-87ee-f3887467d710": {"doc_hash": "ada86bb502ed7537e7c830b26017cc2e65b0f44dfa3f82038a97a5b27a134b9f", "ref_doc_id": "a0eaa9a5-aece-426b-8f20-580de8fb9f35"}, "582ec677-6038-48f8-a30d-e6aabc38349f": {"doc_hash": "0dd9706987e6c7ac53bbf2f9ea2e0795bd4003013e7dff6a0abf830418267396", "ref_doc_id": "a0eaa9a5-aece-426b-8f20-580de8fb9f35"}, "4f999dc1-d2a8-4733-8bcb-ef262464e754": {"doc_hash": "221b9e252e8ac331d8ecc97abc41588fddf9245d4a737887c6cc9334e8355f3b", "ref_doc_id": "a0eaa9a5-aece-426b-8f20-580de8fb9f35"}, "58989e49-3b5b-4716-acfe-9a5da6396e33": {"doc_hash": "1aa783415a6b3126b653f8ca8d6128a5dfdd3c3d3072223a2d84e224d1fb296c", "ref_doc_id": "a0eaa9a5-aece-426b-8f20-580de8fb9f35"}, "554de318-ec6f-4de0-9960-864394ddca79": {"doc_hash": "33804000b2e1f8d608cbb9df99ffe21b4c57c2288b26c880a0ae7ff8a9e02303", "ref_doc_id": "a0eaa9a5-aece-426b-8f20-580de8fb9f35"}, "0e49efe3-ce03-45d0-b299-a67d33696a72": {"doc_hash": "53090799281fadabfff486cbd107684041f16c64c1f805cb998f4312353d5155", "ref_doc_id": "a0eaa9a5-aece-426b-8f20-580de8fb9f35"}, "be4131a0-7c74-4a94-92be-2724d1b79033": {"doc_hash": "b4f2e6bd2a672e2c085d1b92682254ed18638a7dfb7962e95e40021c1bbf6dcd", "ref_doc_id": "a0eaa9a5-aece-426b-8f20-580de8fb9f35"}, "d21131fc-9ed9-4e4a-89b4-b38aac3891fb": {"doc_hash": "ad4991f7a7b11dedf79972a02ed603642c0470812594d2006feb1c612c405d8d", "ref_doc_id": "a0eaa9a5-aece-426b-8f20-580de8fb9f35"}, "b15a7c26-e188-4c10-9c6c-4fdb6456b8e9": {"doc_hash": "c382a75a2a4e65491731688eb6cf44a6d178f8795ab45b5a041d475b6f4efa86", "ref_doc_id": "a0eaa9a5-aece-426b-8f20-580de8fb9f35"}, "ab536b16-72a5-40ed-8fdb-ca39960ca097": {"doc_hash": "ff86836df62b80e052d389d0f51314763814f7dadaa7d668d23c3fb7ce0bf24d", "ref_doc_id": "a0eaa9a5-aece-426b-8f20-580de8fb9f35"}, "cdd30fbc-84ba-473b-8550-cf8b4a337bbf": {"doc_hash": "1f600e9c1373d869deac3cb85b20e8651b62212e3c411fe0d38b8491a1ce294c", "ref_doc_id": "a0eaa9a5-aece-426b-8f20-580de8fb9f35"}, "49e2bc8b-9caa-44af-84c7-1c6db1b3a2f3": {"doc_hash": "fffae9f23e87f8132e78d685e5aeabe556d7ac1f9361fcfb2fae5821bc78b848", "ref_doc_id": "a0eaa9a5-aece-426b-8f20-580de8fb9f35"}, "6ec1c67f-ffb0-48b0-8508-3da256b4dd95": {"doc_hash": "020c981ece80b5a07e2c4c402c5a6519a0046328e0d619e09e1789ecce663dbc", "ref_doc_id": "a0eaa9a5-aece-426b-8f20-580de8fb9f35"}, "0a77778e-2844-4b0d-8977-0a1f423024a6": {"doc_hash": "803d1bfbaaff4a1d04928e0d478f6be5aa371d87372dede17c9d81e3dee9135d", "ref_doc_id": "a0eaa9a5-aece-426b-8f20-580de8fb9f35"}, "1b8b41ec-e48c-4c71-bede-c100b46a35d8": {"doc_hash": "5f890e3e9d58dcc0f10bd3f1b786beef7486c855ad228e9f50c13ac5f79af4ff", "ref_doc_id": "a0eaa9a5-aece-426b-8f20-580de8fb9f35"}, "27b59cff-59a9-41ae-8eb9-03a5f6b63cb9": {"doc_hash": "87e0da3603adfdbf617201529461ef5da1f3385259b973dae4c0a7e8a81d11f2", "ref_doc_id": "a0eaa9a5-aece-426b-8f20-580de8fb9f35"}, "0310fae1-be20-417b-ad3d-62575f97ad54": {"doc_hash": "2f933dca0e903efcbc7199a687b6dad5cbaca8bbd676eff80ee5c0db7127d2a0", "ref_doc_id": "a0eaa9a5-aece-426b-8f20-580de8fb9f35"}, "297306db-ae99-4e76-9307-c0c6f93626eb": {"doc_hash": "de46f60f6da776868bd4a46d4477a9a3079e29129592b4412066a0c31e817477", "ref_doc_id": "a0eaa9a5-aece-426b-8f20-580de8fb9f35"}, "81d39c1d-2db8-4c5c-bb81-0777c471a97a": {"doc_hash": "f55a616a9285bd1e383464055c1f544bb45058ece1f03a77ede3e5bda884342c", "ref_doc_id": "a0eaa9a5-aece-426b-8f20-580de8fb9f35"}, "87f9eb02-5f85-43be-aea7-96d9e24360a0": {"doc_hash": "b3d414351b13cfeb79f7ff0fc3eb163a69e4e9bee63b6ae784fdcacddffefa48", "ref_doc_id": "a0eaa9a5-aece-426b-8f20-580de8fb9f35"}, "2171d15e-6952-45a9-b0db-a0a936392c88": {"doc_hash": "f87096890ac51dd3fa6e28c0e7520c1de924df5c545a5876d24fe5bca2a6e83b", "ref_doc_id": "a0eaa9a5-aece-426b-8f20-580de8fb9f35"}, "6ad0dfb9-91d9-4725-9594-6c934d992a0b": {"doc_hash": "6658cb547fa77debf3b167e29291e10f1d85e884b30ff9eebf367c41575b3dcf", "ref_doc_id": "a0eaa9a5-aece-426b-8f20-580de8fb9f35"}, "ce62f0de-1c59-49cd-90fe-685d0a9a0fa7": {"doc_hash": "ee8dffa29664b18c96f705fab425e3383234f83207e3066f2b730e95bf154b79", "ref_doc_id": "a0eaa9a5-aece-426b-8f20-580de8fb9f35"}, "e4fc6a8f-870a-443a-b60a-769f1be7989b": {"doc_hash": "c7a00e39cd939c725521d7eedd702a152390fc3396d87ffeaad64b4b9975c61b", "ref_doc_id": "a0eaa9a5-aece-426b-8f20-580de8fb9f35"}, "859081fc-ba7a-4fc5-bac0-1fd78811d3e3": {"doc_hash": "85947b2af2a53ac1bfbc1bc6ec47d38a4cdf1a996797d78a3e4eddedc7dbefed", "ref_doc_id": "a0eaa9a5-aece-426b-8f20-580de8fb9f35"}, "1d011d49-3a0b-4261-862c-0db78c3a0e6a": {"doc_hash": "372127d52791b857d7e7dc45c5eaa5241d923bb541ffdf42915bff5a68abac00", "ref_doc_id": "a0eaa9a5-aece-426b-8f20-580de8fb9f35"}, "c816406c-8e25-4267-bf1b-650fd0bd6443": {"doc_hash": "7f1f1dc7c20a939c09d1ea505e016c83021a87bf06a3fca1663f1622af4e7797", "ref_doc_id": "a0eaa9a5-aece-426b-8f20-580de8fb9f35"}, "78ac8d9c-e602-4601-b572-e35eae44b23b": {"doc_hash": "4d2708ddee3e3c0f67ab0b6375ee2943244f6fee7efc66ce91e1c5abb1b4d841", "ref_doc_id": "a0eaa9a5-aece-426b-8f20-580de8fb9f35"}, "aef4c23e-97ef-4287-8abf-9fe19b4d1087": {"doc_hash": "c4444e7f8151205041df88ac131a0895cee79bcd70fb76cf9f1887da3a57504b", "ref_doc_id": "a0eaa9a5-aece-426b-8f20-580de8fb9f35"}, "8e38df85-cd95-414c-b128-e45742367fe7": {"doc_hash": "43b3c3a47ce841f5b2bcbc021ae356ebd1296e15f6a56dce7dd1391ac77b57f9", "ref_doc_id": "a0eaa9a5-aece-426b-8f20-580de8fb9f35"}, "e6beed53-e696-489c-b0a5-5cc306840b34": {"doc_hash": "46da05c8086519e5e12c8f8f291526319b19b9f65e0686f63e2c258b0c379284", "ref_doc_id": "a0eaa9a5-aece-426b-8f20-580de8fb9f35"}, "17bb3a56-9359-47fc-8076-168c7382cf39": {"doc_hash": "6c75f93aee534f33dc672873f0ba4d596bb86f4c6d191031825ec2a5f207d84b", "ref_doc_id": "a0eaa9a5-aece-426b-8f20-580de8fb9f35"}, "8f75f1ce-66c0-4c43-b4ea-c6c3eab01b6b": {"doc_hash": "ff576ab810478a3a99933a4b1a63a61bf05634b6f7caf31da9617b68f39ea58f", "ref_doc_id": "a0eaa9a5-aece-426b-8f20-580de8fb9f35"}, "f1878e25-c289-47e5-b7f7-ac50745103a2": {"doc_hash": "11fcf75d766be18765947a21184339b47ab25d272cbf0317832e908d70ad8702", "ref_doc_id": "a0eaa9a5-aece-426b-8f20-580de8fb9f35"}, "725e92db-cd38-43d4-a732-287851a65b5a": {"doc_hash": "3909d5b0e679e13ba0f8fad40a366b4f3c646f050dcc689dcfcc88572ccf1870", "ref_doc_id": "a0eaa9a5-aece-426b-8f20-580de8fb9f35"}, "44c45d08-35c9-41b3-ad60-cbeeef4660be": {"doc_hash": "42cff9c625dfeaddfa302ad727dd8938691689f7c4db923cbe146e21e32104c2", "ref_doc_id": "a0eaa9a5-aece-426b-8f20-580de8fb9f35"}, "6c46b555-ed9e-4776-8373-6fc61d504f7c": {"doc_hash": "ff0a48841aa7b7185919619a4f20e4b73252220eecfbe8f8aef0df8e889ed999", "ref_doc_id": "a0eaa9a5-aece-426b-8f20-580de8fb9f35"}, "5af7a950-8c25-4e11-a3f1-0734210c6a1d": {"doc_hash": "003933b6a957f57e2e40d5708987145ea56529da977694150b6ebbaddc3c0ade", "ref_doc_id": "a0eaa9a5-aece-426b-8f20-580de8fb9f35"}, "586c219f-ff5c-476e-bf1b-15e5523ecf10": {"doc_hash": "9e9c707dbb5adf831af0a53f20e81b93db01db81213e1eb440f485292cfe8194", "ref_doc_id": "a0eaa9a5-aece-426b-8f20-580de8fb9f35"}, "0d912877-f1cf-4853-9f04-536ce46c0030": {"doc_hash": "72c711df649c1d7d6ecc1202d039060e8b543a2a987b5243ca79301c6e26428f", "ref_doc_id": "a0eaa9a5-aece-426b-8f20-580de8fb9f35"}, "e49f75dc-b4d8-4a71-bc43-d3eceb669e53": {"doc_hash": "08d5b3a0b9fe99c72773566b7b439ca852e4ce34b0528dc9e7f7d1f06abf52b3", "ref_doc_id": "a0eaa9a5-aece-426b-8f20-580de8fb9f35"}, "a63ff3d8-c46e-4a3a-ae38-c46a1d44c433": {"doc_hash": "0294ba17c554b97abc3e2cc168b81d5e7f97782662c50870a4eaebf2ddb5e3b7", "ref_doc_id": "a0eaa9a5-aece-426b-8f20-580de8fb9f35"}, "f3e24b75-a027-4fcc-8b32-8a01a861e485": {"doc_hash": "704c77c9876a9346363db97d908f77d44f302ffb6a2bd1a5608886f119a77817", "ref_doc_id": "a0eaa9a5-aece-426b-8f20-580de8fb9f35"}, "523d3edc-48a4-455a-9084-ddb27f0a9a95": {"doc_hash": "9d78ad92373d566437bfdb177c4a97415d0a3f5aae0f2796e09f2e7ab0151faa", "ref_doc_id": "a0eaa9a5-aece-426b-8f20-580de8fb9f35"}, "c6cd3ca0-4a12-4748-bbc6-4127b39f5344": {"doc_hash": "968f825ffbb7b36f703a770bd7a35853dfe50444d5669a8789cbdb8faeec6a2e", "ref_doc_id": "a0eaa9a5-aece-426b-8f20-580de8fb9f35"}, "af979550-506c-4f5c-a4a2-eea50dccb977": {"doc_hash": "c0cde2f3c02f577cfd1b9579dd5c87be2a8fbd793ef1f058a6dd7b8e41ceab96", "ref_doc_id": "a0eaa9a5-aece-426b-8f20-580de8fb9f35"}, "109f01df-e60b-472a-8ba4-9e653eb78d8b": {"doc_hash": "3ee7163c064292c1e47131b03642dcd6191817646e297480a461bbf1868f7c86", "ref_doc_id": "a0eaa9a5-aece-426b-8f20-580de8fb9f35"}, "25b00e9f-371e-4fc4-ac25-0c8c1a74f1bc": {"doc_hash": "471848ddfae8017e49133dd8d89a272b6a5455807fd95ffbcb4eabb5fb720260", "ref_doc_id": "a0eaa9a5-aece-426b-8f20-580de8fb9f35"}, "684feb52-2005-46b1-ab17-653cf3ab6268": {"doc_hash": "54949d8906617e93f348ff6258da940b604cce72aaf3a996d0645ecf5e150f93", "ref_doc_id": "a0eaa9a5-aece-426b-8f20-580de8fb9f35"}, "eb0f1fa7-cbb5-40fd-a88f-d527d7597b79": {"doc_hash": "959b84a3c77e1161ba2842d88f4851b36da03ad49f79b7a2c18f6daadf6076fb", "ref_doc_id": "a0eaa9a5-aece-426b-8f20-580de8fb9f35"}, "ea28b0ec-98c0-4b8b-8896-b4245d50a8f1": {"doc_hash": "458317861f5d0b07454803550f14faf8bf4ba09cd2573d54e1cf5721aecebefc", "ref_doc_id": "a0eaa9a5-aece-426b-8f20-580de8fb9f35"}, "d5138923-b7e6-4b97-9a17-dfada78d923d": {"doc_hash": "af23ddf86a7d742e20fd227085076a1d604948e6c5ad74ba6a206bd0b22fff23", "ref_doc_id": "a0eaa9a5-aece-426b-8f20-580de8fb9f35"}, "6f4d0be6-8ef0-4edf-95cb-b194c64934c9": {"doc_hash": "73f0f52b61f1ffe49b96a3e3e2307b9c0bff6c65e15a523c39b25cde9518ea42", "ref_doc_id": "a0eaa9a5-aece-426b-8f20-580de8fb9f35"}, "d3f2e237-5c5e-4a3b-b615-fed7b7af1e7c": {"doc_hash": "ab6f7d1e88a1a8cad08a6a4ce84c8c50565e77d21929b4954510bd71e46abc51", "ref_doc_id": "a0eaa9a5-aece-426b-8f20-580de8fb9f35"}, "902ad6b6-bb31-488f-b9ee-8301e9847041": {"doc_hash": "7e0107a1039befd06ab1cc107f21ea142bb0566fe8465245a6aa749ee9dc0afd", "ref_doc_id": "a0eaa9a5-aece-426b-8f20-580de8fb9f35"}, "aa520e95-55a5-413b-a75d-c5d2011df863": {"doc_hash": "ec8b016a00b006483d58fd280834e5613f614b74361eeac3772d2551262ed107", "ref_doc_id": "a0eaa9a5-aece-426b-8f20-580de8fb9f35"}, "a88a84be-4fa2-45da-887a-60818c78c939": {"doc_hash": "607d23530ebbfa8ededf01dcbdc87dfc8d4f09166d2e63877cbe09de70aa8e2b", "ref_doc_id": "a0eaa9a5-aece-426b-8f20-580de8fb9f35"}, "fed6bb5f-8768-43d5-be0c-a1b4ff5f0d21": {"doc_hash": "bf0b2228c80056989a0f03bcd476d09a0950267c8ed6015ae441415657a03324", "ref_doc_id": "a0eaa9a5-aece-426b-8f20-580de8fb9f35"}, "5b103750-f08c-4e09-b77a-3c205676bf1c": {"doc_hash": "4cd1a5413a9cfc4a3a38ca733809c4772af578528671adb88ebdc17924c2da00", "ref_doc_id": "a0eaa9a5-aece-426b-8f20-580de8fb9f35"}, "319bb8d7-acc6-405c-bc48-df8265a7bb86": {"doc_hash": "80002a8b4379ff9aeaa0906eaf8620ad6c93eaf51daefe714e93a042887e5118", "ref_doc_id": "a0eaa9a5-aece-426b-8f20-580de8fb9f35"}, "103b97df-d755-4b63-be76-6840ec16cfa1": {"doc_hash": "97fc20a5f71a1f202dc83b428922d087684cfe6ed6fbc6c7195ccbda685023a0", "ref_doc_id": "a0eaa9a5-aece-426b-8f20-580de8fb9f35"}, "1b2c36f0-72ab-459a-9055-d5d7c9a274ce": {"doc_hash": "b3a065ddbb3beafd99aa9ffd8903ffcfe16e10f3145bd68f196a73e1d68f8fc3", "ref_doc_id": "a0eaa9a5-aece-426b-8f20-580de8fb9f35"}, "35200c13-4f4a-497c-bee7-7d7d8d9589c5": {"doc_hash": "69937b3deb10ee3b8873f92d283162b344f0f4e28c1c7d78f9f5774b94e13d92", "ref_doc_id": "a0eaa9a5-aece-426b-8f20-580de8fb9f35"}, "33c809d4-e77c-4603-bbd3-66a70bc6bf47": {"doc_hash": "b3fc0d3077f054a8c91d83944762512ae57542865b93f8992e008f951963c5c5", "ref_doc_id": "a0eaa9a5-aece-426b-8f20-580de8fb9f35"}, "a9ca6388-e41e-42cb-ad1c-999e850932ab": {"doc_hash": "1187b11ee427428b7fe01266d4b8cbc0d04013a2a0bba4e228605435ac4774e5", "ref_doc_id": "a0eaa9a5-aece-426b-8f20-580de8fb9f35"}, "d6246a73-1943-481a-ab8e-2b9661c18fb2": {"doc_hash": "02138b2110fb2d295ad8b249707f3d9eba31f8b34e6ce7994b927da475c49494", "ref_doc_id": "a0eaa9a5-aece-426b-8f20-580de8fb9f35"}, "3204607e-e603-476d-8c50-1aae82cb447c": {"doc_hash": "41d7d72e1730d13762d4349509a21adbcf2b87781f647d5d271e6d7f5ab1d966", "ref_doc_id": "a0eaa9a5-aece-426b-8f20-580de8fb9f35"}, "c69f5e0b-ea37-4df0-a15e-cd12c78a34da": {"doc_hash": "a5f9cfdb662a017f22b4bb57c86680bce900f1290288e8ca9f94306fbe1047fb", "ref_doc_id": "a0eaa9a5-aece-426b-8f20-580de8fb9f35"}, "13e0d659-a453-41be-a5b9-0ba7ffe4dae8": {"doc_hash": "b2c0d54fc9d7465ff513c16c6adb0098c9227a452f9cd33024362fc7e86b0fc5", "ref_doc_id": "a0eaa9a5-aece-426b-8f20-580de8fb9f35"}, "fba4bc5e-619c-4d9b-9b08-ebc769f3550c": {"doc_hash": "f421912c7e2c515ef601d2962fda3bf7f151eddba4cbdef131741d8f37f87062", "ref_doc_id": "a0eaa9a5-aece-426b-8f20-580de8fb9f35"}, "b0319540-80fa-471c-843e-0730841cdd81": {"doc_hash": "be37a542e37ccc6a21acbecba5334ff9d067560e741d906982fa9feb04051471", "ref_doc_id": "a0eaa9a5-aece-426b-8f20-580de8fb9f35"}, "84fe4345-b40d-42a8-a74c-dee60c5ed80d": {"doc_hash": "52adfa08b805629992fb51e9c8374584807b511d541c87ff0e2f96940019c73a", "ref_doc_id": "a0eaa9a5-aece-426b-8f20-580de8fb9f35"}, "a22344f3-2e99-4e4a-af67-c45508d4cf5f": {"doc_hash": "af4e1a034ccc61b1a52202017edb09742166512b8970e6d815dea1ed6e8795f0", "ref_doc_id": "a0eaa9a5-aece-426b-8f20-580de8fb9f35"}, "28386f62-f721-484b-be83-2620373773d5": {"doc_hash": "09b47bbb7f337818a03d08a8b5b380e6fe219f147f786fdfc46d0129458caf2e", "ref_doc_id": "a0eaa9a5-aece-426b-8f20-580de8fb9f35"}, "bf9d4c1d-b7f5-4be0-a883-5f14e75b093c": {"doc_hash": "ad9bdff9e6d36083683e1594cdacd3ec375926963a3797d9cc33eb60c163d215", "ref_doc_id": "a0eaa9a5-aece-426b-8f20-580de8fb9f35"}}, "docstore/data": {"bbd4baa4-ae84-4508-bfed-a7c2cb433d1a": {"__data__": {"id_": "bbd4baa4-ae84-4508-bfed-a7c2cb433d1a", "embedding": null, "metadata": {"file_path": "data/brandt-no-intro.txt", "file_name": "brandt-no-intro.txt", "file_type": "text/plain", "file_size": 239829, "creation_date": "2023-12-31", "last_modified_date": "2023-12-31", "last_accessed_date": "2023-12-31"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "a0eaa9a5-aece-426b-8f20-580de8fb9f35", "node_type": "4", "metadata": {"file_path": "data/brandt-no-intro.txt", "file_name": "brandt-no-intro.txt", "file_type": "text/plain", "file_size": 239829, "creation_date": "2023-12-31", "last_modified_date": "2023-12-31", "last_accessed_date": "2023-12-31"}, "hash": "76e194b2637b440a1b1cdf5698cae061524bb4d7a3b73dfc2ba71d268a3f7019", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f8f153ef-0f33-40c9-b07a-1edb5ddeacdc", "node_type": "1", "metadata": {}, "hash": "625afe6165ad917cc4d71ddaa73aebbe2cf0735957677afb7328bae70e6465ac", "class_name": "RelatedNodeInfo"}}, "hash": "ceb5aada31c18041f13c6672171f942ebff98887eb584345a2153ad374b573a7", "text": "IN-VITRO AND IN-SILICO COMPUTATIONAL MODELLING OF THE CANNABINOID\nTYPE 1 AND SEROTONIN 2A CLASS A G PROTEIN \u2013 COUPLED RECEPTORS\n\nA Thesis Submitted to the\nCollege of Graduate and Postdoctoral Studies\nIn Partial Fulfilment of the Requirements\nFor the Degree of Doctor of Philosophy\nIn the Department of Pharmacy and Nutrition\nUniversity of Saskatchewan\nSaskatoon Canada\nBy\nAsher Leib Brandt\n\n\u00a9 Copyright Asher Leib Brandt, August 2022. All rights reserved. Unless otherwise noted, copyright of the material in this thesis belongs to the author.\n\niii\nPermission to use\n\nIn presenting this thesis in partial fulfillment of the requirements for a Postgraduate degree from the University of Saskatchewan, I agree that the Libraries of this University may make it freely available for inspection. I further agree that permission for copying of this thesis in any manner, in whole or in part, for scholarly purposes may be granted by the professor or professors who supervised my thesis work or, in their absence, by the Head of the Department or the Dean of the College in which my thesis work was done. It is understood that any copying or publication or use of this thesis/dissertation or parts thereof for financial gain shall not be allowed without my written permission. It is also understood that due recognition shall be given to me and to the University of Saskatchewan in any scholarly use which may be made of any material in my thesis/dissertation.\n\nDISCLAIMER\n\nReference in this thesis to any specific commercial products, process, or service by trade name, trademark, manufacturer, or otherwise, does not constitute or imply its endorsement, recommendation, or favoring by the University of Saskatchewan. The views and opinions of the author expressed herein do not state or reflect those of the University of Saskatchewan and shall not be used for advertising or product endorsement purposes.  Requests for permission to copy or to make other uses of materials in this thesis in whole or part should be addressed to:\n\nHead of the College of Pharmacy and Nutrition\n107 Wiggins Road, Saskatoon SK\nUniversity of Saskatchewan\nSaskatoon, Saskatchewan, S7N 5E5, Canada\n\nOR\n\nDean\nCollege of Graduate and Postdoctoral Studies\nUniversity of Saskatchewan\n116 Thorvaldson Building, 110 Science Place\nSaskatoon, Saskatchewan, S7N 5C9, Canada\n\nTABLE OF CONTENTS\nList of Figures. vii\nList of Tables . ix\nList of Equations. x\nList of Abbreviations . xi\nAbstract. xiii\nAcknowledgements. xiv\nCHAPTER 1 INTRODUCTION . 1\n1.1 G Protein-Coupled Receptors. 2\n1.2 GPCR Intra-Cellular Signaling Cascades . 4\n1.3 Allosteric Site on GPCRs as FDA approved Drugs. 8\n1.4 Cannabinoid Receptor Type 1. 8\n1.5 Cannabinoid Receptor Type 2. 10\n1.6 Psychedelics and the Serotonin 2a Receptor (5-HT2AR) . 10\n1.7 Computational Modelling of G protein-coupled receptors. 13\n1.7.1 In silico Modelling of CB1R allosteric ligands. 16\n1.8 Objectives of This Research. 20\nCHAPTER 2 PHARMACOLOGICAL EVALUAITON OF ENANTIOMERICALLY\nSEPARATED POSITIVE ALLOSTERIC MODULATORS OF CANNABINOID TYPE 1\nRECEPTOR, GAT591 AND GAT593. 22\n2.1 Introduction . 23\n2.2 Experimental Section . 26\n2.2.1 In vitro evaluation. 26\n2.2.2 In vivo evaluation. 28\n2.2.3 In silico evaluation. 29\n2.2.4 Statistical Analysis . 32\n2.3 Results and Discussion. 33\n2.3.1 Synthesis, chiral separation and absolute stereochemistry determination. 33\n2.3.2 In vitro evaluation. 33\n2.3.3 In vivo evaluation. 44\n2.3.4 In silico studies. 46\nv\n2.4 Conclusion. 51\n2.5 Supplementary Info. 53\n2.5.1 NMR Data. 53\nCHAPTER 3 IN SILICO EVALUATION OF HALOGENATED BIOISOSTERES AT THE\nTYPE 1 CANNABINOID RECEPTOR ALLOSTERIC AGONIST SITE . 58\n3.1 Introduction . 59\n3.2 Materials and Methods.", "start_char_idx": 0, "end_char_idx": 3699, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f8f153ef-0f33-40c9-b07a-1edb5ddeacdc": {"__data__": {"id_": "f8f153ef-0f33-40c9-b07a-1edb5ddeacdc", "embedding": null, "metadata": {"file_path": "data/brandt-no-intro.txt", "file_name": "brandt-no-intro.txt", "file_type": "text/plain", "file_size": 239829, "creation_date": "2023-12-31", "last_modified_date": "2023-12-31", "last_accessed_date": "2023-12-31"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "a0eaa9a5-aece-426b-8f20-580de8fb9f35", "node_type": "4", "metadata": {"file_path": "data/brandt-no-intro.txt", "file_name": "brandt-no-intro.txt", "file_type": "text/plain", "file_size": 239829, "creation_date": "2023-12-31", "last_modified_date": "2023-12-31", "last_accessed_date": "2023-12-31"}, "hash": "76e194b2637b440a1b1cdf5698cae061524bb4d7a3b73dfc2ba71d268a3f7019", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bbd4baa4-ae84-4508-bfed-a7c2cb433d1a", "node_type": "1", "metadata": {"file_path": "data/brandt-no-intro.txt", "file_name": "brandt-no-intro.txt", "file_type": "text/plain", "file_size": 239829, "creation_date": "2023-12-31", "last_modified_date": "2023-12-31", "last_accessed_date": "2023-12-31"}, "hash": "ceb5aada31c18041f13c6672171f942ebff98887eb584345a2153ad374b573a7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8e69c8bc-27ca-4263-a3b9-21a66520c4bd", "node_type": "1", "metadata": {}, "hash": "1ad51b29a6ad4b874cf2837710b7df177a9fe68a34be3fd7222efe378ec1117f", "class_name": "RelatedNodeInfo"}}, "hash": "625afe6165ad917cc4d71ddaa73aebbe2cf0735957677afb7328bae70e6465ac", "text": "26\n2.2.2 In vivo evaluation. 28\n2.2.3 In silico evaluation. 29\n2.2.4 Statistical Analysis . 32\n2.3 Results and Discussion. 33\n2.3.1 Synthesis, chiral separation and absolute stereochemistry determination. 33\n2.3.2 In vitro evaluation. 33\n2.3.3 In vivo evaluation. 44\n2.3.4 In silico studies. 46\nv\n2.4 Conclusion. 51\n2.5 Supplementary Info. 53\n2.5.1 NMR Data. 53\nCHAPTER 3 IN SILICO EVALUATION OF HALOGENATED BIOISOSTERES AT THE\nTYPE 1 CANNABINOID RECEPTOR ALLOSTERIC AGONIST SITE . 58\n3.1 Introduction . 59\n3.2 Materials and Methods. 61\n3.2.1 In Silico receptor preparation . 61\n3.2.2 Ligand Preparation . 61\n3.2.3 Receptor grid generation and molecular docking. 62\n3.2.4 Physicochemical and Pharmacokinetic Properties Prediction. 63\nTable 3-1. Physicochemical and Pharmacokinetic Properties modeled in this study . 63\n3.3 Results and Discussion. 65\n3.3.1 GAT228 Isomers Effect on MMGBSA (\u2206G). 65\n3.3.2 GAT228 Isomers Differ in their Physicochemical and Pharmacokinetic Properties. 72\n3.3.3 Selecting Lead Compounds. 73\n3.4 Conclusion. 75\n3.5 Supplementary Info. 76\nCHAPTER 4 ASSESSMENT OF SELECT SYNTHETIC CANNABINOID RECEPTOR\nAGONIST BIAS SELECTIVITY BETWEEN THE TYPE 1 AND TYPE 2 CANNABINOID\nRECEPTOR. 88\n4.1 Introduction . 89\n4.2 Experimental Section . 92\n4.2.1 In vitro evaluation. 92\n4.2.2 In silico evaluation. 94\n4.2.3 Statistical Analysis . 94\n4.3 Results and Discussion. 95\n4.3.1 In Vitro Evaluation of CB1R. 95\n4.3.2 In Vitro Evaluation of CB2R. 101\n4.3.3 In Silico Evaluation of CB1R and CB2R. 110\n4.4 Conclusion. 119\nCHAPTER 5 IN VITRO AND IN SILICO EVALUATION OF METHOXY SUBSTITUTED 25HNBOME ISOMERS AT 5HT2AR. 121\nvi\n5.1 Introduction . 122\n5.2 Materials and Methods. 125\n5.2.1 Chemicals and Reagents. 125\n5.2.2 Data Processing and Analysis. 125\n5.2.3 Statistical Analysis . 126\n5.2.4 Molecular Docking . 126\n5.3 Results and Discussion. 127\n5.3.1 Pharmacological Characterization. 127\n5.3.2 2-Methoxy NBOMe is are more Potent than 3-Methoxy NBOMe Compounds. 128\n5.3.3 NBOMe displays biased agonism towards \u03b2arrestin2 over Gq Pathway. 133\n5.3.4 Molecular Docking . 135\n5.4 Conclusion. 140\nCHAPTER 6 DISCUSSION. 142\n6.1 Objectives Of This Research. 143\n6.2 Summary of Research . 143\n6.2.1 Enantiomers of GAT and Isomers Show a Difference in Activity at CB1R. 143\n6.2.2 In silico Methods Can Be Used to Optimize Existing Compounds . 144\n6.2.3 In silico methods can be used to discriminate G protein from \u03b2arrestin2 biased\ncompounds. 146\n6.2.4 2-Methoxy NBOMe is more Potent than 3-Methoxy NBOMe Compounds. 147\n6.3 Philosophical Considerations Surrounding this Research. 148\n6.3.1 Ambiguity of full vs partial agonist/antagonist . 148\n6.3.2 Pharmacology in a Multidimensional System. 149\n6.3.3 SAR relationship is not straight forward in measuring agonism. 150\n6.3.4 5-HT2AR Receptor agonists Psychedelics issue . 151\n6.3.5 Will computational methods replace experimental pharmacology?.", "start_char_idx": 3166, "end_char_idx": 6062, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8e69c8bc-27ca-4263-a3b9-21a66520c4bd": {"__data__": {"id_": "8e69c8bc-27ca-4263-a3b9-21a66520c4bd", "embedding": null, "metadata": {"file_path": "data/brandt-no-intro.txt", "file_name": "brandt-no-intro.txt", "file_type": "text/plain", "file_size": 239829, "creation_date": "2023-12-31", "last_modified_date": "2023-12-31", "last_accessed_date": "2023-12-31"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "a0eaa9a5-aece-426b-8f20-580de8fb9f35", "node_type": "4", "metadata": {"file_path": "data/brandt-no-intro.txt", "file_name": "brandt-no-intro.txt", "file_type": "text/plain", "file_size": 239829, "creation_date": "2023-12-31", "last_modified_date": "2023-12-31", "last_accessed_date": "2023-12-31"}, "hash": "76e194b2637b440a1b1cdf5698cae061524bb4d7a3b73dfc2ba71d268a3f7019", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f8f153ef-0f33-40c9-b07a-1edb5ddeacdc", "node_type": "1", "metadata": {"file_path": "data/brandt-no-intro.txt", "file_name": "brandt-no-intro.txt", "file_type": "text/plain", "file_size": 239829, "creation_date": "2023-12-31", "last_modified_date": "2023-12-31", "last_accessed_date": "2023-12-31"}, "hash": "625afe6165ad917cc4d71ddaa73aebbe2cf0735957677afb7328bae70e6465ac", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c837b524-37dd-4a8d-80f5-04f501ea5d94", "node_type": "1", "metadata": {}, "hash": "f2a2670cac0f60bab8da207404d6abd853d7a661f5c0fec9479d976c286352e3", "class_name": "RelatedNodeInfo"}}, "hash": "1ad51b29a6ad4b874cf2837710b7df177a9fe68a34be3fd7222efe378ec1117f", "text": "143\n6.2.2 In silico Methods Can Be Used to Optimize Existing Compounds . 144\n6.2.3 In silico methods can be used to discriminate G protein from \u03b2arrestin2 biased\ncompounds. 146\n6.2.4 2-Methoxy NBOMe is more Potent than 3-Methoxy NBOMe Compounds. 147\n6.3 Philosophical Considerations Surrounding this Research. 148\n6.3.1 Ambiguity of full vs partial agonist/antagonist . 148\n6.3.2 Pharmacology in a Multidimensional System. 149\n6.3.3 SAR relationship is not straight forward in measuring agonism. 150\n6.3.4 5-HT2AR Receptor agonists Psychedelics issue . 151\n6.3.5 Will computational methods replace experimental pharmacology?. 152\nReferences. 153\nvii\nList of Figures\nFIGURE 1-1. GPCR STRUCTURE. 3\nFIGURE 1-2. LIGAND BIAS. . 7\nFIGURE 1-3. 5-HT2AR CRYSTAL STRUCTURE WITH LSD BOUND PDB ID: GWGT. 12\nFIGURE 1-4. BALLESTEROS-WEINSTEIN NUMBERING SYSTEM. . 15\nFIGURE 1-5. CB1R WITH THREE DIFFERENT BINDING SITES SHOWN. . 19\nFIGURE 2-1. GAT591 PREVIOUSLY STUDIED WAS SEPARATED OUT INTO ITS RESPECTIVE\nENANTIOMERS (GAT1664 AND GAT1665) AND GAT593 WAS SEPARATED OUT INTO ITS\nRESPECTIVE ENANTIOMERS (GAT1666 AND GAT1667). 25\nFIGURE 2-2. ORTEP DIAGRAM OF (+)-GAT1664 AND (+)-GAT1666 . 25\nFIGURE 2-3. ASSESSMENT OF GAT1664, GAT1665. GAT1666, AND GAT1667 SIGNALING. . 38\nFIGURE 2-4. CB1R CHO-K1 CELLS WERE TREATED WITH 0.10 NM \u2013 10 \u00b5M SR141716A + 1 \u00b5M\nCP55,940, GAT1665, OR GAT1667. . 41\nFIGURE 2-5. (A) RADIOLIGAND BINDING OF 1 NM [\n3H]CP55,940 AND (B,C) G PROTEIN BINDING OF\n[\n35S]GTPGS TO MEMBRANES FROM CB1R CHO-K1 CELLS . 43\nFIGURE 2-6. IN VIVO EFFECTS OF GAT1664, GAT1665, GAT1666 AND GAT1667 IN MALE C57BL/6\nMICE . 45\nFIGURE 2-7. CB1R WITH THREE DIFFERENT BINDING SITES SHOWN . 47\nFIGURE 2-8. GAT1664 BINDS TO AN ALLOSTERIC AGONIST SITE. 47\nFIGURE 2-9. GAT1665 BINDS TO THE PAM. 50\nFIGURE 2-10. PREPARATIVE HPLC CHROMATOGRAM FOR (+)-GAT1664 . 54\nFIGURE 2-11. PREPARATIVE HPLC CHROMATOGRAM FOR (-)-GAT1665 . 55\nFIGURE 2-12. PREPARATIVE HPLC CHROMATOGRAM FOR (+)-GAT1666 . 56\nFIGURE 2-13. PREPARATIVE HPLC CHROMATOGRAM FOR (-)-GAT1667 . 57\nFIGURE 3-1. (A) GAT228 SCAFFOLD HAS SITE X SITE Y AND SITE Z . 64\nFIGURE 3-2. THE MMGBSA VALUES WERE PLOTTED IN GRAPHPAD PRISM (V.9.1.1) AND DISPLAYED\nAS A HEATMAP . 67\nFIGURE 3-3. MMGBSA VALUES WERE PLOTTED USING GRAPHPAD PRISM (V.9.1.1) AND DISPLAYED\nAS A HEATMAP . 69\nFIGURE 3-4.", "start_char_idx": 5437, "end_char_idx": 7749, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c837b524-37dd-4a8d-80f5-04f501ea5d94": {"__data__": {"id_": "c837b524-37dd-4a8d-80f5-04f501ea5d94", "embedding": null, "metadata": {"file_path": "data/brandt-no-intro.txt", "file_name": "brandt-no-intro.txt", "file_type": "text/plain", "file_size": 239829, "creation_date": "2023-12-31", "last_modified_date": "2023-12-31", "last_accessed_date": "2023-12-31"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "a0eaa9a5-aece-426b-8f20-580de8fb9f35", "node_type": "4", "metadata": {"file_path": "data/brandt-no-intro.txt", "file_name": "brandt-no-intro.txt", "file_type": "text/plain", "file_size": 239829, "creation_date": "2023-12-31", "last_modified_date": "2023-12-31", "last_accessed_date": "2023-12-31"}, "hash": "76e194b2637b440a1b1cdf5698cae061524bb4d7a3b73dfc2ba71d268a3f7019", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8e69c8bc-27ca-4263-a3b9-21a66520c4bd", "node_type": "1", "metadata": {"file_path": "data/brandt-no-intro.txt", "file_name": "brandt-no-intro.txt", "file_type": "text/plain", "file_size": 239829, "creation_date": "2023-12-31", "last_modified_date": "2023-12-31", "last_accessed_date": "2023-12-31"}, "hash": "1ad51b29a6ad4b874cf2837710b7df177a9fe68a34be3fd7222efe378ec1117f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "69becf14-6c0c-4e2c-962b-19f81cb59e48", "node_type": "1", "metadata": {}, "hash": "791f3e65dac3ee308a5982d84d58edfa785cce84dd1d8ed13cbac5f1c6681720", "class_name": "RelatedNodeInfo"}}, "hash": "f2a2670cac0f60bab8da207404d6abd853d7a661f5c0fec9479d976c286352e3", "text": "55\nFIGURE 2-12. PREPARATIVE HPLC CHROMATOGRAM FOR (+)-GAT1666 . 56\nFIGURE 2-13. PREPARATIVE HPLC CHROMATOGRAM FOR (-)-GAT1667 . 57\nFIGURE 3-1. (A) GAT228 SCAFFOLD HAS SITE X SITE Y AND SITE Z . 64\nFIGURE 3-2. THE MMGBSA VALUES WERE PLOTTED IN GRAPHPAD PRISM (V.9.1.1) AND DISPLAYED\nAS A HEATMAP . 67\nFIGURE 3-3. MMGBSA VALUES WERE PLOTTED USING GRAPHPAD PRISM (V.9.1.1) AND DISPLAYED\nAS A HEATMAP . 69\nFIGURE 3-4. MMGBSA VALUES WERE PLOTTED IN GRAPHPAD PRISM (V.9.1.1) AND DISPLAYED AS\nA HEATMAP. 71\nFIGURE 3-5. FOUR LEAD COMPOUNDS. 74\nFIGURE 4-1. STRUCTURE OF SCRAS STUDIED. 91\nFIGURE 4-2. RADIOLIGAND BINDING OF 1 NM [\n3H]CP55,940 TO MEMBRANES FROM CB1R CHO-K1\nCELLS. 97\nFIGURE 4-3. CB1R-DEPENDENT INHIBITION OF FSK-STIMULATED CAMP . 98\nFIGURE 4-4. \u0392ARRESTIN2 RECRUITMENT TO CB1R FOLLOWING SCRA TREATMENT. . 99\nFIGURE 4-5. CB1R SCRA BIAS . 100\nFIGURE 4-6. RADIOLIGAND BINDING OF 1 NM [\n3H]CP55,940 TO MEMBRANES FROM CB2R CHO-K1\nCELLS. 103\nFIGURE 4-7. CB2R CHO-K1 WERE TREATED WITH 0.10 NM \u2013 10 \u00b5M GAT COMPOUNDS AND\nINHIBITION OF CAMP WAS MEASURED. . 104\nviii\nFIGURE 4-8. CB2R CHO-K1 WERE TREATED WITH 0.10 NM \u2013 10 \u00b5M GAT COMPOUNDS AND\n\u0392ARRESTIN2 RECRUITMENT WAS MEASURED. . 105\nFIGURE 4-9. CB2R SCRA BIAS . 106\nFIGURE 4-10. JWH 018 2\u2019-NAPHTHYL-N-(3-METHYLBUTYL) ISOMER BOUND TO CB1R AND CB2R\n. 113\nFIGURE 4-11. 4F-MDMB-BINACA BOUND TO CB1R AND CB2R . 114\nFIGURE 4-12. EXPERIMENTALLY DETERMINED KI COMPARED TO COMPUTATIONALLY DETERMINED\nMM-GBSA. 118\nFIGURE 5-1. 25CN-NBOH IS THE CO-CRYSTALLIZED LIGAND IN PDB ID: 6WHA BOUND TO 5-\nHT2AR. 124\nFIGURE 5-2. THE CONCENTRATION-RESPONSE CURVES OBTAINED BY STIMULATION OF THE 5-HT2AR\nFOLLOWED BY RECRUITMENT OF (PANELS A AND C) \u0392ARRESTIN2 OR (PANELS B AND D) MINIGQ\nCONSTRUCTS IN THE NANOBIT\n\u00ae SYSTEM. 130\nFIGURE 5-3. CONCENTRATION-RESPONSE DATA WERE FIT TO THE OPERATIONAL MODEL OF BLACK\nAND LEFF (1983) (GRAPHPAD V. 9.0). 134\nFIGURE 5-4. VISUAL REPRESENTATIONS OF THE NBOME ISOMERS AND 25CN-NBOH DOCKED INTO\nTHE BINDING POCKET OF THE 5-HT2AR (BASED ON PDB: 6WHA). . 136\nFIGURE 5-5. VISUAL REPRESENTATIONS OF THE NBOME ISOMERS DOCKED INTO THE BINDING\nPOCKET OF THE 5-HT2AR WITH HELICES SHOWN (BASED ON PDB: 6WHA) . 137\nix\n\nList of Tables\n\nTABLE 2-1.", "start_char_idx": 7336, "end_char_idx": 9529, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "69becf14-6c0c-4e2c-962b-19f81cb59e48": {"__data__": {"id_": "69becf14-6c0c-4e2c-962b-19f81cb59e48", "embedding": null, "metadata": {"file_path": "data/brandt-no-intro.txt", "file_name": "brandt-no-intro.txt", "file_type": "text/plain", "file_size": 239829, "creation_date": "2023-12-31", "last_modified_date": "2023-12-31", "last_accessed_date": "2023-12-31"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "a0eaa9a5-aece-426b-8f20-580de8fb9f35", "node_type": "4", "metadata": {"file_path": "data/brandt-no-intro.txt", "file_name": "brandt-no-intro.txt", "file_type": "text/plain", "file_size": 239829, "creation_date": "2023-12-31", "last_modified_date": "2023-12-31", "last_accessed_date": "2023-12-31"}, "hash": "76e194b2637b440a1b1cdf5698cae061524bb4d7a3b73dfc2ba71d268a3f7019", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c837b524-37dd-4a8d-80f5-04f501ea5d94", "node_type": "1", "metadata": {"file_path": "data/brandt-no-intro.txt", "file_name": "brandt-no-intro.txt", "file_type": "text/plain", "file_size": 239829, "creation_date": "2023-12-31", "last_modified_date": "2023-12-31", "last_accessed_date": "2023-12-31"}, "hash": "f2a2670cac0f60bab8da207404d6abd853d7a661f5c0fec9479d976c286352e3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e9751117-56d0-4930-95a8-de8a758fcec7", "node_type": "1", "metadata": {}, "hash": "e42fbaba11ab09422af23115558c18a95c7db074a6e44bc79e553e7483ddd2be", "class_name": "RelatedNodeInfo"}}, "hash": "791f3e65dac3ee308a5982d84d58edfa785cce84dd1d8ed13cbac5f1c6681720", "text": "130\nFIGURE 5-3. CONCENTRATION-RESPONSE DATA WERE FIT TO THE OPERATIONAL MODEL OF BLACK\nAND LEFF (1983) (GRAPHPAD V. 9.0). 134\nFIGURE 5-4. VISUAL REPRESENTATIONS OF THE NBOME ISOMERS AND 25CN-NBOH DOCKED INTO\nTHE BINDING POCKET OF THE 5-HT2AR (BASED ON PDB: 6WHA). . 136\nFIGURE 5-5. VISUAL REPRESENTATIONS OF THE NBOME ISOMERS DOCKED INTO THE BINDING\nPOCKET OF THE 5-HT2AR WITH HELICES SHOWN (BASED ON PDB: 6WHA) . 137\nix\n\nList of Tables\n\nTABLE 2-1. THE CONFORMATIONAL COST OF GAT COMPOUNDS . 48\nTABLE 3-1. PHYSICOCHEMICAL AND PHARMACOKINETIC PROPERTIES MODELED IN THIS STUDY . 63\nTABLE 3-2. ADME ANALYSIS OF FLUORINATED SUBSTITUTED GAT228 COMPOUNDS. 76\nTABLE 3-3. ADME ANALYSIS OF CHLORINATED SUBSTITUTED GAT228 COMPOUNDS . 78\nTABLE 3-4. ADME ANALYSIS OF BROMINATED SUBSTITUTED GAT228 COMPOUNDS. 80\nTABLE 3-5. ADME ANALYSIS OF IODINATED SUBSTITUTED GAT228 COMPOUNDS. 82\nTABLE 3-6. ADME ANALYSIS OF NITRO SUBSTITUTED GAT228 COMPOUNDS . 84\nTABLE 3-7. ADME ANALYSIS OF PYRIDINE AND CYCLOPENTADIENE SUBSTITUTED GAT228\nCOMPOUNDS. 86\nTABLE 4-1. ACTIVITY OF SCRAS AT CB1R AND CB2R . 107\nTABLE 4-2. SUMMARY OF THE INTERACTIONS BETWEEN THE RESIDUES OF THE CB1R. 115\nTABLE 4-3. SUMMARY OF THE INTERACTIONS BETWEEN THE RESIDUES OF THE CB2R. 116\nTABLE 4-4. THE MOST G PROTEIN BIASED COMPOUND JWH 018 2'-NAPHTHYL-N-(3-METHYLBUTYL)\nISOMER AND THE MOST BIASED \u0392ARRESTIN COMPOUND 4F-MDMB-BINACA BOUND TO 6N4B\nWITH AND WITHOUT THE G PROTEIN. 117\nTABLE 5-1. SUMMARY OF THE POTENCY AND EFFICACY IN THE \u0392ARRESTIN2 ASSAY . 131\nTABLE 5-2. SUMMARY OF THE POTENCY AND EFFICACY IN THE MINIGQ RECRUITMENT ASSAY . 132\nTABLE 5-3. SUMMARY OF THE INTERACTION ENERGIES (KCAL/MOL) BETWEEN COMPOUNDS AND THE\n5-HT2AR AS SEEN FROM THE PERSPECTIVE OF THE N-BENZYL MOIETY. 139\nTABLE 5-4. SUMMARY OF THE INTERACTION ENERGIES (KCAL/MOL) INVOLVED IN THE INTERACTION\nBETWEEN THE METHOXY GROUPS ON THE PHENYL RING AND NEARBY AMINO ACID RESIDUES ON\nTHE 5-HT2AR. 139\n\nList of Equations\n\nEQ. 2-1. 33\nEQ. 2-2. 33\nEQ. 2-3. 33\nEQ. 3-1.", "start_char_idx": 9081, "end_char_idx": 11068, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e9751117-56d0-4930-95a8-de8a758fcec7": {"__data__": {"id_": "e9751117-56d0-4930-95a8-de8a758fcec7", "embedding": null, "metadata": {"file_path": "data/brandt-no-intro.txt", "file_name": "brandt-no-intro.txt", "file_type": "text/plain", "file_size": 239829, "creation_date": "2023-12-31", "last_modified_date": "2023-12-31", "last_accessed_date": "2023-12-31"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "a0eaa9a5-aece-426b-8f20-580de8fb9f35", "node_type": "4", "metadata": {"file_path": "data/brandt-no-intro.txt", "file_name": "brandt-no-intro.txt", "file_type": "text/plain", "file_size": 239829, "creation_date": "2023-12-31", "last_modified_date": "2023-12-31", "last_accessed_date": "2023-12-31"}, "hash": "76e194b2637b440a1b1cdf5698cae061524bb4d7a3b73dfc2ba71d268a3f7019", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "69becf14-6c0c-4e2c-962b-19f81cb59e48", "node_type": "1", "metadata": {"file_path": "data/brandt-no-intro.txt", "file_name": "brandt-no-intro.txt", "file_type": "text/plain", "file_size": 239829, "creation_date": "2023-12-31", "last_modified_date": "2023-12-31", "last_accessed_date": "2023-12-31"}, "hash": "791f3e65dac3ee308a5982d84d58edfa785cce84dd1d8ed13cbac5f1c6681720", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "34e6b0a0-591f-4efa-997a-a1923c8fad58", "node_type": "1", "metadata": {}, "hash": "5ad16e145e03603ed616981011fbcdb9946fabf3ea2683245345c89bde8440de", "class_name": "RelatedNodeInfo"}}, "hash": "e42fbaba11ab09422af23115558c18a95c7db074a6e44bc79e553e7483ddd2be", "text": "SUMMARY OF THE POTENCY AND EFFICACY IN THE MINIGQ RECRUITMENT ASSAY . 132\nTABLE 5-3. SUMMARY OF THE INTERACTION ENERGIES (KCAL/MOL) BETWEEN COMPOUNDS AND THE\n5-HT2AR AS SEEN FROM THE PERSPECTIVE OF THE N-BENZYL MOIETY. 139\nTABLE 5-4. SUMMARY OF THE INTERACTION ENERGIES (KCAL/MOL) INVOLVED IN THE INTERACTION\nBETWEEN THE METHOXY GROUPS ON THE PHENYL RING AND NEARBY AMINO ACID RESIDUES ON\nTHE 5-HT2AR. 139\n\nList of Equations\n\nEQ. 2-1. 33\nEQ. 2-2. 33\nEQ. 2-3. 33\nEQ. 3-1. 62\n\nList of Abbreviations\n\n2-AG 2-Arachidonylglycerol\n5-HT2AR Serotonin 2A Receptor\nAI Artificial Intelligence\nAC Adenylate Cyclase\nAUC Area Under the Curve\nAEA Anandamide\ncAMP Cyclic Adenosine Monophosphate\nCB1R Type 1 Cannabinoid Receptor\nCB2R Type 2 Cannabinoid Receptor\nCI Confidence Interval\nCNR1 Human Type 1 Cannabinoid Receptor Gene\nCNS Central Nervous System\nCPU Central Processing Unit\nDAG Diacylglycerol\nDMSO Dimethyl sulfoxide\nEmax The Maximum Effect\nEC50 Half Maximal Effective Concentration\nECL Extracellular Loop\nECS Endocannabinoid System\nER Endoplasmic Reticulum\nEDTA Ethylenediaminetetraacetic acid\nFDA Food and Drug Administration\nGPCR G-Protein Coupled Receptor\nGPU Graphics Processing Unit\nICL Intracellular Loop\nLSD Lysergic Acid Diethylamide\nMMGBSA Molecular Mechanics/Generalised-Born Surface Area\nNAM Negative Allosteric Modulator \nxii\nPAM Positive Allosteric Modulator\nPBS Phosphate Buffered Saline\nPDB Protein Data Bank\nPNS Peripheral Nervous System\nPTSD Post Traumatic Stress Disorder\nSCRA Synthetic Cannabinoid Receptor Agonists\nSAR Structure Activity Relationship\nTHC \u22069 -Tetrahydrocannabinol\nTM Transmembrane\nTMH Transmembrane Helix\nWT Wild-type\nNBOMe N-Methoxybenzyl\nGAT Ganesh A. Thakur, referring to any compounds followed by a number code for\nallosteric ligands synthesized by Ganesh A. Thakur \nxiii\n\nAbstract\n\nG protein-coupled receptors (GPCRs) represent one of the most important families of drug targets.  Approximately 700 drugs target GPCR\u2019s, which accounts for 35% of FDA approved drugs. The type 1 cannabinoid receptor (CB1R), type 2 cannabinoid receptor (CB2R), and serotonin 2a receptor (5-HT2AR) are 3 GPCRs being intensively studied as new therapeutic targets. These receptors are involved in pain, depression, anxiety, memory impairment, nausea and body temperature. Due to the vast spectrum of conditions these receptors modulate, development of novel drugs to target these receptors is paramount. Specifically, the studies outlined in this thesis explored the structure activity relationship between ligands that bind CB1R, CB2R and 5-HT2AR using both in silico and in vitro methods. In vitro methods were utilized to determine whether novel ligands bound to the receptor using radioligand binding to measure affinity and functional assays to determine whether ligands activated receptor-dependent signaling cascades such as G protein-dependent inhibition of cAMP accumulation and recruitment of \u03b2arrestin2. Computational in silico methods were then explored to determine if the in vitro data could be supported. With these in silico methods the precise site(s) of ligand-GPCR interaction could be mapped down to the amino acid residue for precision structure-activity determination. From this interaction a computational proxy for binding affinity was used to measure the strength of the interaction.  Looking forward, data compiled in these studies can now be applied to the high-throughput design and assessment of novel CB1R, CB2R, and 5-HT2AR ligands and potential therapeutics.\n\n\nAcknowledgements\n\nI am extremely grateful for an experience I had with LSD at the age of 19-years old with my dear friend Andrew. During this experience I had the realization that small molecules can drastically change our perception of reality and was inspired to learn more about pharmacology.", "start_char_idx": 10598, "end_char_idx": 14400, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "34e6b0a0-591f-4efa-997a-a1923c8fad58": {"__data__": {"id_": "34e6b0a0-591f-4efa-997a-a1923c8fad58", "embedding": null, "metadata": {"file_path": "data/brandt-no-intro.txt", "file_name": "brandt-no-intro.txt", "file_type": "text/plain", "file_size": 239829, "creation_date": "2023-12-31", "last_modified_date": "2023-12-31", "last_accessed_date": "2023-12-31"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "a0eaa9a5-aece-426b-8f20-580de8fb9f35", "node_type": "4", "metadata": {"file_path": "data/brandt-no-intro.txt", "file_name": "brandt-no-intro.txt", "file_type": "text/plain", "file_size": 239829, "creation_date": "2023-12-31", "last_modified_date": "2023-12-31", "last_accessed_date": "2023-12-31"}, "hash": "76e194b2637b440a1b1cdf5698cae061524bb4d7a3b73dfc2ba71d268a3f7019", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e9751117-56d0-4930-95a8-de8a758fcec7", "node_type": "1", "metadata": {"file_path": "data/brandt-no-intro.txt", "file_name": "brandt-no-intro.txt", "file_type": "text/plain", "file_size": 239829, "creation_date": "2023-12-31", "last_modified_date": "2023-12-31", "last_accessed_date": "2023-12-31"}, "hash": "e42fbaba11ab09422af23115558c18a95c7db074a6e44bc79e553e7483ddd2be", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ed0262b0-e314-429f-8eff-5b23a68c375a", "node_type": "1", "metadata": {}, "hash": "4e17421e51b78443c688653b298e8081f85f6d3045757e98b7b7a54e8701e08c", "class_name": "RelatedNodeInfo"}}, "hash": "5ad16e145e03603ed616981011fbcdb9946fabf3ea2683245345c89bde8440de", "text": "Computational in silico methods were then explored to determine if the in vitro data could be supported. With these in silico methods the precise site(s) of ligand-GPCR interaction could be mapped down to the amino acid residue for precision structure-activity determination. From this interaction a computational proxy for binding affinity was used to measure the strength of the interaction.  Looking forward, data compiled in these studies can now be applied to the high-throughput design and assessment of novel CB1R, CB2R, and 5-HT2AR ligands and potential therapeutics.\n\n\nAcknowledgements\n\nI am extremely grateful for an experience I had with LSD at the age of 19-years old with my dear friend Andrew. During this experience I had the realization that small molecules can drastically change our perception of reality and was inspired to learn more about pharmacology. My local University had a bio-chemistry program and during my studies I learned that molecules and the receptors they bind to are 3-dimensional and somehow this interaction can change the \u201cnormal\u201d mode of reality we interact with daily. I really fell in love with organic chemistry and biochemistry during this time. The study of psychedelics continues to be the driving force and inspiration for my lifelong curiosity in science.  To Dr. Robert B. Laprairie: You have let me combine my interest in chemistry with your knowledge of pharmacology to discover the beautiful world of computational molecular pharmacology. Without your continued support I likely would not have found this niche research area. I will always remember the day you taught me how to use AutoDock Vina in your office which changed my life. I could not have asked for a more compassionate kind human being to be my mentor. The University of Saskatchewan and your trainees are extremely lucky to have you.  To Dow. P Hurst: I will be forever grateful for the training in in silico molecular modelling you taught me during my stay at the University of North Carolina Greensboro.  To my wife Sloan and son Jasper: Jasper although you are only an infant now, I am so excited to see what you become. I will likely tell you bedtime stories about the ligand and the receptor instead of the tortoise and the hair.\n\nCHAPTER 1\n\nIntroduction\n\nContribution Statement\n\nThe contents of this chapter are an expanded version of the previously published review article and book chapter \u201cComputer modeling of allosteric modulators at G protein-coupled receptors\u201d.  1 The entirety of the publication was written by Asher L. Brandt with guidance from Dr. Robert B.  Laprairie. The present chapter was adapter and expanded to encompass the scope of the thesis.  2\n\n1.1 G Protein-Coupled Receptors\n\nG protein-coupled receptors (GPCRs) represent the largest protein family encoded by the human genome. Activated GPCRs transduce extracellular signals which in turn control key physiological effects. The endogenous ligands that activate GPCRs include odors, photons, hormones and neurotransmitters. Due to the ubiquitous nature of GPCRs they play a role in many diseases such as obesity, depression, cancer, type 2 diabetes, Alzheimer\u2019s and Parkinson\u2019s.\n\nFor this reason, approximately 35% of FDA-approved drugs target GPCRs. The human genome encodes approximately 800 GPCRs, which are subdivided into 6 classes; class A (Rhodopsin-like), class B (Secretin receptor family), class C (Metabotropic glutamate), class D (Fungal mating pheromone receptors), class E (Cyclic AMP receptors) and class F (Frizzled/Smoothed).  GPCRs consist of 7 transmembrane (TM) helices connected via 3 extracellular (ECL) and 3 intracellular loops (ICL), a disulfide bridge between ECL2 and TM3 and a cytoplasmic C-terminus containing an \u03b1-helix (helix 8) parallel to the cell membrane (Figure 1-1).  Ligands such as peptide hormones bind to the extracellular domain and trigger intracellular signaling cascades which mediate the functions of the GPCR.\n\nFigure 1-1. GPCR Structure. (a) Visualization of a GPCR. The perspective here is looking at the side of the GPCR from within the plasma membrane with a slight angle looking down from the extracellular surface. A defining feature of all GPCRs is having 7-Transmembrane helices.  Transmembrane helices are: I red, II orange, III green, IV pink, V blue, VI purple, and VII grey.  (b) Visualization of (a) rotated 180\u00ba.", "start_char_idx": 13527, "end_char_idx": 17897, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ed0262b0-e314-429f-8eff-5b23a68c375a": {"__data__": {"id_": "ed0262b0-e314-429f-8eff-5b23a68c375a", "embedding": null, "metadata": {"file_path": "data/brandt-no-intro.txt", "file_name": "brandt-no-intro.txt", "file_type": "text/plain", "file_size": 239829, "creation_date": "2023-12-31", "last_modified_date": "2023-12-31", "last_accessed_date": "2023-12-31"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "a0eaa9a5-aece-426b-8f20-580de8fb9f35", "node_type": "4", "metadata": {"file_path": "data/brandt-no-intro.txt", "file_name": "brandt-no-intro.txt", "file_type": "text/plain", "file_size": 239829, "creation_date": "2023-12-31", "last_modified_date": "2023-12-31", "last_accessed_date": "2023-12-31"}, "hash": "76e194b2637b440a1b1cdf5698cae061524bb4d7a3b73dfc2ba71d268a3f7019", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "34e6b0a0-591f-4efa-997a-a1923c8fad58", "node_type": "1", "metadata": {"file_path": "data/brandt-no-intro.txt", "file_name": "brandt-no-intro.txt", "file_type": "text/plain", "file_size": 239829, "creation_date": "2023-12-31", "last_modified_date": "2023-12-31", "last_accessed_date": "2023-12-31"}, "hash": "5ad16e145e03603ed616981011fbcdb9946fabf3ea2683245345c89bde8440de", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "82d970d1-55ff-47b1-991a-424227d2a819", "node_type": "1", "metadata": {}, "hash": "de85034f7deb387d4bb914d8a7e939474f3f46f34aa3bf047c9db4b167220b2c", "class_name": "RelatedNodeInfo"}}, "hash": "4e17421e51b78443c688653b298e8081f85f6d3045757e98b7b7a54e8701e08c", "text": "Ligands such as peptide hormones bind to the extracellular domain and trigger intracellular signaling cascades which mediate the functions of the GPCR.\n\nFigure 1-1. GPCR Structure. (a) Visualization of a GPCR. The perspective here is looking at the side of the GPCR from within the plasma membrane with a slight angle looking down from the extracellular surface. A defining feature of all GPCRs is having 7-Transmembrane helices.  Transmembrane helices are: I red, II orange, III green, IV pink, V blue, VI purple, and VII grey.  (b) Visualization of (a) rotated 180\u00ba.\n\n1.2 GPCR Intra-Cellular Signaling Cascades\n\nTODO(sness) : REDACTED for AI\n\n1.5 Cannabinoid Receptor Type 2\n\nSimilarly, the type 2 cannabinoid receptor (CB2R) is a class A GPCR encoded by the CNR2 gene in humans.56 CB2R is located in the PNS specifically immune cells. While activation of CB1R typically leads to intoxication, activation of CB2R inhibits proinflammatory cytokine production and subsequent release of anti-inflammatory cytokines.  57 The CB2R agonist GW842166x has been shown to produce neuroprotective effects in the 6-OHDA mouse model of Parkinson\u2019s disease.58 CB2R is comprised of 360 amino acids and 4 solved crystal structures exist on the Protein Data Bank (PDB).  50,59,60,61 Due to quite similar sequence homology of CB1R and CB2R especially in the orthosteric binding site, developing selective CB2R ligands remains a challenge.\n\n1.6 Psychedelics and the Serotonin 2a Receptor (5-HT2AR)\n\nSerotonin binds to 14 different serotonin receptors in order to mediate its biological effects.  62 Of these 14 receptors, the 5-HT2AR has been under heavy investigation recently for its potential as a molecular target to treat post-traumatic stress disorder (PTSD) and depression.  63 Specifically, this applies to 5-HT2AR agonists that are colloquially referred to as psychedelics including LSD, mescaline, and psilocybin.  64 5-HT2AR is found in high levels in the CNS specifically cortex, caudate nucleus, nucleus accumbens, locus coeruleus, olfactory tubercle, and hippocampus.  65 It was discovered in 1998 by Franz Vollenweider that 5-HT2AR is the key site for psychedelics\u2019 mechanism of action.  66 The first 5-HT2AR crystal structure to be solved with a psychedelic bound was published in 2020 which showed LSD bound to 5-HT2AR (Figure 1-3).  29 The structure elucidated the presence of a salt bridge between the protonated amine on LSD and a negatively charged oxygen atom on 11 D1553.32, a common interaction that appears in all 5-HT2AR active compounds.29 The indole hydrogen also forms a H-bond with S2425.46 .  29 This H-bond likely occurs amongst other psychedelics with an indole scaffold such as psilocin and the endogenous ligand serotonin. This is supported by mutagenesis studies that show mutation S2425.46A mutation leads to a drastic decrease in LSD and other psychedelics tryptamines binding affinity.  67,68 Unfortunately, these data have become a controversial topic as a recent crystal structure published with psilocin and serotonin do not include an interaction at S242.  5.46,69,70 Of note, data from the earlier study are supported by in vitro pharmacological evidence whereas the more recent 2022 data are not.  70 The final notable interaction that came from the 2020 study was the L229ECL2 forming hydrophobic interactions with the diethylamide moiety of LSD. The authors provide compelling in vitro data that correlate the interaction between LSD and L229ECL2 with the long residence time of LSD at the receptor.  29,71 L229ECL2 functions as a lid above the LSD binding site of 5-HT2AR making it difficult for LSD to dissociate from the receptor.  29,71 Mutation of L229ECL2 to alanine results in a 10-fold increase in the rate of LSD\u2019s dissociation from 5-HT2AR.  29,71 In contrast, the endogenous ligand, serotonin, does not interact with L229ECL2 and therefore has a much briefer residence time at the receptor as shown through functional in vitro and computational experiments.", "start_char_idx": 17329, "end_char_idx": 21327, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "82d970d1-55ff-47b1-991a-424227d2a819": {"__data__": {"id_": "82d970d1-55ff-47b1-991a-424227d2a819", "embedding": null, "metadata": {"file_path": "data/brandt-no-intro.txt", "file_name": "brandt-no-intro.txt", "file_type": "text/plain", "file_size": 239829, "creation_date": "2023-12-31", "last_modified_date": "2023-12-31", "last_accessed_date": "2023-12-31"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "a0eaa9a5-aece-426b-8f20-580de8fb9f35", "node_type": "4", "metadata": {"file_path": "data/brandt-no-intro.txt", "file_name": "brandt-no-intro.txt", "file_type": "text/plain", "file_size": 239829, "creation_date": "2023-12-31", "last_modified_date": "2023-12-31", "last_accessed_date": "2023-12-31"}, "hash": "76e194b2637b440a1b1cdf5698cae061524bb4d7a3b73dfc2ba71d268a3f7019", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ed0262b0-e314-429f-8eff-5b23a68c375a", "node_type": "1", "metadata": {"file_path": "data/brandt-no-intro.txt", "file_name": "brandt-no-intro.txt", "file_type": "text/plain", "file_size": 239829, "creation_date": "2023-12-31", "last_modified_date": "2023-12-31", "last_accessed_date": "2023-12-31"}, "hash": "4e17421e51b78443c688653b298e8081f85f6d3045757e98b7b7a54e8701e08c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7fb4cb7f-3756-4de5-83f4-4c46edf5db68", "node_type": "1", "metadata": {}, "hash": "0562b419a5e0a5b1b657caee93f43a79dce663a960931d2be9e26a5571563cfd", "class_name": "RelatedNodeInfo"}}, "hash": "de85034f7deb387d4bb914d8a7e939474f3f46f34aa3bf047c9db4b167220b2c", "text": "70 The final notable interaction that came from the 2020 study was the L229ECL2 forming hydrophobic interactions with the diethylamide moiety of LSD. The authors provide compelling in vitro data that correlate the interaction between LSD and L229ECL2 with the long residence time of LSD at the receptor.  29,71 L229ECL2 functions as a lid above the LSD binding site of 5-HT2AR making it difficult for LSD to dissociate from the receptor.  29,71 Mutation of L229ECL2 to alanine results in a 10-fold increase in the rate of LSD\u2019s dissociation from 5-HT2AR.  29,71 In contrast, the endogenous ligand, serotonin, does not interact with L229ECL2 and therefore has a much briefer residence time at the receptor as shown through functional in vitro and computational experiments.  29,68,71 Based on their in vitro and computational data, the authors hypothesize that ligand residence time at 5- HT2AR correlates with \u03b2arrestin2 recruitment and some of the psychotropic effects of LSD.  Consequently, the data support a direct through line from ligand structure-activity relationships to ligand bias and drug safety. Studies such as Wacker et al. 202029 are compelling examples of how insights into GPCR structure-activity relationships can be developed using a combination of crystallographic data, in vitro and computational modelling.\n\nFigure 1-3. 5-HT2AR Crystal Structure with LSD bound PDB ID: GWGT. In this view of 5- HT2AR LSD is shown as the blue, white and red spheres in the center as VDW. Transmembrane helices are: I orange, II red, III yellow, IV grey, V green, VI purple, and VII blue. LSD is stabilized via a salt bridge with D1553.32 and a H-bond with S2425.46.\n\n1.7 Computational Modelling of G protein-coupled receptors\n\nComputational modelling in pharmacology refers to the use of computers coupled with mathematical modelling and quantum mechanics [specifically central processing units (CPUs) and graphics processing units (GPUs)] to uncover how biomolecules interact with one another.72 With computational modelling one can generate on a computer how both protein-protein interactions occur as well as ligand-protein interactions. This is especially useful in understanding interactions (H-bond, Salt Bridge, Hydrophobic, \u03c0-\u03c0, Cation- \u03c0) between amino acids on the protein and functional groups on a ligand necessary for biological activity of a ligand-receptor complex. This is used for making future predictions about whether or not a ligand with a known structure will bind to and activate a protein before having to run an in vitro experiment.  For this dissertation, the goal of computational modelling is to (1) create a 3D model of how a given ligand binds to a receptor and (2) use this information to support in vitro data. The use of computational modelling in GPCR drug discovery began roughly in 2007, when the human \u03b2 2- adrenergic receptor structure was solved via x-ray diffraction.  73 Seven years earlier in 2000 the structure of a mammalian GPCR, bovine rhodopsin was solved.  74 As of August 5th, 2022, 788 GPCR structures have been solved for 136 different receptors. Early-stage computational work focused on creating ligands that bound to the orthosteric binding pocket, which is where each GPCRs respective endogenous ligand binds. Although this method works well for solving the crystal structure of a GPCR, it does not work well for therapeutic ligand design. This is due to the highly conserved nature of a GPCRs orthosteric site, which makes developing selective ligands extremely difficult.  40 In addition, because orthosteric agonists bind the same sites as endogenous ligands, all physiological signals from a GPCR are superseded by exogenous orthosteric agonists.  75 Moreover, accumulating data demonstrate exogeneous orthosteric agonists have a higher potential 14 to produce intoxication, receptor desensitization, tolerance and dependence than allosteric ligands.  76 Ligands that bind to allosteric sites have become much more attractive targets for drug discovery for this reason. A growing number of researchers have solved GPCR structures with allosteric modulators bound using both cryo-EM and X-ray crystallography. This in turn has allowed for the discovery of (1) more allosteric sties on GPCRs, and (2) the development of allosteric modulators with higher selectivity.", "start_char_idx": 20555, "end_char_idx": 24883, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7fb4cb7f-3756-4de5-83f4-4c46edf5db68": {"__data__": {"id_": "7fb4cb7f-3756-4de5-83f4-4c46edf5db68", "embedding": null, "metadata": {"file_path": "data/brandt-no-intro.txt", "file_name": "brandt-no-intro.txt", "file_type": "text/plain", "file_size": 239829, "creation_date": "2023-12-31", "last_modified_date": "2023-12-31", "last_accessed_date": "2023-12-31"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "a0eaa9a5-aece-426b-8f20-580de8fb9f35", "node_type": "4", "metadata": {"file_path": "data/brandt-no-intro.txt", "file_name": "brandt-no-intro.txt", "file_type": "text/plain", "file_size": 239829, "creation_date": "2023-12-31", "last_modified_date": "2023-12-31", "last_accessed_date": "2023-12-31"}, "hash": "76e194b2637b440a1b1cdf5698cae061524bb4d7a3b73dfc2ba71d268a3f7019", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "82d970d1-55ff-47b1-991a-424227d2a819", "node_type": "1", "metadata": {"file_path": "data/brandt-no-intro.txt", "file_name": "brandt-no-intro.txt", "file_type": "text/plain", "file_size": 239829, "creation_date": "2023-12-31", "last_modified_date": "2023-12-31", "last_accessed_date": "2023-12-31"}, "hash": "de85034f7deb387d4bb914d8a7e939474f3f46f34aa3bf047c9db4b167220b2c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "13098646-5b47-4002-8d99-d0f177e3eff8", "node_type": "1", "metadata": {}, "hash": "143091b52bbf3888674c75090c7631acc4ebde80adf2ef1b4c9904b3f6aff2c5", "class_name": "RelatedNodeInfo"}}, "hash": "0562b419a5e0a5b1b657caee93f43a79dce663a960931d2be9e26a5571563cfd", "text": "40 In addition, because orthosteric agonists bind the same sites as endogenous ligands, all physiological signals from a GPCR are superseded by exogenous orthosteric agonists.  75 Moreover, accumulating data demonstrate exogeneous orthosteric agonists have a higher potential 14 to produce intoxication, receptor desensitization, tolerance and dependence than allosteric ligands.  76 Ligands that bind to allosteric sites have become much more attractive targets for drug discovery for this reason. A growing number of researchers have solved GPCR structures with allosteric modulators bound using both cryo-EM and X-ray crystallography. This in turn has allowed for the discovery of (1) more allosteric sties on GPCRs, and (2) the development of allosteric modulators with higher selectivity. However, allosteric sites can be problematic to probe or assess by cryo-EM and crystallography because allosteric ligands tend to have lower affinity at allosteric sites, which are often \u201csuperficial\u201d or sit on the surfaces of a protein, or because allosteric sites may overlap with of modulators of the receptor, such as cholesterol that could themselves be considered allosteric. Given the number of GPCR structures solved to date, computer modelling has become a growing field in drug discovery and pharmacology. It has also highlighted the considerable similarity of GPCR structure and highly conserved nature of a number of TMH residues which has required scientists to use the Ballesteros-Weinstein nomenclature system for naming specific residues (Figure 1-4).  15 Figure 1-4. Ballesteros-Weinstein Numbering System. The numbering scheme by BallesterosWeinstein is a method for numbering amino acid positions in GPCRs. In each of the 7-TMH\u2019s the most conserved residue is denoted 50. While in TMH1 (red) this is Asparagine (N) on TMH4 (pink) this is Tryptophan (W). In this case these amino acids are denoted at N1.50 and W4.50. Any amino acid going in the direction of the N-terminus is treated as the negative direction whereas the C-terminus being the positive direction. For example, the cysteine residue is denoted at C1.55 because it is 5 amino acids closer to the C-terminus than N1.50 whereas L1.48 is 2 positions closer to the N-terminus than N1.50 .  16 1.7.1 In silico Modelling of CB1R allosteric ligands Within this thesis, development of allosteric ligands is focused of CB1R. CB1R is a key mediator in the endocannabinoid system which has 2 endogenous agonists: AEA and 2-AG. With growing number of constituencies decriminalizing or legalizing cannabis globally, research concerning CB1R and cannabinoids has grown. THC is the psychoactive and intoxicating compound present in cannabis and is known to be a partial agonist that binds the orthosteric sites of CB1R and CB2R.  Targeting CB1R has applications in treating pain, movement disorders, epilepsy and obesity.  77 Because direct-acting orthosteric agonists of CB1R produce intoxication, the development of allosteric modulators at CB1R may provide the most promise. In terms of the orthosteric binding site there are 6 crystal structures that show the binding site in high resolution. Despite this little in silico work has been conducted as CB1R orthosteric ligands are intoxicating thus are not sought after as therapeutic agents but rather tool compounds for studying the receptor. However, using these crystal structures mutagenesis studies have shown that S3837.39A mutation drastically reduced (50 \u2013 100 fold) the affinity of both AM4056 and HU210 (CB1R orthosteric agonists).  54 The only CB1R allosteric modulator to have a known solved binding site is the CB1R NAM ORG27569 (PDB 6KQI).  47 Although ORG27569 significantly increases binding affinity of CP55,940 (a synthetic CB1R orthosteric agonist) at CB1R and decreases the binding affinity of rimonabant (a CB1R inverse agonist) it decreases the efficacy of CP55,940 in G protein-mediated coupling and therefore is functionally considered a NAM.", "start_char_idx": 24090, "end_char_idx": 28070, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "13098646-5b47-4002-8d99-d0f177e3eff8": {"__data__": {"id_": "13098646-5b47-4002-8d99-d0f177e3eff8", "embedding": null, "metadata": {"file_path": "data/brandt-no-intro.txt", "file_name": "brandt-no-intro.txt", "file_type": "text/plain", "file_size": 239829, "creation_date": "2023-12-31", "last_modified_date": "2023-12-31", "last_accessed_date": "2023-12-31"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "a0eaa9a5-aece-426b-8f20-580de8fb9f35", "node_type": "4", "metadata": {"file_path": "data/brandt-no-intro.txt", "file_name": "brandt-no-intro.txt", "file_type": "text/plain", "file_size": 239829, "creation_date": "2023-12-31", "last_modified_date": "2023-12-31", "last_accessed_date": "2023-12-31"}, "hash": "76e194b2637b440a1b1cdf5698cae061524bb4d7a3b73dfc2ba71d268a3f7019", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7fb4cb7f-3756-4de5-83f4-4c46edf5db68", "node_type": "1", "metadata": {"file_path": "data/brandt-no-intro.txt", "file_name": "brandt-no-intro.txt", "file_type": "text/plain", "file_size": 239829, "creation_date": "2023-12-31", "last_modified_date": "2023-12-31", "last_accessed_date": "2023-12-31"}, "hash": "0562b419a5e0a5b1b657caee93f43a79dce663a960931d2be9e26a5571563cfd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "dd1adc35-aa10-418c-a564-07dd8f0ff28f", "node_type": "1", "metadata": {}, "hash": "08284b50b09d4e0828264dabd568db1897321a16ca632bf529a82e3ddc29860f", "class_name": "RelatedNodeInfo"}}, "hash": "143091b52bbf3888674c75090c7631acc4ebde80adf2ef1b4c9904b3f6aff2c5", "text": "However, using these crystal structures mutagenesis studies have shown that S3837.39A mutation drastically reduced (50 \u2013 100 fold) the affinity of both AM4056 and HU210 (CB1R orthosteric agonists).  54 The only CB1R allosteric modulator to have a known solved binding site is the CB1R NAM ORG27569 (PDB 6KQI).  47 Although ORG27569 significantly increases binding affinity of CP55,940 (a synthetic CB1R orthosteric agonist) at CB1R and decreases the binding affinity of rimonabant (a CB1R inverse agonist) it decreases the efficacy of CP55,940 in G protein-mediated coupling and therefore is functionally considered a NAM.  78 The ORG27569 isothiocyanate analog GAT100 has been shown to be a more potent and efficacious CB1R NAM than ORG27569 for \u03b2arrestin1 recruitment, PLC\u03b23 and ERK1/2 phosphorylation, cAMP accumulation, and CB1R internalization in HEK293A cells overexpressing CB1R and in Neuro2a and STHdhQ7/Q7 cells endogenously expressing CB1R.  79 The rationale for making the isothiocyanate derivative was to 17 form a covalent bond on CB1R which was found to occur at C3827.38 .  80 PDB ID 6KQI shows us that ORG27569 binds to an extrahelical site on the inner leaflet of the membrane. Most of the contacts interact with TM4 however the ligand extends along a lipid-facing hydrophobic surface to additionally contact TM2.  47 This binding site overlaps with the cholesterol binding site on multiple GPCRs including CB1R.  48 Upon ORG27569 binding CB1R adopts an inactive conformation such that TM6 packs against TM3 and TM5.  47 This causes a blockage of the G protein-interacting residues observed in the crystal structure of CB1 with the Gi complex.  51 This observation is consistent with experiments that show ORG27569 diminishes Gi coupling in the presence of an agonist.78 Another allosteric modulator of CB1R that holds potential in understanding the function of allosteric sites is the racemic compound GAT211 and its purified enantiomers (R)-GAT228 and (S)-GAT229.81 GAT211 has been shown to be a selective CB1R allosteric agonist-PAM (i.e. agoPAM) because it displays both PAM and agonist activity in HEK293A cells expressing CB1R.  82 By purifying GAT211 into its respective enantiomers it was found that the allosteric agonist activity resided with the R-enantiomer GAT228, whereas the PAM activity resided with the Senantiomer GAT229.81 In binding experiments, GAT211 enhances the binding of the orthosteric agonist [3H]CP55,940 and reduces the binding of orthosteric inverse agonist rimonabant.  82 Being that neither GAT211 nor its enantiomers competed for binding with [3H]CP55,940 it is unlikely that the agonist nature of GAT211 and GAT228 is the result of their binding to the orthosteric site.  Using a computational modelling-based approach known as forced-biased MMC simulated annealing that GAT228 and GAT229 have distinct binding sites on CB1R (Figure 1-5).  83 GAT228 binds in the IC TMH1-2-4 exosite.83 The 2 oxygens on the NO2 form a dual H-bond with 2 hydrogens on R148IC1 and another H-bond exist between the hydrogen on the indole and a nitrogen 18 atom on H1542.41 .  83 Face-to-face aromatic stacking was observed between the indole ring phenyl substituent and F2374.46 and a T-shaped aromatic stack was observed between the phenyl ring attached to the stereocenter and W2.414.50 .  83 This binding site promotes agonism via a conformation change in F2374.46 into a \u03b31 g+ \u2192 trans state causing the breaking of the R3.50/D6.30 ionic lock which in turn appears to activate CB1R.  83 GAT229 binds to the EC TMH2-3-ECL1 binding stie.83 The indole hydrogen forms an H-bond with D1762.63 and another H-bond was observed between the NO2 group and Y1722.59 .", "start_char_idx": 27448, "end_char_idx": 31140, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "dd1adc35-aa10-418c-a564-07dd8f0ff28f": {"__data__": {"id_": "dd1adc35-aa10-418c-a564-07dd8f0ff28f", "embedding": null, "metadata": {"file_path": "data/brandt-no-intro.txt", "file_name": "brandt-no-intro.txt", "file_type": "text/plain", "file_size": 239829, "creation_date": "2023-12-31", "last_modified_date": "2023-12-31", "last_accessed_date": "2023-12-31"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "a0eaa9a5-aece-426b-8f20-580de8fb9f35", "node_type": "4", "metadata": {"file_path": "data/brandt-no-intro.txt", "file_name": "brandt-no-intro.txt", "file_type": "text/plain", "file_size": 239829, "creation_date": "2023-12-31", "last_modified_date": "2023-12-31", "last_accessed_date": "2023-12-31"}, "hash": "76e194b2637b440a1b1cdf5698cae061524bb4d7a3b73dfc2ba71d268a3f7019", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "13098646-5b47-4002-8d99-d0f177e3eff8", "node_type": "1", "metadata": {"file_path": "data/brandt-no-intro.txt", "file_name": "brandt-no-intro.txt", "file_type": "text/plain", "file_size": 239829, "creation_date": "2023-12-31", "last_modified_date": "2023-12-31", "last_accessed_date": "2023-12-31"}, "hash": "143091b52bbf3888674c75090c7631acc4ebde80adf2ef1b4c9904b3f6aff2c5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "424f8406-2074-4a46-b943-c95f9a7d79e3", "node_type": "1", "metadata": {}, "hash": "59d239ec13e0fbb3c819dd44cbb44f8b64e5930b2f12111d122c59767ace03c3", "class_name": "RelatedNodeInfo"}}, "hash": "08284b50b09d4e0828264dabd568db1897321a16ca632bf529a82e3ddc29860f", "text": "83 Face-to-face aromatic stacking was observed between the indole ring phenyl substituent and F2374.46 and a T-shaped aromatic stack was observed between the phenyl ring attached to the stereocenter and W2.414.50 .  83 This binding site promotes agonism via a conformation change in F2374.46 into a \u03b31 g+ \u2192 trans state causing the breaking of the R3.50/D6.30 ionic lock which in turn appears to activate CB1R.  83 GAT229 binds to the EC TMH2-3-ECL1 binding stie.83 The indole hydrogen forms an H-bond with D1762.63 and another H-bond was observed between the NO2 group and Y1722.59 .  83 A cation-\u03c0 interaction was observed between the indole ring of GAT229 and R182ECL1 .  83 The indole ring phenyl ring substituent was observed to have an off-set parallel aromatic stack with Y1722.59 .  83 GAT229 alone can not break the ionic lock that activates CB1R and thus alone is not an agonist, but because it stabilizes an orthosteric agonist when bound it acts as a PAM.  19 Figure 1-5. CB1R with three different binding sites shown. In these views of CB1R the orthosteric site is shown in magenta, an identified PAM site in blue, and another identified agoPAM site in tan. Transmembrane helices are: I red, II orange, III yellow, IV light green, V green, VI cyan, and VII blue.  20\n\n1.8 Objectives of This Research\n\nGPCRs continue to be among the leading class of protein targets for drug development. At the leading edge of this area is a need to understand previously poorly-characterized GPCRs that are the primary targets for controlled and prohibited substances, namely cannabinoids, and psychedelics. As the control status, legality, and medical access to cannabis and psychedelics continue to shift research is desperately needed to understand the potential harms and therapeutic utility of cannabinoids and psychedelics. In addition, the opportunity to develop allosteric ligands that target the cannabinoid receptor in particular may represent a means to bypass the undesirable effects of orthosteric ligands.  The long-term hypothesis of this research is that the cannabinoid and serotonin receptors are tractable therapeutic targets for the development of drugs for unmet clinical needs including pain, epilepsy, and anxiety. To this end, the overall objective of this research is to advance knowledge of these receptors\u2019 fundamental structure-activity relationships through the use of in vitro and in silico computer modelling assays performed on CB1R, CB2R, and 5-HT2AR. The aims of this research were to understand (1) The SAR between compounds that separately bind CB1R, CB2R and 5-HT2AR; (2) How this SAR can be used to elucidate biased agonism at CB1R, CB2R and 5- HT2AR; and (3) How computational methodologies can be employed to explain pharmacological properties of these compounds.  Each chapter in this thesis represents work already published or under peer review. Although methodologies and approaches overlap between each individual study all methods have been included in order to illustrate key differences in technique and approach. Chapter 2 shows that enantiomerically separated compounds display a difference in pharmacology and binding sites on CB1R. Chapter 3 builds upon chapter 2 and shows that computational modelling can be used to 21 optimize ligands that bind to the CB1R ago-PAM site. Chapter 4 characterizes select synthetic cannabinoid receptor agonists at CB1R and CB2R. Chapter 5 characterizes NBOMe compounds at 5-HT2AR looking at the relationship in vitro and in silico of changing methoxy groups on the phenethylamine ring. Lastly chapter 6 summarizes the research provided and looks at philosophical considerations regarding this research.  22\n\n\nCopyright statement\n\nThis chapter is in review for publication. The manuscript has been modified to meet formatting requirements.\n\nContribution statement\n\nThe manuscript used as the basis for this chapter was written by me \u2013 Asher Brandt \u2013 with guidance from Dr. Robert B. Laprairie. In silico and in vitro data were collected and analyzed by myself with technical assistance from Dr. Robert B. Laprairie and Dow P. Hurst (University of North Carolina, Greensboro). GTP\uf067S experiments were performed in the laboratory of Dr. Roger Pertwee (University of Aberdeen) and analyzed by Asher Brandt and Dr. Robert B. Laprairie.", "start_char_idx": 30557, "end_char_idx": 34868, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "424f8406-2074-4a46-b943-c95f9a7d79e3": {"__data__": {"id_": "424f8406-2074-4a46-b943-c95f9a7d79e3", "embedding": null, "metadata": {"file_path": "data/brandt-no-intro.txt", "file_name": "brandt-no-intro.txt", "file_type": "text/plain", "file_size": 239829, "creation_date": "2023-12-31", "last_modified_date": "2023-12-31", "last_accessed_date": "2023-12-31"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "a0eaa9a5-aece-426b-8f20-580de8fb9f35", "node_type": "4", "metadata": {"file_path": "data/brandt-no-intro.txt", "file_name": "brandt-no-intro.txt", "file_type": "text/plain", "file_size": 239829, "creation_date": "2023-12-31", "last_modified_date": "2023-12-31", "last_accessed_date": "2023-12-31"}, "hash": "76e194b2637b440a1b1cdf5698cae061524bb4d7a3b73dfc2ba71d268a3f7019", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "dd1adc35-aa10-418c-a564-07dd8f0ff28f", "node_type": "1", "metadata": {"file_path": "data/brandt-no-intro.txt", "file_name": "brandt-no-intro.txt", "file_type": "text/plain", "file_size": 239829, "creation_date": "2023-12-31", "last_modified_date": "2023-12-31", "last_accessed_date": "2023-12-31"}, "hash": "08284b50b09d4e0828264dabd568db1897321a16ca632bf529a82e3ddc29860f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4a52ea30-c9bb-420f-a744-059010702fa2", "node_type": "1", "metadata": {}, "hash": "aa12c10812a5f305153d69b97a10c6e9baa1942fb83f8be2223d2cc3755166a6", "class_name": "RelatedNodeInfo"}}, "hash": "59d239ec13e0fbb3c819dd44cbb44f8b64e5930b2f12111d122c59767ace03c3", "text": "Lastly chapter 6 summarizes the research provided and looks at philosophical considerations regarding this research.  22\n\n\nCopyright statement\n\nThis chapter is in review for publication. The manuscript has been modified to meet formatting requirements.\n\nContribution statement\n\nThe manuscript used as the basis for this chapter was written by me \u2013 Asher Brandt \u2013 with guidance from Dr. Robert B. Laprairie. In silico and in vitro data were collected and analyzed by myself with technical assistance from Dr. Robert B. Laprairie and Dow P. Hurst (University of North Carolina, Greensboro). GTP\uf067S experiments were performed in the laboratory of Dr. Roger Pertwee (University of Aberdeen) and analyzed by Asher Brandt and Dr. Robert B. Laprairie. In vivo experiments were performed with the assistance of Ayat Zagzoog (University of Saskatchewan).\n\nCHAPTER 2 Pharmacological Evaluation of Enantiomerically Separated Positive Allosteric\nModulators of Cannabinoid 1 Receptor, GAT591 and GAT593\n \n2.1 Introduction\n\nThe endogenous cannabinoid system (ECS) is composed of endogenous ligands (e.g. anandamide [AEA] and 2-arachidonoylglycerol [2-AG]), anabolic and catabolic enzymes, and receptors (the predominant receptors being the type 1 and 2 cannabinoid receptors [CB1R, CB2R]).   The ECS is ubiquitous in the human body.  Both CB1R and CB2R are class A G protein-coupled receptors (GPCRs).  CB1R is most-abundant in the brain and central nervous system (CNS) whereas CB2R is most-abundant in cells of the immune system.  88 The primary role of CB1R is to regulate mood, diet, sleep and pain sensation whereas CB2R regulates immune responses.  89 Both receptors are activated by the endogenous ligands AEA and 2-AG.  90 Due to the ubiquitous nature of CB1R and CB2R, the ECS is considered a potential target for a wide array of diseases, but CB1R in particular is considered a target for the treatment of pain and neurological disorders such as epilepsy, Huntington\u2019s disease, and glaucoma.  91 The intoxicating effects of Cannabis represent a major limitation to its use as medicine. The intoxicating effects of Cannabis are due to \u22069 -tetrahydrocannabinol (THC) binding to the orthosteric site of CB1R. It is hypothesized that the intoxicating properties of CB1R activation could be avoided if a drug bound to the allosteric site of the receptor. Allosteric modulators may be positive allosteric modulators (PAMs), negative allosteric modulators (NAMs), or silent allosteric modulators.  92 A PAM enhances the effect of the primary ligand, a NAM reduces the effect of the primary ligand, and a silent allosteric ligand does not affect the pharmacology of the orthosteric ligand.  36 The first described CB1R allosteric modulator was Org27569, which drove the development of indole sulfonamides as potent CB1R NAMs.  93 In an earlier study published by the Laprairie lab94 , we reported on the pharmacology of racemic CB1R allosteric modulators GAT591 and GAT593 (Figure 2-1), wherein we observed these 24 ligands have both allosteric-agonist and positive allosteric modulator (ago-PAM) properties. We found that GAT591 and GAT593 act at allosteric sites due to their ability to enhance the binding of [3H]CP55,940 at CB1R and at the same time modulate the receptor in absence of an orthosteric ligand.  91 Biased agonism describes the ability of a ligand to preferentially activate one signalling pathway compared to another; 92,36 for example G protein- versus \u03b2arrestin-mediated signaling.  93 Previous work has shown that the racemic mixtures GAT591 and GAT593 displayed bias towards Gi/o signaling as compared to \u03b2arrestin, which is correlated with improved cell viability.  91 Additional studies from our group support the idea that G protein bias of PAMs is correlated with improved outcomes in rodent models of Huntington\u2019s disease, pain, and absence epilepsy 95,96,81; whereas \uf062arrestin bias may be correlated with reduced cell viability and increased pathology in animal models of absence epilepsy and Huntington\u2019s disease.  81,97 One of the challenges in developing ligands for GPCRs is biased agonism.", "start_char_idx": 34125, "end_char_idx": 38235, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4a52ea30-c9bb-420f-a744-059010702fa2": {"__data__": {"id_": "4a52ea30-c9bb-420f-a744-059010702fa2", "embedding": null, "metadata": {"file_path": "data/brandt-no-intro.txt", "file_name": "brandt-no-intro.txt", "file_type": "text/plain", "file_size": 239829, "creation_date": "2023-12-31", "last_modified_date": "2023-12-31", "last_accessed_date": "2023-12-31"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "a0eaa9a5-aece-426b-8f20-580de8fb9f35", "node_type": "4", "metadata": {"file_path": "data/brandt-no-intro.txt", "file_name": "brandt-no-intro.txt", "file_type": "text/plain", "file_size": 239829, "creation_date": "2023-12-31", "last_modified_date": "2023-12-31", "last_accessed_date": "2023-12-31"}, "hash": "76e194b2637b440a1b1cdf5698cae061524bb4d7a3b73dfc2ba71d268a3f7019", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "424f8406-2074-4a46-b943-c95f9a7d79e3", "node_type": "1", "metadata": {"file_path": "data/brandt-no-intro.txt", "file_name": "brandt-no-intro.txt", "file_type": "text/plain", "file_size": 239829, "creation_date": "2023-12-31", "last_modified_date": "2023-12-31", "last_accessed_date": "2023-12-31"}, "hash": "59d239ec13e0fbb3c819dd44cbb44f8b64e5930b2f12111d122c59767ace03c3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e1a669e6-7a0a-4bff-bf8a-09398503f04c", "node_type": "1", "metadata": {}, "hash": "9ce965522b9ab9e3559828abf8426c8e1bcc1056b4283fb40f75ae1c9258d366", "class_name": "RelatedNodeInfo"}}, "hash": "aa12c10812a5f305153d69b97a10c6e9baa1942fb83f8be2223d2cc3755166a6", "text": "91 Biased agonism describes the ability of a ligand to preferentially activate one signalling pathway compared to another; 92,36 for example G protein- versus \u03b2arrestin-mediated signaling.  93 Previous work has shown that the racemic mixtures GAT591 and GAT593 displayed bias towards Gi/o signaling as compared to \u03b2arrestin, which is correlated with improved cell viability.  91 Additional studies from our group support the idea that G protein bias of PAMs is correlated with improved outcomes in rodent models of Huntington\u2019s disease, pain, and absence epilepsy 95,96,81; whereas \uf062arrestin bias may be correlated with reduced cell viability and increased pathology in animal models of absence epilepsy and Huntington\u2019s disease.  81,97 One of the challenges in developing ligands for GPCRs is biased agonism.  92 To further understand the molecular mechanism(s) of action and probe for potential enantiospecific interactions, we separated the enantiomers, determined their absolute stereochemistry and conducted a biochemical characterization using cAMP and \uf062arrestin2 assays to determine their allosteric-agonist and PAM activity. Previously we observed the distinct pharmacology between the enantiomers of (\u00b1)-GAT211, where (R)-GAT228 was an allosteric-agonist, (S)-GAT229 showed pure PAM activity at CB1R.  95 In this study we observed that the enantiomers of GAT591 and GAT593 display unique in vitro and in vivo effects that are likely to be associated with their unique modes of binding to CB1R.\n\nFigure 2-1. GAT591 previously studied was separated out into its respective enantiomers (GAT1664 and GAT1665) and GAT593 was separated out into its respective enantiomers (GAT1666 and GAT1667). The difference between GAT1664 and GAT1665 vs GAT1666 and GAT1667 is the position of the fluorine.  Figure 2-2. ORTEP diagram of (+)-GAT1664 (a, CCDC no. 2086717) and (+)-GAT1666 (b, CCDC no. 2086718)\n\n2.2 Experimental Section\n\n2.2.1 In vitro evaluation\n\nCompounds used. Unless otherwise noted, all reagents and chemicals were purchased from SigmaAldrich (Mississauga, ON). CP55,940 and THC were purchased from Cayman (Ann Arbor, MI) and Sigma-Aldrich, respectively. All other tested compounds were obtained from Dr. Ganesh Thakur, Northeastern University. All compounds were initially dissolved in DMSO and diluted in a 10% DMSO solution in PBS. Compounds were added directly to cell culture at the time and concentrations indicated at a final concentration of 0.1% DMSO.  Cell culture. HitHunter (cAMP) and PathHunter (\u03b2arrestin2) CHO-K1 cells stably-expressing human CB1R (CB1R) from DiscoveRx (Eurofins, Freemont, CA) were maintained at 37\u00b0C, 5% CO2 in DMEM/F-12 containing 10% FBS and 1% penicillin/streptomycin. Cell media was changed approximately every 48 h and cell passage number was maintained below 35. In addition, 0.5% geneticin was used for CHO-K1 CB1R HitHunter cAMP cells and 1% geneticin and 0.5% hygromycin b was used for CHO-K1 CB1R PathHunter \u03b2arrestin2 cells.  HitHunter cAMP assay. cAMP inhibition was performed in the presence of 10 \u00b5M forskolin (FSK) using the DiscoveRx HitHunter assay in CHO-K1 CB1R cells. Cells (160,000 cells/well in 96 well plates) were incubated overnight in Opti-MEM (Invitrogen) containing 1% FBS at 37\u00b0C and 5% CO2. Opti-MEM media was removed and replaced with cell assay buffer (DiscoveRx) and then cells were simultaneously treated with 10 \u00b5M FSK and experimental compounds (0.10 nM - 10 \u00b5M) for 90 min. cAMP antibody solution and working detection solutions were the added according to the manufactures protocol (DiscoveRx), and cells were incubated for 60 min at room temperature.", "start_char_idx": 37426, "end_char_idx": 41059, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e1a669e6-7a0a-4bff-bf8a-09398503f04c": {"__data__": {"id_": "e1a669e6-7a0a-4bff-bf8a-09398503f04c", "embedding": null, "metadata": {"file_path": "data/brandt-no-intro.txt", "file_name": "brandt-no-intro.txt", "file_type": "text/plain", "file_size": 239829, "creation_date": "2023-12-31", "last_modified_date": "2023-12-31", "last_accessed_date": "2023-12-31"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "a0eaa9a5-aece-426b-8f20-580de8fb9f35", "node_type": "4", "metadata": {"file_path": "data/brandt-no-intro.txt", "file_name": "brandt-no-intro.txt", "file_type": "text/plain", "file_size": 239829, "creation_date": "2023-12-31", "last_modified_date": "2023-12-31", "last_accessed_date": "2023-12-31"}, "hash": "76e194b2637b440a1b1cdf5698cae061524bb4d7a3b73dfc2ba71d268a3f7019", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4a52ea30-c9bb-420f-a744-059010702fa2", "node_type": "1", "metadata": {"file_path": "data/brandt-no-intro.txt", "file_name": "brandt-no-intro.txt", "file_type": "text/plain", "file_size": 239829, "creation_date": "2023-12-31", "last_modified_date": "2023-12-31", "last_accessed_date": "2023-12-31"}, "hash": "aa12c10812a5f305153d69b97a10c6e9baa1942fb83f8be2223d2cc3755166a6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "08d2fdaf-e724-4186-85cb-bcb1d36bc6d6", "node_type": "1", "metadata": {}, "hash": "97747ab5c4aa5cd4858f0cb8e9b8110e4b13acd73323aa027514c450ed6dcd88", "class_name": "RelatedNodeInfo"}}, "hash": "9ce965522b9ab9e3559828abf8426c8e1bcc1056b4283fb40f75ae1c9258d366", "text": "HitHunter cAMP assay. cAMP inhibition was performed in the presence of 10 \u00b5M forskolin (FSK) using the DiscoveRx HitHunter assay in CHO-K1 CB1R cells. Cells (160,000 cells/well in 96 well plates) were incubated overnight in Opti-MEM (Invitrogen) containing 1% FBS at 37\u00b0C and 5% CO2. Opti-MEM media was removed and replaced with cell assay buffer (DiscoveRx) and then cells were simultaneously treated with 10 \u00b5M FSK and experimental compounds (0.10 nM - 10 \u00b5M) for 90 min. cAMP antibody solution and working detection solutions were the added according to the manufactures protocol (DiscoveRx), and cells were incubated for 60 min at room temperature. cAMP solution A was added according to the manufacturer\u2019s protocol (DiscoveRx) and cells were incubated for an additional 60 minutes at room temperature before 27 chemiluminescence was measured on a Cytation5 plate reader (top read, gain 200, integration time 10 sec). Data are presented as percent maximal CP55,940-dependent inhibition of cAMP accumulation.  PathHunter \u03b2arrestin2 assay. \u03b2arrestin2 recruitment was determined using the CB1R CHO-K1 cell PathHunter assay (DiscoveRx). Cells (160,000 cells/well in 96 well plates) were incubated overnight in Opti-MEM (Invitrogen) containing 1% FBS at 37\u00b0C and 5% CO2. Cells were then simultaneously treated with experimental compounds (0.10 nM - 10 \u00b5M) for 90 min. Detection solution was the added to cells according to the manufacturer\u2019s protocol (DiscoveRx), and cells were incubated for 60 minutes at room temperature. Chemiluminescence was measured on a Cytation5 plate reader (top read, gain 200, integration time 10 sec). Data are presented as percent maximal CP55,940-dependent stimulation or fold over vehicle.  [ 3H]CP55,940 radioligand displacement assay. Previous studies have shown that CB1R PAMs enhance orthosteric agonist binding (e.g. CP55,940).  98 Radioligand binding assays were carried out with 1 nM [3H]CP55,940 in Tris buffer (75 mM Tris-HCl, 12.5 mM MgCl2, 1 mM EDTA, 1% BSA, pH 7.4) with a total assay volume of 200 \u00b5L. The assay began with the addition of transfected CB1R CHO-K1 cell membranes (25 \u00b5g protein per well). The assays were left to equilibrate at room temperature for 2 h before vacuum filtration using a Millipore Sigma 12-well sampling manifold and filter paper that had been soaked in wash buffer. Each reaction well was washed 3 times with a 2 mL aliquot of Tris-binding buffer. The filters were removed then submerged in 5 mL of scintillation fluid (Ultima Gold F, PerkinElmer, Woodbridge ON). Radioactivity was quantified by liquid scintillation spectrometry. Specific binding was defined as the difference between binding that occurred in the presence and in the absence of 1 \u00b5M unlabeled or CP55,940.  Data are presented as percent [3H]CP55,940 bound.  28 [ 35S]GTP\uf067S assay: This assay was conducted in the laboratory of Dr. Roger Pertwee as described in previous reports.  95 To summarize, the assay was completed in the presence of [35S]GTP\u03b3S (0.1 nM), GDP (30 \u00b5M), GTP\u03b3S (30 \u00b5M) using membranes derived from CHO-K1 cells (1 mg/mL) overexpressing CB1R. Assay buffer consisted of 50 mM Tris, 10 mM MgCl2, 100 mM NaCl, 0.2 mM EDTA and 1 mM DTT at pH 7.4. Membranes were incubated at 30\u00b0C for 90 min in a total volume of 500 mL. Reactions were ended by the addition of ice-cold wash buffer (50 mM Tris and 1 mg/mL BSA, pH 7.4) followed by rapid filtration under vacuum through presoaked Whatman GF/B glass-fibre filters in a 24-well sampling manifold (Brandel Cell Harvester; Brandel Inc, Gaithersburg, MD, USA).", "start_char_idx": 40407, "end_char_idx": 43966, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "08d2fdaf-e724-4186-85cb-bcb1d36bc6d6": {"__data__": {"id_": "08d2fdaf-e724-4186-85cb-bcb1d36bc6d6", "embedding": null, "metadata": {"file_path": "data/brandt-no-intro.txt", "file_name": "brandt-no-intro.txt", "file_type": "text/plain", "file_size": 239829, "creation_date": "2023-12-31", "last_modified_date": "2023-12-31", "last_accessed_date": "2023-12-31"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "a0eaa9a5-aece-426b-8f20-580de8fb9f35", "node_type": "4", "metadata": {"file_path": "data/brandt-no-intro.txt", "file_name": "brandt-no-intro.txt", "file_type": "text/plain", "file_size": 239829, "creation_date": "2023-12-31", "last_modified_date": "2023-12-31", "last_accessed_date": "2023-12-31"}, "hash": "76e194b2637b440a1b1cdf5698cae061524bb4d7a3b73dfc2ba71d268a3f7019", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e1a669e6-7a0a-4bff-bf8a-09398503f04c", "node_type": "1", "metadata": {"file_path": "data/brandt-no-intro.txt", "file_name": "brandt-no-intro.txt", "file_type": "text/plain", "file_size": 239829, "creation_date": "2023-12-31", "last_modified_date": "2023-12-31", "last_accessed_date": "2023-12-31"}, "hash": "9ce965522b9ab9e3559828abf8426c8e1bcc1056b4283fb40f75ae1c9258d366", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "701d2f9e-cdd0-4984-9ee1-dc83c5eb2357", "node_type": "1", "metadata": {}, "hash": "2789a830034becc3b1235b4b76e42c98743aab324d900c9a9f108449074e2629", "class_name": "RelatedNodeInfo"}}, "hash": "97747ab5c4aa5cd4858f0cb8e9b8110e4b13acd73323aa027514c450ed6dcd88", "text": "Assay buffer consisted of 50 mM Tris, 10 mM MgCl2, 100 mM NaCl, 0.2 mM EDTA and 1 mM DTT at pH 7.4. Membranes were incubated at 30\u00b0C for 90 min in a total volume of 500 mL. Reactions were ended by the addition of ice-cold wash buffer (50 mM Tris and 1 mg/mL BSA, pH 7.4) followed by rapid filtration under vacuum through presoaked Whatman GF/B glass-fibre filters in a 24-well sampling manifold (Brandel Cell Harvester; Brandel Inc, Gaithersburg, MD, USA). Reaction wells were washed six times with a 1.2 mL aliquot of Tris-binding buffer. Filters were subsequently oven-dried for 60 min and placed in 3 mL of scintillation fluid (Ultima Gold XR, PerkinElmer). Bound radioactivity was determined by liquid scintillation counting. Basal [35S]GTP\u03b3S binding was determined in the presence of 20 mM GDP without any compounds present. Non-specific binding was determined in the presence of 10 mM GTP\u03b3S.\n\n2.2.2 In vivo evaluation\n\nTriad assessment in mice. Male C57BL/6 mice (Charles River, Senneville, QC) between 4 and 7 months of age were used for these studies. Animals were group housed at the Laboratory Animal Services Unit (LASU) at the University of Saskatchewan (3-5 animals/cage) with a standard 12:12 light-dark cycle, ad libitum access to food and water, and environmental enrichment. Mice were randomly assigned to receive either vehicle or 0.1, 1, 3 or 10 mg/kg compound as indicated in figure legends (n = 5 \u2013 6 mice/treatment group). Compounds administered intraperitoneally (i.p.)  were prepared in vehicle [ethanol and cremaphor in saline (1:1:18)]. Catalepsy was assessed in the bar holding assay 5 min after drug administration. Mice were placed so that their forepaws clasped 29 a 0.7 cm ring clamp positioned 4.5 cm above the surface of the testing space.  99 The length of time the ring was held was recorded in seconds. The trial ended if the mouse turned its head or body or made 3 consecutive escape attempts to a maximum of 60 sec. Body temperature was measured by rectal thermometer 15 min after drug administration. Anti-nociceptive effects were measured in the warm water (52\u00b12\u00b0C) tail-flick test 20 min after drug administration. Response in this case was defined by the removal of the tail from the warm water, with a maximal response time of 20 sec. Catalepsy and tail flick data are presented as percent maximum possible effect (MPE).  Compounds were administered at the doses indicated. Experimenters were blinded to treatment for all behavioral assessments and analyses. Animals were purchased, rather than bred, to reduce animal numbers. In all cases, experiments were performed with the approval of the University Animal Care Committee (UACC) at the University of Saskatchewan and are in keeping with the guidelines of the Canadian Council on Animal Care (CCAC) and the ARRIVE guidelines.  100\n\n2.2.3 In silico evaluation\n\nMolecular docking. A conformational analysis was performed on GAT1664, GAT1665, GAT1666 and GAT1667 using Spartan \u201918 V1.4.5.  101 Molecular mechanics were applied to each rotamer to obtain a local minimum.  101 After duplicates were eliminated, HF/6-31G* was applied to the remaining rotamers to obtain the global minimum energy conformation.  101 CB1R model: The CB1R model has been described in detail83, but in brief: The CB1R model used in this study was based on the CB1R activated state crystal structure (PDB-ID: 5XRA) and the cryo-EM CB1R/Gi bound structure (PDB-ID: 6N4B). Structures were prepared with the Protein Preparation protocol102, mutations in the 5XRA structure were returned to wild-type (WT), and both models were inspected for close contacts and crystal packing effects. Modification of the 5XRA structure to create the CB1R model involved calculating low free energy conformations for 30 TMH2/7 to accommodate mutation data for S3837.39, F2.61, F2.64 54,103.", "start_char_idx": 43510, "end_char_idx": 47348, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "701d2f9e-cdd0-4984-9ee1-dc83c5eb2357": {"__data__": {"id_": "701d2f9e-cdd0-4984-9ee1-dc83c5eb2357", "embedding": null, "metadata": {"file_path": "data/brandt-no-intro.txt", "file_name": "brandt-no-intro.txt", "file_type": "text/plain", "file_size": 239829, "creation_date": "2023-12-31", "last_modified_date": "2023-12-31", "last_accessed_date": "2023-12-31"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "a0eaa9a5-aece-426b-8f20-580de8fb9f35", "node_type": "4", "metadata": {"file_path": "data/brandt-no-intro.txt", "file_name": "brandt-no-intro.txt", "file_type": "text/plain", "file_size": 239829, "creation_date": "2023-12-31", "last_modified_date": "2023-12-31", "last_accessed_date": "2023-12-31"}, "hash": "76e194b2637b440a1b1cdf5698cae061524bb4d7a3b73dfc2ba71d268a3f7019", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "08d2fdaf-e724-4186-85cb-bcb1d36bc6d6", "node_type": "1", "metadata": {"file_path": "data/brandt-no-intro.txt", "file_name": "brandt-no-intro.txt", "file_type": "text/plain", "file_size": 239829, "creation_date": "2023-12-31", "last_modified_date": "2023-12-31", "last_accessed_date": "2023-12-31"}, "hash": "97747ab5c4aa5cd4858f0cb8e9b8110e4b13acd73323aa027514c450ed6dcd88", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "267009fd-b62c-49da-ad26-725119870165", "node_type": "1", "metadata": {}, "hash": "6478e6575e28f9c4719084126ab3c5af2e5a6ec332b0ddfcf8b76a51f7870f04", "class_name": "RelatedNodeInfo"}}, "hash": "2789a830034becc3b1235b4b76e42c98743aab324d900c9a9f108449074e2629", "text": "101 CB1R model: The CB1R model has been described in detail83, but in brief: The CB1R model used in this study was based on the CB1R activated state crystal structure (PDB-ID: 5XRA) and the cryo-EM CB1R/Gi bound structure (PDB-ID: 6N4B). Structures were prepared with the Protein Preparation protocol102, mutations in the 5XRA structure were returned to wild-type (WT), and both models were inspected for close contacts and crystal packing effects. Modification of the 5XRA structure to create the CB1R model involved calculating low free energy conformations for 30 TMH2/7 to accommodate mutation data for S3837.39, F2.61, F2.64 54,103. In addition, because of loop compression in the 5XRA structure, the IC1 loop from the 6N4B Gi bound structure was used in the model. TMH4 in the 5XRA CB1R R* structure has tight crystal contacts on its IC end with TMH1 of another bundle because of antiparallel packing. For this reason, the conformation of TMH4 in the 6N4B Gi bound structure was used in the model. Modeller was used to remodel the EC3 loop (D6.58 to T7.33) and allow K(373) to interact with D2.63, consistent with mutation results.  104,105 Modeller was also used to extend and model the N-terminus to S(88) with inclusion of the C(98) to C(107) disulfide bridge.  106,107 The receptor/ligand complex was energy minimized in Prime.  102 The Prime implicit membrane functionality was employed. Hydrophilic residues facing the binding crevice and within the low dielectric region of the implicit membrane were excluded from the low dielectric via exclusion spheres placed on each residue. The Generalized Born/Surface Area (GB/SA) continuum solvation model for water was used with the dielectric set to 80 outside of the implicit membrane region and 2 within. A truncated Newton conjugate gradient minimization was performed using the OPLS3e force field for one iteration up to a maximum of 1000 steps and with a 0.1 kcal/mol gradient endpoint. Constraints of 1 kcal/mol were placed on the C-alpha atoms of residues R3.50, Y5.58, L6.33, and Y7.53 to prevent the intracellular opening present in the R* structures from closing during the minimization.  MMC calculations: Confirmation of the binding site by Metropolis Monte Carlo calculations had been published previously on fragments of GAT228/229.  83 We repeated these calculations on identically designed fragments from GAT591/593 and found similar results. Docking: Once the two sites were confirmed, the structures of GAT1664-7 were docked in the intracellular TMH1/2/4 site with H2.41, F4.46, and W4.50 used as direct interaction sites. GAT1664 and GAT1666 were docked in the TM2/3/ECL1 site with Y2.59 and D2.63 as direct interaction sites. In addition, after 31 extensive previously published molecular dynamics calculations on unfluorinated versions of the GAT compounds (GAT1600-3), R(148) was modeled to interact directly with the carbonyl oxygens of the last turn of TMH1 and not the nitro group within the compounds.  108 The receptor/ligand complexes were energy minimized in Prime.  102 The Prime implicit membrane functionality was employed. Hydrophilic residues facing the binding crevice and within the low dielectric region of the implicit membrane were excluded from the low dielectric via exclusion spheres placed on each residue. The Generalized Born/Surface Area (GB/SA) continuum solvation model for water was used with the dielectric set to 80 outside of the implicit membrane region and 1 within. A truncated Newton conjugate gradient minimization was performed using the OPLS3e force field for 1 iteration, up to a maximum of 1000 steps and with a 0.1 kcal/mol gradient endpoint. Constraints of 1 kcal/mol placed on the c-alpha atoms of residues R3.50, Y5.58, L6.33, and Y7.53 were set to prevent the intracellular opening from closing during the minimization. The resulting docks were refined with the Induced Fit protocol.  102 The Glide box size was set to 12 \u00c53 centered on the ligand and the SP docking algorithm employed.", "start_char_idx": 46711, "end_char_idx": 50720, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "267009fd-b62c-49da-ad26-725119870165": {"__data__": {"id_": "267009fd-b62c-49da-ad26-725119870165", "embedding": null, "metadata": {"file_path": "data/brandt-no-intro.txt", "file_name": "brandt-no-intro.txt", "file_type": "text/plain", "file_size": 239829, "creation_date": "2023-12-31", "last_modified_date": "2023-12-31", "last_accessed_date": "2023-12-31"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "a0eaa9a5-aece-426b-8f20-580de8fb9f35", "node_type": "4", "metadata": {"file_path": "data/brandt-no-intro.txt", "file_name": "brandt-no-intro.txt", "file_type": "text/plain", "file_size": 239829, "creation_date": "2023-12-31", "last_modified_date": "2023-12-31", "last_accessed_date": "2023-12-31"}, "hash": "76e194b2637b440a1b1cdf5698cae061524bb4d7a3b73dfc2ba71d268a3f7019", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "701d2f9e-cdd0-4984-9ee1-dc83c5eb2357", "node_type": "1", "metadata": {"file_path": "data/brandt-no-intro.txt", "file_name": "brandt-no-intro.txt", "file_type": "text/plain", "file_size": 239829, "creation_date": "2023-12-31", "last_modified_date": "2023-12-31", "last_accessed_date": "2023-12-31"}, "hash": "2789a830034becc3b1235b4b76e42c98743aab324d900c9a9f108449074e2629", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "370b0028-229f-4784-9254-d7c7919356f1", "node_type": "1", "metadata": {}, "hash": "ba964cca80af22e0afa46b712875e71bfc41ce1469fad77457a23f545de0658d", "class_name": "RelatedNodeInfo"}}, "hash": "6478e6575e28f9c4719084126ab3c5af2e5a6ec332b0ddfcf8b76a51f7870f04", "text": "The Generalized Born/Surface Area (GB/SA) continuum solvation model for water was used with the dielectric set to 80 outside of the implicit membrane region and 1 within. A truncated Newton conjugate gradient minimization was performed using the OPLS3e force field for 1 iteration, up to a maximum of 1000 steps and with a 0.1 kcal/mol gradient endpoint. Constraints of 1 kcal/mol placed on the c-alpha atoms of residues R3.50, Y5.58, L6.33, and Y7.53 were set to prevent the intracellular opening from closing during the minimization. The resulting docks were refined with the Induced Fit protocol.  102 The Glide box size was set to 12 \u00c53 centered on the ligand and the SP docking algorithm employed. Residues within 5 \u00c5 of the docked ligand were included in the Prime refinement stage, except in the case of the TM2/3 PAM site where S2.60 and K3.28 were excluded based on mutation data.  54,109 The implicit membrane previously used during the initial Prime minimization was employed here as well.  MMGBSA analysis: Each of the GAT1664-7 ligand receptor complexes were evaluated via MMGBSA. This was the scoring function used to evaluate each complex and not glide scores.  This method is used to estimate the relative binding affinities for a list of ligands (reported in kcal/mol). As the MMGBSA binding energies are approximate free energies of binding, a more negative value indicated stronger binding. For this computation the VSGB solvation model was employed while the chosen force field OPLS4 was used.  32\n\n2.2.4 Statistical Analysis\n\nData related to EC50 and Emax in Figure 2-3 and Figure 2-5 were obtained with nonlinear regression models (4-parameter model, GraphPad Prism 9.0, San Diego, CA). Results were calculated as percent response relative to the reference agonist CP55,940 (Figure 2-3), percent [ 3H]CP55,940 bound (Figure 2-5a), or percent stimulation above baseline (Figure 2-5b,c).  Significance was determined by non-overlapping 95% C.I. or by one-way ANOVA followed by Bonferroni\u2019s post-hoc test. p < 0.05 was considered significant. In order to estimate bias, concentration-response curves were globally fit to the operational model (Eq. 2-1; Prism).  110 In the operational model, E is efficacy, Emax is the maximum response, [A] is agonist concentration, n is the Hill Slope, \u03c4 is the transducer constant (i.e., the inverse of the fraction of receptors that must be occupied to achieve a half-maximal response), and KA is the estimated agonist affinity.111 To best fit data, the transduction coefficient log(\u03c4/KA) (i.e. logR), n, and EMax were shared and logKA was constrained between 0 and -15. In cases where a compound did not achieve a clear plateau in the concentration-response, Emax was set to the maximum response observed and EC50 was set to 10,000 nM. Relative agonist activity compared to a reference agonist (CP55,940) was calculated as show in Eq. 2-2.  111 \u2206logR values were compared for test compounds between assays measuring inhibition of cAMP and \u03b2arrestin2 recruitment to determine bias factor (\u2206\u2206logR) (Eq. 2-3).  112 Data related to Figure 2-6 was analyzed via a two-way mixed ANOVA. This was implemented to analyze the main effect of drug treatments and main effects of groups as well as interaction between drug treatments and group. Bonferroni\u2019s post-hoc test was performed for all pairwise comparisons. GraphPad Prism 9.0 was used to analyze in vivo data and p < 0.05 was considered to be statistically significant. Data are expressed as mean \u00b1 SEM of at least 6 independent experiments.\n\n\ud835\udc38 = \ud835\udc38\ud835\udc5a\ud835\udc4e\ud835\udc65[\ud835\udc34] \ud835\udc5b \ud835\udf0f \ud835\udc5b [\ud835\udc34] \ud835\udc5b\ud835\udf0f \ud835\udc5b + ([\ud835\udc34] + \ud835\udc3e\ud835\udc34 ) \ud835\udc5b Eq.", "start_char_idx": 50018, "end_char_idx": 53609, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "370b0028-229f-4784-9254-d7c7919356f1": {"__data__": {"id_": "370b0028-229f-4784-9254-d7c7919356f1", "embedding": null, "metadata": {"file_path": "data/brandt-no-intro.txt", "file_name": "brandt-no-intro.txt", "file_type": "text/plain", "file_size": 239829, "creation_date": "2023-12-31", "last_modified_date": "2023-12-31", "last_accessed_date": "2023-12-31"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "a0eaa9a5-aece-426b-8f20-580de8fb9f35", "node_type": "4", "metadata": {"file_path": "data/brandt-no-intro.txt", "file_name": "brandt-no-intro.txt", "file_type": "text/plain", "file_size": 239829, "creation_date": "2023-12-31", "last_modified_date": "2023-12-31", "last_accessed_date": "2023-12-31"}, "hash": "76e194b2637b440a1b1cdf5698cae061524bb4d7a3b73dfc2ba71d268a3f7019", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "267009fd-b62c-49da-ad26-725119870165", "node_type": "1", "metadata": {"file_path": "data/brandt-no-intro.txt", "file_name": "brandt-no-intro.txt", "file_type": "text/plain", "file_size": 239829, "creation_date": "2023-12-31", "last_modified_date": "2023-12-31", "last_accessed_date": "2023-12-31"}, "hash": "6478e6575e28f9c4719084126ab3c5af2e5a6ec332b0ddfcf8b76a51f7870f04", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b7857807-c303-450e-a91d-a1063c15668b", "node_type": "1", "metadata": {}, "hash": "1fc5cd2ffc66e4c4d4b892652e33cb823a0689a1aa84de52920bf5053eb06c8a", "class_name": "RelatedNodeInfo"}}, "hash": "ba964cca80af22e0afa46b712875e71bfc41ce1469fad77457a23f545de0658d", "text": "2-3).  112 Data related to Figure 2-6 was analyzed via a two-way mixed ANOVA. This was implemented to analyze the main effect of drug treatments and main effects of groups as well as interaction between drug treatments and group. Bonferroni\u2019s post-hoc test was performed for all pairwise comparisons. GraphPad Prism 9.0 was used to analyze in vivo data and p < 0.05 was considered to be statistically significant. Data are expressed as mean \u00b1 SEM of at least 6 independent experiments.\n\n\ud835\udc38 = \ud835\udc38\ud835\udc5a\ud835\udc4e\ud835\udc65[\ud835\udc34] \ud835\udc5b \ud835\udf0f \ud835\udc5b [\ud835\udc34] \ud835\udc5b\ud835\udf0f \ud835\udc5b + ([\ud835\udc34] + \ud835\udc3e\ud835\udc34 ) \ud835\udc5b Eq. 2-1 \u2206\ud835\udc59\ud835\udc5c\ud835\udc54\ud835\udc45 = \ud835\udc59\ud835\udc5c \ud835\udc54(\ud835\udf0f\u2044\ud835\udc3e\ud835\udc34 )\ud835\udc47\ud835\udc52\ud835\udc60\ud835\udc61\ud835\udc50\ud835\udc5c\ud835\udc5a\ud835\udc5d\ud835\udc5c\ud835\udc62\ud835\udc5b\ud835\udc51 \u2212 \ud835\udc59\ud835\udc5c\ud835\udc54(\ud835\udf0f\u2044\ud835\udc3e\ud835\udc34 )\ud835\udc45\ud835\udc52\ud835\udc53\ud835\udc50\ud835\udc5c\ud835\udc5a\ud835\udc5d\ud835\udc5c\ud835\udc62\ud835\udc5b\ud835\udc51 Eq. 2-2 \ud835\udc59\ud835\udc5c\ud835\udc54\ud835\udc4f\ud835\udc56\ud835\udc4e\ud835\udc60 = \u2206\u2206\ud835\udc59\ud835\udc5c\ud835\udc54\ud835\udc45 = \u2206\u2206\ud835\udc59\ud835\udc5c\ud835\udc54 (\ud835\udf0f\u2044\ud835\udc3e\ud835\udc34 )\ud835\udc451\u2212\ud835\udc452 = \u2206\ud835\udc59\ud835\udc5c\ud835\udc54(\ud835\udf0f\u2044\ud835\udc3e\ud835\udc34 )\ud835\udc451 \u2212 \u2206\ud835\udc59\ud835\udc5c\ud835\udc54(\ud835\udf0f\u2044\ud835\udc3e\ud835\udc34 )\ud835\udc452 Eq. 2-3\n\n2.3 Results and Discussion\n\n2.3.1 Synthesis, chiral separation and absolute stereochemistry determination\n\nGAT591 and GAT593 were synthesized on a multigram scale in the laboratory of Dr. Ganesh Thakur (Northeastern University) using our previously published method.  95 Both enantiomers of each compound were separated in high optical purity (>99%) using superfluid chiral HPLC (for details see Supplementary Info 2.5). The absolute stereochemistry of (+)-GAT1664 and (+)- GAT1666 was determined by single-crystal X-ray diffraction technique (Figure 2-2) and was found to be \u201cS\u201d for both of these enantiomers (Figure 2-2). Based on this study, we can predict the absolute stereochemistry of each opposite enantiomers, (-)-GAT1665 and (-)-GAT1667 as \u201cR\u201d (Figure 2-1 and Figure 2-2) 2.3.2 In vitro evaluation Our in vitro study explored CB1R-dependent modulation of cAMP inhibition and \u03b2arrestin2 recruitment in CHO-K1 cells stably-expressing CB1R with or without CP55,940. Inhibition of cAMP accumulation is Gi/o-protein mediated whereas recruitment of \u03b2arrestin2 is G protein independent.  113 In a previous paper, GAT591 and GAT593 displayed mixed agonist and PAM (i.e.  ago-PAM) activity.  95 The compounds GAT591 and GAT593 contain a 50:50 racemic mixture of both R and S enantiomers. In this paper each enantiomer was investigated to determine which enantiomer had agonist activity and which had the PAM activity, as we previously observed these 34 properties to be enantiomerically distinct in the compounds GAT211, GAT228, and GAT229.  82 Separating GAT591 and GAT593 into their respective enantiomers gave GAT1664, GAT1665, GAT1666 and GAT1667 (Figure 2-1).  All enantiomers displayed G protein-mediated agonist activity at CB1R as shown by their ability to inhibit cAMP in the absence of an orthosteric agonist (Figure 2-3a). Similarly, all 4 compounds displayed activity consistent with positive allosteric modulation of CB1R in the presence of the orthosteric agonist CP55,940 in the cAMP assay (Figure 2-3d).", "start_char_idx": 53076, "end_char_idx": 55777, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b7857807-c303-450e-a91d-a1063c15668b": {"__data__": {"id_": "b7857807-c303-450e-a91d-a1063c15668b", "embedding": null, "metadata": {"file_path": "data/brandt-no-intro.txt", "file_name": "brandt-no-intro.txt", "file_type": "text/plain", "file_size": 239829, "creation_date": "2023-12-31", "last_modified_date": "2023-12-31", "last_accessed_date": "2023-12-31"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "a0eaa9a5-aece-426b-8f20-580de8fb9f35", "node_type": "4", "metadata": {"file_path": "data/brandt-no-intro.txt", "file_name": "brandt-no-intro.txt", "file_type": "text/plain", "file_size": 239829, "creation_date": "2023-12-31", "last_modified_date": "2023-12-31", "last_accessed_date": "2023-12-31"}, "hash": "76e194b2637b440a1b1cdf5698cae061524bb4d7a3b73dfc2ba71d268a3f7019", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "370b0028-229f-4784-9254-d7c7919356f1", "node_type": "1", "metadata": {"file_path": "data/brandt-no-intro.txt", "file_name": "brandt-no-intro.txt", "file_type": "text/plain", "file_size": 239829, "creation_date": "2023-12-31", "last_modified_date": "2023-12-31", "last_accessed_date": "2023-12-31"}, "hash": "ba964cca80af22e0afa46b712875e71bfc41ce1469fad77457a23f545de0658d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "37406ad9-817c-43d4-aa71-f5cf3a6c0830", "node_type": "1", "metadata": {}, "hash": "2d6a600fe22c25865b245e2e2dbdf57ee8fe539bd5fbf52b5f264470366bc5cd", "class_name": "RelatedNodeInfo"}}, "hash": "1fc5cd2ffc66e4c4d4b892652e33cb823a0689a1aa84de52920bf5053eb06c8a", "text": "In this paper each enantiomer was investigated to determine which enantiomer had agonist activity and which had the PAM activity, as we previously observed these 34 properties to be enantiomerically distinct in the compounds GAT211, GAT228, and GAT229.  82 Separating GAT591 and GAT593 into their respective enantiomers gave GAT1664, GAT1665, GAT1666 and GAT1667 (Figure 2-1).  All enantiomers displayed G protein-mediated agonist activity at CB1R as shown by their ability to inhibit cAMP in the absence of an orthosteric agonist (Figure 2-3a). Similarly, all 4 compounds displayed activity consistent with positive allosteric modulation of CB1R in the presence of the orthosteric agonist CP55,940 in the cAMP assay (Figure 2-3d). Comparing Figure 2-3a to Figure 2-3d, the studied GAT compounds were more efficacious as PAMs but display allosteric agonist activity. As an agonist, GAT1666 displayed the greatest efficacy, and GAT1667 displayed the greatest efficacy at inhibiting cAMP as a PAM. All enantiomers displayed low nanomolar potency as agonists with no statistical difference among the compounds (Figure 2-3). Both R-enantiomers (GAT1665 and GAT1667) displayed greater PAM potency and efficacy than the S-enantiomers (GAT1664 and GAT1666), with GAT1667 being the most-potent and efficacious (Figure 2-3d).  These observations are in keeping with our earlier findings with the parent racemic ligands wherein PAM activity is predominantly attributable to GAT229, which shares the same spatial orientation as GAT1665 and GAT1667, and agonist activity is predominantly attributable to GAT228, which shares the same spatial orientation as GAT1664 and GAT1666.  82 Both GAT1665 and GAT1667 recruited \u03b2arrestin2 as low-potency agonists and PAMs at CB1R (Figure 2-3e). GAT1664 did not recruit \u03b2arrestin2 to CB1R while GAT1666 displayed a weak ability to do so as an agonist (Figure 2-3b,e). This suggest that as agonists, GAT1665 and GAT1667 (the R-enantiomers) recruit \u03b2arrestin2.  From these data, bias (\u2206\u2206logR) was estimated between cAMP inhibition and \u03b2arrestin2 recruitment (Figure 2-3c,f). In instances where Emax for \u03b2arrestin2 was not reached as shown by a 35 clear plateau in data, Emax was set to the maximum response observed and EC50 was set to 10,000 nM to provide some estimate of bias. As an agonist, GAT1664 displayed no activity for \u03b2arrestin2 recruitment and calculations of \u2206\u2206logR are therefore not possible for this compound which appears to heavily favour G protein-dependent inhibition of cAMP (Figure 2-3c). GAT1666 displayed signaling bias towards cAMP inhibition (Figure 2-3c). GAT1665 did not display significant signaling bias although its potency and efficacy generally favored cAMP inhibition (Figure 2-3).  GAT1667 did display signaling bias for the inhibition of cAMP as an agonist (Figure 2-3). As PAMs, GAT1664 and GAT1666 displayed no activity in the \u03b2arrestin2 recruitment assay and therefore calculations of \u2206\u2206logR are not possible (Figure 2-3f). GAT1665 and GAT1667 displayed signaling bias towards cAMP inhibition relative to \u03b2arrestin2 recruitment (Figure 2-3f).  The parent compound GAT229 shares the same spatial orientation as GAT1665 and GAT1667 and is also a cAMP inhibition-biased PAM.  82 Therefore, these data confirm previous observations that this scaffold\u2019s spatial orientation promotes G protein-biased PAM activity and extends earlier reports to demonstrate increased potency and efficacy of fluorine-substituted ligands as compared to parent compounds.  82 36 37 38 Figure 2-3. Assessment of GAT1664, GAT1665. GAT1666, and GAT1667 signaling. CB1R CHO-K1 were treated with 0.10 nM \u2013 10 \u00b5M GAT compounds \u00b1 100 nM CP55,940.", "start_char_idx": 55046, "end_char_idx": 58722, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "37406ad9-817c-43d4-aa71-f5cf3a6c0830": {"__data__": {"id_": "37406ad9-817c-43d4-aa71-f5cf3a6c0830", "embedding": null, "metadata": {"file_path": "data/brandt-no-intro.txt", "file_name": "brandt-no-intro.txt", "file_type": "text/plain", "file_size": 239829, "creation_date": "2023-12-31", "last_modified_date": "2023-12-31", "last_accessed_date": "2023-12-31"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "a0eaa9a5-aece-426b-8f20-580de8fb9f35", "node_type": "4", "metadata": {"file_path": "data/brandt-no-intro.txt", "file_name": "brandt-no-intro.txt", "file_type": "text/plain", "file_size": 239829, "creation_date": "2023-12-31", "last_modified_date": "2023-12-31", "last_accessed_date": "2023-12-31"}, "hash": "76e194b2637b440a1b1cdf5698cae061524bb4d7a3b73dfc2ba71d268a3f7019", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b7857807-c303-450e-a91d-a1063c15668b", "node_type": "1", "metadata": {"file_path": "data/brandt-no-intro.txt", "file_name": "brandt-no-intro.txt", "file_type": "text/plain", "file_size": 239829, "creation_date": "2023-12-31", "last_modified_date": "2023-12-31", "last_accessed_date": "2023-12-31"}, "hash": "1fc5cd2ffc66e4c4d4b892652e33cb823a0689a1aa84de52920bf5053eb06c8a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "79f04175-06e1-4be6-a6a5-87fe45e0a8d0", "node_type": "1", "metadata": {}, "hash": "b8bbc656f6cf3fbbfd4debc894e052dc5c29faaf7548827daed1fb4faa943a04", "class_name": "RelatedNodeInfo"}}, "hash": "2d6a600fe22c25865b245e2e2dbdf57ee8fe539bd5fbf52b5f264470366bc5cd", "text": "GAT1665 and GAT1667 displayed signaling bias towards cAMP inhibition relative to \u03b2arrestin2 recruitment (Figure 2-3f).  The parent compound GAT229 shares the same spatial orientation as GAT1665 and GAT1667 and is also a cAMP inhibition-biased PAM.  82 Therefore, these data confirm previous observations that this scaffold\u2019s spatial orientation promotes G protein-biased PAM activity and extends earlier reports to demonstrate increased potency and efficacy of fluorine-substituted ligands as compared to parent compounds.  82 36 37 38 Figure 2-3. Assessment of GAT1664, GAT1665. GAT1666, and GAT1667 signaling. CB1R CHO-K1 were treated with 0.10 nM \u2013 10 \u00b5M GAT compounds \u00b1 100 nM CP55,940. (a) cAMP inhibition of GAT compounds as agonists, (b) \u03b2arrestin2 recruitment of GAT compounds as agonists, (d) cAMP inhibition of GAT compounds as PAMs in the presence of 100 nM CP55,940, and (e) \u03b2arrestin2 recruitment of GAT compounds as PAMs in the presence of 100 nM CP55,940.  (a,b,d,e) cAMP inhibition and \u03b2arrestin2 recruitment data are expressed as % CP55,940 max. Data were fit to a nonlinear regression (4-parameter model, GraphPad v. 9.0) to determine EC50 and Emax. Data are mean \u00b1 SEM (Emax) or 95% CI (EC50); n = 4 - 12 independent experiments 39 performed in triplicate. *p < 0.05 compared to CP55,940 as determined by one-way ANOVA followed by Bonferroni\u2019s post-hoc test or non-overlapping 95% CI. (c,f) Concentration-response data were fit to the operational model of Black and Leff (1983) (GraphPad v. 9.0). Data are mean with 95% CI. *p < 0.05 compared to 0 as determined by non-overlapping 95% CI; n = 4 - 6 (c) Agonist bias [\u2206\u2206logR (cAMP \u2013 \u03b2arrestin2)] between cAMP inhibition and \u03b2arrestin2 recruitment.  (f) PAM bias [\u2206\u2206logR (cAMP \u2013 \u03b2arrestin2)] between cAMP inhibition and \u03b2arrestin2 recruitment.  40 In the previous set of experiments, we determined the agonist and PAM activity of compounds in the \u03b2arrestin2 recruitment assay was attributed to the R-enantiomers GAT1665 and GAT1667 while the S-enantiomers showed little (GAT1666) to no (GAT1664) agonist or PAM activity in the \u03b2arrestin2 recruitment assay. Due to this, we sought to understand whether these agonist effects could be reversed using the inverse agonist SR141716A. Co-treatment of CHO-K1 CB1R cells with 1 \u00b5M GAT1665 or GAT1667 and increasing concentrations of SR141716A resulted in an SR141716A concentration-dependent decrease in \u03b2arrestin2 recruitment (Figure 2-4). Therefore, the orthosteric inverse agonist SR141716A was able to prevent the agonist activity of the 2 putative allosteric ligands, suggesting an overlap in either the physical binding sites of these ligands or their functional interactions within the receptor or both.  41 -10 -9 -8 -7 -6 -5 0 5 10 15 Log[SR141716A], (M) \uf062arrestin2 recruitment (Fold over vehicle) 1 \u00b5M CP55,940 + SR141716A 1 \u00b5M GAT1665 + SR141716A 1 \u00b5M GAT1667 + SR141716A IC50 (nM) 95% C.I. Emin \u00b1 S.E.M. 580 (320 - 890) 1.0 \u00b1 0.06 29 (13 - 64)* 1.3 \u00b1 0.08 66 (31 - 130)* 1.2 \u00b1 0.07 Figure 2-4. CB1R CHO-K1 cells were treated with 0.10 nM \u2013 10 \u00b5M SR141716A + 1 \u00b5M CP55,940, GAT1665, or GAT1667. Data are expressed as fold over the vehicle.", "start_char_idx": 58032, "end_char_idx": 61191, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "79f04175-06e1-4be6-a6a5-87fe45e0a8d0": {"__data__": {"id_": "79f04175-06e1-4be6-a6a5-87fe45e0a8d0", "embedding": null, "metadata": {"file_path": "data/brandt-no-intro.txt", "file_name": "brandt-no-intro.txt", "file_type": "text/plain", "file_size": 239829, "creation_date": "2023-12-31", "last_modified_date": "2023-12-31", "last_accessed_date": "2023-12-31"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "a0eaa9a5-aece-426b-8f20-580de8fb9f35", "node_type": "4", "metadata": {"file_path": "data/brandt-no-intro.txt", "file_name": "brandt-no-intro.txt", "file_type": "text/plain", "file_size": 239829, "creation_date": "2023-12-31", "last_modified_date": "2023-12-31", "last_accessed_date": "2023-12-31"}, "hash": "76e194b2637b440a1b1cdf5698cae061524bb4d7a3b73dfc2ba71d268a3f7019", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "37406ad9-817c-43d4-aa71-f5cf3a6c0830", "node_type": "1", "metadata": {"file_path": "data/brandt-no-intro.txt", "file_name": "brandt-no-intro.txt", "file_type": "text/plain", "file_size": 239829, "creation_date": "2023-12-31", "last_modified_date": "2023-12-31", "last_accessed_date": "2023-12-31"}, "hash": "2d6a600fe22c25865b245e2e2dbdf57ee8fe539bd5fbf52b5f264470366bc5cd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7cf6ad74-5796-4e7b-a5db-a597641b605f", "node_type": "1", "metadata": {}, "hash": "8e981ec713cc20426637a2289dc03ad3375f0cbf59b7cf4cc1bbd0f7a455240d", "class_name": "RelatedNodeInfo"}}, "hash": "b8bbc656f6cf3fbbfd4debc894e052dc5c29faaf7548827daed1fb4faa943a04", "text": "Emin \u00b1 S.E.M. 580 (320 - 890) 1.0 \u00b1 0.06 29 (13 - 64)* 1.3 \u00b1 0.08 66 (31 - 130)* 1.2 \u00b1 0.07 Figure 2-4. CB1R CHO-K1 cells were treated with 0.10 nM \u2013 10 \u00b5M SR141716A + 1 \u00b5M CP55,940, GAT1665, or GAT1667. Data are expressed as fold over the vehicle. Data were fit to a nonlinear regression (4-parameter model, GraphPad v. 9.0) to determine EC50 and Emax. Data are mean \u00b1 SEM (Emax) or 95% CI (EC50); n \u2265 6 independent experiments performed in triplicate. *p < 0.05 compared to CP55,940 as determined by one-way ANOVA followed by Bonferroni\u2019s posthoc test or non-overlapping 95% CI.  42 Next, we sought to assess the ability of these compounds to modulate orthosteric agonist binding to CB1R. All enantiomers studied augmented [3H]CP55,940 binding, consistent with their proposed PAM activity, with the R-enantiomers GAT1665 and to a greater extent GAT1667 increasing [3H]CP55,940 binding (Figure 2-5). GAT1667 displayed the highest affinity among the enantiomers tested (KD = 28 [15 \u2013 52] nM). Enantiomers were also tested for their ability to promote G protein coupling in the GTP\uf067S assay (Figure 2-5b,c). All of the enantiomers tested increased G protein coupling alone (i.e. in the absence of the orthosteric agonist CP55,940) with the R-enantiomers GAT1665 and GAT1667 being more potent than the S-enantiomers and GAT1667 in particular displaying the greatest potency (EC50 = 8.0 [3.4 \u2013 17] nM) (Figure 2-5b).  GAT1666 displayed a lower efficacy than other compounds tested (Figure 2-5b). When 1 \uf06dM of each enantiomer was tested in the presence of CP55,940 each enantiomer augmented G protein coupling in the presence of 1 and 10 nM, consistent with positive allosteric modulation (Figure 2-5c). The stimulatory activity of these enantiomers at 1 \uf06dM ablated the concentration-response curve for these experiments; however no difference in maximum effect was observed. Consistent with earlier observations, GAT1667 produced the largest increase in G protein coupling among the enantiomers tested here (Figure 2-5c). Therefore, all enantiomers tested were able to enhance CP55,940 binding and stimulate G protein coupling alone or in the presence of CP55,940, which is consistent with their activity as ago-PAMs. Between the enantiomers tested, GAT1667 consistently displayed the greatest potency and efficacy.  43 -10 -9 -8 -7 -6 -5 0 50 100 150 200 250 Log[Compound], (M) % [3H]CP55,940 Bound GAT1664 GAT1665 GAT1666 GAT1667 CP55,940 KD (nM) 95% C.I. Emax \u00b1 S.E.M. 13 (5.6 - 33) 110 (56 - 660)* 140 (70 - 340)* 140 (33 - 440) 28 (15 - 52) 4.8 \u00b1 0.51 140 \u00b1 7.0* 190 \u00b1 8.5* 140 \u00b1 6.1* 230 \u00b1 5.4* -10 -9 -8 -7 -6 -5 0 25 50 75 Log[Compound], (M) % Stimulation above baseline CP55,940 GAT1664 GAT1665 GAT1666 GAT1667 EC50 (nM) 95% C.I. Emax \u00b1 S.E.M.", "start_char_idx": 60943, "end_char_idx": 63691, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7cf6ad74-5796-4e7b-a5db-a597641b605f": {"__data__": {"id_": "7cf6ad74-5796-4e7b-a5db-a597641b605f", "embedding": null, "metadata": {"file_path": "data/brandt-no-intro.txt", "file_name": "brandt-no-intro.txt", "file_type": "text/plain", "file_size": 239829, "creation_date": "2023-12-31", "last_modified_date": "2023-12-31", "last_accessed_date": "2023-12-31"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "a0eaa9a5-aece-426b-8f20-580de8fb9f35", "node_type": "4", "metadata": {"file_path": "data/brandt-no-intro.txt", "file_name": "brandt-no-intro.txt", "file_type": "text/plain", "file_size": 239829, "creation_date": "2023-12-31", "last_modified_date": "2023-12-31", "last_accessed_date": "2023-12-31"}, "hash": "76e194b2637b440a1b1cdf5698cae061524bb4d7a3b73dfc2ba71d268a3f7019", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "79f04175-06e1-4be6-a6a5-87fe45e0a8d0", "node_type": "1", "metadata": {"file_path": "data/brandt-no-intro.txt", "file_name": "brandt-no-intro.txt", "file_type": "text/plain", "file_size": 239829, "creation_date": "2023-12-31", "last_modified_date": "2023-12-31", "last_accessed_date": "2023-12-31"}, "hash": "b8bbc656f6cf3fbbfd4debc894e052dc5c29faaf7548827daed1fb4faa943a04", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "58f038fc-7646-4ea8-87ee-f3887467d710", "node_type": "1", "metadata": {}, "hash": "ada86bb502ed7537e7c830b26017cc2e65b0f44dfa3f82038a97a5b27a134b9f", "class_name": "RelatedNodeInfo"}}, "hash": "8e981ec713cc20426637a2289dc03ad3375f0cbf59b7cf4cc1bbd0f7a455240d", "text": "Emax \u00b1 S.E.M. 13 (5.6 - 33) 110 (56 - 660)* 140 (70 - 340)* 140 (33 - 440) 28 (15 - 52) 4.8 \u00b1 0.51 140 \u00b1 7.0* 190 \u00b1 8.5* 140 \u00b1 6.1* 230 \u00b1 5.4* -10 -9 -8 -7 -6 -5 0 25 50 75 Log[Compound], (M) % Stimulation above baseline CP55,940 GAT1664 GAT1665 GAT1666 GAT1667 EC50 (nM) 95% C.I. Emax \u00b1 S.E.M. 18 (12 - 30) 110 (27 - 170) 21 (3.4 - 120) 120 (20 - 200) 8.0 (3.4 - 17) 41 \u00b1 1.7 38 \u00b1 3.1 41 \u00b1 4.2 29 \u00b1 2.6* 34 \u00b1 2.3 -10 -9 -8 -7 -6 -5 0 25 50 75 Log[Compound], (M) % Stimulation above baseline CP55,940 CP55,940 + 1 \u03bcM GAT1664 CP55,940 + 1 \u03bcM GAT1665 CP55,940 + 1 \u03bcM GAT1666 CP55,940 + 1 \u03bcM GAT1667 EC50 (nM) 95% C.I. Emax \u00b1 S.E.M. 18 (12 - 30) n.c. n.c. n.c. 420 (46 - 530) 41 \u00b1 1.7 35 \u00b1 2.1 36 \u00b1 5.2 45 \u00b1 3.1 38 \u00b1 3.1 a.  b.  c.  Figure 2-5. (a) Radioligand binding of 1 nM [3H]CP55,940 and (b,c) G protein binding of [ 35S]GTPgS to membranes from CB1R CHO-K1 cells. CB1R CHO-K1 cells were treated with 0.10 nM \u2013 10 \u00b5M compounds in the presence 1 nM [3H]CP55,940 (a) or 1.0 nM [35S]GTP\uf067S (b).  Data are expressed as % radioligand bound (a) or % stimulation above baseline (i.e. vehicle) levels (b,c). Data were fit to a nonlinear regression (4-parameter model, GraphPad v. 9.0) to determine KD, EC50, and Emax. Data are mean \u00b1 SEM (Emax) or 95% CI (KD, EC50); n \u2265 6 independent experiments. *p < 0.05 compared to CP55,940 as determined by one-way ANOVA followed by Bonferroni\u2019s post-hoc test or non-overlapping 95% CI.  44 2.3.3 In vivo evaluation All enantiomers were evaluated in male C57BL/6 mice using a triad of outcomes consisting of catalepsy, body temperature, and nociception. Previous studies have shown that the racemic GAT591 and GAT593 did not produce catalepsy or hypothermia at 0.1, 1, 3, or 10 mg/kg (i.p.)  compared to vehicle 95 . Both GAT591 and GAT593 however did produce a dose-dependent antinociceptive effect in the tail flick assay that was significant relative to vehicle at 3 and 10 mg/kg.  95 In this study we evaluated all separated optically pure enantiomers in a triad assay. When tested alone, GAT1664, GAT1665, GAT1666 and GAT1667 did not produce catalepsy, hypothermia, or anti-nociceptive effects at 0.1, 1, 3, or 10 mg/kg i.p. compared to vehicle (Figure 2-6a-c). We also tested these enantiomers as PAMs by co-administering a sub-threshold dose of 1 mg/kg THC with each GAT compound. It was found that GAT1665 and GAT1667 displayed significant cataleptic, hypothermic, and anti-nociceptive effects at 3 and 10 mg/kg i.p. compared to vehicle (Figure 2-6df).", "start_char_idx": 63397, "end_char_idx": 65889, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "58f038fc-7646-4ea8-87ee-f3887467d710": {"__data__": {"id_": "58f038fc-7646-4ea8-87ee-f3887467d710", "embedding": null, "metadata": {"file_path": "data/brandt-no-intro.txt", "file_name": "brandt-no-intro.txt", "file_type": "text/plain", "file_size": 239829, "creation_date": "2023-12-31", "last_modified_date": "2023-12-31", "last_accessed_date": "2023-12-31"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "a0eaa9a5-aece-426b-8f20-580de8fb9f35", "node_type": "4", "metadata": {"file_path": "data/brandt-no-intro.txt", "file_name": "brandt-no-intro.txt", "file_type": "text/plain", "file_size": 239829, "creation_date": "2023-12-31", "last_modified_date": "2023-12-31", "last_accessed_date": "2023-12-31"}, "hash": "76e194b2637b440a1b1cdf5698cae061524bb4d7a3b73dfc2ba71d268a3f7019", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7cf6ad74-5796-4e7b-a5db-a597641b605f", "node_type": "1", "metadata": {"file_path": "data/brandt-no-intro.txt", "file_name": "brandt-no-intro.txt", "file_type": "text/plain", "file_size": 239829, "creation_date": "2023-12-31", "last_modified_date": "2023-12-31", "last_accessed_date": "2023-12-31"}, "hash": "8e981ec713cc20426637a2289dc03ad3375f0cbf59b7cf4cc1bbd0f7a455240d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "582ec677-6038-48f8-a30d-e6aabc38349f", "node_type": "1", "metadata": {}, "hash": "0dd9706987e6c7ac53bbf2f9ea2e0795bd4003013e7dff6a0abf830418267396", "class_name": "RelatedNodeInfo"}}, "hash": "ada86bb502ed7537e7c830b26017cc2e65b0f44dfa3f82038a97a5b27a134b9f", "text": "95 In this study we evaluated all separated optically pure enantiomers in a triad assay. When tested alone, GAT1664, GAT1665, GAT1666 and GAT1667 did not produce catalepsy, hypothermia, or anti-nociceptive effects at 0.1, 1, 3, or 10 mg/kg i.p. compared to vehicle (Figure 2-6a-c). We also tested these enantiomers as PAMs by co-administering a sub-threshold dose of 1 mg/kg THC with each GAT compound. It was found that GAT1665 and GAT1667 displayed significant cataleptic, hypothermic, and anti-nociceptive effects at 3 and 10 mg/kg i.p. compared to vehicle (Figure 2-6df). Therefore, GAT1664, GAT1665, GAT1666, and GAT1667 do not alter physiology in normal, otherwise healthy adult mice as agonists, but GAT1665 and GAT1667 are able to augment THC\u2019s effects as PAMs when administered once. For comparison, the racemic parent compounds, GAT591 and GAT593, do dispaly nociception in vivo.  95,82 45 0 2 4 6 8 10 0 25 50 75 100 125 Dose (mg/kg) Catalepsy (% MPE) Vehicle 0.1 mg/kg CP55,940 THC GAT1664 GAT1665 GAT1666 GAT1667 0 2 4 6 8 10 30 32 34 36 38 40 Dose (mg/kg) Body Temperature (\u00b0C) Vehicle 0.1 mg/kg CP55,940 THC GAT1664 GAT1665 GAT1666 GAT1667 0 25 50 75 100 125 0 2 4 6 8 10 Dose (mg/kg) Tail Flick Latency (% MPE) Vehicle 0.1 mg/kg CP55,940 THC GAT1664 GAT1665 GAT1666 GAT1667 a.  b.  c.  0 2 4 6 8 10 0 25 50 75 100 125 Dose (mg/kg) Catalepsy (% MPE) Vehicle 0.1 mg/kg CP55,940THC GAT1664 + 1 mg/kgTHCGAT1665 + 1 mg/kgTHCGAT1666 + 1 mg/kgTHCGAT1667 + 1 mg/kgTHC* * ^ 0 2 4 6 8 10 30 32 34 36 38 40 Dose (mg/kg) Body Temperature (\u00b0C) Vehicle 0.1 mg/kg CP55,940THC GAT1664 + 1 mg/kgTHCGAT1665 + 1 mg/kgTHCGAT1666 + 1 mg/kgTHCGAT1667 + 1 mg/kgTHC* * ^ ^ 0 25 50 75 100 125 0 2 4 6 8 10 Dose (mg/kg) Tail Flick Latency (% MPE) Vehicle 0.1 mg/kg CP55,940THC GAT1664 + 1 mg/kgTHCGAT1665 + 1 mg/kgTHCGAT1666 + 1 mg/kgTHCGAT1667 + 1 mg/kgTHC^ ^*\n* d.  e.  f.  Figure 2-6. In vivo effects of GAT1664, GAT1665, GAT1666 and GAT1667 in male C57BL/6 mice. C57BL/6 mice were administered compounds either alone (a,b,c) or co-administered with 1 mg/kg THC (d,e,f) to assess catalepsy, hypothermia and nociception. Doses used were 0.1 \u2013 10 mg/kg compound or volume-matched vehicle control (1:1:18 ethanol/cremaphor/saline) and assessment of catalepsy (% MPE 60 sec) (a), body temperature (b), and nociception in the tail flick assay (% MPE 20 sec) (c) were performed; n = 5-6/group; data are mean \u00b1 SEM. ^p < 0.05 for GAT1665 compared to vehicle; *p < 0.05 for GAT1667 compared to vehicle as determined by two-way ANOVA followed by Bonferroni\u2019s post-hoc test.", "start_char_idx": 65314, "end_char_idx": 67871, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "582ec677-6038-48f8-a30d-e6aabc38349f": {"__data__": {"id_": "582ec677-6038-48f8-a30d-e6aabc38349f", "embedding": null, "metadata": {"file_path": "data/brandt-no-intro.txt", "file_name": "brandt-no-intro.txt", "file_type": "text/plain", "file_size": 239829, "creation_date": "2023-12-31", "last_modified_date": "2023-12-31", "last_accessed_date": "2023-12-31"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "a0eaa9a5-aece-426b-8f20-580de8fb9f35", "node_type": "4", "metadata": {"file_path": "data/brandt-no-intro.txt", "file_name": "brandt-no-intro.txt", "file_type": "text/plain", "file_size": 239829, "creation_date": "2023-12-31", "last_modified_date": "2023-12-31", "last_accessed_date": "2023-12-31"}, "hash": "76e194b2637b440a1b1cdf5698cae061524bb4d7a3b73dfc2ba71d268a3f7019", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "58f038fc-7646-4ea8-87ee-f3887467d710", "node_type": "1", "metadata": {"file_path": "data/brandt-no-intro.txt", "file_name": "brandt-no-intro.txt", "file_type": "text/plain", "file_size": 239829, "creation_date": "2023-12-31", "last_modified_date": "2023-12-31", "last_accessed_date": "2023-12-31"}, "hash": "ada86bb502ed7537e7c830b26017cc2e65b0f44dfa3f82038a97a5b27a134b9f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4f999dc1-d2a8-4733-8bcb-ef262464e754", "node_type": "1", "metadata": {}, "hash": "221b9e252e8ac331d8ecc97abc41588fddf9245d4a737887c6cc9334e8355f3b", "class_name": "RelatedNodeInfo"}}, "hash": "0dd9706987e6c7ac53bbf2f9ea2e0795bd4003013e7dff6a0abf830418267396", "text": "C57BL/6 mice were administered compounds either alone (a,b,c) or co-administered with 1 mg/kg THC (d,e,f) to assess catalepsy, hypothermia and nociception. Doses used were 0.1 \u2013 10 mg/kg compound or volume-matched vehicle control (1:1:18 ethanol/cremaphor/saline) and assessment of catalepsy (% MPE 60 sec) (a), body temperature (b), and nociception in the tail flick assay (% MPE 20 sec) (c) were performed; n = 5-6/group; data are mean \u00b1 SEM. ^p < 0.05 for GAT1665 compared to vehicle; *p < 0.05 for GAT1667 compared to vehicle as determined by two-way ANOVA followed by Bonferroni\u2019s post-hoc test.  46 2.3.4 In silico studies Compounds were docked to a modelled structure of CB1R to determine their putative binding sites within the receptor. GAT1664 and GAT1666 bound to an allosteric site on CB1R proximal to the intracellular face of the receptor in tan (Figure 2-7). An H-bond exists between the indole hydrogen in white and the nitrogen atom in blue (H \u2013 N distance 1.96 \u00c5) on H1542.41 (Figure 2-7a). One of the fluorobenzyl groups on GAT has a face-to-face \u03c0-\u03c0 interaction with F2374.46 (4.03\u00c5) while the other fluorobenzyl has a T-shaped \u03c0-\u03c0 interaction with each ring on W2414.50 (4.96\u00c5 to the 6 \u2013 membered ring; 5.09\u00c5 to the 5 \u2013 membered ring) (Figure 2-8). Upon binding to CB1R the conformation of the ortho-fluorobenzyl substituent on GAT1664 rotates 90\u00b0. The conformational cost for this rotation is 2.35 kcal/mol (Table 2-1). GAT1666 has the same binding pose, thus the binding energy was measured to look at the relative affinity. GAT1666 is more stable than GAT1664 by 2.31 kcal/mol (\u2206G GAT1666 - \u2206G GAT1664) which suggests that it has a higher affinity to the allosteric site of CB1R shown in tan (Figure 2-7). This can be attributed to changing the fluorine on the 6th position of the indole (GAT1664) to the 7th position on the indole (GAT1666). The binding of a compound to this site may allow it to act as an agonist by promoting the X1 = g+ \u2192 trans conformation of residue F4.46, facilitating breaking of the R3.50/D6.30 ionic lock which has been shown to activate CB1R (Figure 2-7 and Figure 2-8).  83 47 Figure 2-7. CB1R with three different binding sites shown. In these views of CB1R the orthosteric site is shown in magenta, an identified PAM site in blue, and another identified agoPAM site in tan. Transmembrane helices are: I red, II orange, III yellow, IV light green, V green, VI cyan, and VII blue. (a) is a visualization of CB1R looking down on the extracellular surface.  (b) is a visualization of CB1R looking across at the transmembrane domains.  Figure 2-8. GAT1664 binds to an allosteric agonist site. (a) Main interactions between GAT1664 and the amino acid residues in the binding pocket. The conformation of GAT1664 (b1) before it binds to CB1R and then the conformation of GAT1664 (b2) after it binds to CB1R.  48 Table 2-1. The conformational cost of GAT compounds is displayed as well as the relative affinity represented by binding energy.", "start_char_idx": 67271, "end_char_idx": 70258, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4f999dc1-d2a8-4733-8bcb-ef262464e754": {"__data__": {"id_": "4f999dc1-d2a8-4733-8bcb-ef262464e754", "embedding": null, "metadata": {"file_path": "data/brandt-no-intro.txt", "file_name": "brandt-no-intro.txt", "file_type": "text/plain", "file_size": 239829, "creation_date": "2023-12-31", "last_modified_date": "2023-12-31", "last_accessed_date": "2023-12-31"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "a0eaa9a5-aece-426b-8f20-580de8fb9f35", "node_type": "4", "metadata": {"file_path": "data/brandt-no-intro.txt", "file_name": "brandt-no-intro.txt", "file_type": "text/plain", "file_size": 239829, "creation_date": "2023-12-31", "last_modified_date": "2023-12-31", "last_accessed_date": "2023-12-31"}, "hash": "76e194b2637b440a1b1cdf5698cae061524bb4d7a3b73dfc2ba71d268a3f7019", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "582ec677-6038-48f8-a30d-e6aabc38349f", "node_type": "1", "metadata": {"file_path": "data/brandt-no-intro.txt", "file_name": "brandt-no-intro.txt", "file_type": "text/plain", "file_size": 239829, "creation_date": "2023-12-31", "last_modified_date": "2023-12-31", "last_accessed_date": "2023-12-31"}, "hash": "0dd9706987e6c7ac53bbf2f9ea2e0795bd4003013e7dff6a0abf830418267396", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "58989e49-3b5b-4716-acfe-9a5da6396e33", "node_type": "1", "metadata": {}, "hash": "1aa783415a6b3126b653f8ca8d6128a5dfdd3c3d3072223a2d84e224d1fb296c", "class_name": "RelatedNodeInfo"}}, "hash": "221b9e252e8ac331d8ecc97abc41588fddf9245d4a737887c6cc9334e8355f3b", "text": "Transmembrane helices are: I red, II orange, III yellow, IV light green, V green, VI cyan, and VII blue. (a) is a visualization of CB1R looking down on the extracellular surface.  (b) is a visualization of CB1R looking across at the transmembrane domains.  Figure 2-8. GAT1664 binds to an allosteric agonist site. (a) Main interactions between GAT1664 and the amino acid residues in the binding pocket. The conformation of GAT1664 (b1) before it binds to CB1R and then the conformation of GAT1664 (b2) after it binds to CB1R.  48 Table 2-1. The conformational cost of GAT compounds is displayed as well as the relative affinity represented by binding energy.  Compound Conformational cost (kcal/mol) \u2206G (kcal/mol) GAT1664 2.35 -69.68 GAT1665 3.27 -60.77 GAT1666 2.48 -71.99 GAT1667 3.60 -64.55 GAT1665 and GAT1667 bind to a distinct allosteric site on CB1R relative to GAT1664 and GAT1666 (Figure 2-7 and Figure 2-9). The NO2 group on GAT1665 has a H-bond between 1 of the oxygens shown in red and a hydrogen atom on Y1722.59 (O \u2013 H distance 2.17\u00c5) (Figure 2-9).  Another H-bond exists between the indole hydrogen in white and an oxygen atom in red on D1762.63 (H \u2013 O distance 2.29\u00c5) (Figure 2-9). A cation-\u03c0 interaction exists between R182ECL1 and each ring on the indole on GAT1665 (six \u2013 membered ring centroid on indole to NH2\n+ on\nR182ECL1 distance 3.59\u00c5; five \u2013 membered ring centroid on indole to NH2\n+ on R182ECL1 distance\n3.66\u00c5) (Figure 2-9). One of the fluorobenzyl groups on GAT has a face-to-face \u03c0-\u03c0 interaction\nwith Y1722.59 (4.05\u00c5) (Figure 2-9). Upon binding to CB1R the conformation of the NO2 rotates\nin order to H-bond with Y1722.59 (Table 2-1). The conformational cost for this rotation is 3.27\nkcal/mol. If we compare the binding energy of GAT1665 and GAT1667 it is apparent that\nGAT1667 is more stable than GAT1665 bound to the PAM site by 4.78 kcal/mol (\u2206G GAT1667\n- \u2206G GAT1665). This can be attributed to changing the fluorine on the 6th position of the indole\n(GAT1665) to the 7th position on the indole (GAT1667). The previously characterized compound GAT229 also binds to this site and lacks intrinsic activity thus both these compounds alone can not induce the active state of CB1R and thus are PAMs. The R-enantiomers (GAT1665 and 49 GAT1667) undergo a smaller conformational cost than the S-enantiomers (GAT1664 and GAT1666) upon binding to their respective sites on CB1R (Table 2-1). The R-enantiomers (GAT1665 and GAT1667) bind to the ago-PAM site (\u2206G = -60.77 and -64.55 kcal/mol) significantly weaker than the S-enantiomers (GAT1664 and GAT1666) bind to the PAM site (- 69.68 and 71.99 kcal/mol).  50 Figure 2-9. GAT1665 binds to the PAM site in blue (Fig. 6). (a) Main interactions between GAT1665 and the amino acid residues in the binding pocket. (b) The conformation of GAT1665 (b1) it binds to CB1R and then the conformation of GAT1665 (b2) after it binds to CB1R.  51\n\n2.4 Conclusion\n\nIn summary, the purified enantiomers of GAT591 and GAT593 displayed unique pharmacology.", "start_char_idx": 69600, "end_char_idx": 72612, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "58989e49-3b5b-4716-acfe-9a5da6396e33": {"__data__": {"id_": "58989e49-3b5b-4716-acfe-9a5da6396e33", "embedding": null, "metadata": {"file_path": "data/brandt-no-intro.txt", "file_name": "brandt-no-intro.txt", "file_type": "text/plain", "file_size": 239829, "creation_date": "2023-12-31", "last_modified_date": "2023-12-31", "last_accessed_date": "2023-12-31"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "a0eaa9a5-aece-426b-8f20-580de8fb9f35", "node_type": "4", "metadata": {"file_path": "data/brandt-no-intro.txt", "file_name": "brandt-no-intro.txt", "file_type": "text/plain", "file_size": 239829, "creation_date": "2023-12-31", "last_modified_date": "2023-12-31", "last_accessed_date": "2023-12-31"}, "hash": "76e194b2637b440a1b1cdf5698cae061524bb4d7a3b73dfc2ba71d268a3f7019", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4f999dc1-d2a8-4733-8bcb-ef262464e754", "node_type": "1", "metadata": {"file_path": "data/brandt-no-intro.txt", "file_name": "brandt-no-intro.txt", "file_type": "text/plain", "file_size": 239829, "creation_date": "2023-12-31", "last_modified_date": "2023-12-31", "last_accessed_date": "2023-12-31"}, "hash": "221b9e252e8ac331d8ecc97abc41588fddf9245d4a737887c6cc9334e8355f3b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "554de318-ec6f-4de0-9960-864394ddca79", "node_type": "1", "metadata": {}, "hash": "33804000b2e1f8d608cbb9df99ffe21b4c57c2288b26c880a0ae7ff8a9e02303", "class_name": "RelatedNodeInfo"}}, "hash": "1aa783415a6b3126b653f8ca8d6128a5dfdd3c3d3072223a2d84e224d1fb296c", "text": "The R-enantiomers (GAT1665 and GAT1667) bind to the ago-PAM site (\u2206G = -60.77 and -64.55 kcal/mol) significantly weaker than the S-enantiomers (GAT1664 and GAT1666) bind to the PAM site (- 69.68 and 71.99 kcal/mol).  50 Figure 2-9. GAT1665 binds to the PAM site in blue (Fig. 6). (a) Main interactions between GAT1665 and the amino acid residues in the binding pocket. (b) The conformation of GAT1665 (b1) it binds to CB1R and then the conformation of GAT1665 (b2) after it binds to CB1R.  51\n\n2.4 Conclusion\n\nIn summary, the purified enantiomers of GAT591 and GAT593 displayed unique pharmacology.  The purified enantiomers GAT1664, GAT1665, GAT1666, and GAT1667 bound to CB1R in the low nM range and were shown to enhance binding of [3H]CP55,940 at CB1R. Enhancing the binding of an orthosteric ligand is a characteristic of a PAM and these observations are consistent with all compounds operating in part via positive allostery.  39 In addition to this, we demonstrated that these enantiomers activate CB1R-dependent inhibition of cAMP and \u03b2arrestin2 recruitment. All of the GAT compounds tested here did inhibit cAMP accumulation either as agonists or PAMs, with GAT1665 and GAT1667 displaying the greatest potency and efficacy as CB1R PAMs in the presence of 100 nM CP55,940. In the \u03b2arrestin2 assay GAT1665 and GAT1667 (R-enantiomers) acted as ago-PAM\u2019s while GAT1664 and GAT1666 (Senantiomers) showed little to no activity as either an agonist or PAM. In the G protein coupling assay the R-enantiomers GAT1665 and GAT1667 also showed higher potency and efficacy than S-enantiomers as agonists and PAMs. As for the in vivo studies, no compounds tested produced catalepsy, hypothermia or antinociceptive effects at 0.1, 1, 3 or 10 mg/kg i.p. compared to vehicle as agonists, but GAT1665 and GAT1667 did potentiate the effects of THC as PAMs. These data are congruent with previous observations that CB1R ago-PAMs are inactive or minimally active in vivo in wild-type, otherwise healthy animals under non-pathological and acute conditions.  77 In silico studies revealed that GAT1664 and GAT1666 preferentially bind to a putative allosteric agonist site of CB1R near the intracellular face of the receptor between transmembrane helices I and IV; while GAT1665 and GAT1667 preferentially bind to a putative PAM site of CB1R on the extracellular receptor surface. Enantiomers may display low affinity to multiple allosteric sites, accounting for the allosteric agonist activity of GAT1665 and GAT1667. Collectively, these data 52 support retained, potent, G protein-biased, ago-PAM enantiomeric-specific activity at CB1R for the GAT211 ligand scaffold and demonstrate enhanced potency and efficacy of these ligands relative to the parent compound.  95,82 The absolute orientation of GAT1665 and GAT1667 is maintained relative to the previously-characterized CB1R PAM GAT229.  98 Moreover, recent data from the racemic mixtures of these enantiomers indicates fluorine addition improves both metabolic stability and blood brain barrier penetrance; with GAT593 \u2013 and therefore GAT1667 \u2013 being superior to GAT591.  95 Therefore, studies are now underway to assess the in vivo efficacy of GAT1667 in the contexts of absence epilepsy and pain during both acute and chronic treatment paradigms.", "start_char_idx": 72014, "end_char_idx": 75303, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "554de318-ec6f-4de0-9960-864394ddca79": {"__data__": {"id_": "554de318-ec6f-4de0-9960-864394ddca79", "embedding": null, "metadata": {"file_path": "data/brandt-no-intro.txt", "file_name": "brandt-no-intro.txt", "file_type": "text/plain", "file_size": 239829, "creation_date": "2023-12-31", "last_modified_date": "2023-12-31", "last_accessed_date": "2023-12-31"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "a0eaa9a5-aece-426b-8f20-580de8fb9f35", "node_type": "4", "metadata": {"file_path": "data/brandt-no-intro.txt", "file_name": "brandt-no-intro.txt", "file_type": "text/plain", "file_size": 239829, "creation_date": "2023-12-31", "last_modified_date": "2023-12-31", "last_accessed_date": "2023-12-31"}, "hash": "76e194b2637b440a1b1cdf5698cae061524bb4d7a3b73dfc2ba71d268a3f7019", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "58989e49-3b5b-4716-acfe-9a5da6396e33", "node_type": "1", "metadata": {"file_path": "data/brandt-no-intro.txt", "file_name": "brandt-no-intro.txt", "file_type": "text/plain", "file_size": 239829, "creation_date": "2023-12-31", "last_modified_date": "2023-12-31", "last_accessed_date": "2023-12-31"}, "hash": "1aa783415a6b3126b653f8ca8d6128a5dfdd3c3d3072223a2d84e224d1fb296c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0e49efe3-ce03-45d0-b299-a67d33696a72", "node_type": "1", "metadata": {}, "hash": "53090799281fadabfff486cbd107684041f16c64c1f805cb998f4312353d5155", "class_name": "RelatedNodeInfo"}}, "hash": "33804000b2e1f8d608cbb9df99ffe21b4c57c2288b26c880a0ae7ff8a9e02303", "text": "Collectively, these data 52 support retained, potent, G protein-biased, ago-PAM enantiomeric-specific activity at CB1R for the GAT211 ligand scaffold and demonstrate enhanced potency and efficacy of these ligands relative to the parent compound.  95,82 The absolute orientation of GAT1665 and GAT1667 is maintained relative to the previously-characterized CB1R PAM GAT229.  98 Moreover, recent data from the racemic mixtures of these enantiomers indicates fluorine addition improves both metabolic stability and blood brain barrier penetrance; with GAT593 \u2013 and therefore GAT1667 \u2013 being superior to GAT591.  95 Therefore, studies are now underway to assess the in vivo efficacy of GAT1667 in the contexts of absence epilepsy and pain during both acute and chronic treatment paradigms.  53\n\n2.5 Supplementary Info\n\n2.5.1 NMR Data\n\n(+)-(S)-6-Fluoro-2-(3-fluorophenyl)-3-(1-(2-fluorophenyl)-2-nitroethyl)-1H-indole (GAT1664): 1H NMR (400 MHz, DMSO-d6): \u03b4 11.66 (bs, 1H), 7.77 (dd, J= 5.3, 8.8 Hz, 1H), 7.67\u22127.57 (m, 2H), 7.39\u22127.25 (m, 4H), 7.18\u22127.89 (m, 3H), 6.85 (t, J= 8.7 Hz, 1H,), 5.59-5.53 (m, 2H), 5.43 (d, J= 8.4 Hz, 1H).; [\u03b1]D 24 = +70.80 (c 1 g/100 mL, MeOH); MS-ESI (m/z) 397 [M + H] + .  (-)-(R)-6-Fluoro-2-(3-fluorophenyl)-3-(1-(2-fluorophenyl)-2-nitroethyl)-1H-indole (GAT1665): 1H NMR (400 MHz, DMSO-d6): \u03b4 11.66 (bs, 1H), 7.77 (dd, J= 5.3, 8.8 Hz, 1H), 7.67\u22127.57 (m, 2H), 7.39\u22127.25 (m, 4H), 7.18\u22127.89 (m, 3H), 6.85 (t, J= 8.7 Hz, 1H,), 5.59-5.53 (m, 2H), 5.43 (d, J= 8.4 Hz, 1H).; [\u03b1]D 24 = -87.85 (c 1 g/100 mL, MeOH) ; MS-ESI (m/z) 397 [M + H] + .  (+)-(S)-7-Fluoro-2-(3-fluorophenyl)-3-(1-(2-fluorophenyl)-2-nitroethyl)-1H-indole (GAT1666): 1H NMR (400 MHz, DMSO-d6): \u03b4 11.96 (bs, 1H), 7.67-7.57 (m, 3H), 7.41\u22127.25 (m, 4H), 7.18\u22126.98 (m, 2H), 6.96 (d, J= 8.0 Hz, 1H,), 5.61-5.49 (m, 2H), 5.393 (t, J= 8.4 Hz, 1H).; [\u03b1]D 24 = +24.80 (c 1 g/100 mL, MeOH); MS-ESI (m/z) 397 [M + H] + .", "start_char_idx": 74518, "end_char_idx": 76416, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0e49efe3-ce03-45d0-b299-a67d33696a72": {"__data__": {"id_": "0e49efe3-ce03-45d0-b299-a67d33696a72", "embedding": null, "metadata": {"file_path": "data/brandt-no-intro.txt", "file_name": "brandt-no-intro.txt", "file_type": "text/plain", "file_size": 239829, "creation_date": "2023-12-31", "last_modified_date": "2023-12-31", "last_accessed_date": "2023-12-31"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "a0eaa9a5-aece-426b-8f20-580de8fb9f35", "node_type": "4", "metadata": {"file_path": "data/brandt-no-intro.txt", "file_name": "brandt-no-intro.txt", "file_type": "text/plain", "file_size": 239829, "creation_date": "2023-12-31", "last_modified_date": "2023-12-31", "last_accessed_date": "2023-12-31"}, "hash": "76e194b2637b440a1b1cdf5698cae061524bb4d7a3b73dfc2ba71d268a3f7019", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "554de318-ec6f-4de0-9960-864394ddca79", "node_type": "1", "metadata": {"file_path": "data/brandt-no-intro.txt", "file_name": "brandt-no-intro.txt", "file_type": "text/plain", "file_size": 239829, "creation_date": "2023-12-31", "last_modified_date": "2023-12-31", "last_accessed_date": "2023-12-31"}, "hash": "33804000b2e1f8d608cbb9df99ffe21b4c57c2288b26c880a0ae7ff8a9e02303", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "be4131a0-7c74-4a94-92be-2724d1b79033", "node_type": "1", "metadata": {}, "hash": "b4f2e6bd2a672e2c085d1b92682254ed18638a7dfb7962e95e40021c1bbf6dcd", "class_name": "RelatedNodeInfo"}}, "hash": "53090799281fadabfff486cbd107684041f16c64c1f805cb998f4312353d5155", "text": "; [\u03b1]D 24 = +24.80 (c 1 g/100 mL, MeOH); MS-ESI (m/z) 397 [M + H] + .  (-)-(R)-7-Fluoro-2-(3-fluorophenyl)-3-(1-(2-fluorophenyl)-2-nitroethyl)-1H-indole (GAT1667): 1H NMR (400 MHz, DMSO-d6): \u03b4 11.96 (bs, 1H), 7.67-7.57 (m, 3H), 7.41\u22127.25 (m, 4H), 7.18\u22126.98 (m, 2H), 6.96 (d, J= 8.0 Hz, 1H,), 5.61-5.49 (m, 2H), 5.393 (t, J= 8.4 Hz, 1H).; [\u03b1]D 24 = -75.86 (c 1 g/100 mL, MeOH); MS-ESI (m/z) 397 [M + H] + .  54 Figure 2-10. Preparative HPLC chromatogram for (+)-GAT1664 55 Figure 2-11. Preparative HPLC chromatogram for (-)-GAT1665 56 Figure 2-12. Preparative HPLC chromatogram for (+)-GAT1666 57 Figure 2-13. Preparative HPLC chromatogram for (-)-GAT1667 58 CHAPTER 3 In Silico Evaluation of Halogenated Bioisosteres at the Type 1 Cannabinoid Receptor Allosteric Agonist Site Copyright statement This chapter is in review for publication. The manuscript has been modified to meet formatting requirements.  Contribution statement The manuscript used as the basis for this chapter was written with guidance from Dr. Robert B.  Laprairie. In silico data were collected and analyzed by myself with technical assistance from Dr.  Robert B. Laprairie, Dr. Christopher P. Phenix and Dr. Jane Alcorn.  59\n\n3.1 Introduction\n\nThe type 1 cannabinoid receptor (CB1R) is a class A G protein-couped receptor (GPCR). GPCRs are the target of approximately 35% of approved drugs because they regulate numerous, diverse, physiological processes and have druggable sites that are accessible at the cell surface.  65 Specifically, CB1R has 3 identified ligand binding sites: (1) the orthosteric site where the endogenous ligands 2-arachidonoylglycerol (2-AG) and anandamide (AEA) bind; (2) an allosteric site located between transmembrane helix 2 (TMH2) and extracellular loop 1 (ECL1) where positive allosteric modulators (PAMs) such as GAT229 bind; and (3) an allosteric agonist-PAM (i.e. ago-PAM) site on the intracellular surface of the receptor between TMSs 1, 2, and 4 where compounds such as GAT228 bind (Figure 1-5).83,114 Although CB1R orthosteric ligands have been used as tool compounds in understanding the function of CB1R, their use as therapeutics remains limited due to on-target interference with constitutive physiological signaling and resultant neurological effects.  115 In contrast to orthosteric ligands, allosteric ligands of CB1R are now being studied as a means of modulating CB1R signaling without the potential therapeutic limitations of tolerance, dependence, or intoxication.  116,117 True PAMs do not have an intrinsic agonist activity; instead, they modulate activity through a conformational shape change of the orthosteric binding pocket which alters the GPCRs signaling output.  118 Ago-PAMs do possess intrinsic agonist activity as they can activate GPCR signaling in the absence of an orthosteric ligand.  119 The ability of such compounds to act as agonists may be due to them occupying several binding sites in the absence of a bound agonist.  120 Using ago-PAMs with intrinsic activity may be attractive for treating diseases whose etiology involves decline or loss of endogenous neurotransmitters because such compounds augment the activity of the endogenous system, without producing tolerance or dependence effects, as we have seen previously in rodent models of pain.", "start_char_idx": 76347, "end_char_idx": 79638, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "be4131a0-7c74-4a94-92be-2724d1b79033": {"__data__": {"id_": "be4131a0-7c74-4a94-92be-2724d1b79033", "embedding": null, "metadata": {"file_path": "data/brandt-no-intro.txt", "file_name": "brandt-no-intro.txt", "file_type": "text/plain", "file_size": 239829, "creation_date": "2023-12-31", "last_modified_date": "2023-12-31", "last_accessed_date": "2023-12-31"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "a0eaa9a5-aece-426b-8f20-580de8fb9f35", "node_type": "4", "metadata": {"file_path": "data/brandt-no-intro.txt", "file_name": "brandt-no-intro.txt", "file_type": "text/plain", "file_size": 239829, "creation_date": "2023-12-31", "last_modified_date": "2023-12-31", "last_accessed_date": "2023-12-31"}, "hash": "76e194b2637b440a1b1cdf5698cae061524bb4d7a3b73dfc2ba71d268a3f7019", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0e49efe3-ce03-45d0-b299-a67d33696a72", "node_type": "1", "metadata": {"file_path": "data/brandt-no-intro.txt", "file_name": "brandt-no-intro.txt", "file_type": "text/plain", "file_size": 239829, "creation_date": "2023-12-31", "last_modified_date": "2023-12-31", "last_accessed_date": "2023-12-31"}, "hash": "53090799281fadabfff486cbd107684041f16c64c1f805cb998f4312353d5155", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d21131fc-9ed9-4e4a-89b4-b38aac3891fb", "node_type": "1", "metadata": {}, "hash": "ad4991f7a7b11dedf79972a02ed603642c0470812594d2006feb1c612c405d8d", "class_name": "RelatedNodeInfo"}}, "hash": "b4f2e6bd2a672e2c085d1b92682254ed18638a7dfb7962e95e40021c1bbf6dcd", "text": "116,117 True PAMs do not have an intrinsic agonist activity; instead, they modulate activity through a conformational shape change of the orthosteric binding pocket which alters the GPCRs signaling output.  118 Ago-PAMs do possess intrinsic agonist activity as they can activate GPCR signaling in the absence of an orthosteric ligand.  119 The ability of such compounds to act as agonists may be due to them occupying several binding sites in the absence of a bound agonist.  120 Using ago-PAMs with intrinsic activity may be attractive for treating diseases whose etiology involves decline or loss of endogenous neurotransmitters because such compounds augment the activity of the endogenous system, without producing tolerance or dependence effects, as we have seen previously in rodent models of pain.  82,116.117 We have 60 previously demonstrated that fluorinated and methyl-substituted derivatives of the ago-PAM GAT228 display efficacy in rodent models of pain and glaucoma.  96,108,82,116,117,120 Although these probe compounds display nanomolar potency, their limited solubility in aqueous environments (GAT228 cLogP 5.04) and metabolic stability (GAT228 human microsomal CLint 81.2 \u00b5L/min/mg protein, t1/2 28.4 min) make them poor drug candidates.121 With several CB1R crystal structures now available, in silico modelling is an attractive means of drug discovery and optimization.  48 The advantage of running in silico modelling before synthesis and in vitro and in vivo experiments is to enable the rational design of improved ligands expected to bind to the desired site on the protein target. Moreover, in silico modeling allows for the rapid substitution of known sub-groups and testing to streamline subsequent syntheses. Quick and efficient program scripts are now widely available to conduct such studies with glide ligand docking through Maestro.  102 Such docking studies are referred to as Molecular MechanicsGeneralized Born Surface Area (MMGBSA) in silico studies.  122 Not only can the script dock a large library of ligands, but it also can dock hundreds of poses of each ligand and report ligandreceptor binding poses according to their estimated lowest energy conformers. Once the best pose has been selected, the ligand/receptor complex can undergo a minimization to capture the whole system (i.e., ligand bound to receptor) in its lowest energy state. One can further use the MMGBSA script to compare the relative binding affinity of a library of compounds. It is hoped that the advent and widespread use of these workflow will allow for rational drug design that is low cost and efficient. In the present study, we explored the generation and evaluation of bioisosteres for the GAT228 scaffold. Candidates with various bioisosteres were docked to the ago-PAM site of CB1R to determine what ligand substitutions were tolerated with respect to affinity at the CB1R agoPAM site. From these studies we were able to identify 4 potential leads with improved drug-like 61 properties and CB1R ago-PAM affinity in silico compared to the parent compound, GAT228.  These novel lead compounds with improved drug-like properties can now be synthesized and tested in rodent models of pain, glaucoma, and other neurodegenerative diseases where earlier derivatives demonstrated efficacy.\n\n3.2 Materials and Methods\n\n3.2.1 In Silico receptor preparation\n\nDocking studies were conducted using the agonist bound human CB1R crystal structures PDB: 6N4B51 and 5XR8.  48 Both 6N4B and 5XR8 are modified CB1R. 6N4B is a 3.0 \u00c5 structure of fulllength CB1R having N-terminal FLAG and C-terminal hexahistidine tags in complex with human heterotrimeric Gi\u03b21\u03b32.  51 5XR8 is a 2.95 \u00c5 resolution structure truncated at amino acids 1-98, 307- 331, and 415-472 with a flavodoxin insert at intracellular loop 3 (IC3).  48 Protein modelling before docking was done with SWISS-MODEL for which the UniProt ID: P215541 (CNR1_Human) was used along with PDB 6N4B51 to build a model receptor. This receptor was then prepared in Maestro (v. 12.2) using that program\u2019s protein preparation wizard.  102 During preparation, the ionization of the protein structure was optimized using PROPKA at pH 7.0; and the space-filling of the protein structure and ligands were optimized minimized using OPLS-3e force field.", "start_char_idx": 78834, "end_char_idx": 83133, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d21131fc-9ed9-4e4a-89b4-b38aac3891fb": {"__data__": {"id_": "d21131fc-9ed9-4e4a-89b4-b38aac3891fb", "embedding": null, "metadata": {"file_path": "data/brandt-no-intro.txt", "file_name": "brandt-no-intro.txt", "file_type": "text/plain", "file_size": 239829, "creation_date": "2023-12-31", "last_modified_date": "2023-12-31", "last_accessed_date": "2023-12-31"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "a0eaa9a5-aece-426b-8f20-580de8fb9f35", "node_type": "4", "metadata": {"file_path": "data/brandt-no-intro.txt", "file_name": "brandt-no-intro.txt", "file_type": "text/plain", "file_size": 239829, "creation_date": "2023-12-31", "last_modified_date": "2023-12-31", "last_accessed_date": "2023-12-31"}, "hash": "76e194b2637b440a1b1cdf5698cae061524bb4d7a3b73dfc2ba71d268a3f7019", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "be4131a0-7c74-4a94-92be-2724d1b79033", "node_type": "1", "metadata": {"file_path": "data/brandt-no-intro.txt", "file_name": "brandt-no-intro.txt", "file_type": "text/plain", "file_size": 239829, "creation_date": "2023-12-31", "last_modified_date": "2023-12-31", "last_accessed_date": "2023-12-31"}, "hash": "b4f2e6bd2a672e2c085d1b92682254ed18638a7dfb7962e95e40021c1bbf6dcd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b15a7c26-e188-4c10-9c6c-4fdb6456b8e9", "node_type": "1", "metadata": {}, "hash": "c382a75a2a4e65491731688eb6cf44a6d178f8795ab45b5a041d475b6f4efa86", "class_name": "RelatedNodeInfo"}}, "hash": "ad4991f7a7b11dedf79972a02ed603642c0470812594d2006feb1c612c405d8d", "text": "51 5XR8 is a 2.95 \u00c5 resolution structure truncated at amino acids 1-98, 307- 331, and 415-472 with a flavodoxin insert at intracellular loop 3 (IC3).  48 Protein modelling before docking was done with SWISS-MODEL for which the UniProt ID: P215541 (CNR1_Human) was used along with PDB 6N4B51 to build a model receptor. This receptor was then prepared in Maestro (v. 12.2) using that program\u2019s protein preparation wizard.  102 During preparation, the ionization of the protein structure was optimized using PROPKA at pH 7.0; and the space-filling of the protein structure and ligands were optimized minimized using OPLS-3e force field.  102 Amino acid position is described throughout this study according to the numbering convention of Ballesteros and Weinstein (Figure 1-4).  123 3.2.2 Ligand Preparation All compounds screened in this study were generated via bioisosteric replacement in Maestro (v.  12.2) using GAT228 as a template. Tautomer\u2019s were generated for each ligand and the dominant ionization state of acidic and basic functional groups were used assuming pH 7.0.  62 3.2.3 Receptor grid generation and molecular docking The grid box for receptor-ligand interaction was defined by selecting the residues (R148, H2.41, F2.42, F4.46 and W4.50) that interact with GAT228 at the ago-PAM exosite (IC TMH1-2-4).  83 Standard precision docking was used with enhanced conformational sampling for each ligand to ensure an exhaustive search.  102 Compounds that did not have a dual H-bond with R148 and an Hbond with H2.41 as shown by glide scores were not considered and deleted because these interactions are thought to be critical to ago-PAM activity.  120,51 Energies of the remaining ligandreceptor complexes were minimized using Prime in the Schr\u00f6dinger suite of programs102 and the lipid membrane was set to a thickness of 31.2\u00c5, as recommended and described for other class A GPCRs.  124 This minimization is necessary for further evaluation because although the ligand is docked with enhanced conformational sampling the receptor is fixed. Molecular mechanics generalized Borne surface area (MMGBSA) was used in Prime to predict the relative binding affinity of each ligand in CB1R.  114,116 MMGBSA uses 3 input files to calculate the binding free energy (\u2206Gbind); ligand-receptor complex (Ecompex), the free protein (Eprotein) and the free ligand (Eligand) where \u2206G is calculated via the following equation:125 \u2206Gbind = Ecomplex (minimized) \u2013 [Eligand (minimized) + Ereceptor (minimized)] Eq. 3-1 63 3.2.4 Physicochemical and Pharmacokinetic Properties Prediction Table 3-1. Physicochemical and Pharmacokinetic Properties modeled in this study Property or Descriptor Description Range or recommended values Mol. WT. Molecular weight of the molecule 130.0 \u2013 725.0 QPlogBB Predicted brain/blood barrier partition coefficient.  Note: QikProp predictions are for orally delivered drugs.  -3 \u2013 1.2 Donor HB Estimated number of hydrogen bonds that would be donated by the solute to water molecules in an aqueous solution. Values are averages taken over a number of configurations so they can be a noninteger.  0.0 \u2013 6.0 Acceptor HB Estimated number of hydrogen bonds that would be accepted by the solute from water molecules in an aqueous solution. Values are averages taken over a number of configurations, so they ca be noninteger.  2.0 \u2013 20.0 QPlog o/w Predicted octanol/water coefficient -2.0 \u2013 6.5 Rule of Five Number of violations of Lipinski\u2019s rule of five. The rules are mol_MW < 500, QPlog o/w < 5, donor HB \u2264 5, acceptor HB \u2264 10. Compounds that satisfy these rules are considered drug-like.  Maximum is 4 % Human Oral Absorption Predicted human oral absorption on 0 to 100% scale. The prediction is based on a quantitative multiple linear regression model.  >80% is high.  <25% is poor 64 Figure 3-1.", "start_char_idx": 82500, "end_char_idx": 86317, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b15a7c26-e188-4c10-9c6c-4fdb6456b8e9": {"__data__": {"id_": "b15a7c26-e188-4c10-9c6c-4fdb6456b8e9", "embedding": null, "metadata": {"file_path": "data/brandt-no-intro.txt", "file_name": "brandt-no-intro.txt", "file_type": "text/plain", "file_size": 239829, "creation_date": "2023-12-31", "last_modified_date": "2023-12-31", "last_accessed_date": "2023-12-31"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "a0eaa9a5-aece-426b-8f20-580de8fb9f35", "node_type": "4", "metadata": {"file_path": "data/brandt-no-intro.txt", "file_name": "brandt-no-intro.txt", "file_type": "text/plain", "file_size": 239829, "creation_date": "2023-12-31", "last_modified_date": "2023-12-31", "last_accessed_date": "2023-12-31"}, "hash": "76e194b2637b440a1b1cdf5698cae061524bb4d7a3b73dfc2ba71d268a3f7019", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d21131fc-9ed9-4e4a-89b4-b38aac3891fb", "node_type": "1", "metadata": {"file_path": "data/brandt-no-intro.txt", "file_name": "brandt-no-intro.txt", "file_type": "text/plain", "file_size": 239829, "creation_date": "2023-12-31", "last_modified_date": "2023-12-31", "last_accessed_date": "2023-12-31"}, "hash": "ad4991f7a7b11dedf79972a02ed603642c0470812594d2006feb1c612c405d8d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ab536b16-72a5-40ed-8fdb-ca39960ca097", "node_type": "1", "metadata": {}, "hash": "ff86836df62b80e052d389d0f51314763814f7dadaa7d668d23c3fb7ce0bf24d", "class_name": "RelatedNodeInfo"}}, "hash": "c382a75a2a4e65491731688eb6cf44a6d178f8795ab45b5a041d475b6f4efa86", "text": "0.0 \u2013 6.0 Acceptor HB Estimated number of hydrogen bonds that would be accepted by the solute from water molecules in an aqueous solution. Values are averages taken over a number of configurations, so they ca be noninteger.  2.0 \u2013 20.0 QPlog o/w Predicted octanol/water coefficient -2.0 \u2013 6.5 Rule of Five Number of violations of Lipinski\u2019s rule of five. The rules are mol_MW < 500, QPlog o/w < 5, donor HB \u2264 5, acceptor HB \u2264 10. Compounds that satisfy these rules are considered drug-like.  Maximum is 4 % Human Oral Absorption Predicted human oral absorption on 0 to 100% scale. The prediction is based on a quantitative multiple linear regression model.  >80% is high.  <25% is poor 64 Figure 3-1. (a) The GAT228 scaffold has 3 sites represented by site X site Y and site Z. While sites X and Z have 3 positions that can be halogenated, site Y has 4 which gives a total of 36 isomers for each halogen. (b) The GAT228 scaffold has a dual H-bond with R(148), H-bond with H1.54 and an aromatic stack with both W4.50 and F4.46. In this representation the residues are displayed in their Van der Waal radii representation. (c) The GAT228 scaffold binds to the agoPAM site of CB1R and interacts with residues on TMH1, 2 and 4.  65\n\n3.3 Results and Discussion\n\n3.3.1 GAT228 Isomers Effect on MMGBSA (\u2206G)\n\nIn the first part of the study, we evaluated the effect of a halogen substitutions on each position of\nX, Y, and Z on the GAT228 scaffold (Figure 3-1a). Because position Y has 4 possible\nsubstitutions for a halogen whereas positions X and Z have 3, due to sigma bond rotation of the\nphenyl ring, we evaluated 36 constitutional isomers for each halogen totaling 144 unique ligands.\nThe rationale for studying all 4 halogens (fluorine, chlorine, bromine, and iodine) was to determine\nthe effects that both bond length and atomic radius have on relative binding affinity. In addition,\nhalogen substitution on the aromatic rings \u2013 primarily with fluorine or chlorine \u2013 was expected to\nalter the electron density and affect \u03c0-\u03c0 stacking interactions between ligand and receptor aromatic\nrings. Given that GAT228 is comprised of unmodified phenyl rings and has been experimentally\nshown to bind to the ago-PAM site with high affinity, this compound was used as a control\nproviding a benchmark \u2206G value for comparison that was calculated to be -65.24 kcal/mol (Figure\n3-2). Previous in vitro studies have shown that 2 GAT228 derivatives that each have 3 fluorine\nsubstitutions \u2013 GAT1665 and GAT1667 \u2013 both bind to and activate CB1R, but interestingly a\nsignificant increase in \u2206G was only observed for GAT1667 (\u2206G GAT1667 = -70.88 kcal/mol)\nwhen compared to GAT228, but not GAT1665 (\u2206G GAT1665 = -65.74 kcal/mol) (Figure 3-2).\n95\nFor 20/36 fluorinated analogs, \u2206G was less than -65.24 kcal/mol indicating a greater relative\nbinding affinity at CB1R. Four fluorine analogs displayed a \u2206G less than -70.00 kcal/mol. When\nall 36 fluorine isomers were docked, 16/36 did not meet the requirement of a dual H-bond with\nR148 and an H-bond with H2.41 and thus were not considered (Figure 3-2).\n83 For the remaining\n20 ligands that did dock correctly, a significant increase in relative binding affinity was observed\nas shown by a lower \u2206G. To further evaluate how much space is available to accommodate larger \n66\nsubstituents on each ring inside the CB1R ago-PAM site, 36 brominated analogs were docked.\nEighteen of 36 ligands did not dock to the CB1R ago-PAM site, and for the remaining 18 ligands\nthat did bind the \u2206G was greater than that of the chlorinated analogs indicating a decrease in\nbinding affinity. This suggests that the chlorinated analogs display the greatest relative binding\naffinity.", "start_char_idx": 85617, "end_char_idx": 89306, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ab536b16-72a5-40ed-8fdb-ca39960ca097": {"__data__": {"id_": "ab536b16-72a5-40ed-8fdb-ca39960ca097", "embedding": null, "metadata": {"file_path": "data/brandt-no-intro.txt", "file_name": "brandt-no-intro.txt", "file_type": "text/plain", "file_size": 239829, "creation_date": "2023-12-31", "last_modified_date": "2023-12-31", "last_accessed_date": "2023-12-31"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "a0eaa9a5-aece-426b-8f20-580de8fb9f35", "node_type": "4", "metadata": {"file_path": "data/brandt-no-intro.txt", "file_name": "brandt-no-intro.txt", "file_type": "text/plain", "file_size": 239829, "creation_date": "2023-12-31", "last_modified_date": "2023-12-31", "last_accessed_date": "2023-12-31"}, "hash": "76e194b2637b440a1b1cdf5698cae061524bb4d7a3b73dfc2ba71d268a3f7019", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b15a7c26-e188-4c10-9c6c-4fdb6456b8e9", "node_type": "1", "metadata": {"file_path": "data/brandt-no-intro.txt", "file_name": "brandt-no-intro.txt", "file_type": "text/plain", "file_size": 239829, "creation_date": "2023-12-31", "last_modified_date": "2023-12-31", "last_accessed_date": "2023-12-31"}, "hash": "c382a75a2a4e65491731688eb6cf44a6d178f8795ab45b5a041d475b6f4efa86", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cdd30fbc-84ba-473b-8550-cf8b4a337bbf", "node_type": "1", "metadata": {}, "hash": "1f600e9c1373d869deac3cb85b20e8651b62212e3c411fe0d38b8491a1ce294c", "class_name": "RelatedNodeInfo"}}, "hash": "ff86836df62b80e052d389d0f51314763814f7dadaa7d668d23c3fb7ce0bf24d", "text": "83 For the remaining\n20 ligands that did dock correctly, a significant increase in relative binding affinity was observed\nas shown by a lower \u2206G. To further evaluate how much space is available to accommodate larger \n66\nsubstituents on each ring inside the CB1R ago-PAM site, 36 brominated analogs were docked.\nEighteen of 36 ligands did not dock to the CB1R ago-PAM site, and for the remaining 18 ligands\nthat did bind the \u2206G was greater than that of the chlorinated analogs indicating a decrease in\nbinding affinity. This suggests that the chlorinated analogs display the greatest relative binding\naffinity. Lastly, 36 of the iodinated analogs were docked to the CB1R ago-PAM site and 27/36\nligands did not dock to the targeted ago-PAM site. The remaining 9 ligands showed weaker relative\nbinding affinity than the brominated analogs. Overall, this suggests that to optimize relative\nbinding affinity the aromatic rings within the GAT228 scaffold are best-substituted with chlorine\natoms to minimize the binding energy between CB1R and the ligand within the modelingCB1R\nago-PAM site. \n67\nF Cl Br I GAT228 X1\n,Y1\n,Z1 X1\n,Y1\n,Z2 X1\n,Y1\n,Z3 X1\n,Y2\n,Z1 X1\n,Y2\n,Z2 X1\n,Y2\n,Z3 X1\n,Y3\n,Z1 X1\n,Y3\n,Z2 X1\n,Y3\n,Z3 X1\n,Y4\n,Z1 X1\n,Y4\n,Z2 X1\n,Y4\n,Z3 X2\n,Y1\n,Z1 X2\n,Y1\n,Z2 X2\n,Y1\n,Z3 X2\n,Y2\n,Z1 X2\n,Y2\n,Z2 X2\n,Y2\n,Z3 X2\n,Y3\n,Z1 X2\n,Y3\n,Z2 X2\n,Y3\n,Z3 X2\n,Y4\n,Z1 X2\n,Y4\n,Z2 X2\n,Y4\n,Z3 X3\n,Y1\n,Z1 X3\n,Y1\n,Z2 X3\n,Y1\n,Z3 X3\n,Y2\n,Z1 X3\n,Y2\n,Z2 X3\n,Y2\n,Z3 X3\n,Y3\n,Z1 X3\n,Y3\n,Z2 X3\n,Y3\n,Z3 X3\n,Y4\n,Z1 X3\n,Y4\n,Z2 X3\n,Y4\n,Z3\n\u0394G (kcal/mol) GAT1665 GAT1667\n-85\n-80\n-75\n-70\n-65\n-60\n-55 F Cl Br I GAT228 X1\n,Y1\n,Z1 X1\n,Y1\n,Z2 X1\n,Y1\n,Z3 X2\n,Y1\n,Z1 X2\n,Y1\n,Z2 X2\n,Y1\n,Z3 X3\n,Y1\n,Z1 X3\n,Y1\n,Z2 X3\n,Y1\n,Z3 X1\n,Y2\n,Z1 X1\n,Y2\n,Z2 X1\n,Y2\n,Z3 X2\n,Y2\n,Z1 X2\n,Y2\n,Z2 X2\n,Y2\n,Z3 X3\n,Y2\n,Z1 X3\n,Y2\n,Z2 X3\n,Y2\n,Z3 X1\n,Y3\n,Z1 X1\n,Y3\n,Z2 X1\n,Y3\n,Z3 X2\n,Y3\n,Z1 X2\n,Y3\n,Z2 X2\n,Y3\n,Z3 X3\n,Y3\n,Z1 X3\n,Y3\n,Z2 X3\n,Y3\n,Z3 X1\n,Y4\n,Z1 X1\n,Y4\n,Z2 X1\n,Y4\n,Z3 X2\n,Y4\n,Z1 X2\n,Y4\n,Z2 X2\n,Y4\n,Z3 X3\n,", "start_char_idx": 88697, "end_char_idx": 90643, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cdd30fbc-84ba-473b-8550-cf8b4a337bbf": {"__data__": {"id_": "cdd30fbc-84ba-473b-8550-cf8b4a337bbf", "embedding": null, "metadata": {"file_path": "data/brandt-no-intro.txt", "file_name": "brandt-no-intro.txt", "file_type": "text/plain", "file_size": 239829, "creation_date": "2023-12-31", "last_modified_date": "2023-12-31", "last_accessed_date": "2023-12-31"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "a0eaa9a5-aece-426b-8f20-580de8fb9f35", "node_type": "4", "metadata": {"file_path": "data/brandt-no-intro.txt", "file_name": "brandt-no-intro.txt", "file_type": "text/plain", "file_size": 239829, "creation_date": "2023-12-31", "last_modified_date": "2023-12-31", "last_accessed_date": "2023-12-31"}, "hash": "76e194b2637b440a1b1cdf5698cae061524bb4d7a3b73dfc2ba71d268a3f7019", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ab536b16-72a5-40ed-8fdb-ca39960ca097", "node_type": "1", "metadata": {"file_path": "data/brandt-no-intro.txt", "file_name": "brandt-no-intro.txt", "file_type": "text/plain", "file_size": 239829, "creation_date": "2023-12-31", "last_modified_date": "2023-12-31", "last_accessed_date": "2023-12-31"}, "hash": "ff86836df62b80e052d389d0f51314763814f7dadaa7d668d23c3fb7ce0bf24d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "49e2bc8b-9caa-44af-84c7-1c6db1b3a2f3", "node_type": "1", "metadata": {}, "hash": "fffae9f23e87f8132e78d685e5aeabe556d7ac1f9361fcfb2fae5821bc78b848", "class_name": "RelatedNodeInfo"}}, "hash": "1f600e9c1373d869deac3cb85b20e8651b62212e3c411fe0d38b8491a1ce294c", "text": "Y2\n,Z2 X2\n,Y2\n,Z3 X3\n,Y2\n,Z1 X3\n,Y2\n,Z2 X3\n,Y2\n,Z3 X1\n,Y3\n,Z1 X1\n,Y3\n,Z2 X1\n,Y3\n,Z3 X2\n,Y3\n,Z1 X2\n,Y3\n,Z2 X2\n,Y3\n,Z3 X3\n,Y3\n,Z1 X3\n,Y3\n,Z2 X3\n,Y3\n,Z3 X1\n,Y4\n,Z1 X1\n,Y4\n,Z2 X1\n,Y4\n,Z3 X2\n,Y4\n,Z1 X2\n,Y4\n,Z2 X2\n,Y4\n,Z3 X3\n,Y4\n,Z1 X3\n,Y4\n,Z2 X3\n,Y4\n,Z3\n\u0394G (kcal/mol)\nGAT1665\nGAT1667\n-85\n-80\n-75\n-70\n-65\n-60\n-55 F Cl Br I GAT228 X1\n,Y1\n,Z1 X2\n,Y1\n,Z1 X3\n,Y1\n,Z1 X1\n,Y2\n,Z1 X2\n,Y2\n,Z1 X3\n,Y2\n,Z1 X1\n,Y3\n,Z1 X2\n,Y3\n,Z1 X3\n,Y3\n,Z1 X1\n,Y4\n,Z1 X2\n,Y4\n,Z1 X3\n,Y4\n,Z1 X1\n,Y1\n,Z2 X2\n,Y1\n,Z2 X3\n,Y1\n,Z2 X1\n,Y2\n,Z2 X2\n,Y2\n,Z2 X3\n,Y2\n,Z2 X1\n,Y3\n,Z2 X2\n,Y3\n,Z2 X3\n,Y3\n,Z2 X1\n,Y4\n,Z2 X2\n,Y4\n,Z2 X3\n,Y4\n,Z2 X1\n,Y1\n,Z3 X2\n,Y1\n,Z3 X3\n,Y1\n,Z3 X1\n,Y2\n,Z3 X2\n,Y2\n,Z3 X3\n,Y2\n,Z3 X1\n,Y3\n,Z3 X2\n,Y3\n,Z3 X3\n,Y3\n,Z3 X1\n,Y4\n,Z3 X2\n,Y4\n,Z3 X3\n,Y4\n,Z3\nGAT1665 GAT1667\n\u0394G (kcal/mol)\n-85\n-80\n-75\n-70\n-65\n-60\n-55\na. b. c. Organized by\nsubstition on X Organized by\nsubstition on Y Organized by\nsubstition on Z\nFigure 3-2. The MMGBSA values were plotted in GraphPad Prism (v.9.1.1) and displayed\nas a heatmap. The heat map spans from -55 kcal/mol (light yellow) to -85 kcal/mol (dark purple).\nBecause there are 3 sites that underwent substitution each graph contains identical data that are reorganized by each site to show how each site is affected by specific substitutions of a H with a\nhalogen atom. Areas on the graphs that are white represent compounds that did not have a dual Hbond with R148 and an H-bond with H2.41 (Figure 3-1b).\n68\nUpon further examination of the CB1R ago-PAM site it was observed that an arginine residue\nR(4.39) lies near near site Y of the GAT228 scaffold. Since arginine is an H-bond donor and is\nnear site Y of the GAT228 scaffold, we hypothesized that the introduction of a H-bond acceptor\nplaced at the correct position of site Y could lead to a new H-bond and increase the relative binding\naffinity (Figure 3-1b). To evaluate this design strategy, a nitro group (NO2) was placed on\npositions 1, 2, or 3 of site Y and docked to the ago-PAM site of CB1R.", "start_char_idx": 90423, "end_char_idx": 92374, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "49e2bc8b-9caa-44af-84c7-1c6db1b3a2f3": {"__data__": {"id_": "49e2bc8b-9caa-44af-84c7-1c6db1b3a2f3", "embedding": null, "metadata": {"file_path": "data/brandt-no-intro.txt", "file_name": "brandt-no-intro.txt", "file_type": "text/plain", "file_size": 239829, "creation_date": "2023-12-31", "last_modified_date": "2023-12-31", "last_accessed_date": "2023-12-31"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "a0eaa9a5-aece-426b-8f20-580de8fb9f35", "node_type": "4", "metadata": {"file_path": "data/brandt-no-intro.txt", "file_name": "brandt-no-intro.txt", "file_type": "text/plain", "file_size": 239829, "creation_date": "2023-12-31", "last_modified_date": "2023-12-31", "last_accessed_date": "2023-12-31"}, "hash": "76e194b2637b440a1b1cdf5698cae061524bb4d7a3b73dfc2ba71d268a3f7019", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cdd30fbc-84ba-473b-8550-cf8b4a337bbf", "node_type": "1", "metadata": {"file_path": "data/brandt-no-intro.txt", "file_name": "brandt-no-intro.txt", "file_type": "text/plain", "file_size": 239829, "creation_date": "2023-12-31", "last_modified_date": "2023-12-31", "last_accessed_date": "2023-12-31"}, "hash": "1f600e9c1373d869deac3cb85b20e8651b62212e3c411fe0d38b8491a1ce294c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6ec1c67f-ffb0-48b0-8508-3da256b4dd95", "node_type": "1", "metadata": {}, "hash": "020c981ece80b5a07e2c4c402c5a6519a0046328e0d619e09e1789ecce663dbc", "class_name": "RelatedNodeInfo"}}, "hash": "fffae9f23e87f8132e78d685e5aeabe556d7ac1f9361fcfb2fae5821bc78b848", "text": "Areas on the graphs that are white represent compounds that did not have a dual Hbond with R148 and an H-bond with H2.41 (Figure 3-1b).\n68\nUpon further examination of the CB1R ago-PAM site it was observed that an arginine residue\nR(4.39) lies near near site Y of the GAT228 scaffold. Since arginine is an H-bond donor and is\nnear site Y of the GAT228 scaffold, we hypothesized that the introduction of a H-bond acceptor\nplaced at the correct position of site Y could lead to a new H-bond and increase the relative binding\naffinity (Figure 3-1b). To evaluate this design strategy, a nitro group (NO2) was placed on\npositions 1, 2, or 3 of site Y and docked to the ago-PAM site of CB1R.\n126,127 Interestingly, analogs\nwith the NO2 group at positions 1 and 3 did not form this H-bond with R4.39 presumably because\nthe NO2 group was too far away. In contrast, those derivatives with NO2 at position 2 formed a\ndual H-bond with R4.39. While the control compound GAT228 had a \u2206G of -65.24 kcal/mol, the\nNO2 derivative at position 2 of site Y had a \u2206G of -71.70 kcal/mol, which is likely attributable to\nthe NO2 group. Eight fluorinated analogs of the NO2 derivative were also docked to the ago-PAM\nsite of CB1R with 6/8 showing greater relative binding affinity than GAT228 or the NO2-\nsubstituted GAT228 analog (Figure 3-3). This same approach was executed for 8 of the\nchlorinated analogs and only 3 docked to the CB1R ago-PAM site; with 2 analogs having increased\nbinding affinity over the fluorinated analogs (Figure 3-3). The addition of the dual H-bond with\nR4.39 slightly changes the binding pose in such a way that when chlorines are added little room is\navailable in the binding pocket, which leads to unfavorable steric clashing. We then created a series\nof 8 NO2-fluorinated or -chlorinated compounds on site X and Z. It was observed that a\ncombination of fluorine and chlorine increased \u2206G relative to GAT228 but performed worse than\nthe fluorine substitution. Overall, in this set of compounds studied fluorine substitution performed\nthe best when a NO2 group was placed on position 2 of site Y.\n69\nX1 F X2 F X1 Cl X2 Cl GAT228 Z2 NO2 Y1 F Y2 F Y3 F Y4 F Y1 Cl Y2 Cl Y3 Cl Y4 Cl\n\u0394G (kcal/mol)\n-85\n-80\n-75\n-70\n-65\n-60\n-55\nFigure 3-3. MMGBSA values were plotted using GraphPad Prism (v.9.1.1) and displayed as\na heatmap. The heat map spans from -55 kcal/mol (light yellow) to -85 kcal/mol (dark purple).\nFor this series of ligands Z2 was set as a NO2 to form the H-bond with R4.39 while sites X and Y\nwere set to evaluate different derivatives bearing fluorine and chlorine. Blank spots are\nrepresentative of compound that did not dock in the correct pose (Figure 3-1b). \n70\nWe then looked at the effects of replacing the ring at site X with a series of pyridine derivatives.\nIt was found that the optimal position for the nitrogen in the pyridine ring was para to the R\nsubstituent (Figure 3-4a), which was 2.25 kcal/mol more stable than the fluorinated GAT228\ncontrol (GAT1665). Placing the nitrogen at any other position within the ring led to reduced\nbinding affinity compared to the control compound. This was further tested with a series of\npyrimidine derivatives. Although the 1,2 and 4,5 analogs bound to the site with higher affinity, all\nperformed worse than the control, GAT1665. The phenyl ring at site X was also changed to several\nother 5 membered thiazole and thiophene rings (Figure 3-4b). The compounds of this class that\nperformed the best were the thiazole substituted compounds where 2/3 of them showed higher\nrelative binding affinity than the control.", "start_char_idx": 91690, "end_char_idx": 95268, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6ec1c67f-ffb0-48b0-8508-3da256b4dd95": {"__data__": {"id_": "6ec1c67f-ffb0-48b0-8508-3da256b4dd95", "embedding": null, "metadata": {"file_path": "data/brandt-no-intro.txt", "file_name": "brandt-no-intro.txt", "file_type": "text/plain", "file_size": 239829, "creation_date": "2023-12-31", "last_modified_date": "2023-12-31", "last_accessed_date": "2023-12-31"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "a0eaa9a5-aece-426b-8f20-580de8fb9f35", "node_type": "4", "metadata": {"file_path": "data/brandt-no-intro.txt", "file_name": "brandt-no-intro.txt", "file_type": "text/plain", "file_size": 239829, "creation_date": "2023-12-31", "last_modified_date": "2023-12-31", "last_accessed_date": "2023-12-31"}, "hash": "76e194b2637b440a1b1cdf5698cae061524bb4d7a3b73dfc2ba71d268a3f7019", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "49e2bc8b-9caa-44af-84c7-1c6db1b3a2f3", "node_type": "1", "metadata": {"file_path": "data/brandt-no-intro.txt", "file_name": "brandt-no-intro.txt", "file_type": "text/plain", "file_size": 239829, "creation_date": "2023-12-31", "last_modified_date": "2023-12-31", "last_accessed_date": "2023-12-31"}, "hash": "fffae9f23e87f8132e78d685e5aeabe556d7ac1f9361fcfb2fae5821bc78b848", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0a77778e-2844-4b0d-8977-0a1f423024a6", "node_type": "1", "metadata": {}, "hash": "803d1bfbaaff4a1d04928e0d478f6be5aa371d87372dede17c9d81e3dee9135d", "class_name": "RelatedNodeInfo"}}, "hash": "020c981ece80b5a07e2c4c402c5a6519a0046328e0d619e09e1789ecce663dbc", "text": "Placing the nitrogen at any other position within the ring led to reduced\nbinding affinity compared to the control compound. This was further tested with a series of\npyrimidine derivatives. Although the 1,2 and 4,5 analogs bound to the site with higher affinity, all\nperformed worse than the control, GAT1665. The phenyl ring at site X was also changed to several\nother 5 membered thiazole and thiophene rings (Figure 3-4b). The compounds of this class that\nperformed the best were the thiazole substituted compounds where 2/3 of them showed higher\nrelative binding affinity than the control. This systematic approach was also applied to site Y. All\nbut 1 of the pyridine derivatives at this site performed worse than the control whereas for the\npyrimidine derivatives 4/6 performed better than the control. Substitution of site Z with thiophene\n(Figure 3-4c) was well tolerated but performed worse than the control. Overall, this suggest that\nchanging site X or Z to a heterocyclic functional group does not seem to cause drastic changes to\nrelative binding affinity.\n71\nFigure 3-4. MMGBSA values were plotted in GraphPad Prism (v.9.1.1) and displayed as a\nheatmap. The heat map spans from -55 kcal/mol (light yellow) to -85 kcal/mol (dark purple). For\nthis series of ligands, calculations were performed on a series of both pyridine and cyclopentadiene\nderivatives.\n72\n3.3.2 GAT228 Isomers Differ in their Physicochemical and Pharmacokinetic Properties\nAlthough MMGBSA is a validated tool for predicting the relative binding affinity of a\nligand/receptor complex, these measurements are representative of the pharmacodynamics of the\nligand only. In order to further evaluate each analog to assist in identifying potential therapeutic\ncandidates, we predicted the PK properties of each ligand using the QikProp module in Maestro.\nFor the halogenated GAT228 compounds, each analog broke at least 1 of Lipinski\u2019s rules having\nan n-octanol-water partition coefficient (KOW) > 5. (Table 3-2 \u2013 Table 3-7). However, 11\ncompounds from Table 3-6 and 4 compounds from Table 3-7 display a Kow < 5 thus making these\nmore attractive candidates as lead compounds. Select compounds also had a molecular weight >\n500 Da. From this perspective the fluorinated and chlorinated derivatives were better candidates\nthat could potentially be used as a drug-like molecules compared to the brominated and iodinated\nderivatives. Notably, all fluorinated and chlorinated analogs are predicted to have 100% oral\nabsorption whereas the brominated and iodinated derivatives do not. Because the structures of the\nhalogenated derivatives are quite similar, the number of H-bond acceptors is 2 and donors are 1.\nAs discussed above, the H-bond donor is the hydrogen on the indole while the H-bond acceptors\nare the 2 oxygens on the NO2 group. For all the halogenated GAT228 derivatives, the predicted\nblood/brain barrier partition coefficient (QPlogBB) fell within the reference range. For ligands in\nTable 3-6 NO2 substitution at site Z reduces the bioavailability of ligands in Table 3-2 and Table\n3-3 by approximately 12%. For the last set of compounds where the ring at site X or Z was replaced\nwith pyridine and cyclopentadiene rings all but 4 of the compounds broke 1 Lipinski rule being\nQPlog o/w but were still within the recommended range. All of these 25 compounds except for 2\ndisplayed human oral absorption greater than 80% (Table 3-7)\n73\n3.3.3 Selecting Lead Compounds\nA lead compound in this case should display greater relative binding affinity than GAT228, break\nnone of Lipinski\u2019s rules and be able to cross the blood-brain barrier. In terms of the blood-brain\nbarrier metric (QPlogBB) larger negative values are indicative of limited accessibility into the\nblood brain barrier by passive diffusion and will likely become concentrated in the periphery.\n128\nEven though the compounds in Table 3-6 6 are still within the accepted range of QPlogBB, the\nadded NO2 group limits their ability to cross the blood-brain barrier via passive diffusion thus these\ncompounds would not be considered lead candidates.", "start_char_idx": 94676, "end_char_idx": 98766, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0a77778e-2844-4b0d-8977-0a1f423024a6": {"__data__": {"id_": "0a77778e-2844-4b0d-8977-0a1f423024a6", "embedding": null, "metadata": {"file_path": "data/brandt-no-intro.txt", "file_name": "brandt-no-intro.txt", "file_type": "text/plain", "file_size": 239829, "creation_date": "2023-12-31", "last_modified_date": "2023-12-31", "last_accessed_date": "2023-12-31"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "a0eaa9a5-aece-426b-8f20-580de8fb9f35", "node_type": "4", "metadata": {"file_path": "data/brandt-no-intro.txt", "file_name": "brandt-no-intro.txt", "file_type": "text/plain", "file_size": 239829, "creation_date": "2023-12-31", "last_modified_date": "2023-12-31", "last_accessed_date": "2023-12-31"}, "hash": "76e194b2637b440a1b1cdf5698cae061524bb4d7a3b73dfc2ba71d268a3f7019", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6ec1c67f-ffb0-48b0-8508-3da256b4dd95", "node_type": "1", "metadata": {"file_path": "data/brandt-no-intro.txt", "file_name": "brandt-no-intro.txt", "file_type": "text/plain", "file_size": 239829, "creation_date": "2023-12-31", "last_modified_date": "2023-12-31", "last_accessed_date": "2023-12-31"}, "hash": "020c981ece80b5a07e2c4c402c5a6519a0046328e0d619e09e1789ecce663dbc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1b8b41ec-e48c-4c71-bede-c100b46a35d8", "node_type": "1", "metadata": {}, "hash": "5f890e3e9d58dcc0f10bd3f1b786beef7486c855ad228e9f50c13ac5f79af4ff", "class_name": "RelatedNodeInfo"}}, "hash": "803d1bfbaaff4a1d04928e0d478f6be5aa371d87372dede17c9d81e3dee9135d", "text": "All of these 25 compounds except for 2\ndisplayed human oral absorption greater than 80% (Table 3-7)\n73\n3.3.3 Selecting Lead Compounds\nA lead compound in this case should display greater relative binding affinity than GAT228, break\nnone of Lipinski\u2019s rules and be able to cross the blood-brain barrier. In terms of the blood-brain\nbarrier metric (QPlogBB) larger negative values are indicative of limited accessibility into the\nblood brain barrier by passive diffusion and will likely become concentrated in the periphery.\n128\nEven though the compounds in Table 3-6 6 are still within the accepted range of QPlogBB, the\nadded NO2 group limits their ability to cross the blood-brain barrier via passive diffusion thus these\ncompounds would not be considered lead candidates. The fluorinated, chlorinated, brominated,\nand iodinated compounds in Table 3-2 \u2013 Table 3-5 break at least one of Lipinsk\u2019si rules and these\ncompounds can be disregarded. Of the fluorinated and chlorinated compounds in Table 3-2 and\nTable 3-3, 3 disobey QPlog o/w rules, the brominated and iodinated compounds in Table 3-4 and\nTable 3-5 break the molecular mass rule (i.e. mass > 500 kDa). With all of these factors considered,\nonly 4 compounds from Table 3-7 satisfy all criteria and are considered lead candidates (Figure\n5). While GAT228 breaks one of Lipinski\u2019s rules, compounds \u2018a\u2019 \u2013 \u2018d\u2019 do not. All of these\ncompounds have a significantly better MMGBSA than GAT228. Overall compound C shows the\ngreatest promise as it theoretically crosses the blood-brain barrier better than GAT228 when the\nQPlogBB values are compared. However, in an in vivo or in vitro setting these slight differences\nmight be negligible and or non-translatable and thus future in vitro assessment of compounds \u2018a\u2019\n\u2013 \u2018d\u2019 would test the reliability of these modeling softwares and their utility in the advancement of\nnovel CB1R ligands.\n74\nFigure 3-5. Four lead compounds were selected of the 202 compounds analyzed based on modeled\nMMGBSA and PK data.\n75\n\n3.4 Conclusion\n\nHerein, we report the use of computational methods to identify lead compounds, based on\nderivatives of the GAT scaffold, predicted to bind to the CB1R ago-PAM site as potential drug\ncandidates. This was achieved by combining MMGBSA calculations to identify compounds that\nhave greater relative affinity towards CB1R than GAT228 along with predictions of\nphysicochemical and PK parameters. In general, we determined that the addition of chlorine atoms\nonto the phenyl rings as well as introduction of a pyridine ring into the GAT228 scaffold led to\nimproved binding affinity. Subsequent studies are required to synthetize the lead compounds\nidentified here followed by experiments, in vitro and in vivo, to determine their potency, efficacy\nand PK properties. Ultimately it is hoped that the technologies incorporated into the present study\ncan be implemented to expedite CB1R drug discovery specifically \u2013 and GPCR drug discovery\ngenerally \u2013 while also avoiding costly in vitro experimentation and unnecessary animal usage for\nin vivo studies.\n76\n\n3.5 Supplementary Info\n\nTable 3-2. ADME analysis of Fluorinated Substituted GAT228 Compounds Compound Mol. WT. QPlogBB Donor HB Accept HB QPlog o/w Rule Of Five\n% Human\nOral\nAbsorption\nMM- GBSA\n(kkal/mol)\nReference 130 \u2013\n725\n-3.0 \u2013 1.2 0 \u2013 6.0 2.0 \u2013 20.0 -2.0 \u2013 6.5 4 is Max >80% is\nhigh\nn/a\nGAT228 342.396 -0.579 1 2 5.215 1 100 -65.24\nX1 =F, Y1 = F,\nZ1 = F\n396.368\n-0.331\n1.000 2.000\n5.453\n1 100.000 -66.73\nX1 =F, Y1 = F,\nZ2 = F\n396.368\n-0.288\n1.000 2.000\n5.605\n1 100.000 -70.88\nX1 =F, Y1 = F,\nZ3 = F\n396.368\n-0.286\n1.000 2.000\n5.609\n1 100.", "start_char_idx": 97994, "end_char_idx": 101605, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1b8b41ec-e48c-4c71-bede-c100b46a35d8": {"__data__": {"id_": "1b8b41ec-e48c-4c71-bede-c100b46a35d8", "embedding": null, "metadata": {"file_path": "data/brandt-no-intro.txt", "file_name": "brandt-no-intro.txt", "file_type": "text/plain", "file_size": 239829, "creation_date": "2023-12-31", "last_modified_date": "2023-12-31", "last_accessed_date": "2023-12-31"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "a0eaa9a5-aece-426b-8f20-580de8fb9f35", "node_type": "4", "metadata": {"file_path": "data/brandt-no-intro.txt", "file_name": "brandt-no-intro.txt", "file_type": "text/plain", "file_size": 239829, "creation_date": "2023-12-31", "last_modified_date": "2023-12-31", "last_accessed_date": "2023-12-31"}, "hash": "76e194b2637b440a1b1cdf5698cae061524bb4d7a3b73dfc2ba71d268a3f7019", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0a77778e-2844-4b0d-8977-0a1f423024a6", "node_type": "1", "metadata": {"file_path": "data/brandt-no-intro.txt", "file_name": "brandt-no-intro.txt", "file_type": "text/plain", "file_size": 239829, "creation_date": "2023-12-31", "last_modified_date": "2023-12-31", "last_accessed_date": "2023-12-31"}, "hash": "803d1bfbaaff4a1d04928e0d478f6be5aa371d87372dede17c9d81e3dee9135d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "27b59cff-59a9-41ae-8eb9-03a5f6b63cb9", "node_type": "1", "metadata": {}, "hash": "87e0da3603adfdbf617201529461ef5da1f3385259b973dae4c0a7e8a81d11f2", "class_name": "RelatedNodeInfo"}}, "hash": "5f890e3e9d58dcc0f10bd3f1b786beef7486c855ad228e9f50c13ac5f79af4ff", "text": "0 2.0 \u2013 20.0 -2.0 \u2013 6.5 4 is Max >80% is\nhigh\nn/a\nGAT228 342.396 -0.579 1 2 5.215 1 100 -65.24\nX1 =F, Y1 = F,\nZ1 = F\n396.368\n-0.331\n1.000 2.000\n5.453\n1 100.000 -66.73\nX1 =F, Y1 = F,\nZ2 = F\n396.368\n-0.288\n1.000 2.000\n5.605\n1 100.000 -70.88\nX1 =F, Y1 = F,\nZ3 = F\n396.368\n-0.286\n1.000 2.000\n5.609\n1 100.000 -70.29\nX2 =F, Y1 = F,\nZ1 = F\n396.368\n-0.252\n1.000 2.000\n5.654\n1 100.000 -66.06\nX2 =F, Y1 = F,\nZ2 = F\n396.368\n-0.238\n1.000 2.000\n5.682\n1 100.000 -66.99\nX2 =F, Y1 = F,\nZ3 = F\n396.368\n-0.141\n1.000 2.000\n5.769\n1 100.000 -70.09\nX3 =F, Y1 = F,\nZ1 = F\n396.368\n-0.253\n1.000 2.000\n5.652\n1 100.000 -64.65\nX3 =F, Y1 = F,\nZ2 = F\n396.368\n-0.244\n1.000 2.000\n5.693\n1 100.000 -65.43\nX3 =F, Y1 = F,\nZ3 = F\n396.368\n-0.245\n1.000 2.000\n5.692\n1 100.000 -64.75\nX1 =F, Y2 = F,\nZ1 = F\n396.368\n-0.306\n1.000 2.000\n5.551\n1 100.000 -66.27\nX1 =F, Y2 = F,\nZ2 = F\n396.368\n-0.321\n1.000 2.000\n5.584\n1 100.000 -65.74\nX1 =F, Y2 = F,\nZ3 = F\n396.368\n-0.307\n1.000 2.000\n5.578\n1 100.000 -68.77\nX2 =F, Y2 = F,\nZ1 = F\n396.368\n-0.268\n1.000 2.000\n5.65\n1 100.000 -64.69\nX2 =F, Y2 = F,\nZ2 = F\n396.368\n-0.262\n1.000 2.000\n5.686\n1 100.000 -65.86\nX2 =F, Y2 = F,\nZ3 = F\n396.368\n-0.261\n1.000 2.000\n5.667\n1 100.000 -65.34\nX3 =F, Y2 = F,\nZ1 = F\n396.368\n-0.276\n1.000 2.000\n5.589\n1 100.000 -63.44\nX3 =F, Y2 = F,\nZ2 = F\n396.368\n-0.26\n1.000 2.000\n5.67\n1 100.000 -64.48\nX3 =F, Y2 = F,\nZ3 = F\n396.368\n-0.27\n1.000 2.000\n5.769\n1 100.000 -62.95\nX1 =F, Y3 = F,\nZ1 = F\n396.368\n-0.313\n1.000 2.000\n5.57\n1 100.000 -64.78\nX1 =F, Y3 = F,\nZ2 = F\n396.368\n-0.326\n1.000 2.000\n5.597\n1 100.000 -64.85\nX1 =F, Y3 = F,", "start_char_idx": 101305, "end_char_idx": 102849, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "27b59cff-59a9-41ae-8eb9-03a5f6b63cb9": {"__data__": {"id_": "27b59cff-59a9-41ae-8eb9-03a5f6b63cb9", "embedding": null, "metadata": {"file_path": "data/brandt-no-intro.txt", "file_name": "brandt-no-intro.txt", "file_type": "text/plain", "file_size": 239829, "creation_date": "2023-12-31", "last_modified_date": "2023-12-31", "last_accessed_date": "2023-12-31"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "a0eaa9a5-aece-426b-8f20-580de8fb9f35", "node_type": "4", "metadata": {"file_path": "data/brandt-no-intro.txt", "file_name": "brandt-no-intro.txt", "file_type": "text/plain", "file_size": 239829, "creation_date": "2023-12-31", "last_modified_date": "2023-12-31", "last_accessed_date": "2023-12-31"}, "hash": "76e194b2637b440a1b1cdf5698cae061524bb4d7a3b73dfc2ba71d268a3f7019", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1b8b41ec-e48c-4c71-bede-c100b46a35d8", "node_type": "1", "metadata": {"file_path": "data/brandt-no-intro.txt", "file_name": "brandt-no-intro.txt", "file_type": "text/plain", "file_size": 239829, "creation_date": "2023-12-31", "last_modified_date": "2023-12-31", "last_accessed_date": "2023-12-31"}, "hash": "5f890e3e9d58dcc0f10bd3f1b786beef7486c855ad228e9f50c13ac5f79af4ff", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0310fae1-be20-417b-ad3d-62575f97ad54", "node_type": "1", "metadata": {}, "hash": "2f933dca0e903efcbc7199a687b6dad5cbaca8bbd676eff80ee5c0db7127d2a0", "class_name": "RelatedNodeInfo"}}, "hash": "87e0da3603adfdbf617201529461ef5da1f3385259b973dae4c0a7e8a81d11f2", "text": "44\nX3 =F, Y2 = F,\nZ2 = F\n396.368\n-0.26\n1.000 2.000\n5.67\n1 100.000 -64.48\nX3 =F, Y2 = F,\nZ3 = F\n396.368\n-0.27\n1.000 2.000\n5.769\n1 100.000 -62.95\nX1 =F, Y3 = F,\nZ1 = F\n396.368\n-0.313\n1.000 2.000\n5.57\n1 100.000 -64.78\nX1 =F, Y3 = F,\nZ2 = F\n396.368\n-0.326\n1.000 2.000\n5.597\n1 100.000 -64.85\nX1 =F, Y3 = F,\nZ3 = F\n396.368\n-0.301\n1.000 2.000\n5.584\n1 100.000 -70.01\n77\nX2 =F, Y3 = F,\nZ1 = F\n396.368\n-0.177\n1.000 2.000\n5.656\n1 100.000 -66.05\nX2 =F, Y3 = F,\nZ2 = F\n396.368\n-0.259\n1.000 2.000\n5.682\n1 100.000 -67.01\nX2 =F, Y3 = F,\nZ3 = F\n396.368\n-0.274\n1.000 2.000\n5.704\n1 100.000 -69.91\nX3 =F, Y3 = F,\nZ1 = F\n396.368\n-0.218\n1.000 2.000\n5.641\n1 100.000 -63.92\nX3 =F, Y3 = F,\nZ2 = F\n396.368\n-0.249\n1.000 2.000\n5.649\n1 100.000 -65.06\nX3 =F, Y3 = F,\nZ3 = F\n396.368\n-0.261\n1.000 2.000\n5.693\n1 100.000 -63.79\nX1 =F, Y4 = F,\nZ1 = F\n396.368\n-0.349\n1.000 2.000\n5.283\n1 100.000 -69.50\nX1 =F, Y4 = F,\nZ2 = F\n396.368\n-0.33\n1.000 2.000\n5.429\n1 100.000 -66.79\nX1 =F, Y4 = F,\nZ3 = F\n396.368\n-0.324\n1.000 2.000\n5.407\n1 100.000 -66.28\nX2 =F, Y4 = F,\nZ1 = F\n396.368\n-0.457\n1.000 2.000\n5.998\n1 100.000 -65.38\nX2 =F, Y4 = F,\nZ2 = F\n396.368\n-0.353\n1.000 2.000\n5.699\n1 100.000 -66.29\nX2 =F, Y4 = F,\nZ3 = F\n396.368\n-0.361\n1.000 2.000\n5.667\n1 100.000 -65.22\nX3 =F, Y4 = F,\nZ1 = F\n396.368\n-0.354\n1.000 2.000\n5.631\n1 100.000 -63.84\nX3 =F, Y4 = F,\nZ2 = F\n396.368\n-0.328\n1.000 2.000\n5.541\n1 100.000 -64.25\nX3 =F, Y4 = F,\nZ3 = F\n396.368\n-0.334\n1.000 2.000\n5.553\n1 100.000 -63.49\n78\nTable 3-3. ADME analysis of Chlorinated Substituted GAT228 Compounds Compound Mol. WT.", "start_char_idx": 102548, "end_char_idx": 104078, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0310fae1-be20-417b-ad3d-62575f97ad54": {"__data__": {"id_": "0310fae1-be20-417b-ad3d-62575f97ad54", "embedding": null, "metadata": {"file_path": "data/brandt-no-intro.txt", "file_name": "brandt-no-intro.txt", "file_type": "text/plain", "file_size": 239829, "creation_date": "2023-12-31", "last_modified_date": "2023-12-31", "last_accessed_date": "2023-12-31"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "a0eaa9a5-aece-426b-8f20-580de8fb9f35", "node_type": "4", "metadata": {"file_path": "data/brandt-no-intro.txt", "file_name": "brandt-no-intro.txt", "file_type": "text/plain", "file_size": 239829, "creation_date": "2023-12-31", "last_modified_date": "2023-12-31", "last_accessed_date": "2023-12-31"}, "hash": "76e194b2637b440a1b1cdf5698cae061524bb4d7a3b73dfc2ba71d268a3f7019", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "27b59cff-59a9-41ae-8eb9-03a5f6b63cb9", "node_type": "1", "metadata": {"file_path": "data/brandt-no-intro.txt", "file_name": "brandt-no-intro.txt", "file_type": "text/plain", "file_size": 239829, "creation_date": "2023-12-31", "last_modified_date": "2023-12-31", "last_accessed_date": "2023-12-31"}, "hash": "87e0da3603adfdbf617201529461ef5da1f3385259b973dae4c0a7e8a81d11f2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "297306db-ae99-4e76-9307-c0c6f93626eb", "node_type": "1", "metadata": {}, "hash": "de46f60f6da776868bd4a46d4477a9a3079e29129592b4412066a0c31e817477", "class_name": "RelatedNodeInfo"}}, "hash": "2f933dca0e903efcbc7199a687b6dad5cbaca8bbd676eff80ee5c0db7127d2a0", "text": "368\n-0.361\n1.000 2.000\n5.667\n1 100.000 -65.22\nX3 =F, Y4 = F,\nZ1 = F\n396.368\n-0.354\n1.000 2.000\n5.631\n1 100.000 -63.84\nX3 =F, Y4 = F,\nZ2 = F\n396.368\n-0.328\n1.000 2.000\n5.541\n1 100.000 -64.25\nX3 =F, Y4 = F,\nZ3 = F\n396.368\n-0.334\n1.000 2.000\n5.553\n1 100.000 -63.49\n78\nTable 3-3. ADME analysis of Chlorinated Substituted GAT228 Compounds Compound Mol. WT. QPlogBB Donor HB Accept HB QPlog o/w Rule of five\n% Human\nOral\nAbosorptio\nn\nMM- GBSA\n(kkal/mol)\nReference 130 \u2013 725 -3.0 \u2013\n1.2\n0 \u2013\n6.0\n2.0 \u2013 20.0 -2.0 \u2013 6.5 4 is\nMax\n>80%\nis high\nn/a\nGAT228 342.396 -0.579 1 2 5.215 1 100 -65.24\nX1 = Cl, Y1 = Cl,\nZ1 = Cl 445.732 -0.134 1 2 6.297 1 100\nX1 = Cl, Y1 = Cl,\nZ2 = Cl 445.732 -0.091 1 2 6.368 1 100\nX1 = Cl, Y1 = Cl,\nZ3 = Cl 445.732 -0.079 1 2 6.355 1 100\nX2 = Cl, Y1 = Cl,\nZ1 = Cl 445.732 -0.075 1 2 6.439 1 100\nX2 = Cl, Y1 = Cl,\nZ2 = Cl 445.732 -0.06 1 2 6.449 1 100\n-80.31\nX2 = Cl, Y1 = Cl,\nZ3 = Cl 445.732 -0.071 1 2 6.41 1 100\nX3 = Cl, Y1 = Cl,\nZ1 = Cl 445.732 -0.07 1 2 6.459 1 100\n-67.78\nX3 = Cl, Y1 = Cl,\nZ2 = Cl 445.732 -0.077 1 2 6.459 1 100\n-74.67\nX3 = Cl, Y1 = Cl,\nZ3 = Cl 445.732 -0.118 1 2 6.241 1 100\nX1 = Cl, Y2 = Cl,\nZ1 = Cl 445.732 -0.155 1 2 6.347 1 100\nX1 = Cl, Y2 = Cl,\nZ2 = Cl 445.732 -0.155 1 2 6.354 1 100\n-78.19\nX1 = Cl, Y2 = Cl,\nZ3 = Cl 445.732 -0.128 1 2 6.305 1 100\nX2 = Cl, Y2 = Cl,\nZ1 = Cl 445.732 -0.124 1 2 6.379 1 100\n-74.76\nX2 = Cl, Y2 = Cl,\nZ2 = Cl 445.732 -0.121 1 2 6.407 1 100\n-80.23\nX2 = Cl, Y2 = Cl,\nZ3 = Cl 445.732 -0.118 1 2 6.295 1 100\nX3 = Cl, Y2 = Cl,\nZ1 = Cl 445.732 -0.121 1 2 6.419 1 100\n-68.26\nX3 = Cl, Y2 = Cl,\nZ2 = Cl 445.732 -0.122 1 2 6.422 1 100\n-76.80\nX3 = Cl, Y2 = Cl,\nZ3 = Cl 445.732 -0.165 1 2 6.", "start_char_idx": 103727, "end_char_idx": 105376, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "297306db-ae99-4e76-9307-c0c6f93626eb": {"__data__": {"id_": "297306db-ae99-4e76-9307-c0c6f93626eb", "embedding": null, "metadata": {"file_path": "data/brandt-no-intro.txt", "file_name": "brandt-no-intro.txt", "file_type": "text/plain", "file_size": 239829, "creation_date": "2023-12-31", "last_modified_date": "2023-12-31", "last_accessed_date": "2023-12-31"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "a0eaa9a5-aece-426b-8f20-580de8fb9f35", "node_type": "4", "metadata": {"file_path": "data/brandt-no-intro.txt", "file_name": "brandt-no-intro.txt", "file_type": "text/plain", "file_size": 239829, "creation_date": "2023-12-31", "last_modified_date": "2023-12-31", "last_accessed_date": "2023-12-31"}, "hash": "76e194b2637b440a1b1cdf5698cae061524bb4d7a3b73dfc2ba71d268a3f7019", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0310fae1-be20-417b-ad3d-62575f97ad54", "node_type": "1", "metadata": {"file_path": "data/brandt-no-intro.txt", "file_name": "brandt-no-intro.txt", "file_type": "text/plain", "file_size": 239829, "creation_date": "2023-12-31", "last_modified_date": "2023-12-31", "last_accessed_date": "2023-12-31"}, "hash": "2f933dca0e903efcbc7199a687b6dad5cbaca8bbd676eff80ee5c0db7127d2a0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "81d39c1d-2db8-4c5c-bb81-0777c471a97a", "node_type": "1", "metadata": {}, "hash": "f55a616a9285bd1e383464055c1f544bb45058ece1f03a77ede3e5bda884342c", "class_name": "RelatedNodeInfo"}}, "hash": "de46f60f6da776868bd4a46d4477a9a3079e29129592b4412066a0c31e817477", "text": "379 1 100\n-74.76\nX2 = Cl, Y2 = Cl,\nZ2 = Cl 445.732 -0.121 1 2 6.407 1 100\n-80.23\nX2 = Cl, Y2 = Cl,\nZ3 = Cl 445.732 -0.118 1 2 6.295 1 100\nX3 = Cl, Y2 = Cl,\nZ1 = Cl 445.732 -0.121 1 2 6.419 1 100\n-68.26\nX3 = Cl, Y2 = Cl,\nZ2 = Cl 445.732 -0.122 1 2 6.422 1 100\n-76.80\nX3 = Cl, Y2 = Cl,\nZ3 = Cl 445.732 -0.165 1 2 6.143 1 100\n-69.26\nX1 = Cl, Y3 = Cl,\nZ1 = Cl 445.732 -0.185 1 2 6.268 1 100\n-73.21\nX1 = Cl, Y3 = Cl,\nZ2 = Cl 445.732 -0.148 1 2 6.369 1 100\n-76.84\nX1 = Cl, Y3 = Cl,\nZ3 = Cl 445.732 -0.127 1 2 6.335 1 100\nX2 = Cl, Y3 = Cl,\nZ1 = Cl 445.732 -0.127 1 2 6.401 1 100\n-72.21\nX2 = Cl, Y3 = Cl,\nZ2 = Cl 445.732 -0.155 1 2 6.4 1 100\n-79.63\n79\nX2 = Cl, Y3 = Cl,\nZ3 = Cl 445.732 -0.107 1 2 6.379 1 100\nX3 = Cl, Y3 = Cl,\nZ1 = Cl 445.732 -0.123 1 2 6.433 1 100\n-66.32\nX3 = Cl, Y3 = Cl,\nZ2 = Cl 445.732 -0.139 1 2 6.496 1 100\n-73.14\nX3 = Cl, Y3 = Cl,\nZ3 = Cl 445.732 -0.271 1 2 6.226 1 100\nX1 = Cl, Y4 = Cl,\nZ1 = Cl 445.732 -0.21 1 2 6.265 1 100\n-68.23\nX1 = Cl, Y4 = Cl,\nZ2 = Cl 445.732 -0.156 1 2 6.187 1 100\n-73.13\nX1 = Cl, Y4 = Cl,\nZ3 = Cl 445.732 -0.193 1 2 6.132 1 100\nX2 = Cl, Y4 = Cl,\nZ1 = Cl 445.732 -0.148 1 2 6.22 1 100\n-69.59\nX2 = Cl, Y4 = Cl,\nZ2 = Cl 445.732 -0.306 1 2 6.21 1 100\n-75.42\nX2 = Cl, Y4 = Cl,\nZ3 = Cl 445.732 -0.223 1 2 6.309 1 100\nX3 = Cl, Y4 = Cl,\nZ1 = Cl 445.732 -0.232 1 2 6.394 1 100\nX3 = Cl, Y4 = Cl,\nZ2 = Cl 445.732 -0.218 1 2 6.407 1 100\n-69.69\nX3 = Cl, Y4 = Cl,\nZ3 = Cl 445.732 -0.134 1 2 6.297 1 100\n80\nTable 3-4. ADME analysis of Brominated Substituted GAT228 Compounds Compoun\nd\nMol. WT.\nQPlogBB\nDonor HB\nAcceptor\nHB\nQPlog o/w\nRule of 5\n% Human\nOral\nAbsorption\nMM- GBSA\n(kkal/mol)\nReference 130 \u2013 725 -3.0 \u2013 1.2 0 \u2013 6.", "start_char_idx": 105063, "end_char_idx": 106714, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "81d39c1d-2db8-4c5c-bb81-0777c471a97a": {"__data__": {"id_": "81d39c1d-2db8-4c5c-bb81-0777c471a97a", "embedding": null, "metadata": {"file_path": "data/brandt-no-intro.txt", "file_name": "brandt-no-intro.txt", "file_type": "text/plain", "file_size": 239829, "creation_date": "2023-12-31", "last_modified_date": "2023-12-31", "last_accessed_date": "2023-12-31"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "a0eaa9a5-aece-426b-8f20-580de8fb9f35", "node_type": "4", "metadata": {"file_path": "data/brandt-no-intro.txt", "file_name": "brandt-no-intro.txt", "file_type": "text/plain", "file_size": 239829, "creation_date": "2023-12-31", "last_modified_date": "2023-12-31", "last_accessed_date": "2023-12-31"}, "hash": "76e194b2637b440a1b1cdf5698cae061524bb4d7a3b73dfc2ba71d268a3f7019", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "297306db-ae99-4e76-9307-c0c6f93626eb", "node_type": "1", "metadata": {"file_path": "data/brandt-no-intro.txt", "file_name": "brandt-no-intro.txt", "file_type": "text/plain", "file_size": 239829, "creation_date": "2023-12-31", "last_modified_date": "2023-12-31", "last_accessed_date": "2023-12-31"}, "hash": "de46f60f6da776868bd4a46d4477a9a3079e29129592b4412066a0c31e817477", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "87f9eb02-5f85-43be-aea7-96d9e24360a0", "node_type": "1", "metadata": {}, "hash": "b3d414351b13cfeb79f7ff0fc3eb163a69e4e9bee63b6ae784fdcacddffefa48", "class_name": "RelatedNodeInfo"}}, "hash": "f55a616a9285bd1e383464055c1f544bb45058ece1f03a77ede3e5bda884342c", "text": "Z1 = Cl 445.732 -0.232 1 2 6.394 1 100\nX3 = Cl, Y4 = Cl,\nZ2 = Cl 445.732 -0.218 1 2 6.407 1 100\n-69.69\nX3 = Cl, Y4 = Cl,\nZ3 = Cl 445.732 -0.134 1 2 6.297 1 100\n80\nTable 3-4. ADME analysis of Brominated Substituted GAT228 Compounds Compoun\nd\nMol. WT.\nQPlogBB\nDonor HB\nAcceptor\nHB\nQPlog o/w\nRule of 5\n% Human\nOral\nAbsorption\nMM- GBSA\n(kkal/mol)\nReference 130 \u2013 725 -3.0 \u2013 1.2 0 \u2013 6.0 2.0 \u2013 20.0 -2.0 \u2013 6.5 4 is\nMax\n>80% is\nhigh\nn/a\nGAT228 342.396 -0.579 1 2 5.215 1 100 -65.24\nX1 = Br, Y1 = Br,\nZ1 = Br 579.085 -0.059 1 2 6.461 2 95.575\nX1 = Br, Y1 = Br,\nZ2 = Br 579.085 -0.054 1 2 6.573 2 95.791\nX1 = Br, Y1 = Br,\nZ3 = Br 579.085 -0.055 1 2 6.579 2 95.849\nX2 = Br, Y1 = Br,\nZ1 = Br 579.085 -0.065 1 2 6.438 2 95.321\nX2 = Br, Y1 = Br,\nZ2 = Br 579.085 -0.028 1 2 6.652 2 95.768\n-80.31\nX2 = Br, Y1 = Br,\nZ3 = Br 579.085 -0.049 1 2 6.651 2 95.762\nX3 = Br, Y1 = Br,\nZ1 = Br 579.085 -0.113 1 2 6.939 2 100\n-63.22\nX3 = Br, Y1 = Br,\nZ2 = Br 579.085 -0.046 1 2 6.667 2 95.718\n-65.41\nX3 = Br, Y1 = Br,\nZ3 = Br 579.085 0.078 1 2 6.746 2 100\nX1 = Br, Y2 = Br,\nZ1 = Br 579.085 -0.204 1 2 6.054 2 92.204\n-70.10\nX1 = Br, Y2 = Br,\nZ2 = Br 579.085 -0.095 1 2 6.517 2 94.499\nX1 = Br, Y2 = Br,\nZ3 = Br 579.085 -0.146 1 2 6.403 2 93.835\nX2 = Br, Y2 = Br,\nZ1 = Br 579.085 -0.11 1 2 6.576 2 94.362\n-71.56\nX2 = Br, Y2 = Br,\nZ2 = Br 579.085 -0.107 1 2 6.622 2 94.562\n-75.76\nX2 = Br, Y2 = Br,\nZ3 = Br 579.085 -0.213 1 2 7.101 2 100\nX3 = Br, Y2 = Br,\nZ1 = Br 579.085 -0.101 1 2 6.642 2 94.596\n-63.50\nX3 = Br, Y2 = Br,\nZ2 = Br 579.085 -0.148 1 2 6.667 2 93.982\n-67.95\nX3 = Br, Y2 = Br,\nZ3 = Br 579.085 -0.129 1 2 6.237 2 93.898\nX1 = Br, Y3 = Br,\nZ1 = Br 579.085 -0.124 1 2 6.", "start_char_idx": 106334, "end_char_idx": 107981, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "87f9eb02-5f85-43be-aea7-96d9e24360a0": {"__data__": {"id_": "87f9eb02-5f85-43be-aea7-96d9e24360a0", "embedding": null, "metadata": {"file_path": "data/brandt-no-intro.txt", "file_name": "brandt-no-intro.txt", "file_type": "text/plain", "file_size": 239829, "creation_date": "2023-12-31", "last_modified_date": "2023-12-31", "last_accessed_date": "2023-12-31"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "a0eaa9a5-aece-426b-8f20-580de8fb9f35", "node_type": "4", "metadata": {"file_path": "data/brandt-no-intro.txt", "file_name": "brandt-no-intro.txt", "file_type": "text/plain", "file_size": 239829, "creation_date": "2023-12-31", "last_modified_date": "2023-12-31", "last_accessed_date": "2023-12-31"}, "hash": "76e194b2637b440a1b1cdf5698cae061524bb4d7a3b73dfc2ba71d268a3f7019", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "81d39c1d-2db8-4c5c-bb81-0777c471a97a", "node_type": "1", "metadata": {"file_path": "data/brandt-no-intro.txt", "file_name": "brandt-no-intro.txt", "file_type": "text/plain", "file_size": 239829, "creation_date": "2023-12-31", "last_modified_date": "2023-12-31", "last_accessed_date": "2023-12-31"}, "hash": "f55a616a9285bd1e383464055c1f544bb45058ece1f03a77ede3e5bda884342c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2171d15e-6952-45a9-b0db-a0a936392c88", "node_type": "1", "metadata": {}, "hash": "f87096890ac51dd3fa6e28c0e7520c1de924df5c545a5876d24fe5bca2a6e83b", "class_name": "RelatedNodeInfo"}}, "hash": "b3d414351b13cfeb79f7ff0fc3eb163a69e4e9bee63b6ae784fdcacddffefa48", "text": "562\n-75.76\nX2 = Br, Y2 = Br,\nZ3 = Br 579.085 -0.213 1 2 7.101 2 100\nX3 = Br, Y2 = Br,\nZ1 = Br 579.085 -0.101 1 2 6.642 2 94.596\n-63.50\nX3 = Br, Y2 = Br,\nZ2 = Br 579.085 -0.148 1 2 6.667 2 93.982\n-67.95\nX3 = Br, Y2 = Br,\nZ3 = Br 579.085 -0.129 1 2 6.237 2 93.898\nX1 = Br, Y3 = Br,\nZ1 = Br 579.085 -0.124 1 2 6.482 2 94.119\nX1 = Br, Y3 = Br,\nZ2 = Br 579.085 -0.169 1 2 6.322 2 93.034\n-67.63\nX1 = Br, Y3 = Br,\nZ3 = Br 579.085 -0.11 1 2 6.53 2 94.484\nX2 = Br, Y3 = Br,\nZ1 = Br 579.085 -0.121 1 2 6.508 2 93.646\n81\nX2 = Br, Y3 = Br,\nZ2 = Br 579.085 -0.135 1 2 6.622 2 94.048\n-73.08\nX2 = Br, Y3 = Br,\nZ3 = Br 579.085 -0.122 1 2 6.54 2 94.271\nX3 = Br, Y3 = Br,\nZ1 = Br 579.085 -0.099 1 2 6.68 2 94.733\n-59.51\nX3 = Br, Y3 = Br,\nZ2 = Br 579.085 -0.103 1 2 6.666 2 94.878\n-65.01\nX3 = Br, Y3 = Br,\nZ3 = Br 579.085 -0.236 1 2 5.816 2 91.337\nX1 = Br, Y4 = Br,\nZ1 = Br 579.085 -0.182 1 2 6.148 2 92.767\n-65.38\nX1 = Br, Y4 = Br,\nZ2 = Br 579.085 -0.18 1 2 6.168 2 92.97\n-71.11\nX1 = Br, Y4 = Br,\nZ3 = Br 579.085 -0.264 1 2 6.616 2 95.139\nX2 = Br, Y4 = Br,\nZ1 = Br 579.085 -0.21 1 2 6.405 2 92.955\n-68.83\nX2 = Br, Y4 = Br,\nZ2 = Br 579.085 -0.201 1 2 6.335 2 92.568\n-73.30\nX2 = Br, Y4 = Br,\nZ3 = Br 579.085 -0.12 1 2 6.179 2 93.664\nX3 = Br, Y4 = Br,\nZ1 = Br 579.085 -0.216 1 2 6.406 2 91.68\n-59.32\nX3 = Br, Y4 = Br,\nZ2 = Br 579.085 -0.179 1 2 6.361 2 92.862\n-64.13\nX3 = Br, Y4 = Br,\nZ3 = Br 579.085 -0.182 1 2 6.531 2 93.84\n82\nTable 3-5. ADME analysis of Iodinated Substituted GAT228 Compounds Compound Mol. WT. QPlogBB Donor HB Acceptor HBQPlog o/w Rule of 5\n% Human\nOral\nAbsorption\nMM- GBSA\n(kkal/mol)\nReference 130 \u2013 725 -3.0 \u2013 1.2 0 \u2013\n6.0\n2.0 \u2013\n20.0\n-2.0 \u2013 6.", "start_char_idx": 107672, "end_char_idx": 109316, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2171d15e-6952-45a9-b0db-a0a936392c88": {"__data__": {"id_": "2171d15e-6952-45a9-b0db-a0a936392c88", "embedding": null, "metadata": {"file_path": "data/brandt-no-intro.txt", "file_name": "brandt-no-intro.txt", "file_type": "text/plain", "file_size": 239829, "creation_date": "2023-12-31", "last_modified_date": "2023-12-31", "last_accessed_date": "2023-12-31"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "a0eaa9a5-aece-426b-8f20-580de8fb9f35", "node_type": "4", "metadata": {"file_path": "data/brandt-no-intro.txt", "file_name": "brandt-no-intro.txt", "file_type": "text/plain", "file_size": 239829, "creation_date": "2023-12-31", "last_modified_date": "2023-12-31", "last_accessed_date": "2023-12-31"}, "hash": "76e194b2637b440a1b1cdf5698cae061524bb4d7a3b73dfc2ba71d268a3f7019", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "87f9eb02-5f85-43be-aea7-96d9e24360a0", "node_type": "1", "metadata": {"file_path": "data/brandt-no-intro.txt", "file_name": "brandt-no-intro.txt", "file_type": "text/plain", "file_size": 239829, "creation_date": "2023-12-31", "last_modified_date": "2023-12-31", "last_accessed_date": "2023-12-31"}, "hash": "b3d414351b13cfeb79f7ff0fc3eb163a69e4e9bee63b6ae784fdcacddffefa48", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6ad0dfb9-91d9-4725-9594-6c934d992a0b", "node_type": "1", "metadata": {}, "hash": "6658cb547fa77debf3b167e29291e10f1d85e884b30ff9eebf367c41575b3dcf", "class_name": "RelatedNodeInfo"}}, "hash": "f87096890ac51dd3fa6e28c0e7520c1de924df5c545a5876d24fe5bca2a6e83b", "text": "68\n-59.32\nX3 = Br, Y4 = Br,\nZ2 = Br 579.085 -0.179 1 2 6.361 2 92.862\n-64.13\nX3 = Br, Y4 = Br,\nZ3 = Br 579.085 -0.182 1 2 6.531 2 93.84\n82\nTable 3-5. ADME analysis of Iodinated Substituted GAT228 Compounds Compound Mol. WT. QPlogBB Donor HB Acceptor HBQPlog o/w Rule of 5\n% Human\nOral\nAbsorption\nMM- GBSA\n(kkal/mol)\nReference 130 \u2013 725 -3.0 \u2013 1.2 0 \u2013\n6.0\n2.0 \u2013\n20.0\n-2.0 \u2013 6.5 4 is\nMax\n>80% is\nhigh\nn/a\nGAT228 342.396 -0.579 1 2 5.215 1 100 -65.24\nX1 = I, Y1 = I, Z1\n= I 720.086 -0.182 1 2 6.531 2 93.84\nX1 = I, Y1 = I, Z2\n= I 720.086 -0.127 1 2 7.326 2 100\nX1 = I, Y1 = I, Z3\n= I 720.086 0.043 1 2 6.77 2 100\nX2 = I, Y1 = I, Z1\n= I 720.086 -0.028 1 2 6.806 2 100\nX2 = I, Y1 = I, Z2\n= I 720.086 -0.012 1 2 6.804 2 96.603\n-68.74\nX2 = I, Y1 = I, Z3\n= I 720.086 -0.172 1 2 6.819 2 94.598\nX3 = I, Y1 = I, Z1\n= I 720.086 -0.091 1 2 6.766 2 95.788\n-63.25\nX3 = I, Y1 = I, Z2\n= I 720.086 -0.134 1 2 6.675 2 95.15\nX3 = I, Y1 = I, Z3\n= I 720.086 -0.047 1 2 6.851 2 96.286\nX1 = I, Y2 = I, Z1\n= I 720.086 -0.008 1 2 6.829 2 96.749\nX1 = I, Y2 = I, Z2\n= I 720.086 -0.024 1 2 6.818 2 100\n-70.88\nX1 = I, Y2 = I, Z3\n= I 720.086 -0.085 1 2 6.785 2 95.9\nX2 = I, Y2 = I, Z1\n= I 720.086 -0.066 1 2 6.783 2 95.421\nX2 = I, Y2 = I, Z2\n= I 720.086 -0.237 1 2 6.777 2 93.362\n-73.59\nX2 = I, Y2 = I, Z3\n= I 720.086 -0.178 1 2 6.693 2 93.449\nX3 = I, Y2 = I, Z1\n= I 720.086 -0.087 1 2 6.773 2 95.854\n-63.30\nX3 = I, Y2 = I, Z2\n= I 720.086 -0.064 1 2 6.785 2 95.442\n-65.73\nX3 = I, Y2 = I, Z3\n= I 720.086 -0.082 1 2 6.879 2 95.899\nX1 = I, Y3 = I, Z1\n= I 720.086 -0.147 1 2 6.958 2 96.81\nX1 = I, Y3 = I, Z2\n= I 720.086 -0.", "start_char_idx": 108941, "end_char_idx": 110529, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6ad0dfb9-91d9-4725-9594-6c934d992a0b": {"__data__": {"id_": "6ad0dfb9-91d9-4725-9594-6c934d992a0b", "embedding": null, "metadata": {"file_path": "data/brandt-no-intro.txt", "file_name": "brandt-no-intro.txt", "file_type": "text/plain", "file_size": 239829, "creation_date": "2023-12-31", "last_modified_date": "2023-12-31", "last_accessed_date": "2023-12-31"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "a0eaa9a5-aece-426b-8f20-580de8fb9f35", "node_type": "4", "metadata": {"file_path": "data/brandt-no-intro.txt", "file_name": "brandt-no-intro.txt", "file_type": "text/plain", "file_size": 239829, "creation_date": "2023-12-31", "last_modified_date": "2023-12-31", "last_accessed_date": "2023-12-31"}, "hash": "76e194b2637b440a1b1cdf5698cae061524bb4d7a3b73dfc2ba71d268a3f7019", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2171d15e-6952-45a9-b0db-a0a936392c88", "node_type": "1", "metadata": {"file_path": "data/brandt-no-intro.txt", "file_name": "brandt-no-intro.txt", "file_type": "text/plain", "file_size": 239829, "creation_date": "2023-12-31", "last_modified_date": "2023-12-31", "last_accessed_date": "2023-12-31"}, "hash": "f87096890ac51dd3fa6e28c0e7520c1de924df5c545a5876d24fe5bca2a6e83b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ce62f0de-1c59-49cd-90fe-685d0a9a0fa7", "node_type": "1", "metadata": {}, "hash": "ee8dffa29664b18c96f705fab425e3383234f83207e3066f2b730e95bf154b79", "class_name": "RelatedNodeInfo"}}, "hash": "6658cb547fa77debf3b167e29291e10f1d85e884b30ff9eebf367c41575b3dcf", "text": "178 1 2 6.693 2 93.449\nX3 = I, Y2 = I, Z1\n= I 720.086 -0.087 1 2 6.773 2 95.854\n-63.30\nX3 = I, Y2 = I, Z2\n= I 720.086 -0.064 1 2 6.785 2 95.442\n-65.73\nX3 = I, Y2 = I, Z3\n= I 720.086 -0.082 1 2 6.879 2 95.899\nX1 = I, Y3 = I, Z1\n= I 720.086 -0.147 1 2 6.958 2 96.81\nX1 = I, Y3 = I, Z2\n= I 720.086 -0.199 1 2 7.288 2 100\nX1 = I, Y3 = I, Z3\n= I 720.086 -0.178 1 2 7.255 2 100\nX2 = I, Y3 = I, Z1\n= I 720.086 -0.087 1 2 6.769 2 95.829\nX2 = I, Y3 = I, Z2\n= I 720.086 -0.083 1 2 6.827 2 95.593\n83\nX2 = I, Y3 = I, Z3\n= I 720.086 -0.081 1 2 6.819 2 95.51\nX3 = I, Y3 = I, Z1\n= I 720.086 -0.081 1 2 6.774 2 95.887\n-58.51\nX3 = I, Y3 = I, Z2\n= I 720.086 -0.085 1 2 6.868 2 95.834\nX3 = I, Y3 = I, Z3\n= I 720.086 -0.092 1 2 6.863 2 95.765\nX1 = I, Y4 = I, Z1\n= I 720.086 -0.143 1 2 6.395 2 93.732\nX1 = I, Y4 = I, Z2\n= I 720.086 -0.037 1 2 6.526 2 95.929\n-70.73\nX1 = I, Y4 = I, Z3\n= I 720.086 -0.037 1 2 6.548 2 96.002\nX2 = I, Y4 = I, Z1\n= I 720.086 -0.245 1 2 6.535 2 92.511\n-67.76\nX2 = I, Y4 = I, Z2\n= I 720.086 -0.066 1 2 6.71 2 95.755\nX2 = I, Y4 = I, Z3\n= I 720.086 -0.02 1 2 6.709 2 95.994\nX3 = I, Y4 = I, Z1\n= I 720.086 -0.239 1 2 6.526 2 92.462\nX3 = I, Y4 = I, Z2\n= I 720.086 -0.067 1 2 6.706 2 95.712\nX3 = I, Y4 = I, Z3\n= I 720.086 -0.059 1 2 6.713 2 95.772\n84\nTable 3-6. ADME analysis of Nitro Substituted GAT228 Compounds Compound Mol. WT. QPlogBB Donor HB Acceptor HBQPlog o/w Rule of 5\n% Human\nOral\nAbsorption\nMM- GBSA\n(kkal/mol)\nReference 130 \u2013\n725\n-3.0 \u2013\n1.2\n0 \u2013 6.0 2.0 \u2013\n20.0\n-2.0 \u2013\n6.5\n4 is\nMax\n>80% is\nhigh\nGAT228 342.396 -0.579 1 2.00 5.215 1 100 -65.24\nZ2 = NO2 (Control) 387.394 -1.732 1.00 3.", "start_char_idx": 110231, "end_char_idx": 111827, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ce62f0de-1c59-49cd-90fe-685d0a9a0fa7": {"__data__": {"id_": "ce62f0de-1c59-49cd-90fe-685d0a9a0fa7", "embedding": null, "metadata": {"file_path": "data/brandt-no-intro.txt", "file_name": "brandt-no-intro.txt", "file_type": "text/plain", "file_size": 239829, "creation_date": "2023-12-31", "last_modified_date": "2023-12-31", "last_accessed_date": "2023-12-31"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "a0eaa9a5-aece-426b-8f20-580de8fb9f35", "node_type": "4", "metadata": {"file_path": "data/brandt-no-intro.txt", "file_name": "brandt-no-intro.txt", "file_type": "text/plain", "file_size": 239829, "creation_date": "2023-12-31", "last_modified_date": "2023-12-31", "last_accessed_date": "2023-12-31"}, "hash": "76e194b2637b440a1b1cdf5698cae061524bb4d7a3b73dfc2ba71d268a3f7019", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6ad0dfb9-91d9-4725-9594-6c934d992a0b", "node_type": "1", "metadata": {"file_path": "data/brandt-no-intro.txt", "file_name": "brandt-no-intro.txt", "file_type": "text/plain", "file_size": 239829, "creation_date": "2023-12-31", "last_modified_date": "2023-12-31", "last_accessed_date": "2023-12-31"}, "hash": "6658cb547fa77debf3b167e29291e10f1d85e884b30ff9eebf367c41575b3dcf", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e4fc6a8f-870a-443a-b60a-769f1be7989b", "node_type": "1", "metadata": {}, "hash": "c7a00e39cd939c725521d7eedd702a152390fc3396d87ffeaad64b4b9975c61b", "class_name": "RelatedNodeInfo"}}, "hash": "ee8dffa29664b18c96f705fab425e3383234f83207e3066f2b730e95bf154b79", "text": "086 -0.059 1 2 6.713 2 95.772\n84\nTable 3-6. ADME analysis of Nitro Substituted GAT228 Compounds Compound Mol. WT. QPlogBB Donor HB Acceptor HBQPlog o/w Rule of 5\n% Human\nOral\nAbsorption\nMM- GBSA\n(kkal/mol)\nReference 130 \u2013\n725\n-3.0 \u2013\n1.2\n0 \u2013 6.0 2.0 \u2013\n20.0\n-2.0 \u2013\n6.5\n4 is\nMax\n>80% is\nhigh\nGAT228 342.396 -0.579 1 2.00 5.215 1 100 -65.24\nZ2 = NO2 (Control) 387.394 -1.732 1.00 3.00 4.237 0 88.432 -71.70\nX1 = F, Y1 = F, Z2 =\nNO2 423.375 -1.379\n1.00 3.00\n4.958 0 92.389\n-75.97\nX2 = F, Y1 = F, Z2 =\nNO2 423.375 -1.186\n1.00 3.00\n4.829 0 95.558\n-77.65\nX1 = F, Y2 = F, Z2 =\nNO2 423.375 -1.533\n1.00 3.00\n4.980 0 94.228\n-72.59\nX2 = F, Y2 = F, Z2 =\nNO2 423.375 -1.236\n1.00 3.00\n4.746 0 95.122\n-69.47\nX1 = F, Y3 = F, Z2 =\nNO2 423.375 -1.511\n1.00 3.00\n4.776 0 92.568\n-75.34\nX2 = F, Y3 = F, Z2 =\nNO2 423.375 -1.376\n1.00 3.00\n4.722 0 93.431\n-70.29\nX1 = F, Y4 = F, Z2 =\nNO2 423.375 -1.301\n1.00 3.00\n4.508 0 93.505\n-76.47\nX2 = F, Y4 = F, Z2 =\nNO2 423.375 -1.337\n1.00 3.00\n4.643 0 94.177\n-74.66\nX1 = Cl, Y1 = Cl, Z2\n= NO2 456.284 -1.355\n1.00 3.00\n5.410 1 85.143\nX2 = Cl, Y1 = Cl, Z2\n= NO2 456.284 -1.104\n1.00 3.00\n5.252 1 85.986\nX1 = Cl, Y2 = Cl, Z2\n= NO2 456.284 -1.454\n1.00 3.00\n5.391 1 83.685\nX2 = Cl, Y2 = Cl, Z2\n= NO2 456.284 -1.136\n1.00 3.00\n5.234 1 85.352\n-68.27\nX1 = Cl, Y3 = Cl, Z2\n= NO2 456.284 -1.442\n1.00 3.00\n5.415 1 84.004\nX2 = Cl, Y3 = Cl, Z2\n= NO2 456.284 -1.112\n1.00 3.00\n5.172 1 84.981\nX1 = Cl, Y4 = Cl, Z2\n= NO2 456.284 -1.442\n1.00 3.00\n5.224 1 83.282\n-81.65\nX2 = Cl, Y4 = Cl, Z2\n= NO2 456.284 -1.451\n1.00 3.00\n5.393 1 83.381\n-81.69\nX1 = Cl, Y1 = F, Z2\n= NO2 439.830 -1.243\n1.00 3.00\n5.061 1 84.774\nX1 = F, Y1 = Cl, Z2\n= NO2 439.830 -1.", "start_char_idx": 111449, "end_char_idx": 113088, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e4fc6a8f-870a-443a-b60a-769f1be7989b": {"__data__": {"id_": "e4fc6a8f-870a-443a-b60a-769f1be7989b", "embedding": null, "metadata": {"file_path": "data/brandt-no-intro.txt", "file_name": "brandt-no-intro.txt", "file_type": "text/plain", "file_size": 239829, "creation_date": "2023-12-31", "last_modified_date": "2023-12-31", "last_accessed_date": "2023-12-31"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "a0eaa9a5-aece-426b-8f20-580de8fb9f35", "node_type": "4", "metadata": {"file_path": "data/brandt-no-intro.txt", "file_name": "brandt-no-intro.txt", "file_type": "text/plain", "file_size": 239829, "creation_date": "2023-12-31", "last_modified_date": "2023-12-31", "last_accessed_date": "2023-12-31"}, "hash": "76e194b2637b440a1b1cdf5698cae061524bb4d7a3b73dfc2ba71d268a3f7019", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ce62f0de-1c59-49cd-90fe-685d0a9a0fa7", "node_type": "1", "metadata": {"file_path": "data/brandt-no-intro.txt", "file_name": "brandt-no-intro.txt", "file_type": "text/plain", "file_size": 239829, "creation_date": "2023-12-31", "last_modified_date": "2023-12-31", "last_accessed_date": "2023-12-31"}, "hash": "ee8dffa29664b18c96f705fab425e3383234f83207e3066f2b730e95bf154b79", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "859081fc-ba7a-4fc5-bac0-1fd78811d3e3", "node_type": "1", "metadata": {}, "hash": "85947b2af2a53ac1bfbc1bc6ec47d38a4cdf1a996797d78a3e4eddedc7dbefed", "class_name": "RelatedNodeInfo"}}, "hash": "c7a00e39cd939c725521d7eedd702a152390fc3396d87ffeaad64b4b9975c61b", "text": "Y3 = Cl, Z2\n= NO2 456.284 -1.112\n1.00 3.00\n5.172 1 84.981\nX1 = Cl, Y4 = Cl, Z2\n= NO2 456.284 -1.442\n1.00 3.00\n5.224 1 83.282\n-81.65\nX2 = Cl, Y4 = Cl, Z2\n= NO2 456.284 -1.451\n1.00 3.00\n5.393 1 83.381\n-81.69\nX1 = Cl, Y1 = F, Z2\n= NO2 439.830 -1.243\n1.00 3.00\n5.061 1 84.774\nX1 = F, Y1 = Cl, Z2\n= NO2 439.830 -1.062\n1.00 3.00\n5.231 1 88.370\n-75.89\nX1 = F, Y2 = Cl, Z2\n= NO2 439.830 -1.248\n1.00 3.00\n5.188 1 85.629\n-71.72\nX1 = Cl, Y2 = F, Z2\n= NO2 439.830 -1.251\n1.00 3.00\n5.095 1 84.605\n-70.04\nX1 = Cl, Y3 = F, Z2\n= NO2 439.830 -1.204\n1.00 3.00\n5.106 1 85.189\n-75.15\nX1 = F, Y3 = Cl, Z2\n= NO2 439.830 -1.181\n1.00 3.00\n5.100 1 86.231\n85\nX1 = F, Y4 = Cl, Z2\n= NO2 439.830 -1.339\n1.00 3.00\n4.910 0 96.167\n-75.93\nX1 = Cl, Y4 = F, Z2\n= NO2 439.830 -1.289\n1.00 3.00\n4.984 0 100.000\n-74.23\nX2 = Cl, Y1 = F, Z2\n= NO2 439.830 -1.328\n1.00 3.00\n5.195 1 84.206\n-77.25\nX2 = F, Y1 = Cl, Z2\n= NO2 439.830 -1.073\n1.00 3.00\n5.277 1 88.119\n-74.40\nX2 = F, Y2 = Cl, Z2\n= NO2 439.830 -1.206\n1.00 3.00\n5.252 1 86.215\n-75.08\nX2 = Cl, Y2 = F, Z2\n= NO2 439.830 -1.351\n1.00 3.00\n5.182 1 83.766\n-76.36\nX2 = Cl, Y3 = F, Z2\n= NO2 439.830 -1.143\n1.00 3.00\n5.267 1 86.956\n-76.43\nX2 = F, Y3 = Cl, Z2\n= NO2 439.830 -1.148\n1.00 3.00\n5.255 1 86.819\nX2 = F, Y4 = Cl, Z2\n= NO2 439.830 -1.287\n1.00 3.00\n5.022 1 83.612\n-77.38\nX2 = Cl, Y4 = F, Z2\n= NO2 439.830 -1.369\n1.00 3.00\n5.513 1 83.847\n-79.08\n86\nTable 3-7. ADME analysis of Pyridine and Cyclopentadiene Substituted GAT228 Compounds Compound Mol. Wt.", "start_char_idx": 112779, "end_char_idx": 114242, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "859081fc-ba7a-4fc5-bac0-1fd78811d3e3": {"__data__": {"id_": "859081fc-ba7a-4fc5-bac0-1fd78811d3e3", "embedding": null, "metadata": {"file_path": "data/brandt-no-intro.txt", "file_name": "brandt-no-intro.txt", "file_type": "text/plain", "file_size": 239829, "creation_date": "2023-12-31", "last_modified_date": "2023-12-31", "last_accessed_date": "2023-12-31"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "a0eaa9a5-aece-426b-8f20-580de8fb9f35", "node_type": "4", "metadata": {"file_path": "data/brandt-no-intro.txt", "file_name": "brandt-no-intro.txt", "file_type": "text/plain", "file_size": 239829, "creation_date": "2023-12-31", "last_modified_date": "2023-12-31", "last_accessed_date": "2023-12-31"}, "hash": "76e194b2637b440a1b1cdf5698cae061524bb4d7a3b73dfc2ba71d268a3f7019", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e4fc6a8f-870a-443a-b60a-769f1be7989b", "node_type": "1", "metadata": {"file_path": "data/brandt-no-intro.txt", "file_name": "brandt-no-intro.txt", "file_type": "text/plain", "file_size": 239829, "creation_date": "2023-12-31", "last_modified_date": "2023-12-31", "last_accessed_date": "2023-12-31"}, "hash": "c7a00e39cd939c725521d7eedd702a152390fc3396d87ffeaad64b4b9975c61b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1d011d49-3a0b-4261-862c-0db78c3a0e6a", "node_type": "1", "metadata": {}, "hash": "372127d52791b857d7e7dc45c5eaa5241d923bb541ffdf42915bff5a68abac00", "class_name": "RelatedNodeInfo"}}, "hash": "85947b2af2a53ac1bfbc1bc6ec47d38a4cdf1a996797d78a3e4eddedc7dbefed", "text": "00 3.00\n5.267 1 86.956\n-76.43\nX2 = F, Y3 = Cl, Z2\n= NO2 439.830 -1.148\n1.00 3.00\n5.255 1 86.819\nX2 = F, Y4 = Cl, Z2\n= NO2 439.830 -1.287\n1.00 3.00\n5.022 1 83.612\n-77.38\nX2 = Cl, Y4 = F, Z2\n= NO2 439.830 -1.369\n1.00 3.00\n5.513 1 83.847\n-79.08\n86\nTable 3-7. ADME analysis of Pyridine and Cyclopentadiene Substituted GAT228 Compounds Compound Mol. Wt. QPlogBB Donor HB Accept HB QPlog o/w Rule of Five % Human Oral Absorption MM-GBSA (kkcal/mol)\nRecommended 130 \u2013\n725\n-3.0 \u2013\n1.2\n0 \u2013 6.0 2.0 \u2013\n20.0\n-2.0 \u2013\n6.5\n4 is\nMax\n>80% is\nhigh\nn/a\nGAT1665-Cl\n445.732 -0.155 1.00 2.00 6.354 1 100\n-\n78.19\nX = C5H6, X4 = N 446.719 -0.066 1.00 3.00 6.031 1 100.000 -\n73.04\n2 446.719 -0.294 1.00 3.50 5.526 1 100.000 -\n72.44\n3 446.719 -0.295 1.00 3.50 5.535 1 100.000 -\n71.65\n4 446.719 -0.261 1.00 3.00 5.852 1 100.000 -\n81.44\n5 447.719 -0.298 1.00 4.00 5.400 1 100.000 -\n73.44\n6 447.719 -0.457 1.00 4.50 5.083 1 93.659 -\n76.87\n7 447.719 -0.659 1.00 5.00 4.613 0 100.000 -\n73.60\n8 447.719 -0.618 1.00 4.50 4.886 0 100.000 -\n76.68\n9 451.754 0.019 1.00 2.00 6.370 1 100.000 -\n77.59\n10 452.742 -0.220 1.00 3.50 5.552 1 100.000 -\n74.88\n11 452.742 -0.096 1.00 3.50 5.508 1 100.000 -\n74.97\n12 451.754 0.089 1.00 2.00 6.522 1 100.000 -\n78.57\n13 451.754 0.078 1.00 2.00 6.530 1 100.000 -\n78.70\n14 446.719 -0.178 1.00 3.00 5.911 1 100.000 -\n79.90\n15 446.719 -0.238 1.00 3.00 5.818 1 100.000 -\n77.96\n16 446.719 -0.281 1.00 3.50 5.518 1 100.000 -\n76.58\n17 446.719 -0.237 1.00 3.00 5.773 1 100.000 -\n76.65\n18 447.707 -0.247 1.00 4.00 5.411 1 100.000 -\n79.14\n19 447.707 -0.388 1.00 4.00 5.187 1 94.864 -\n82.87\n20 447.707 -0.463 1.00 4.00 5.115 1 93.413 -\n81.45\n21 447.707 -0.453 1.00 4.50 4.991 0 100.00 -\n77.02\n22 451.754 0.090 1.00 2.00 6.398 1 100.00 -\n77.34\n87\n23 451.754 0.101 1.00 2.00 6.503 1 100.00 -\n76.65\n24 447.707 -0.604 1.00 4.50 4.839 0 100.00 -\n78.15\n25 447.707 -0.420 1.00 4.50 5.090 1 94.480 -\n81.10\n88\nCHAPTER 4\nAssessment of select synthetic cannabinoid receptor agonist bias and selectivity between the\ntype 1 and type 2 cannabinoid receptor\nCopyright statement\nThis chapter has been previously published as: Zagzoog A, Brandt AL, Black T, Kim ED, Burkart\nR, Patel M, et al.", "start_char_idx": 113894, "end_char_idx": 116055, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1d011d49-3a0b-4261-862c-0db78c3a0e6a": {"__data__": {"id_": "1d011d49-3a0b-4261-862c-0db78c3a0e6a", "embedding": null, "metadata": {"file_path": "data/brandt-no-intro.txt", "file_name": "brandt-no-intro.txt", "file_type": "text/plain", "file_size": 239829, "creation_date": "2023-12-31", "last_modified_date": "2023-12-31", "last_accessed_date": "2023-12-31"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "a0eaa9a5-aece-426b-8f20-580de8fb9f35", "node_type": "4", "metadata": {"file_path": "data/brandt-no-intro.txt", "file_name": "brandt-no-intro.txt", "file_type": "text/plain", "file_size": 239829, "creation_date": "2023-12-31", "last_modified_date": "2023-12-31", "last_accessed_date": "2023-12-31"}, "hash": "76e194b2637b440a1b1cdf5698cae061524bb4d7a3b73dfc2ba71d268a3f7019", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "859081fc-ba7a-4fc5-bac0-1fd78811d3e3", "node_type": "1", "metadata": {"file_path": "data/brandt-no-intro.txt", "file_name": "brandt-no-intro.txt", "file_type": "text/plain", "file_size": 239829, "creation_date": "2023-12-31", "last_modified_date": "2023-12-31", "last_accessed_date": "2023-12-31"}, "hash": "85947b2af2a53ac1bfbc1bc6ec47d38a4cdf1a996797d78a3e4eddedc7dbefed", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c816406c-8e25-4267-bf1b-650fd0bd6443", "node_type": "1", "metadata": {}, "hash": "7f1f1dc7c20a939c09d1ea505e016c83021a87bf06a3fca1663f1622af4e7797", "class_name": "RelatedNodeInfo"}}, "hash": "372127d52791b857d7e7dc45c5eaa5241d923bb541ffdf42915bff5a68abac00", "text": "Assessment of select synthetic cannabinoid receptor agonist bias and selectivity\nbetween the type 1 and type 2 cannabinoid receptor. Sci Rep. 2021;11: 1\u201318. doi:10.1038/s41598-\n021-90167-w. The manuscript has been modified to meet formatting requirements.\nContribution statement\nThe manuscript used as the basis for this chapter was written by Ayat Zagzoog and myself \u2013 Asher\nBrandt with guidance from Dr. Robert B. Laprairie. In vitro data were collected by Ayat Zagzoog\nwhereas in silico data were collected by myself. All data were analyzed by myself with technical\nassistance from Dr. Robert B. Laprairie. \n89\n4.1 Introduction\nThe availability of different synthetic cannabinoid receptor agonists (SCRAs) as new psychoactive\nsubstances (NPS) over the past decade has vastly grown.129 SCRAs were first reported as NPS in\nEurope in 2008 and the first case report of acute toxicity was reported from forensic investigators\nin Austria and Germany in 2008.130 Although the original intended use of SCRA was as tool\ncompounds for studying CB1R and CB2R they became widespread throughout north American\nand Europe. Unfortunately, numerous cases of harm and death in the United States, Europe and\nAustralia as well as psychological, neurological, cardiovascular, pulmonary and renal adverse\neffects have been reported with their use.\n131 As a consequence, in 2012 the Synthetic Drug Abuse\nPrevention Act made 15 synthetic cannabinoids Schedule I products which are illegal to sell, buy\nor possess.\n132 In 2016 U.S. senators Shumer and Grassley proposed legislation to add 22 additional\nsynthetic cannabinoids to the list after 130 emergency department visits due to synthetic\ncannabinoids occurred in a 1-week span in New York City.\n131 The federal analogs act which says\nthat any chemical \u201csubstantially similar\u201d to a controlled substance listed in Schedule I or II shall\nbe treated as if it were listed in schedule 1, but only if identified for human consumption.\n133 The\nmajor issue here is that its exceedingly hard for prosecutors to convince non-science-minded jurors\nthat the chemical is \u201csubstantially similar\u201d and that the non-science-minded sellers or purchasers\nknew it was. Thus, an improvement on the original Federal Analogs Act is needed.\nSCRAs produce their effects by binding to the orhosteric site of CB1R which is also the same\nmechanism under which \u2206\n9\n-THC produces intoxication.\n134 In addition to CB1R it has also been\nshown that cannabinoids bind to CB2R.135 CB1R and CB2R are Gi-coupled GPCRs and thus\nmodulate intracellular signaling through \u03b2arrestin2 and other G proteins.136 Ligand activation of\nboth CB1R and CB2R inhibit the production of cAMP and recruitment \u03b2arrestin2 which results in \n90\nreceptor internalization, recycling or turnover.\n137 Measuring these two intracellular outcomes is\nimportant in understanding which pathway is activated to a greater effect; that is, the ligand bias\nfor Gi relative to \u03b2arrestin2, although it does not capture potential biases at other output pathways\nsuch as Gq or G12/13.\n138 In this study we aimed to quantify ligand bias between Gi and \u03b2arrestin2,\naffinity of SCRAs at CB1R and CB2R, as well as in silico studies to provide molecular\ndeterminants for the observed outcomes. \n91\nFigure 4-1. Structure of SCRAs studied\n92\n4.2 Experimental Section\n4.2.1 In vitro evaluation\nCompounds used. All compounds were purchased from Cayman Chemicals (Ann Arbor, MI) with\nthe exception of \u22069\n-tetrahydrocannabinol, which was purchased from Toronto Research Chemicals\n(Toronto, ON). [\n3H]CP55,940 (174.6 Ci/mmol) was obtained from PerkinElmer (Guelph, ON).\nAll other reagents were obtained from Sigma-Aldrich (Oakville, ON) unless specifically noted.\nCompounds were dissolved in DMSO (final concentration of 0.1% in assay media for all assays)\nand added directly to the media at the concentrations and times indicated.\nCell culture.", "start_char_idx": 116056, "end_char_idx": 119946, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c816406c-8e25-4267-bf1b-650fd0bd6443": {"__data__": {"id_": "c816406c-8e25-4267-bf1b-650fd0bd6443", "embedding": null, "metadata": {"file_path": "data/brandt-no-intro.txt", "file_name": "brandt-no-intro.txt", "file_type": "text/plain", "file_size": 239829, "creation_date": "2023-12-31", "last_modified_date": "2023-12-31", "last_accessed_date": "2023-12-31"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "a0eaa9a5-aece-426b-8f20-580de8fb9f35", "node_type": "4", "metadata": {"file_path": "data/brandt-no-intro.txt", "file_name": "brandt-no-intro.txt", "file_type": "text/plain", "file_size": 239829, "creation_date": "2023-12-31", "last_modified_date": "2023-12-31", "last_accessed_date": "2023-12-31"}, "hash": "76e194b2637b440a1b1cdf5698cae061524bb4d7a3b73dfc2ba71d268a3f7019", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1d011d49-3a0b-4261-862c-0db78c3a0e6a", "node_type": "1", "metadata": {"file_path": "data/brandt-no-intro.txt", "file_name": "brandt-no-intro.txt", "file_type": "text/plain", "file_size": 239829, "creation_date": "2023-12-31", "last_modified_date": "2023-12-31", "last_accessed_date": "2023-12-31"}, "hash": "372127d52791b857d7e7dc45c5eaa5241d923bb541ffdf42915bff5a68abac00", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "78ac8d9c-e602-4601-b572-e35eae44b23b", "node_type": "1", "metadata": {}, "hash": "4d2708ddee3e3c0f67ab0b6375ee2943244f6fee7efc66ce91e1c5abb1b4d841", "class_name": "RelatedNodeInfo"}}, "hash": "7f1f1dc7c20a939c09d1ea505e016c83021a87bf06a3fca1663f1622af4e7797", "text": "91\nFigure 4-1. Structure of SCRAs studied\n92\n4.2 Experimental Section\n4.2.1 In vitro evaluation\nCompounds used. All compounds were purchased from Cayman Chemicals (Ann Arbor, MI) with\nthe exception of \u22069\n-tetrahydrocannabinol, which was purchased from Toronto Research Chemicals\n(Toronto, ON). [\n3H]CP55,940 (174.6 Ci/mmol) was obtained from PerkinElmer (Guelph, ON).\nAll other reagents were obtained from Sigma-Aldrich (Oakville, ON) unless specifically noted.\nCompounds were dissolved in DMSO (final concentration of 0.1% in assay media for all assays)\nand added directly to the media at the concentrations and times indicated.\nCell culture. Chinese hamster ovary (CHO)-K1 cells, either untransfected for use as controls in\nsaturation binding studies or stably expressing human CB1R or CB2R, were cultured as described\nin earlier studies from our group.95 Briefly, cells were maintained at 37\u00b0C, 5% CO2 in F-12/DMEM\ncontaining 1 mM L-glutamine, 10% FBS, and 1% Pen/Strep as well as hygromycin B (300 \u00b5g/mL)\nand G418 (600 \u00b5g/mL) for CHO-K1 CB1R cells or G418 (400 \u00b5g/mL) for CHO-K1 CB2R\ncells.82,95 In the case of membrane collection for radioligand binding, cells were scraped from\nflasks, centrifuged, and frozen at -80\u00b0C until required. HitHunter (cAMP) and PathHunter\n(\u03b2arrestin2) CHO-K1 cells stably-expressing CB1R or CB2R from DiscoveRx (Eurofins, Fremont,\nCA) were maintained at 37\u00b0C, 5% CO2 in F-12 DMEM containing 10% FBS and 1% penicillinstreptomycin with 800 \u00b5g/mL geneticin (HitHunter) or 800 \u00b5g/mL G418 and 300 \u00b5g/mL\nhygromycin B (PathHunter), as described previously.\n139\n[\n3H]CP55,940 radioligand displacement assay. Saturation binding experiments were conducted\nwith 0.1 \u2013 100 nM [3H]CP55,940 and Tris binding buffer (50 mM Tris\u2013HCl, 50 mM Tris\u2013base,\n0.1% BSA, pH 7.4, 2 mL).\n139,140 Saturation binding experiments utilized CHO-K1 cells expressing\neither CB1R or CB2R (total bound) and untransfected CHO-K1 cells (non-specific bound). \n93\nSpecific binding curves were calculated as the difference between total and non-specific for each\nconcentration of [3H]CP55,940 used and fit to a one site total binding non-linear regression\n(GraphPad, Prism, v. 9.0). Competition binding experiments were conducted with 0.7 nM\n[\n3H]CP55,940, SCRAs as described, and Tris binding buffer (50 mM Tris\u2013HCl, 50 mM Tris\u2013base,\n0.1% BSA, pH 7.4, 2 mL).\n139,140 Radioligand binding began with the addition of CHO-K1 cell\nmembranes (50 \u00b5g protein per sample). Assays were performed for 120 min at 37\u00b0C and stopped\nby the addition of ice-cold Tris binding buffer, followed by vacuum filtration using a 24-well\nsampling manifold (Brandel Cell Harvester; Brandel Inc, Gaithersburg, MD, USA). Brandel GF/B\nfilter paper was soaked with wash buffer at 4\u00b0C for at least 24 h. Each filter paper was washed 6\ntimes with 1.2 mL aliquots of Tris-binding buffer, then air-dried overnight and submerged in 5 mL\nof scintillation fluid (Ultima Gold XR, PerkinElmer). Liquid scintillation spectrometry was used\nto quantify radioactivity. For competition binding experiments, specific binding was equal to the\ndifference in radioactivity with or without 1 \u00b5M unlabelled CP55,940.\nHitHunter cAMP assay \u2013 Cells (20,000 cells/well in low-volume 96 well plates) were incubated\novernight in Opti-MEM containing 1% FBS at 37\u00b0C and 5% CO2.", "start_char_idx": 119303, "end_char_idx": 122615, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "78ac8d9c-e602-4601-b572-e35eae44b23b": {"__data__": {"id_": "78ac8d9c-e602-4601-b572-e35eae44b23b", "embedding": null, "metadata": {"file_path": "data/brandt-no-intro.txt", "file_name": "brandt-no-intro.txt", "file_type": "text/plain", "file_size": 239829, "creation_date": "2023-12-31", "last_modified_date": "2023-12-31", "last_accessed_date": "2023-12-31"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "a0eaa9a5-aece-426b-8f20-580de8fb9f35", "node_type": "4", "metadata": {"file_path": "data/brandt-no-intro.txt", "file_name": "brandt-no-intro.txt", "file_type": "text/plain", "file_size": 239829, "creation_date": "2023-12-31", "last_modified_date": "2023-12-31", "last_accessed_date": "2023-12-31"}, "hash": "76e194b2637b440a1b1cdf5698cae061524bb4d7a3b73dfc2ba71d268a3f7019", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c816406c-8e25-4267-bf1b-650fd0bd6443", "node_type": "1", "metadata": {"file_path": "data/brandt-no-intro.txt", "file_name": "brandt-no-intro.txt", "file_type": "text/plain", "file_size": 239829, "creation_date": "2023-12-31", "last_modified_date": "2023-12-31", "last_accessed_date": "2023-12-31"}, "hash": "7f1f1dc7c20a939c09d1ea505e016c83021a87bf06a3fca1663f1622af4e7797", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "aef4c23e-97ef-4287-8abf-9fe19b4d1087", "node_type": "1", "metadata": {}, "hash": "c4444e7f8151205041df88ac131a0895cee79bcd70fb76cf9f1887da3a57504b", "class_name": "RelatedNodeInfo"}}, "hash": "4d2708ddee3e3c0f67ab0b6375ee2943244f6fee7efc66ce91e1c5abb1b4d841", "text": "Brandel GF/B\nfilter paper was soaked with wash buffer at 4\u00b0C for at least 24 h. Each filter paper was washed 6\ntimes with 1.2 mL aliquots of Tris-binding buffer, then air-dried overnight and submerged in 5 mL\nof scintillation fluid (Ultima Gold XR, PerkinElmer). Liquid scintillation spectrometry was used\nto quantify radioactivity. For competition binding experiments, specific binding was equal to the\ndifference in radioactivity with or without 1 \u00b5M unlabelled CP55,940.\nHitHunter cAMP assay \u2013 Cells (20,000 cells/well in low-volume 96 well plates) were incubated\novernight in Opti-MEM containing 1% FBS at 37\u00b0C and 5% CO2. Following this, Opti-MEM\nmedia was removed and replaced with cell assay buffer (DiscoveRx) and cells were co-treated at\n37\u00b0C with 10 \u00b5M FSK and ligands for 90 min. cAMP antibody solution and cAMP working\ndetection solutions were added to cells (DiscoveRx), and cells were incubated for 60 min at room\ntemperature. cAMP solution A (DiscoveRx) was added and cells were incubated for an additional\n60 min at room temperature before chemiluminescence was measured on a Cytation5 plate reader\n(top read, gain 200, integration time 10,000 ms).\nPathHunter \u03b2arrestin2 assay. Briefly, cells (20,000 cells/well in low-volume 96 well plates) were\nincubated overnight in Opti-MEM containing 1% FBS at 37\u00b0C and 5% CO2. Cells were co-treated \n94\nwith ligands for 90 min at 37\u00b0C. Detection solution was added to cells (DiscoveRx), and cells were\nincubated for 60 min at room temperature. Chemiluminescence was measured on a Cytation5 plate\nreader (top read, gain 200, integration time 10,000 ms).\n4.2.2 In silico evaluation\nMolecular docking \u2013 The published cryo-EM structure PDB: 6N4B.\n51 was used for the molecular\nmodelling of CB1R. This cryo-EM structure contains the agonist MDMB-FUBINACA bound to\nCB1R-Gai. CB2R modelling utilized PBD: 6PT059 which contains the agonist WIN 55,212-2\nbound to CB2R-Gai. Cannabinoids were modelled docking to GPCRs both with the Gi present to\nsimulate the G protein-bound state or with the Gai removed to simulate the G protein-absent state\nthat may be more conducive to \u03b2arrestin2 coupling. The G protein-absent state is limited by not\nhaving \uf062arrestin2 within the crystal; however, no such crystal exists as of the time of writing. Each\nof the cannabinoids was built and optimized in Spartan \u201918 Parallel Suite101 and docked via induced\nfit docking in Schr\u00f6dinger.\n102,141 To reduce atom clashing, ligand-receptor complexes were\nminimized using the OPLS3 force field in Prime.\n102 Prime MM-GBSA was used to calculate the\ninteraction energy between each ligand and the receptor.\n102\n4.2.3 Statistical Analysis\n[\n3H]CP55,940 radioligand saturation binding data are provided as raw counts per minute (cpm)\nbound and fit to a one site total binding non-linear regression (GraphPad). [3H]CP55,940\nradioligand competition binding data are provided as % change from maximal 3H bound (i.e.\n100%). Data for HitHunter cAMP and PathHunter \u03b2arrestin2 data are shown as % of maximal\nCP55,940 response (i.e. 100%). Estimates of Ki, EC50, Emin, and Emax were determined using nonlinear regression with variable slope (4 parameters) (GraphPad, Prism, v. 8.0). The operational\nmodel of Black and Leff 142 was used to estimate bias (\u2206\u2206LogR) with CP55,940 as the reference \n95\nagonist.\n82,139,143 One-way analysis of variance (ANOVA), followed by Tukey\u2019s post-hoc test, was\nused for statistical analyses (p < 0.05 determined to be significant). Bartlett\u2019s test was used to\nconfirm homogeneity of variance (GraphPad).", "start_char_idx": 121989, "end_char_idx": 125537, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "aef4c23e-97ef-4287-8abf-9fe19b4d1087": {"__data__": {"id_": "aef4c23e-97ef-4287-8abf-9fe19b4d1087", "embedding": null, "metadata": {"file_path": "data/brandt-no-intro.txt", "file_name": "brandt-no-intro.txt", "file_type": "text/plain", "file_size": 239829, "creation_date": "2023-12-31", "last_modified_date": "2023-12-31", "last_accessed_date": "2023-12-31"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "a0eaa9a5-aece-426b-8f20-580de8fb9f35", "node_type": "4", "metadata": {"file_path": "data/brandt-no-intro.txt", "file_name": "brandt-no-intro.txt", "file_type": "text/plain", "file_size": 239829, "creation_date": "2023-12-31", "last_modified_date": "2023-12-31", "last_accessed_date": "2023-12-31"}, "hash": "76e194b2637b440a1b1cdf5698cae061524bb4d7a3b73dfc2ba71d268a3f7019", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "78ac8d9c-e602-4601-b572-e35eae44b23b", "node_type": "1", "metadata": {"file_path": "data/brandt-no-intro.txt", "file_name": "brandt-no-intro.txt", "file_type": "text/plain", "file_size": 239829, "creation_date": "2023-12-31", "last_modified_date": "2023-12-31", "last_accessed_date": "2023-12-31"}, "hash": "4d2708ddee3e3c0f67ab0b6375ee2943244f6fee7efc66ce91e1c5abb1b4d841", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8e38df85-cd95-414c-b128-e45742367fe7", "node_type": "1", "metadata": {}, "hash": "43b3c3a47ce841f5b2bcbc021ae356ebd1296e15f6a56dce7dd1391ac77b57f9", "class_name": "RelatedNodeInfo"}}, "hash": "c4444e7f8151205041df88ac131a0895cee79bcd70fb76cf9f1887da3a57504b", "text": "100%). Data for HitHunter cAMP and PathHunter \u03b2arrestin2 data are shown as % of maximal\nCP55,940 response (i.e. 100%). Estimates of Ki, EC50, Emin, and Emax were determined using nonlinear regression with variable slope (4 parameters) (GraphPad, Prism, v. 8.0). The operational\nmodel of Black and Leff 142 was used to estimate bias (\u2206\u2206LogR) with CP55,940 as the reference \n95\nagonist.\n82,139,143 One-way analysis of variance (ANOVA), followed by Tukey\u2019s post-hoc test, was\nused for statistical analyses (p < 0.05 determined to be significant). Bartlett\u2019s test was used to\nconfirm homogeneity of variance (GraphPad). Values are presented as the mean \u00b1 the standard\nerror of the mean (SEM) or 95% confidence interval (CI), as indicated in tables and figure legends.\n4.3 Results and Discussion\n4.3.1 In Vitro Evaluation of CB1R\nIn the radioligand binding assays we observed that all ligands studied bound to and displaced\n[\n3H]CP55,940 from CB1R (Figure 4-2). However not all ligands fully displaced [3H]CP55,940\nfrom CB1R. The highest affinity ligands which displayed affinity under 1nM were JWH-182, JWH\n018 2'-naphthyl-N-(3-methylbutyl) isomer, AM 2232 and Cl 2201 (Figure 4-2 and Table 4-1).\nThe common scaffold between the high affinity ligands at CB1R is a naphthalene group linked to\nan alkyl substituted indole by a ketone (Figure 4-1). The lowest affinity ligands over (i.e. >100nM)\nwere 3-chloro AB-PINACA, JWH 145, 4-fluoro MDMB-BINACA and 5-fluoro MPP-PICA. In\ngeneral, non-fused aromatic rings in the naphthyl position seemed to drastically reduce binding\naffinity. For example, substitutions in this position that have a high degree of rotatable bonds (i.e.,\n4-fluoro MDMB-BINACA) tend to drastically reduce binding affinity.\nNext, we looked at CB1R G protein activation by quantifying cAMP inhibition. It was observed\nthat all 15 SCRAs studied were agonists in terms of their ability to inhibit cAMP. The SCRAs that\nproduced the greatest Emax (> 90%) were CP55,940, MAM2201 N-(5-chloropentyl) analog, metaAB-FUBINACA, AM 2232, FDU-NNEI, 5-fluoro NPB-22, 3-chloro AB-PINACA, EG 018, and\n5-fluoro MPP-PICA (Figure 4-3 and Table 4-1). Only 2 of these compounds displayed an Emax\ngreater than or equal to the reference agonist CP55,940: AM 2232 and EG 018 (Figure 4-3 and\nTable 4-1). In terms of potency, there were 9 compounds that displayed greater potency than \n96\nCP55,940: MAM2201 N-(5-chloropentyl) analog, meta-AB-FUBINACA, ortho-ABFUBINACA, FDU-NNEI, Cl 2201, AB-PINACA N-(2-fluoropentyl) isomer, 3-chloro ABPINACA, JWH 145 and 5-fluoro MPP-PICA (Table 4-1).\nTo better understand pathway selectivity, we also quantified \u03b2arrestin2 recruitment (Figure 4-4\nand Table 4-1). In terms of Emax there were 7 compounds that were more efficacious than the\nreference agonist CP55,940: JWH 182, ortho-AB-FUBINACA, 5-fluoro NPB-22, ABPINACA N-(2-fluoropentyl) isomer, 3-chloro AB-PINACA, 4-fluoro MDMB-BINACA, and 5-\nfluoro MPP-PICA (Figure 4-4 and Table 4-1). In measuring the EC50 at this pathway, overall, the\npotency was rather low with 9 of the SCRAs displaying an EC50 greater than 10,000 nM (Table\n4-1).", "start_char_idx": 124922, "end_char_idx": 128036, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8e38df85-cd95-414c-b128-e45742367fe7": {"__data__": {"id_": "8e38df85-cd95-414c-b128-e45742367fe7", "embedding": null, "metadata": {"file_path": "data/brandt-no-intro.txt", "file_name": "brandt-no-intro.txt", "file_type": "text/plain", "file_size": 239829, "creation_date": "2023-12-31", "last_modified_date": "2023-12-31", "last_accessed_date": "2023-12-31"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "a0eaa9a5-aece-426b-8f20-580de8fb9f35", "node_type": "4", "metadata": {"file_path": "data/brandt-no-intro.txt", "file_name": "brandt-no-intro.txt", "file_type": "text/plain", "file_size": 239829, "creation_date": "2023-12-31", "last_modified_date": "2023-12-31", "last_accessed_date": "2023-12-31"}, "hash": "76e194b2637b440a1b1cdf5698cae061524bb4d7a3b73dfc2ba71d268a3f7019", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "aef4c23e-97ef-4287-8abf-9fe19b4d1087", "node_type": "1", "metadata": {"file_path": "data/brandt-no-intro.txt", "file_name": "brandt-no-intro.txt", "file_type": "text/plain", "file_size": 239829, "creation_date": "2023-12-31", "last_modified_date": "2023-12-31", "last_accessed_date": "2023-12-31"}, "hash": "c4444e7f8151205041df88ac131a0895cee79bcd70fb76cf9f1887da3a57504b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e6beed53-e696-489c-b0a5-5cc306840b34", "node_type": "1", "metadata": {}, "hash": "46da05c8086519e5e12c8f8f291526319b19b9f65e0686f63e2c258b0c379284", "class_name": "RelatedNodeInfo"}}, "hash": "43b3c3a47ce841f5b2bcbc021ae356ebd1296e15f6a56dce7dd1391ac77b57f9", "text": "To better understand pathway selectivity, we also quantified \u03b2arrestin2 recruitment (Figure 4-4\nand Table 4-1). In terms of Emax there were 7 compounds that were more efficacious than the\nreference agonist CP55,940: JWH 182, ortho-AB-FUBINACA, 5-fluoro NPB-22, ABPINACA N-(2-fluoropentyl) isomer, 3-chloro AB-PINACA, 4-fluoro MDMB-BINACA, and 5-\nfluoro MPP-PICA (Figure 4-4 and Table 4-1). In measuring the EC50 at this pathway, overall, the\npotency was rather low with 9 of the SCRAs displaying an EC50 greater than 10,000 nM (Table\n4-1). There were 5 compounds that displayed higher potency than CP55,940 which were \u2206\n9\n-THC,\northo-AB-FUBINACA, 5-fluoro NPB-22, AB-PINACA N-(2-fluoropentyl) isomer, 3-chloro ABPINACA, and 4-fluoro MDMB-BINACA (Table 4-1). Even though 4-fluoro MDMB-BINACA\ndisplayed the greatest potency in this assay the potencies measured in the cAMP assay were much\ngreater (Table 4-1). Conversely, although the potencies were much greater in the cAMP assay\nsome of the efficacies measured were much greater in the \u03b2arrestin2 assay (Table 4-1). With this\nbeing the case, we measured the \u0394\u0394LogR to see which pathway is preferred relative to the\nreference agonist, CP55,940 (Figure 4-5). It was observed that \u2206\n9\n-THC, meta-AB-FUBINACA,\n5-fluoro NPB-22, 5-fluoro MPP-PICA were unbiased, AB-PINACA N-(2-fluoropentyl) isomer,\n3-chloro AB-PINACA, 4-Fluoro MDMB-BINACA were \u03b2arrestin2-biased and FDU-NNEI, JWH\n145, EG018 were cAMP-biased (Figure 4-5). From these data alone it is not clear what structural\nfeatures lead to pathway selectivity. \n97\nFigure 4-2. (a,b,c,d) Radioligand binding of 1 nM [3H]CP55,940 to membranes from CB1R\nCHO-K1 cells. CB1R CHO-K1 cells were treated with 0.10 nM \u2013 10 \u00b5M compounds in the\npresence 1 nM [3H]CP55,940. Data are expressed as % radioligand bound. Data were fit to a\nnonlinear regression (4-parameter model, GraphPad v. 9.0) to determine KD, EC50, and Emax. Data\nare mean \u00b1 SEM (Emax) or 95% CI (KD, EC50); n \u2265 6 independent experiments. *p < 0.05 compared\nto CP55,940 as determined by one-way ANOVA followed by Bonferroni\u2019s post-hoc test or nonoverlapping 95% CI.\n98\nFigure 4-3. CB1R-dependent inhibition of FSK-stimulated cAMP. CB1R CHO-K1 were\ntreated with 0.10 nM \u2013 10 \u00b5M GAT compounds. (a,b,c.d) cAMP inhibition of GAT compounds\nas agonists. (a,b,d,e) Data are expressed as % CP55,940 max. Data were fit to a nonlinear\nregression (4-parameter model, GraphPad v. 9.0) to determine EC50 and Emax. Data are mean \u00b1\nSEM (Emax) or 95% CI (EC50); n \u2265 6 independent experiments performed in triplicate. *p < 0.05\ncompared to CP55,940 as determined by one-way ANOVA followed by Bonferroni\u2019s post-hoc test\nor non-overlapping 95% CI. Concentration-response data were fit to the operational model of\nBlack and Leff (1983) (GraphPad v. 9.0).\n99\nFigure 4-4. \u03b2arrestin2 recruitment to CB1R following SCRA treatment.", "start_char_idx": 127497, "end_char_idx": 130357, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e6beed53-e696-489c-b0a5-5cc306840b34": {"__data__": {"id_": "e6beed53-e696-489c-b0a5-5cc306840b34", "embedding": null, "metadata": {"file_path": "data/brandt-no-intro.txt", "file_name": "brandt-no-intro.txt", "file_type": "text/plain", "file_size": 239829, "creation_date": "2023-12-31", "last_modified_date": "2023-12-31", "last_accessed_date": "2023-12-31"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "a0eaa9a5-aece-426b-8f20-580de8fb9f35", "node_type": "4", "metadata": {"file_path": "data/brandt-no-intro.txt", "file_name": "brandt-no-intro.txt", "file_type": "text/plain", "file_size": 239829, "creation_date": "2023-12-31", "last_modified_date": "2023-12-31", "last_accessed_date": "2023-12-31"}, "hash": "76e194b2637b440a1b1cdf5698cae061524bb4d7a3b73dfc2ba71d268a3f7019", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8e38df85-cd95-414c-b128-e45742367fe7", "node_type": "1", "metadata": {"file_path": "data/brandt-no-intro.txt", "file_name": "brandt-no-intro.txt", "file_type": "text/plain", "file_size": 239829, "creation_date": "2023-12-31", "last_modified_date": "2023-12-31", "last_accessed_date": "2023-12-31"}, "hash": "43b3c3a47ce841f5b2bcbc021ae356ebd1296e15f6a56dce7dd1391ac77b57f9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "17bb3a56-9359-47fc-8076-168c7382cf39", "node_type": "1", "metadata": {}, "hash": "6c75f93aee534f33dc672873f0ba4d596bb86f4c6d191031825ec2a5f207d84b", "class_name": "RelatedNodeInfo"}}, "hash": "46da05c8086519e5e12c8f8f291526319b19b9f65e0686f63e2c258b0c379284", "text": "(a,b,c.d) cAMP inhibition of GAT compounds\nas agonists. (a,b,d,e) Data are expressed as % CP55,940 max. Data were fit to a nonlinear\nregression (4-parameter model, GraphPad v. 9.0) to determine EC50 and Emax. Data are mean \u00b1\nSEM (Emax) or 95% CI (EC50); n \u2265 6 independent experiments performed in triplicate. *p < 0.05\ncompared to CP55,940 as determined by one-way ANOVA followed by Bonferroni\u2019s post-hoc test\nor non-overlapping 95% CI. Concentration-response data were fit to the operational model of\nBlack and Leff (1983) (GraphPad v. 9.0).\n99\nFigure 4-4. \u03b2arrestin2 recruitment to CB1R following SCRA treatment. CB1R CHO-K1 were\ntreated with 0.10 nM \u2013 10 \u00b5M GAT compounds. (b,c,d,e) \u03b2arrestin2 recruitment of GAT\ncompounds as agonists (a,b,c,d). Data are expressed as % CP55,940 max. Data were fit to a\nnonlinear regression (4-parameter model, GraphPad v. 9.0) to determine EC50 and Emax. Data are\nmean \u00b1 SEM (Emax) or 95% CI (EC50); n \u2265 6 independent experiments performed in triplicate. *p\n< 0.05 compared to CP55,940 as determined by one-way ANOVA followed by Bonferroni\u2019s posthoc test or non-overlapping 95% CI.\n100\nFigure 4-5. CB1R SCRA bias. Compound bias between cAMP inhibition and \u03b2arrestin2\nrecruitment [\u0394\u0394LogR (cAMP - \u03b2arrestin2)] is shown here for data presented in Figure 4-3 and\nFigure 4-4. Data were fit to the operational model to calculate bias. Data are mean with 95% CI,\nn \u2265 6 independent experiments performed in triplicate. Values > 0 represent cAMP bias (white),\nvalues < 0 represent \u03b2arrestin2 bias (red), and values not different from 0 are unbiased (blue) as\ndetermined by 95% CI not overlapping with 0.\n101\n4.3.2 In Vitro Evaluation of CB2R\nThe same set of experiments were performed at CB2R given that both receptors are part of the\nendocannabinoid system and bind the same endogenous ligands. As it will be discussed in a later\nsection of this manuscript CB1R and CB2R have very similar sequence homology in the\northosteric binding site. There were 9 SCRAs with stronger binding affinity than the reference full\nagonist CP55,940; JWH 182, JWH 018 2'-naphthyl-N-(3-methylbutyl) isomer, meta-ABFUBINACA, ortho-AB-FUBINACA, FDU-NNEI, Cl 2201, 5-fluoro NPB-22, EG 018, and 4-\nfluoro MDMB-BINACA. Of these SCRAs there were 3 that displayed affinity stronger than 1 nM;\nmeta-AB-FUBINACA, ortho-AB-FUBINACA, and 4-fluoro MDMB-BINACA (Figure 4-6 and\nTable 4-1).As seen in meta and ortho-AB-FUBINACA changing the chloro from the ortho to meta\ndoes increase binding affinity (Figure 4-1, Figure 4-6 and Table 4-1). A stark observation can be\nseen in the binding affinity difference between MAM220 N-(5-chloropnetyl) analog and Cl\n2201(Figure 4-6 and Table 4-1). When compared structurally there are 2 differences being a\nchloro pentyl chain (MAM2201 N-(5-chloropentyl) analog) vs a fluoro pentyl chain (Cl 2201) and\na methyl-naphthyl (MAM2201 N-(5-chloropentyl) analog) vs a chloro-naphthyl (Cl 2201) and yet\nthe affinity differs by over 4 orders of magnitude (Figure 4-1, Figure 4-6 and Table 4-1).", "start_char_idx": 129743, "end_char_idx": 132763, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "17bb3a56-9359-47fc-8076-168c7382cf39": {"__data__": {"id_": "17bb3a56-9359-47fc-8076-168c7382cf39", "embedding": null, "metadata": {"file_path": "data/brandt-no-intro.txt", "file_name": "brandt-no-intro.txt", "file_type": "text/plain", "file_size": 239829, "creation_date": "2023-12-31", "last_modified_date": "2023-12-31", "last_accessed_date": "2023-12-31"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "a0eaa9a5-aece-426b-8f20-580de8fb9f35", "node_type": "4", "metadata": {"file_path": "data/brandt-no-intro.txt", "file_name": "brandt-no-intro.txt", "file_type": "text/plain", "file_size": 239829, "creation_date": "2023-12-31", "last_modified_date": "2023-12-31", "last_accessed_date": "2023-12-31"}, "hash": "76e194b2637b440a1b1cdf5698cae061524bb4d7a3b73dfc2ba71d268a3f7019", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e6beed53-e696-489c-b0a5-5cc306840b34", "node_type": "1", "metadata": {"file_path": "data/brandt-no-intro.txt", "file_name": "brandt-no-intro.txt", "file_type": "text/plain", "file_size": 239829, "creation_date": "2023-12-31", "last_modified_date": "2023-12-31", "last_accessed_date": "2023-12-31"}, "hash": "46da05c8086519e5e12c8f8f291526319b19b9f65e0686f63e2c258b0c379284", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8f75f1ce-66c0-4c43-b4ea-c6c3eab01b6b", "node_type": "1", "metadata": {}, "hash": "ff576ab810478a3a99933a4b1a63a61bf05634b6f7caf31da9617b68f39ea58f", "class_name": "RelatedNodeInfo"}}, "hash": "6c75f93aee534f33dc672873f0ba4d596bb86f4c6d191031825ec2a5f207d84b", "text": "A stark observation can be\nseen in the binding affinity difference between MAM220 N-(5-chloropnetyl) analog and Cl\n2201(Figure 4-6 and Table 4-1). When compared structurally there are 2 differences being a\nchloro pentyl chain (MAM2201 N-(5-chloropentyl) analog) vs a fluoro pentyl chain (Cl 2201) and\na methyl-naphthyl (MAM2201 N-(5-chloropentyl) analog) vs a chloro-naphthyl (Cl 2201) and yet\nthe affinity differs by over 4 orders of magnitude (Figure 4-1, Figure 4-6 and Table 4-1). This is\nlikely the combinatorial effect of a chloro having a larger atomic radius than fluoro and similarly\na methyl having a larger atomic radius than a chloro. However, to know with certainty the affinity\nof MAM2201 N-(5-chloropentyl) analog with a chloro substituent in the position of the methyl\nwould need to be measured.\nAll SCRAs acted as agonists in terms of their ability to inhibit cAMP accumulation (Figure 4-7\nand Table 4-1). Seven agonists displayed greater potency than CP55,940: JWH 018 2'-naphthylN-(3-methylbutyl) isomer, ortho-AB-FUBINACA, AM 2232, FDU-NNEI, Cl 2201, 5-fluoro \n102\nNPB-22, and 4-fluoro MDMB-BINACA (Figure 4-7 and Table 4-1). Of these agonists, 5\ndisplayed potency greater than 1 nM: JWH 018 2'-naphthyl-N-(3-methylbutyl) isomer, ortho-ABFUBINACA, FDU-NNEI and 4-fluoro MDMB-BINACA (Figure 4-7 and Table 4-1).\nInterestingly if we compare ortho and meta-AB-FUBINACA, ortho (0.06 nM) displays a potency\nthat is 90x greater than meta-AB-FUBINACA (5.4 nM). As for Emax, 8 SCRAs produced greater\nefficacy than the reference agonists CP55,940 (Figure 4-7 and Table 4-1).\nIn terms of \u03b2arrestin2 recruitment, 11 SCRAs showed greater potency than the reference ligand\n(Figure 4-8 and Table 4-1). Of these ligands, only 2 had potencies greater than 10 nm: ABPINACA N-(2-fluoropentyl) isomer and 3-chloro AB-PINACA (Figure 4-8 and Table 4-1). Given\nthe similarities in potencies there does not seem to be a noticeable effect in changing the chloro\nfrom a 3 position (3-chloro AB-PINACA) to a fluoro in the 2 position (AB-PINACA N-(2-\nfluoropentyl) isomer) (Figure 4-8 and Table 4-1). As for efficacy all of the SCRAs acted as\nagonists in their ability to recruit \u03b2arrestin2 (Figure 4-8 and Table 4-1). Of these SCRAs 7 of them\nshowed greater efficacy than the reference agonist CP55,940 including both AB-PINACA N-(2-\nfluoropentyl) isomer and 3-chloro AB-PINACA (Figure 4-8 and Table 4-1).\nWe also evaluated pathway selectivity of the SCRAs at CBR2 (Figure 4-9). It was observed that\northo-AB-FUBINACA, AM2232, FDU-NNE, Cl 2201, JWH-145 and EG 018 were cAMP biased\nwhile AB-PINACA N-(2-fluoro pentyl) isomer, 3-chloro AB-PINACA and 4-fluoro MDMBBINACA were \u03b2arrestin2 bias and lastly THC, meta-AB-FUBINACA, 5-fluoro NPB-22, 5-fluoro\nMPP-PICA are unbiased (Figure 4-9).", "start_char_idx": 132279, "end_char_idx": 135056, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8f75f1ce-66c0-4c43-b4ea-c6c3eab01b6b": {"__data__": {"id_": "8f75f1ce-66c0-4c43-b4ea-c6c3eab01b6b", "embedding": null, "metadata": {"file_path": "data/brandt-no-intro.txt", "file_name": "brandt-no-intro.txt", "file_type": "text/plain", "file_size": 239829, "creation_date": "2023-12-31", "last_modified_date": "2023-12-31", "last_accessed_date": "2023-12-31"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "a0eaa9a5-aece-426b-8f20-580de8fb9f35", "node_type": "4", "metadata": {"file_path": "data/brandt-no-intro.txt", "file_name": "brandt-no-intro.txt", "file_type": "text/plain", "file_size": 239829, "creation_date": "2023-12-31", "last_modified_date": "2023-12-31", "last_accessed_date": "2023-12-31"}, "hash": "76e194b2637b440a1b1cdf5698cae061524bb4d7a3b73dfc2ba71d268a3f7019", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "17bb3a56-9359-47fc-8076-168c7382cf39", "node_type": "1", "metadata": {"file_path": "data/brandt-no-intro.txt", "file_name": "brandt-no-intro.txt", "file_type": "text/plain", "file_size": 239829, "creation_date": "2023-12-31", "last_modified_date": "2023-12-31", "last_accessed_date": "2023-12-31"}, "hash": "6c75f93aee534f33dc672873f0ba4d596bb86f4c6d191031825ec2a5f207d84b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f1878e25-c289-47e5-b7f7-ac50745103a2", "node_type": "1", "metadata": {}, "hash": "11fcf75d766be18765947a21184339b47ab25d272cbf0317832e908d70ad8702", "class_name": "RelatedNodeInfo"}}, "hash": "ff576ab810478a3a99933a4b1a63a61bf05634b6f7caf31da9617b68f39ea58f", "text": "We also evaluated pathway selectivity of the SCRAs at CBR2 (Figure 4-9). It was observed that\northo-AB-FUBINACA, AM2232, FDU-NNE, Cl 2201, JWH-145 and EG 018 were cAMP biased\nwhile AB-PINACA N-(2-fluoro pentyl) isomer, 3-chloro AB-PINACA and 4-fluoro MDMBBINACA were \u03b2arrestin2 bias and lastly THC, meta-AB-FUBINACA, 5-fluoro NPB-22, 5-fluoro\nMPP-PICA are unbiased (Figure 4-9). For the cAMP biased compounds all but ortho-ABFUBINACA contain a naphthalene substituent whereas all \u03b2arrestin2 biased compounds contain\na substituted amide or ester group (Figure 4-1 and Figure 4-9). \n103\nFigure 4-6. (a,b,c,d) Radioligand binding of 1 nM [3H]CP55,940 to membranes from CB2R\nCHO-K1 cells. CB2R CHO-K1 cells were treated with 0.10 nM \u2013 10 \u00b5M compounds in the\npresence 1 nM [3H]CP55,940. Data are expressed as % radioligand bound or % stimulation above\nbaseline (i.e. vehicle) levels. Data were fit to a nonlinear regression (4-parameter model, GraphPad\nv. 9.0) to determine KD, EC50, and Emax. Data are mean \u00b1 SEM (Emax) or 95% CI (KD, EC50); n \u2265\n6 independent experiments. *p < 0.05 compared to CP55,940 as determined by one-way ANOVA\nfollowed by Bonferroni\u2019s post-hoc test or non-overlapping 95% CI.\n104\nFigure 4-7. CB2R CHO-K1 were treated with 0.10 nM \u2013 10 \u00b5M GAT compounds. (a,b,c.d)\ncAMP inhibition of GAT compounds as agonists. (a,b,d,e). Data are expressed as % CP55,940\nmax. Data were fit to a nonlinear regression (4-parameter model, GraphPad v. 9.0) to determine\nEC50 and Emax. Data are mean \u00b1 SEM (Emax) or 95% CI (EC50); n \u2265 6 independent experiments\nperformed in triplicate. *p < 0.05 compared to CP55,940 as determined by one-way ANOVA\nfollowed by Bonferroni\u2019s post-hoc test or non-overlapping 95% CI. Concentration-response data\nwere fit to the operational model of Black and Leff (1983) (GraphPad v. 9.0).\n105\nFigure 4-8. CB2R CHO-K1 were treated with 0.10 nM \u2013 10 \u00b5M GAT compounds. (b,c,d,e)\n\u03b2arrestin2 recruitment of GAT compounds as agonists (a,b,c,d). Data are expressed as %\nCP55,940 max. Data were fit to a nonlinear regression (4-parameter model, GraphPad v. 9.0) to\ndetermine EC50 and Emax. Data are mean \u00b1 SEM (Emax) or 95% CI (EC50); n \u2265 6 independent\nexperiments performed in triplicate. *p < 0.05 compared to CP55,940 as determined by one-way\nANOVA followed by Bonferroni\u2019s post-hoc test or non-overlapping 95% CI.\n106\nFigure 4-9. CB2R SCRA bias. Compound bias between cAMP inhibition and \u03b2arrestin2\nrecruitment [\u0394\u0394LogR (cAMP - \u03b2arrestin2)] is shown here for data presented. Data were fit to the\noperational model to calculate bias. Data are mean with 95% CI, n \u2265 6 independent experiments\nperformed in triplicate. Values > 0 represent cAMP bias (white), values < 0 represent \u03b2arrestin2\nbias (red), and values not different from 0 are unbiased (blue) as determined by 95% CI not\noverlapping with 0.\n107\nTable 4-1. Activity of SCRAs at CB1R and CB2R\nCompound\nCB1R CB2R\n[\n3H]CP55,940\ncAMP\nInhibition\n\uf062arrestin2\nrecruitment\n[\n3H]CP55,", "start_char_idx": 134678, "end_char_idx": 137633, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f1878e25-c289-47e5-b7f7-ac50745103a2": {"__data__": {"id_": "f1878e25-c289-47e5-b7f7-ac50745103a2", "embedding": null, "metadata": {"file_path": "data/brandt-no-intro.txt", "file_name": "brandt-no-intro.txt", "file_type": "text/plain", "file_size": 239829, "creation_date": "2023-12-31", "last_modified_date": "2023-12-31", "last_accessed_date": "2023-12-31"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "a0eaa9a5-aece-426b-8f20-580de8fb9f35", "node_type": "4", "metadata": {"file_path": "data/brandt-no-intro.txt", "file_name": "brandt-no-intro.txt", "file_type": "text/plain", "file_size": 239829, "creation_date": "2023-12-31", "last_modified_date": "2023-12-31", "last_accessed_date": "2023-12-31"}, "hash": "76e194b2637b440a1b1cdf5698cae061524bb4d7a3b73dfc2ba71d268a3f7019", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8f75f1ce-66c0-4c43-b4ea-c6c3eab01b6b", "node_type": "1", "metadata": {"file_path": "data/brandt-no-intro.txt", "file_name": "brandt-no-intro.txt", "file_type": "text/plain", "file_size": 239829, "creation_date": "2023-12-31", "last_modified_date": "2023-12-31", "last_accessed_date": "2023-12-31"}, "hash": "ff576ab810478a3a99933a4b1a63a61bf05634b6f7caf31da9617b68f39ea58f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "725e92db-cd38-43d4-a732-287851a65b5a", "node_type": "1", "metadata": {}, "hash": "3909d5b0e679e13ba0f8fad40a366b4f3c646f050dcc689dcfcc88572ccf1870", "class_name": "RelatedNodeInfo"}}, "hash": "11fcf75d766be18765947a21184339b47ab25d272cbf0317832e908d70ad8702", "text": "Compound bias between cAMP inhibition and \u03b2arrestin2\nrecruitment [\u0394\u0394LogR (cAMP - \u03b2arrestin2)] is shown here for data presented. Data were fit to the\noperational model to calculate bias. Data are mean with 95% CI, n \u2265 6 independent experiments\nperformed in triplicate. Values > 0 represent cAMP bias (white), values < 0 represent \u03b2arrestin2\nbias (red), and values not different from 0 are unbiased (blue) as determined by 95% CI not\noverlapping with 0.\n107\nTable 4-1. Activity of SCRAs at CB1R and CB2R\nCompound\nCB1R CB2R\n[\n3H]CP55,940\ncAMP\nInhibition\n\uf062arrestin2\nrecruitment\n[\n3H]CP55,940 cAMP Inhibition\n\uf062arrestin2\nrecruitment\nKi\n(nM)\nEmin\n(%)\nEC50\n(nM)\nEmax\n(%)\nEC50\n(nM)\nEmax\n(%)\nKi\n(nM)\nEmin\n(%)\nEC50\n(nM)\nEmax\n(%)\nEC50\n(nM)\nEmax\n(%)\nCP55,940\n13\n(5.6-\n33)\n0.0 \u00b1\n5.2\n7.7\n(0.13-\n14)\n100\n\u00b1 6.2\n1,500\n(960-\n2,500)\n100 \u00b1\n5.6\n29 (13-\n67)\n0.0 \u00b1\n5.6\n5.0 (0.92-\n24)\n100 \u00b1\n9.6\n559 (410-\n761)\u2020\n100 \u00b1\n3.4\n\u2206\n9\n-THC\n14\n(7.9-\n27)\n9.1 \u00b1\n1.3\n36\n(21-\n63)*\n72 \u00b1\n1.7*\n1,400\n(540-\n4,300)\n28 \u00b1\n9.8*\n31 (15-\n62)\n65 \u00b1\n7.6*\n13 (2.8-\n61)\n48 \u00b1\n3.8*\u2020\n320 (79-\n730)\n58 \u00b1\n1.1*\u2020\nJWH 182\n0.77\n(0.45-\n1.3)*\n17 \u00b1\n2.2\n24\n(2.2-\n280)\n78 \u00b1\n9.4\n1,600\n(720-\n3,100)\n110 \u00b1\n9.2\n6.2\n(2.3 -\n18)\n21 \u00b1\n1.7*\u2020\n25 (3.2-\n210)\n120 \u00b1\n11\u2020\n> 10,000$\n13 \u00b1\n1.8*\u2020\nJWH 018 2'-\nnaphthyl-N-(3-\nmethylbutyl)\nisomer\n0.93\n(0.51-\n1.8)*\n9.6 \u00b1\n2.7\n98\n(9.6-\n310)\n80 \u00b1\n9.1\n>\n10,00\n0\n4.9 \u00b1\n0.51*\n7.5\n(2.6-\n41)\n54 \u00b1\n3.5*\u2020\n0.52\n(0.01-\n4.2)\u2020\n110 \u00b1\n9.2\n> 10,000\n6.1 \u00b1\n1.3*\nMAM2201 N-\n(5-\nchloropentyl)\nanalog\n10\n(5.9-\n17)\n5.3 \u00b1\n3.0\n2.8\n(0.83-\n9.4)\n98 \u00b1\n8.7\n>\n10,00\n0\n17 \u00b1\n2.7*\n>\n10,000\n$\n40 \u00b1\n3.8*\u2020\n580 (41-\n1,400)*\u2020\n120 \u00b1\n25\n> 10,000\n5.5 \u00b1\n1.9*\nmeta-ABFUBINACA\n16\n(7.1-\n37)\n30 \u00b1\n2.9*\n5.7\n(0.64-\n100)\n91 \u00b1\n12\n>\n10,00\n0\n22 \u00b1\n6.9*\n0.63\n(0.15-\n7.4)*\n89 \u00b1\n6.3*\u2020\n5.4 (2.2-\n14)\n86 \u00b1\n13\n280 (93-\n430)$\n130 \u00b1\n3.7*\u2020\n108\northo-ABFUBINACA\n2.7\n(0.77-\n10)\n16 \u00b1\n5.4\n3.6\n(0.35-\n31)\n83 \u00b1\n8.4\n810\n(560-\n1,", "start_char_idx": 137049, "end_char_idx": 138866, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "725e92db-cd38-43d4-a732-287851a65b5a": {"__data__": {"id_": "725e92db-cd38-43d4-a732-287851a65b5a", "embedding": null, "metadata": {"file_path": "data/brandt-no-intro.txt", "file_name": "brandt-no-intro.txt", "file_type": "text/plain", "file_size": 239829, "creation_date": "2023-12-31", "last_modified_date": "2023-12-31", "last_accessed_date": "2023-12-31"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "a0eaa9a5-aece-426b-8f20-580de8fb9f35", "node_type": "4", "metadata": {"file_path": "data/brandt-no-intro.txt", "file_name": "brandt-no-intro.txt", "file_type": "text/plain", "file_size": 239829, "creation_date": "2023-12-31", "last_modified_date": "2023-12-31", "last_accessed_date": "2023-12-31"}, "hash": "76e194b2637b440a1b1cdf5698cae061524bb4d7a3b73dfc2ba71d268a3f7019", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f1878e25-c289-47e5-b7f7-ac50745103a2", "node_type": "1", "metadata": {"file_path": "data/brandt-no-intro.txt", "file_name": "brandt-no-intro.txt", "file_type": "text/plain", "file_size": 239829, "creation_date": "2023-12-31", "last_modified_date": "2023-12-31", "last_accessed_date": "2023-12-31"}, "hash": "11fcf75d766be18765947a21184339b47ab25d272cbf0317832e908d70ad8702", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "44c45d08-35c9-41b3-ad60-cbeeef4660be", "node_type": "1", "metadata": {}, "hash": "42cff9c625dfeaddfa302ad727dd8938691689f7c4db923cbe146e21e32104c2", "class_name": "RelatedNodeInfo"}}, "hash": "3909d5b0e679e13ba0f8fad40a366b4f3c646f050dcc689dcfcc88572ccf1870", "text": "8*\u2020\n580 (41-\n1,400)*\u2020\n120 \u00b1\n25\n> 10,000\n5.5 \u00b1\n1.9*\nmeta-ABFUBINACA\n16\n(7.1-\n37)\n30 \u00b1\n2.9*\n5.7\n(0.64-\n100)\n91 \u00b1\n12\n>\n10,00\n0\n22 \u00b1\n6.9*\n0.63\n(0.15-\n7.4)*\n89 \u00b1\n6.3*\u2020\n5.4 (2.2-\n14)\n86 \u00b1\n13\n280 (93-\n430)$\n130 \u00b1\n3.7*\u2020\n108\northo-ABFUBINACA\n2.7\n(0.77-\n10)\n16 \u00b1\n5.4\n3.6\n(0.35-\n31)\n83 \u00b1\n8.4\n810\n(560-\n1,100)\n280 \u00b1\n11*\n0.93\n(0.04-\n2.4)*\n17 \u00b1\n1.2\n0.06\n(0.001-\n3.1)\n110 \u00b1\n6.7\n140 (44-\n460)\u2020\n120 \u00b1\n3.1*\u2020\nAM 2232\n0.31\n(0.001-\n2.9)*\n66 \u00b1\n3.6*\n190\n(67-\n700)*\n100\n\u00b1 9.3\n>\n10,00\n0\n68 \u00b1\n1.6*\n600\n(430-\n1,100)\n*\n73 \u00b1\n6.2*\n1.7 (0.48-\n16)\u2020\n86 \u00b1\n1.9\n130 (45-\n370)*\n130 \u00b1\n19*\u2020\nFDU-NNEI\n14\n(2.2-\n71)\n41 \u00b1\n2.8\n1.0\n(0.12-\n9.8)\n96 \u00b1\n8.1\n>\n10,00\n0\n49 \u00b1\n8.2*\n8.8\n(1.8-\n39)\n85 \u00b1\n8.1*\u2020\n0.01\n(0.001-\n7.1)\n103 \u00b1\n7.1\n1,000\n(390-\n1,300)\n25 \u00b1\n1.3*\u2020\nCl 2201\n0.09\n(0.001-\n5.4)*\n76 \u00b1\n2.8*\n2.6\n(1.2-\n5.8)\n89 \u00b1\n3.9\n>\n10,00\n0\n16 \u00b1\n1.0*\n26\n(7.8 -\n82)\n66 \u00b1\n2.5*\n1.0 (0.07-\n8.3)\n110 \u00b1\n8.4\n120 (33-\n560)\n17 \u00b1\n1.1*\n5-fluoro NPB22\n47 (20-\n110)\n2.3 \u00b1\n7.8\n53\n(8.2-\n200)\n96 \u00b1\n7.0\n830\n(500-\n1,300)\n210 \u00b1\n12*\n4.3\n(0.78-\n24)\n34\n\u00b18.1*\n\u2020\n3.2 (1.3-\n7.5)\n110 \u00b1\n7.6\n280 (65-\n580)\n120 \u00b1\n3.7*\u2020\nABPINACA N-(2-\nfluoropentyl)\nisomer\n1.6\n(0.08-\n11)\n76 \u00b1\n6.2*\n7.3\n(0.61-\n100)\n75 \u00b1\n7.5*\n240\n(140-\n450)*\n204 \u00b1\n10*\n270\n(97-\n780)*\n2.8\u00b18\n.1\u2020\n10 (1.8-\n46)\n91 \u00b1\n3.2\n9.4 (3.2-\n27)*\u2020\n140 \u00b1\n12*\u2020\n3-chloro ABPINACA\n170\n(24-\n740)\n65 \u00b1\n5.1*\n0.04\n(0.001\n-0.22)\n94 \u00b1\n2.8\n140\n(93-\n200)*\n340 \u00b1\n11*\n52\n(8.9-\n94)\n84 \u00b1\n4.3*\n19 (5.9-\n110)\u2020\n87 \u00b1\n15\n8.8 (3.0-\n24)*\u2020\n130 \u00b1\n4.5*\u2020\nJWH 145\n110\n(21-\n800)\n69 \u00b1\n7.6*\n0.03\n(0.001\n-1.5)\n82 \u00b1\n9.3\n>\n10,00\n0\n27 \u00b1\n9.0*\n860\n(560-\n1,300)\n*\n70 \u00b1\n6.1*\n61 (2.", "start_char_idx": 138573, "end_char_idx": 140074, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "44c45d08-35c9-41b3-ad60-cbeeef4660be": {"__data__": {"id_": "44c45d08-35c9-41b3-ad60-cbeeef4660be", "embedding": null, "metadata": {"file_path": "data/brandt-no-intro.txt", "file_name": "brandt-no-intro.txt", "file_type": "text/plain", "file_size": 239829, "creation_date": "2023-12-31", "last_modified_date": "2023-12-31", "last_accessed_date": "2023-12-31"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "a0eaa9a5-aece-426b-8f20-580de8fb9f35", "node_type": "4", "metadata": {"file_path": "data/brandt-no-intro.txt", "file_name": "brandt-no-intro.txt", "file_type": "text/plain", "file_size": 239829, "creation_date": "2023-12-31", "last_modified_date": "2023-12-31", "last_accessed_date": "2023-12-31"}, "hash": "76e194b2637b440a1b1cdf5698cae061524bb4d7a3b73dfc2ba71d268a3f7019", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "725e92db-cd38-43d4-a732-287851a65b5a", "node_type": "1", "metadata": {"file_path": "data/brandt-no-intro.txt", "file_name": "brandt-no-intro.txt", "file_type": "text/plain", "file_size": 239829, "creation_date": "2023-12-31", "last_modified_date": "2023-12-31", "last_accessed_date": "2023-12-31"}, "hash": "3909d5b0e679e13ba0f8fad40a366b4f3c646f050dcc689dcfcc88572ccf1870", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6c46b555-ed9e-4776-8373-6fc61d504f7c", "node_type": "1", "metadata": {}, "hash": "ff0a48841aa7b7185919619a4f20e4b73252220eecfbe8f8aef0df8e889ed999", "class_name": "RelatedNodeInfo"}}, "hash": "42cff9c625dfeaddfa302ad727dd8938691689f7c4db923cbe146e21e32104c2", "text": "4 (3.2-\n27)*\u2020\n140 \u00b1\n12*\u2020\n3-chloro ABPINACA\n170\n(24-\n740)\n65 \u00b1\n5.1*\n0.04\n(0.001\n-0.22)\n94 \u00b1\n2.8\n140\n(93-\n200)*\n340 \u00b1\n11*\n52\n(8.9-\n94)\n84 \u00b1\n4.3*\n19 (5.9-\n110)\u2020\n87 \u00b1\n15\n8.8 (3.0-\n24)*\u2020\n130 \u00b1\n4.5*\u2020\nJWH 145\n110\n(21-\n800)\n69 \u00b1\n7.6*\n0.03\n(0.001\n-1.5)\n82 \u00b1\n9.3\n>\n10,00\n0\n27 \u00b1\n9.0*\n860\n(560-\n1,300)\n*\n70 \u00b1\n6.1*\n61 (2.7-\n200)\u2020\n86 \u00b1\n17\n190 (37-\n520)\n15 \u00b1\n1.7*\n109\nEG 018\n8.6\n(0.68-\n76)\n68 \u00b1\n6.1*\n450\n(69-\n2,900)\n*\n104\n\u00b1 18\n>\n10,00\n0\n5.2 \u00b1\n0.54*\n1.9\n(0.27-\n8.0)*\n53 \u00b1\n4.0*\n51 (5.2-\n580)\n85 \u00b1\n17\n770 (350-\n1,700)\n10 \u00b1\n1.9*\n4-fluoro\nMDMBBINACA\n99 (14-\n890)\n52 \u00b1\n7.5*\n10\n(1.8-\n83)\n87 \u00b1\n5.6\n88\n(49-\n150)*\n240 \u00b1\n10*\n0.41\n(0.02-\n8.1)*\n57 \u00b1\n11*\n0.56\n(0.05-22)\n95 \u00b1\n11\n120 (53-\n250)*\n130 \u00b1\n8.2*\u2020\n5-fluoro MPPPICA\n1,200\n(160-\n3,200)\n*\n59 \u00b1\n18*\n6.4\n(1.3-\n30)\n92 \u00b1\n6.8\n>\n10,00\n0\n170 \u00b1\n9.8*\n540\n(150-\n780)*\n89 \u00b1\n6.3*\n12 (1.5-\n77)\n110 \u00b1\n13\n630 (250-\n1,100)$\n82 \u00b1\n1.9*\u2020\n110\n4.3.3 In Silico Evaluation of CB1R and CB2R\nAll 15 cannabinoids studied bind to the orthosteric site of CB1R and CB2R (Figure 4-10). Shown\nin Figure 4-10 is JWH 018 2'-naphthyl-N-(3-methylbutyl) isomer bound to CB1R (a) and CB2R\n(b). Two interactions are conserved between both CB1R and CB2R in terms of the binding of JWH\n018 2'-naphthyl-N-(3-methylbutyl) isomer (Figure 4-10, Table 4-2 and Table 4-3), namely the Hbond with S7.39 and the T-shaped \u03c0- \u03c0 interaction H2.65 (Figure 4-10, Table 4-2 and Table 4-3).\nFurthermore, the similarity in interactions of the synthetic cannabinoids (Table 4-2 and Table 4-3)\nwith both CB1R and CB2R suggests that the binding sites are well conserved between both\nreceptors likely due to nearly identical amino acid sequence between these 2 GPCRs. In 9/15\ncannabinoids the ketone H-bonds with S3837.39 on CB1R while for all of the cannabinoids the\nketone H-bonds to S2857.39 on CB2R which suggests that this is the most conserved interaction\n(Table 4-2 and Table 4-3).\nBecause the amino acid sequence and binding sites are well conserved among CB1R and CB2R\nthe interaction energy was calculated for each cannabinoid as a predictive metric that can be used\nto compare the relative affinity of each cannabinoid at each receptor (Table 4-2 and Table 4-3).", "start_char_idx": 139766, "end_char_idx": 141903, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6c46b555-ed9e-4776-8373-6fc61d504f7c": {"__data__": {"id_": "6c46b555-ed9e-4776-8373-6fc61d504f7c", "embedding": null, "metadata": {"file_path": "data/brandt-no-intro.txt", "file_name": "brandt-no-intro.txt", "file_type": "text/plain", "file_size": 239829, "creation_date": "2023-12-31", "last_modified_date": "2023-12-31", "last_accessed_date": "2023-12-31"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "a0eaa9a5-aece-426b-8f20-580de8fb9f35", "node_type": "4", "metadata": {"file_path": "data/brandt-no-intro.txt", "file_name": "brandt-no-intro.txt", "file_type": "text/plain", "file_size": 239829, "creation_date": "2023-12-31", "last_modified_date": "2023-12-31", "last_accessed_date": "2023-12-31"}, "hash": "76e194b2637b440a1b1cdf5698cae061524bb4d7a3b73dfc2ba71d268a3f7019", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "44c45d08-35c9-41b3-ad60-cbeeef4660be", "node_type": "1", "metadata": {"file_path": "data/brandt-no-intro.txt", "file_name": "brandt-no-intro.txt", "file_type": "text/plain", "file_size": 239829, "creation_date": "2023-12-31", "last_modified_date": "2023-12-31", "last_accessed_date": "2023-12-31"}, "hash": "42cff9c625dfeaddfa302ad727dd8938691689f7c4db923cbe146e21e32104c2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5af7a950-8c25-4e11-a3f1-0734210c6a1d", "node_type": "1", "metadata": {}, "hash": "003933b6a957f57e2e40d5708987145ea56529da977694150b6ebbaddc3c0ade", "class_name": "RelatedNodeInfo"}}, "hash": "ff0a48841aa7b7185919619a4f20e4b73252220eecfbe8f8aef0df8e889ed999", "text": "Furthermore, the similarity in interactions of the synthetic cannabinoids (Table 4-2 and Table 4-3)\nwith both CB1R and CB2R suggests that the binding sites are well conserved between both\nreceptors likely due to nearly identical amino acid sequence between these 2 GPCRs. In 9/15\ncannabinoids the ketone H-bonds with S3837.39 on CB1R while for all of the cannabinoids the\nketone H-bonds to S2857.39 on CB2R which suggests that this is the most conserved interaction\n(Table 4-2 and Table 4-3).\nBecause the amino acid sequence and binding sites are well conserved among CB1R and CB2R\nthe interaction energy was calculated for each cannabinoid as a predictive metric that can be used\nto compare the relative affinity of each cannabinoid at each receptor (Table 4-2 and Table 4-3).\nThis metric would predict JWH-182, JWH 018 2'-naphthyl-N-(3-methylbutyl) isomer, MAM2201\nN-(5-chloropentyl) analog, Cl 2201, AB-PINACA N-(2-fluoropentyl) isomer, JWH 145 and 4-\nfluoro MDMB-BINACA to have higher affinity at CB1R (Table 4-2) while meta-AB-Fubinaca,\northo-AB-Fubinaca, AM 2232, FDU-NNE1, 5-fluoro NPB-22, 3-Chloro AB-PINACA, EG 018\nand 5-fluoro MPP-PICA to have higher affinity at CB2R (Table 4-3). The modeling predictions\nexcept for AM 2232 agreed with experimental binding affinities measured in terms of which\nreceptor each cannabinoid has higher affinity at when comparing CB1R to CB2R. Because the\ncalculated interaction energy for AM 2232 is a more negative number at CB2R it would suggest \n111\nthat the affinity is higher at CB2R, but our experimental binding affinity values suggests the\nopposite. However, in Figure 4-12 there is no correlation between the experimentally determined\nKi values by radioligand binding and computationally determined MMGBSA values when\ncomparing values within the same receptor. Although this model has been successful in showing\ncorrelation between non-GPCR molecular targets it has failed to do so for GPCR\u2019s.144,145 The\npurpose in running this model for GPCR\u2019s is has been shown to discriminate active from inactive\ncompounds.145\nIf we compare the highest affinity CB1R agonist (Cl 2201) to the weakest affinity CB1R agonist\n(JWH 145) we can understand the structural features that make a high affinity CB1R agonist.\nFirstly, the main structural difference between Cl 2201 and JWH 145 is that in Cl 2201 the benzene\nring is fused to the pyridine vs in JWH 145 it is a branched benzene ring. Because of this the two\ncannabinoids only share 1 similar interaction being F268ECL2 (Table 4-2). In fact, JWH 145 only\nhas 2 electrostatic interactions with CB1R (Table 4-2). However, if we compare Cl 2201 with\nMAM2201, which are very similar structurally, we can likely see what interactions are important\nfor CL 2201\u2019s high affinity for CB1R. The major difference between these two structures is that\nMAM 2201 has a methyl coming off the naphthalene group whereas Cl 2201 has a chlorine coming\noff (Figure 4-1). The other difference is that MAM 2201 has a choro pentyl whereas Cl 2201 has\na fluorine. The binding poses of these cannabinoids are identical except for the R182ECL1 halogen\nbond exhibited by Cl 2201 but not by MAM2201 which is the main structural feature that gives\nrise to Cl 2201\u2019s high affinity at CB1R.\nLastly, in Table 4-4 we looked at the most G protein-biased compound JWH 018 2'-naphthyl-N-\n(3-methylbutyl) isomer and the most \u03b2arrestin2-biased compound 4F-MDMB-BINACA bound to\n6N4B with and without the G protein.", "start_char_idx": 141126, "end_char_idx": 144591, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5af7a950-8c25-4e11-a3f1-0734210c6a1d": {"__data__": {"id_": "5af7a950-8c25-4e11-a3f1-0734210c6a1d", "embedding": null, "metadata": {"file_path": "data/brandt-no-intro.txt", "file_name": "brandt-no-intro.txt", "file_type": "text/plain", "file_size": 239829, "creation_date": "2023-12-31", "last_modified_date": "2023-12-31", "last_accessed_date": "2023-12-31"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "a0eaa9a5-aece-426b-8f20-580de8fb9f35", "node_type": "4", "metadata": {"file_path": "data/brandt-no-intro.txt", "file_name": "brandt-no-intro.txt", "file_type": "text/plain", "file_size": 239829, "creation_date": "2023-12-31", "last_modified_date": "2023-12-31", "last_accessed_date": "2023-12-31"}, "hash": "76e194b2637b440a1b1cdf5698cae061524bb4d7a3b73dfc2ba71d268a3f7019", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6c46b555-ed9e-4776-8373-6fc61d504f7c", "node_type": "1", "metadata": {"file_path": "data/brandt-no-intro.txt", "file_name": "brandt-no-intro.txt", "file_type": "text/plain", "file_size": 239829, "creation_date": "2023-12-31", "last_modified_date": "2023-12-31", "last_accessed_date": "2023-12-31"}, "hash": "ff0a48841aa7b7185919619a4f20e4b73252220eecfbe8f8aef0df8e889ed999", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "586c219f-ff5c-476e-bf1b-15e5523ecf10", "node_type": "1", "metadata": {}, "hash": "9e9c707dbb5adf831af0a53f20e81b93db01db81213e1eb440f485292cfe8194", "class_name": "RelatedNodeInfo"}}, "hash": "003933b6a957f57e2e40d5708987145ea56529da977694150b6ebbaddc3c0ade", "text": "The other difference is that MAM 2201 has a choro pentyl whereas Cl 2201 has\na fluorine. The binding poses of these cannabinoids are identical except for the R182ECL1 halogen\nbond exhibited by Cl 2201 but not by MAM2201 which is the main structural feature that gives\nrise to Cl 2201\u2019s high affinity at CB1R.\nLastly, in Table 4-4 we looked at the most G protein-biased compound JWH 018 2'-naphthyl-N-\n(3-methylbutyl) isomer and the most \u03b2arrestin2-biased compound 4F-MDMB-BINACA bound to\n6N4B with and without the G protein. The reason for doing so is to show that the most G protein \n112\nbiased compound (JWH 018 2'-naphthyl-N-(3-methylbutyl) isomer) shows a more negative\ninteraction energy with the G protein bound which makes sense as this compound is G protein\nbiased. In fact, JWH 018 2'-naphthyl-N-(3-methylbutyl) isomer is 3.78 kcal/mol more stable with\nthe G protein bound than without the G protein bound (Table 4-4). The same analysis was\nconducted for the most biased \u03b2arrestin2-baised compound 4F-MDMB-BINACA. It was found\nthat 4F-MDMB-BINACA without the G protein bound was 10.56 kcal/mol more stable that 4FMDMB-BINACA with the G protein bound. It should be mentioned that the ideal method of\nrunning this experiment would be to include a calculation with \u03b2arrestin2 bound to CB1R or\nCB2R. However, this can not be performed because there does not yet exist a CB1R or CB2R\ncrystal structure with \u03b2arrestin2 bound. \n113\nFigure 4-10. JWH 018 2\u2019-naphthyl-N-(3-methylbutyl) isomer bound to CB1 (a) and CB2 (b)\nin 3D. (c) shows the interactions between JWH 018 2\u2019-naphthyl-N-(3-methylbutyl) isomer and\nCB1 while (d) shows the interactions between JWH 018 2\u2019-naphthyl-N-(3-methylbutyl) isomer\nand CB2\n114\nFigure 4-11. 4F-MDMB-BINACA. bound to CB1 (a) and CB2 (b) in 3D. (c) shows the\ninteractions between 4F-MDMB-BINACA and CB1 while (d) shows the interactions between 4FMDMB-BINACA and CB2. \n115\nTable 4-2. Summary of the interactions between the residues of the CB1R (PDB: 6N4B) and each\nof the synthetic cannabinoids. The right column additionally lists the interaction energy of each\nsynthetic cannabinoid.", "start_char_idx": 144067, "end_char_idx": 146186, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "586c219f-ff5c-476e-bf1b-15e5523ecf10": {"__data__": {"id_": "586c219f-ff5c-476e-bf1b-15e5523ecf10", "embedding": null, "metadata": {"file_path": "data/brandt-no-intro.txt", "file_name": "brandt-no-intro.txt", "file_type": "text/plain", "file_size": 239829, "creation_date": "2023-12-31", "last_modified_date": "2023-12-31", "last_accessed_date": "2023-12-31"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "a0eaa9a5-aece-426b-8f20-580de8fb9f35", "node_type": "4", "metadata": {"file_path": "data/brandt-no-intro.txt", "file_name": "brandt-no-intro.txt", "file_type": "text/plain", "file_size": 239829, "creation_date": "2023-12-31", "last_modified_date": "2023-12-31", "last_accessed_date": "2023-12-31"}, "hash": "76e194b2637b440a1b1cdf5698cae061524bb4d7a3b73dfc2ba71d268a3f7019", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5af7a950-8c25-4e11-a3f1-0734210c6a1d", "node_type": "1", "metadata": {"file_path": "data/brandt-no-intro.txt", "file_name": "brandt-no-intro.txt", "file_type": "text/plain", "file_size": 239829, "creation_date": "2023-12-31", "last_modified_date": "2023-12-31", "last_accessed_date": "2023-12-31"}, "hash": "003933b6a957f57e2e40d5708987145ea56529da977694150b6ebbaddc3c0ade", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0d912877-f1cf-4853-9f04-536ce46c0030", "node_type": "1", "metadata": {}, "hash": "72c711df649c1d7d6ecc1202d039060e8b543a2a987b5243ca79301c6e26428f", "class_name": "RelatedNodeInfo"}}, "hash": "9e9c707dbb5adf831af0a53f20e81b93db01db81213e1eb440f485292cfe8194", "text": "4F-MDMB-BINACA. bound to CB1 (a) and CB2 (b) in 3D. (c) shows the\ninteractions between 4F-MDMB-BINACA and CB1 while (d) shows the interactions between 4FMDMB-BINACA and CB2. \n115\nTable 4-2. Summary of the interactions between the residues of the CB1R (PDB: 6N4B) and each\nof the synthetic cannabinoids. The right column additionally lists the interaction energy of each\nsynthetic cannabinoid.\nCompound\nF1702.57\n\u03c0-\u03c0 interaction\nS1732.60\nH-bond\nF1772.64\n\u03c0-\u03c0 interaction\nH1782.65\nH-bond\nH1782.65\n\u03c0-\u03c0 interaction\nR182ECL1 Halogen Bond\nF1893.25\n\u03c0-\u03c0 interaction\nF2003.36\n\u03c0-\u03c0 interaction\nF268\nECL2\n\u03c0-\u03c0 interaction\nW2795.43\n\u03c0-\u03c0 interaction\nL3767.32\nH-bond\nS3837.39\nH-bond\nInteraction energy\n(kcal/mol)\nJWH-182 X X X X X -132.75\nJWH 018 2'-\nnaphthyl-N-\n(3-\nmethylbutyl)\nisomer\nX X X -118.41\nMAM2201\nN-(5-\nchloropentyl)\nanalog\nX X X X X -128.37\nmeta-ABFubinaca\nX X -121.84\northo-ABFubinaca\nX X X X X -117.77\nAM 2232 X X X -113.89\nFDU-NNE1 X X X X X X -114.64\nCl 2201 X X X X X X -123.69\n5-fluoro\nNPB-22\nX X X X X X -112.59\nAB-PINACA\nN-(2-\nfluoropentyl)\nisomer\nX X -116.02\n3-Chloro\nAB-PINACA\nX X -112.12\nJWH 145 X X -134.03\nEG 018 X X X X -126.92\n4-fluoro\nMDMBBINACA\nX X -105.63\n5-fluoro\nMPP-PICA\nX X X -107.13\n116\nTable 4-3. Summary of the interactions between the residues of the CB2R (PDB: 6PT0) and each\nof the synthetic cannabinoids. The right column additionally lists the interaction energy of each\nsynthetic cannabinoid.\nCompound\nF872.57\nH-bond\nS902.60\nH-bond\nF912.61\n\u03c0-\u03c0\ninteraction F942.64\n\u03c0-\u03c0 interaction\nH952.65\n\u03c0-\u03c0 interaction\nT1143.33\n\u03c0-\u03c0\ninteraction F1173.36\n\u03c0-\u03c0\ninteraction F183\nE\nCL2\n\u03c0-\u03c0\ninteraction W1945.43\n\u03c0-\u03c0\ninteraction W2586.48\n\u03c0-\u03c0\ninteraction S2857.39\nH-bond\nInteraction energy\n(kcal/mol)\nJWH-182 X X X X X -119.80\nJWH 018 2'-\nnaphthyl-N-(3-\nmethylbutyl)\nisomer\nX X X X X -111.40\nMAM2201 N-(5-\nchloropentyl)\nanalog\nX X X X -126.21\nmeta-ABFubinaca\nX X X -124.22\northo-ABFubinaca\nX X X X -118.99\nAM 2232 X X -114.25\nFDU-NNE1 X X -116.92\nCl 2201 X X X X -122.02\n5-fluoro NPB-22 X X X X -123.90\nAB-PINACA N-\n(2-fluoropentyl)\nisomer\nX X -105.84\n3-Chloro ABPINACA\nX X X X -115.84\nJWH 145 X X X X -128.12\nEG 018 X X X -129.34\n4-fluoro MDMBBINACA\nX X -112.01\n5-fluoro MPPPICA\nX X X X X -119.45\n117\nTable 4-4.", "start_char_idx": 145794, "end_char_idx": 148007, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0d912877-f1cf-4853-9f04-536ce46c0030": {"__data__": {"id_": "0d912877-f1cf-4853-9f04-536ce46c0030", "embedding": null, "metadata": {"file_path": "data/brandt-no-intro.txt", "file_name": "brandt-no-intro.txt", "file_type": "text/plain", "file_size": 239829, "creation_date": "2023-12-31", "last_modified_date": "2023-12-31", "last_accessed_date": "2023-12-31"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "a0eaa9a5-aece-426b-8f20-580de8fb9f35", "node_type": "4", "metadata": {"file_path": "data/brandt-no-intro.txt", "file_name": "brandt-no-intro.txt", "file_type": "text/plain", "file_size": 239829, "creation_date": "2023-12-31", "last_modified_date": "2023-12-31", "last_accessed_date": "2023-12-31"}, "hash": "76e194b2637b440a1b1cdf5698cae061524bb4d7a3b73dfc2ba71d268a3f7019", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "586c219f-ff5c-476e-bf1b-15e5523ecf10", "node_type": "1", "metadata": {"file_path": "data/brandt-no-intro.txt", "file_name": "brandt-no-intro.txt", "file_type": "text/plain", "file_size": 239829, "creation_date": "2023-12-31", "last_modified_date": "2023-12-31", "last_accessed_date": "2023-12-31"}, "hash": "9e9c707dbb5adf831af0a53f20e81b93db01db81213e1eb440f485292cfe8194", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e49f75dc-b4d8-4a71-bc43-d3eceb669e53", "node_type": "1", "metadata": {}, "hash": "08d5b3a0b9fe99c72773566b7b439ca852e4ce34b0528dc9e7f7d1f06abf52b3", "class_name": "RelatedNodeInfo"}}, "hash": "72c711df649c1d7d6ecc1202d039060e8b543a2a987b5243ca79301c6e26428f", "text": "The most G protein biased compound JWH 018 2'-naphthyl-N-(3-methylbutyl) isomer\nand the most biased \u03b2arrestin compound 4F-MDMB-BINACA bound to 6N4B with and without\nthe G protein\nCompound Interaction Energy\n6N4B w/o G Protein\nInteraction Energy\n6N4B w/G Protein\nBias\nJWH 018 2'-naphthylN-(3-methylbutyl)\nisomer\n-114.63 -118.41 G Protein\n4F-MDMB-BINACA -116.19 -105.63 \u03b2arrestin\n118\nFigure 4-12. Experimentally determined Ki compared to computationally determined MMGBSA to see if correlation exist for (a) CB1R and (b) CB2R. The dotted lines encompass the\n95% confidence interval. \n119\n4.4 Conclusion\nIn summary it was observed that all SCRAs tested behaved as CB1R and CB2R agonists in the\ncAMP assay but not in the \u03b2arrestin2 assay. This suggests that for both CB1R and CB2R the\nligand-receptor-G protein complex is better stabilized than the ligand-receptor- \u03b2arrestin2complex.\nHowever, a few SCRAs produced potent agonism in the \u03b2arrestin2 recruitment assay. Specifically,\nSCRAs with indazole cores rather than indole cores and halogen-substituted butyl or pentyl\ngroups, such as 4-fluoro MDMD-BINACA, were the most-potent and most-efficacious agonists\nof \u03b2arrestin2 recruitment as CB1R and CB2R. The presence of an indole core rather than an\nindazole core (e.g. 5-fluoro MPP-PICA) or a halogen-substituted benzene rather than butyl or\npentyl groups (e.g. meta and ortho AB-FUBINACA) abolished \u03b2arrestin2 activity; whereas\nmoving the halogen from the terminal carbon toward the indazole core (e.g. AB-PINACA N-(2-\nfluoropentyl) isomer and 3-chloro AB PINACA) only reduced \u03b2arrestin2 activity. Similar studies\nhave shown a consistent SAR between SCRA potency and efficacy and the incorporation of\nindazole cores and terminal halogen substitution to butyl and pentyl chains. The indazole core has\nbeen shown to have a stabilizing effect on the \u201ctwin toggle switch\u201d (F2003.36 and W3566.48) that\naffords CB1R-Gai interactions.50,146,147\nThe majority of in silico interactions made between SCRAs and either CB1R or CB2R are highly\nsimilar, with key homologous residues such as Ser3837.39 (CB1R)/Ser2857.39 (CB2R) and\nHis1782.65 (CB1R)/His952.65 (CB2R) present in our models and crystal structures of these receptors\nbound to SCRAs.48,51,59 The shape and position of the binding pocket are retained and consistent\nfor SCRAs at both CB1R and CB2R, with slight differences in amino acid interactions observed\nbetween cAMP-biased and \u03b2arrestin2-biased compounds (Table 4-2, Table 4-3, Table 4-4, Figure\n4-10 and Figure 4-11). Perhaps most-intriguing is the observation that interaction energies differed \n120\ndepending on the inclusion or exclusion of the G protein in our model. The highly \u03b2arrestin2-\nbiased ligand 4-fluoro MDMB-BINACA incurred a 10.56 kcal/mol binding energy penalty in the\npresence of the G protein (Table 4-4). In contrast, the G protein-biased JWH 018 2\u2019-naphthyl-N-\n(3-methylbutyl) isomer gained 3.78 kcal/mol in interaction energy in the presence of the G protein\n(Table 4-4). Although these static in silico models cannot recapitulate the dynamic interactions\noccurring between ligand and receptor in vivo, they do add support to the growing body of evidence\nfor unique binding interactions for \u03b2arrestin2-biased ligands at the cannabinoid receptors.\nLastly this study elucidated which features of SCRAs lead to high affinity and potency SCRAs at\nCB1R and CB2R.", "start_char_idx": 148008, "end_char_idx": 151390, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e49f75dc-b4d8-4a71-bc43-d3eceb669e53": {"__data__": {"id_": "e49f75dc-b4d8-4a71-bc43-d3eceb669e53", "embedding": null, "metadata": {"file_path": "data/brandt-no-intro.txt", "file_name": "brandt-no-intro.txt", "file_type": "text/plain", "file_size": 239829, "creation_date": "2023-12-31", "last_modified_date": "2023-12-31", "last_accessed_date": "2023-12-31"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "a0eaa9a5-aece-426b-8f20-580de8fb9f35", "node_type": "4", "metadata": {"file_path": "data/brandt-no-intro.txt", "file_name": "brandt-no-intro.txt", "file_type": "text/plain", "file_size": 239829, "creation_date": "2023-12-31", "last_modified_date": "2023-12-31", "last_accessed_date": "2023-12-31"}, "hash": "76e194b2637b440a1b1cdf5698cae061524bb4d7a3b73dfc2ba71d268a3f7019", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0d912877-f1cf-4853-9f04-536ce46c0030", "node_type": "1", "metadata": {"file_path": "data/brandt-no-intro.txt", "file_name": "brandt-no-intro.txt", "file_type": "text/plain", "file_size": 239829, "creation_date": "2023-12-31", "last_modified_date": "2023-12-31", "last_accessed_date": "2023-12-31"}, "hash": "72c711df649c1d7d6ecc1202d039060e8b543a2a987b5243ca79301c6e26428f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a63ff3d8-c46e-4a3a-ae38-c46a1d44c433", "node_type": "1", "metadata": {}, "hash": "0294ba17c554b97abc3e2cc168b81d5e7f97782662c50870a4eaebf2ddb5e3b7", "class_name": "RelatedNodeInfo"}}, "hash": "08d5b3a0b9fe99c72773566b7b439ca852e4ce34b0528dc9e7f7d1f06abf52b3", "text": "The highly \u03b2arrestin2-\nbiased ligand 4-fluoro MDMB-BINACA incurred a 10.56 kcal/mol binding energy penalty in the\npresence of the G protein (Table 4-4). In contrast, the G protein-biased JWH 018 2\u2019-naphthyl-N-\n(3-methylbutyl) isomer gained 3.78 kcal/mol in interaction energy in the presence of the G protein\n(Table 4-4). Although these static in silico models cannot recapitulate the dynamic interactions\noccurring between ligand and receptor in vivo, they do add support to the growing body of evidence\nfor unique binding interactions for \u03b2arrestin2-biased ligands at the cannabinoid receptors.\nLastly this study elucidated which features of SCRAs lead to high affinity and potency SCRAs at\nCB1R and CB2R. For CB1R high affinity SCRAs had a naphthalene group linked to an alkyl\nsubstituted indole by a ketone (Figure 4-1), whereas low affinity ligands had functional groups\nwith a high degree of rotatable bonds or non-fused aromatic rings in the naphthyl position. The\nhighest affinity ligand Cl 2201 exhibited a halogen bond with the R182ECL1 which is likely one of\nthe features that leads to high affinity CB1R ligands. This could only be experimentally verified\nby performing site directed mutagenesis to an amino acid that can not participate in a halogen\nbond. It was also shown that in silico modelling could accurately discriminate a G protein-biased\ncompound from a \u03b2arrestin2-biased compound. \n121\nCHAPTER 5\nIn Vitro and In Silico Evaluation of Methoxy Substituted 25H-NBOME Isomers at 5-\nHT2AR\nCopyright statement\nContents of this chapter have been published in: Pottie E, Kupriyanova O V., Brandt AL, Laprairie\nRB, Shevyrin VA, Stove CP. Serotonin 2A Receptor (5-HT2AR) Activation by 25H-NBOMe\nPositional Isomers: In Vitro Functional Evaluation and Molecular Docking. ACS Pharmacol\nTransl Sci. 2021;4: 479\u2013487. doi:10.1021/acsptsci.0c00189. The manuscript has been modified to\nmeet formatting requirements.\nContribution statement\nThe manuscript used as the basis for this chapter was written by myself (in silico data) and Eline\nPottie (in vitro data) with guidance from Drs. Robert B. Laprairie and Christophe Stove. In vitro\ndata were collected by Eline Pottie whereas in silico data were collected by myself and analyses\nwere conducted by myself and Eline Pottie with guidance from Dr. Robert Laprairie and\nChristophe Stove. \n122\n5.1 Introduction\nPsychedelics are compounds that bind to and activate the serotonin 2a receptor (5-HT2AR).\n64 The\nterm psychedelic is derived from 2 words; \u201cpsyche\u201d which means mind and \u201cdelos\u201d meaning\nmanifesting.\n148 This term was coined by Humphrey Osmond in 1957. There are 3 distinct known\nchemical scaffolds that are classified as psychedelics: (1) ergolines [compounds structurally\nsimilar to lysergic acid diethylamide (LSD) and ergotamine], (2) tryptamines (compounds\nstructurally similar to psilocybin) and (3) phenylalkylamines (compounds similar to mescaline).\n149\nWithin the phenethylamines, compounds can be further subdivided into 2C-X (phenethylamines),\nDOx (phenylisopropylamines) and 25X-NBOMe\u2019s (N-benzyl derivatives of 2C-X).\n150 Although\nmany of these compounds are considered controlled substances and illegal, grey market labs in\nEurope and Canada synthesize and sell derivatives of these compounds for those that wish to use\nthese compounds recreationally.\n151 Consequently, most 25X-NBOMe\u2019s can be acquired on the\ngrey or illicit markets but their structure and function remain uncharacterized despite their potential\nto cause serious physical or psychiatric adverse events such as tachycardia, hypertension,\nconvulsions, and dysphoria.", "start_char_idx": 150683, "end_char_idx": 154291, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a63ff3d8-c46e-4a3a-ae38-c46a1d44c433": {"__data__": {"id_": "a63ff3d8-c46e-4a3a-ae38-c46a1d44c433", "embedding": null, "metadata": {"file_path": "data/brandt-no-intro.txt", "file_name": "brandt-no-intro.txt", "file_type": "text/plain", "file_size": 239829, "creation_date": "2023-12-31", "last_modified_date": "2023-12-31", "last_accessed_date": "2023-12-31"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "a0eaa9a5-aece-426b-8f20-580de8fb9f35", "node_type": "4", "metadata": {"file_path": "data/brandt-no-intro.txt", "file_name": "brandt-no-intro.txt", "file_type": "text/plain", "file_size": 239829, "creation_date": "2023-12-31", "last_modified_date": "2023-12-31", "last_accessed_date": "2023-12-31"}, "hash": "76e194b2637b440a1b1cdf5698cae061524bb4d7a3b73dfc2ba71d268a3f7019", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e49f75dc-b4d8-4a71-bc43-d3eceb669e53", "node_type": "1", "metadata": {"file_path": "data/brandt-no-intro.txt", "file_name": "brandt-no-intro.txt", "file_type": "text/plain", "file_size": 239829, "creation_date": "2023-12-31", "last_modified_date": "2023-12-31", "last_accessed_date": "2023-12-31"}, "hash": "08d5b3a0b9fe99c72773566b7b439ca852e4ce34b0528dc9e7f7d1f06abf52b3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f3e24b75-a027-4fcc-8b32-8a01a861e485", "node_type": "1", "metadata": {}, "hash": "704c77c9876a9346363db97d908f77d44f302ffb6a2bd1a5608886f119a77817", "class_name": "RelatedNodeInfo"}}, "hash": "0294ba17c554b97abc3e2cc168b81d5e7f97782662c50870a4eaebf2ddb5e3b7", "text": "149\nWithin the phenethylamines, compounds can be further subdivided into 2C-X (phenethylamines),\nDOx (phenylisopropylamines) and 25X-NBOMe\u2019s (N-benzyl derivatives of 2C-X).\n150 Although\nmany of these compounds are considered controlled substances and illegal, grey market labs in\nEurope and Canada synthesize and sell derivatives of these compounds for those that wish to use\nthese compounds recreationally.\n151 Consequently, most 25X-NBOMe\u2019s can be acquired on the\ngrey or illicit markets but their structure and function remain uncharacterized despite their potential\nto cause serious physical or psychiatric adverse events such as tachycardia, hypertension,\nconvulsions, and dysphoria.\n150 On the other hand, consideration of psychedelics as potential\ntreatments for post traumatic stress disorder (PTSD) and depression is growing as the efficacy of\nLSD, psilocybin, and related chemicals is now being recognized in early stage clinical\ninvestigations.\n152\nSubstantial efforts have been made in the characterization of psychedelics and the receptors they\nbind to by the laboratories of Drs. Roth and Nichols.\n29,71 Recently, structural data has been\npublished showing both LSD and 25CN-NBOH (Figure 5-1) bound to 5-HT2AR.\n29,71 Being that\n25CN-NBOH belongs to the NBOMe class, this crystal structure has vast potential to aid in the\nelucidation of how isomers of this compound influence the structure activity relationship (SAR)\n123\nof NBOMe compounds acting at 5-HT2AR. In this study, we compared the potential of a set of 5\nisomers of 25H-NBOMe to see how changing the position of the methoxy groups affects the SAR\nof this scaffold. Each number (24, 23, 26, 34 and 35) indicates the positions of the methoxy groups,\ni.e., 23H-NBOMe has a methoxy groups at the 2 and 3 position of the phenyl ring of the\nphenethylamine moiety of the molecule. Recently the synthesis and characterization of 25HNBOMe has been described.\n153 Functional characterization was performed by assessing the\npotential of these isomers to induce recruitment of cytosolic proteins to the activated 5-HT2AR. To\nthis end, we employed previously established bioassays, expressing either \u03b2arrestin2 or miniGq\nwith the 5-HT2AR in the NanoBiT\u00ae system, in which a split nanoluciferase is functionally\ncomplemented following recruitment of the cytosolic protein to the activated 5-HT2AR.\n154,155\nAdditionally, each tested substance was docked to 5-HT2AR based on adaptations of the abovementioned published cryo-EM structure.\n29\n5-HT2AR is a Gq coupled GPCR which means that activation of the receptor produces an increase\nof intracellular Ca2+\n.\n156 Gq coupling to the receptor as well as recruitment of \u03b2arrestin2 are the\nmost-utilized measurements for understanding biased agonism.\n157 In the therapeutic context of\npsychedelics this is important as the \u03b2arrestin pathway is thought to be involved in hallucination\nin humans and head-twitch responses in rodents.\n158 Further, it is both \u03b2arrestin -dependent and\n\u03b2arrestin\u2013independent pathways that have been linked to psychedelic drug actions.\n159 However, is\nit still unclear as to whether G protein or \u03b2arrestin biased compounds are favorable for the\ntherapeutic aspect of psychedelics as this will likely be a deterministic factor for development of\npsychedelics.\n160 It is likely the ligand bias profile will be specific for the condition treated. \n124\nFigure 5-1. 25CN-NBOH is the co-crystallized ligand in PDB ID: 6WHA bound to 5-HT2AR.\nThe remaining compounds were tested in functional bioassays at 5-HT2AR to elucidate the SAR\nof NBOMe Isomers\n125\n5.2 Materials and Methods\nThe methods described here are not the full methods. For the purposes of this dissertation, only\nmethods which pertain to the in vitro and in silico data in Figure 5-2, Figure 5-3, Figure 5-4,\nTable 5-1, Table 5-2, Table 5-3 and Table 5-4 are described.", "start_char_idx": 153603, "end_char_idx": 157460, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f3e24b75-a027-4fcc-8b32-8a01a861e485": {"__data__": {"id_": "f3e24b75-a027-4fcc-8b32-8a01a861e485", "embedding": null, "metadata": {"file_path": "data/brandt-no-intro.txt", "file_name": "brandt-no-intro.txt", "file_type": "text/plain", "file_size": 239829, "creation_date": "2023-12-31", "last_modified_date": "2023-12-31", "last_accessed_date": "2023-12-31"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "a0eaa9a5-aece-426b-8f20-580de8fb9f35", "node_type": "4", "metadata": {"file_path": "data/brandt-no-intro.txt", "file_name": "brandt-no-intro.txt", "file_type": "text/plain", "file_size": 239829, "creation_date": "2023-12-31", "last_modified_date": "2023-12-31", "last_accessed_date": "2023-12-31"}, "hash": "76e194b2637b440a1b1cdf5698cae061524bb4d7a3b73dfc2ba71d268a3f7019", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a63ff3d8-c46e-4a3a-ae38-c46a1d44c433", "node_type": "1", "metadata": {"file_path": "data/brandt-no-intro.txt", "file_name": "brandt-no-intro.txt", "file_type": "text/plain", "file_size": 239829, "creation_date": "2023-12-31", "last_modified_date": "2023-12-31", "last_accessed_date": "2023-12-31"}, "hash": "0294ba17c554b97abc3e2cc168b81d5e7f97782662c50870a4eaebf2ddb5e3b7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "523d3edc-48a4-455a-9084-ddb27f0a9a95", "node_type": "1", "metadata": {}, "hash": "9d78ad92373d566437bfdb177c4a97415d0a3f5aae0f2796e09f2e7ab0151faa", "class_name": "RelatedNodeInfo"}}, "hash": "704c77c9876a9346363db97d908f77d44f302ffb6a2bd1a5608886f119a77817", "text": "160 It is likely the ligand bias profile will be specific for the condition treated. \n124\nFigure 5-1. 25CN-NBOH is the co-crystallized ligand in PDB ID: 6WHA bound to 5-HT2AR.\nThe remaining compounds were tested in functional bioassays at 5-HT2AR to elucidate the SAR\nof NBOMe Isomers\n125\n5.2 Materials and Methods\nThe methods described here are not the full methods. For the purposes of this dissertation, only\nmethods which pertain to the in vitro and in silico data in Figure 5-2, Figure 5-3, Figure 5-4,\nTable 5-1, Table 5-2, Table 5-3 and Table 5-4 are described. For the full methods see Pottie et al.,\n2021.161\n5.2.1 Chemicals and Reagents\nDulbecco\u2019s Modified Eagle\u2019s Medium (DMEM, supplemented with GlutaMAX\u00ae), Hank\u2019s\nBalanced Salt Solution (HBSS) and penicillin/streptomycin (10,000 IU/mL and 10,000 \u00b5g/mL)\nwere purchased from Thermo Fisher Scientific (Pittsburg, PA). The FuGENE\u00ae HD Transfection\nReagent, Nano-Glo Live Cell reagent and the Nano-Glo LCS Dilution buffer were procured from\nPromega (Madison, WI). Fetal Bovine Serum (FBS), poly-D-lysine hydrobromide, methanol, and\nthe analytical standards of LSD and serotonin were bought from Sigma-Aldrich (Overijse,\nBelgium). The analytical standard of 25H-NBOMe hydrochloride 2-(2,5-dimethoxyphenyl)-N-(2-\nmethoxybenzyl)ethanamine was from Chiron AS (Trondheim, Norway). The positional isomers\nof 25H-NBOMe, depicted in Figure 5-1, were synthesized as described previously, and dissolved\nin methanol.\n162\n5.2.2 Data Processing and Analysis\nThe obtained time-luminescence profiles were corrected for inter-well variability and used for the\ncalculation of the area under the curve (AUC), using either the full activation profiles of 2 h, or\nonly the first 30 min, as described previously in more detail.\n163 After subtraction of the AUC of\nthe solvent control, the data were used for the fitting of a sigmoidal concentration-response curve\nthrough the four-parametric nonlinear regression model in GraphPad Prism software (San Diego,\nCA). For each separate experiment, the data were normalized to the maximal response of the \n126\nreference agonist, either LSD or serotonin, alternately set at 100% for a comparison between the\nobtained results. The data of all individual experiments were then pooled to determine the total\nEC50 and Emax values per substance.\n5.2.3 Statistical Analysis\nData related to EC50 and Emax in Figure 5-2, Table 5-1 and Table 5-2 were obtained with nonlinear\nregression models (4-parameter model, GraphPad Prism 9.0, San Diego, CA). Results were\ncalculated as percent response relative to the reference agonist LSD or serotonin as percent\nstimulation above baseline. Significance was determined by non-overlapping 95% C.I. or by oneway ANOVA followed by Bonferroni\u2019s post-hoc test. p < 0.05 was considered significant. In order\nto calculate bias as displayed in Figure 5-3, concentration-response curves were globally fit to the\noperational model (Eq. 2-1; Prism).\n110 To best fit data, the transduction coefficient log(\u03c4/KA) (i.e.\nlogR), n, and EMax were shared and logKA was constrained between 0 and -15. Relative agonist\nactivity compared to a reference agonist (CP55,940) was calculated as show in Eq. 2-2.\n111 \u2206logR\nvalues were compared for test compounds between assays measuring inhibition of cAMP and\n\u03b2arrestin2 recruitment to determine bias factor (\u2206\u2206logR) Eq. 2-3.\n112\n5.2.4 Molecular Docking\nThe recently published cryo-EM structure (PDW: 6WHA) of the 5-HT2AR in complex with miniGq\nand the psychedelic substance 25CN-NBOH was used as a starting template.", "start_char_idx": 156892, "end_char_idx": 160445, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "523d3edc-48a4-455a-9084-ddb27f0a9a95": {"__data__": {"id_": "523d3edc-48a4-455a-9084-ddb27f0a9a95", "embedding": null, "metadata": {"file_path": "data/brandt-no-intro.txt", "file_name": "brandt-no-intro.txt", "file_type": "text/plain", "file_size": 239829, "creation_date": "2023-12-31", "last_modified_date": "2023-12-31", "last_accessed_date": "2023-12-31"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "a0eaa9a5-aece-426b-8f20-580de8fb9f35", "node_type": "4", "metadata": {"file_path": "data/brandt-no-intro.txt", "file_name": "brandt-no-intro.txt", "file_type": "text/plain", "file_size": 239829, "creation_date": "2023-12-31", "last_modified_date": "2023-12-31", "last_accessed_date": "2023-12-31"}, "hash": "76e194b2637b440a1b1cdf5698cae061524bb4d7a3b73dfc2ba71d268a3f7019", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f3e24b75-a027-4fcc-8b32-8a01a861e485", "node_type": "1", "metadata": {"file_path": "data/brandt-no-intro.txt", "file_name": "brandt-no-intro.txt", "file_type": "text/plain", "file_size": 239829, "creation_date": "2023-12-31", "last_modified_date": "2023-12-31", "last_accessed_date": "2023-12-31"}, "hash": "704c77c9876a9346363db97d908f77d44f302ffb6a2bd1a5608886f119a77817", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c6cd3ca0-4a12-4748-bbc6-4127b39f5344", "node_type": "1", "metadata": {}, "hash": "968f825ffbb7b36f703a770bd7a35853dfe50444d5669a8789cbdb8faeec6a2e", "class_name": "RelatedNodeInfo"}}, "hash": "9d78ad92373d566437bfdb177c4a97415d0a3f5aae0f2796e09f2e7ab0151faa", "text": "2-1; Prism).\n110 To best fit data, the transduction coefficient log(\u03c4/KA) (i.e.\nlogR), n, and EMax were shared and logKA was constrained between 0 and -15. Relative agonist\nactivity compared to a reference agonist (CP55,940) was calculated as show in Eq. 2-2.\n111 \u2206logR\nvalues were compared for test compounds between assays measuring inhibition of cAMP and\n\u03b2arrestin2 recruitment to determine bias factor (\u2206\u2206logR) Eq. 2-3.\n112\n5.2.4 Molecular Docking\nThe recently published cryo-EM structure (PDW: 6WHA) of the 5-HT2AR in complex with miniGq\nand the psychedelic substance 25CN-NBOH was used as a starting template.\n29 Each of the\nstructures of the \u2013NBOMe isomers and LSD and 25CN-NBOH (as controls) was built and\noptimized in Spartan \u201918 Parallel Suite (Wavefunction, Irvine, CA), and molecularly docked\nemploying induced fit docking (Schr\u00f6dinger, NY). To reduce atom clashing, ligand-receptor\ncomplexes were minimized using the OPLS3 force field in Prime (Schr\u00f6dinger). Prime MMGBSA \n127\n(Schr\u00f6dinger)(See section 3.1 and 3.2.3 for a more through description for MMGBSA) was used\nfor the calculation of the amino acid interaction energy with the individual residues.\n\n5.3 Results and Discussion\n\n5.3.1 Pharmacological Characterization\n\nTo assess the functionality of the NBOMe positional isomers, the Nanoluciferase Binary\nTechnology (NanoBiT\u00ae) was employed. This technique was specifically developed for the realtime monitoring of protein-protein interactions in live cells. To this end, two non-functional parts\nof the nanoluciferase are each fused to one of the potentially interacting proteins, in this case the\n5-HT2AR and a cytosolic protein. When an agonist activates the receptor, the cytosolic protein is\nrecruited, leading to association of the split parts, which can be monitored via a luminescent\nreadout in the presence of the enzyme\u2019s substrate.\n164 A previously established bioassay to monitor\nthe recruitment of \u03b2arrestin2, later complemented with an analogous miniGq recruitment assay,\nallowing us to generate concentration-response curves.\n154,155 These curves were used to compute\nthe potency and efficacy of the compounds as compared to the reference agonist LSD which was\nset to 100% to serve as a positive control. Being that 5-HT2AR is Gq coupled we also measured Gq\nactivation to better elucidate the biased agonism nature of each compound. In both assays both\nserotonin and LSD were included as reference agonists. The data analysis was conducted using the\nAUC of either the first 30 min or the full 2-hour activation profile. This is because the on and off\nrate at which LSD associates with 5-HT2AR is slow (koff = 0.022 \u00b1 0.004 min-1\n) due to hydrophobic\ninteraction with L229ECL2\n.\n71 Generally speaking, if a psychedelic interacts with L229ECL2 both the\non and off rate tend to be slower than that of a compound that does not interact with L229ECL2\n.\n29,71\nThus a 30-minute vs 2-hour time point can be used as a predicative measure as to if this interaction\noccurs or does not. \n128\n\n5.3.2 2-Methoxy NBOMe Compounds are more Potent than 3-Methoxy NBOMe Compounds\n\nTable 5-1 shows differences in potency and efficacy of the methoxy substituted isomers. Being\nthat 25H-NBOMe is the conventional NBOMe compound this was used as a comparative refence\nwhen looking at the other compounds. 25H-NBOMe yielded a low nM potency (EC50 = 11.4nM\n(6.36 - 20.4)) in the 5-HT2AR \u03b2arrestin2 recruitment assay and a higher efficacy than LSD (Emax\n164% relative to LSD). Only 1 of the isomers was slightly more potent than 25H-NBOMe: 24HNBOMe yielded an EC50 value of 3.88 nM (2.33 - 6.37).", "start_char_idx": 159830, "end_char_idx": 163433, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c6cd3ca0-4a12-4748-bbc6-4127b39f5344": {"__data__": {"id_": "c6cd3ca0-4a12-4748-bbc6-4127b39f5344", "embedding": null, "metadata": {"file_path": "data/brandt-no-intro.txt", "file_name": "brandt-no-intro.txt", "file_type": "text/plain", "file_size": 239829, "creation_date": "2023-12-31", "last_modified_date": "2023-12-31", "last_accessed_date": "2023-12-31"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "a0eaa9a5-aece-426b-8f20-580de8fb9f35", "node_type": "4", "metadata": {"file_path": "data/brandt-no-intro.txt", "file_name": "brandt-no-intro.txt", "file_type": "text/plain", "file_size": 239829, "creation_date": "2023-12-31", "last_modified_date": "2023-12-31", "last_accessed_date": "2023-12-31"}, "hash": "76e194b2637b440a1b1cdf5698cae061524bb4d7a3b73dfc2ba71d268a3f7019", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "523d3edc-48a4-455a-9084-ddb27f0a9a95", "node_type": "1", "metadata": {"file_path": "data/brandt-no-intro.txt", "file_name": "brandt-no-intro.txt", "file_type": "text/plain", "file_size": 239829, "creation_date": "2023-12-31", "last_modified_date": "2023-12-31", "last_accessed_date": "2023-12-31"}, "hash": "9d78ad92373d566437bfdb177c4a97415d0a3f5aae0f2796e09f2e7ab0151faa", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "af979550-506c-4f5c-a4a2-eea50dccb977", "node_type": "1", "metadata": {}, "hash": "c0cde2f3c02f577cfd1b9579dd5c87be2a8fbd793ef1f058a6dd7b8e41ceab96", "class_name": "RelatedNodeInfo"}}, "hash": "968f825ffbb7b36f703a770bd7a35853dfe50444d5669a8789cbdb8faeec6a2e", "text": "128\n\n5.3.2 2-Methoxy NBOMe Compounds are more Potent than 3-Methoxy NBOMe Compounds\n\nTable 5-1 shows differences in potency and efficacy of the methoxy substituted isomers. Being\nthat 25H-NBOMe is the conventional NBOMe compound this was used as a comparative refence\nwhen looking at the other compounds. 25H-NBOMe yielded a low nM potency (EC50 = 11.4nM\n(6.36 - 20.4)) in the 5-HT2AR \u03b2arrestin2 recruitment assay and a higher efficacy than LSD (Emax\n164% relative to LSD). Only 1 of the isomers was slightly more potent than 25H-NBOMe: 24HNBOMe yielded an EC50 value of 3.88 nM (2.33 - 6.37). The potency of 26H-NBOMe (8.70 nM\n(5.81 - 12.5)) is similar to that of 25H-NBOMe. The highest EC50 value (33.6 nM (19.8 - 57.3)) of\nall isomers with a 2-methoxy substituent, and hence the lowest potency, was observed for 23HNBOMe. The least potent substances in the \u03b2arrestin2 recruitment assay appeared to be 34HNBOMe and 35H-NBOMe, both lacking the 2-methoxy substituent. This change in the position\nof one of the methoxy groups drastically reduced in vitro potency yielding EC50 values in the\nhigher nM range (248 nM (111 - 646) and 343 nM (187 - 645)). Although 25H-NBOMe had the\nhighest efficacy (164%) the 95% confidence intervals of 24H-, 26H-, and 34H-NBOMe (145%,\n156% and 147%) all overlap with 25H-NBOMe. Although the efficacies obtained for 23HNBOMe (123%) and 35H-NBOMe (118%) were lower than that of 25H-NBOMe they both had\nhigher efficacy than LSD and serotonin.\nTable 5-2 serotonin showed the greatest efficacy (Emax = 305% relative to LSD). For the NBOMe\nisomers although 25H-NBOMe displayed the greatest efficacy the 95% confidence intervals of\n24H-, 26H-, 34H- (171%, 162%, 156%) all overlap with 25H-NBOMe. While 23H-NBOMe was\nthe only compound that showed less efficacy than LSD (89.6%), 35H-NBOMe\u2019s efficacy (107%)\nwas only slightly greater than LSD (98.2%). In terms of potency as measured by EC50 LSD\ndisplayed the greatest potency (EC50 = 17.7 nM (10.1 - 38.6)). For the NBOMe isomers 24H-\n129\nNBOMe displayed the greatest potency (EC50 = 37.4 nM (20.6 - 66.4)) but the 95% confidence\nintervals of 25H- (EC50 = 86.2 nM (57.0 - 124)) and 26H-NBOMe (EC50 = 68.0 nM (38.6 - 115))\ndid overlap with 24H-NBOMe. 23H-NBOMe (EC50 = 236 nM (N.D.)) displayed the weakest\npotency of the 2-methoxy substituted NBOMe isomers. Similarly with the \u03b2arrestin2 recruitment\nassay in the miniGq experiment 34H- (EC50 = 1321 nM (629-33780)) and 35H-NBOMe (EC50 =\n1393 nM (N.D.)) displayed the weakest potency in terms of all the NBOMe isomers in the study. \n130\nFigure 5-2. The concentration-response curves obtained by stimulation of the 5-HT2AR\nfollowed by recruitment of (panels A and C) \u03b2arrestin2 or (panels B and D) miniGq\nconstructs in the NanoBiT\u00ae system. Data points are given as the mean of 3 independent\nexperiments (each performed in duplicate) \u00b1 SEM (Standard Error of the Mean).", "start_char_idx": 162840, "end_char_idx": 165729, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "af979550-506c-4f5c-a4a2-eea50dccb977": {"__data__": {"id_": "af979550-506c-4f5c-a4a2-eea50dccb977", "embedding": null, "metadata": {"file_path": "data/brandt-no-intro.txt", "file_name": "brandt-no-intro.txt", "file_type": "text/plain", "file_size": 239829, "creation_date": "2023-12-31", "last_modified_date": "2023-12-31", "last_accessed_date": "2023-12-31"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "a0eaa9a5-aece-426b-8f20-580de8fb9f35", "node_type": "4", "metadata": {"file_path": "data/brandt-no-intro.txt", "file_name": "brandt-no-intro.txt", "file_type": "text/plain", "file_size": 239829, "creation_date": "2023-12-31", "last_modified_date": "2023-12-31", "last_accessed_date": "2023-12-31"}, "hash": "76e194b2637b440a1b1cdf5698cae061524bb4d7a3b73dfc2ba71d268a3f7019", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c6cd3ca0-4a12-4748-bbc6-4127b39f5344", "node_type": "1", "metadata": {"file_path": "data/brandt-no-intro.txt", "file_name": "brandt-no-intro.txt", "file_type": "text/plain", "file_size": 239829, "creation_date": "2023-12-31", "last_modified_date": "2023-12-31", "last_accessed_date": "2023-12-31"}, "hash": "968f825ffbb7b36f703a770bd7a35853dfe50444d5669a8789cbdb8faeec6a2e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "109f01df-e60b-472a-8ba4-9e653eb78d8b", "node_type": "1", "metadata": {}, "hash": "3ee7163c064292c1e47131b03642dcd6191817646e297480a461bbf1868f7c86", "class_name": "RelatedNodeInfo"}}, "hash": "c0cde2f3c02f577cfd1b9579dd5c87be2a8fbd793ef1f058a6dd7b8e41ceab96", "text": "displayed the weakest\npotency of the 2-methoxy substituted NBOMe isomers. Similarly with the \u03b2arrestin2 recruitment\nassay in the miniGq experiment 34H- (EC50 = 1321 nM (629-33780)) and 35H-NBOMe (EC50 =\n1393 nM (N.D.)) displayed the weakest potency in terms of all the NBOMe isomers in the study. \n130\nFigure 5-2. The concentration-response curves obtained by stimulation of the 5-HT2AR\nfollowed by recruitment of (panels A and C) \u03b2arrestin2 or (panels B and D) miniGq\nconstructs in the NanoBiT\u00ae system. Data points are given as the mean of 3 independent\nexperiments (each performed in duplicate) \u00b1 SEM (Standard Error of the Mean). The AUC (Area\nUnder the Curve) is normalized in each independent experiment for the maximum response\n(100%) of the reference agonist LSD (panels A and B) or serotonin (panels C and D). \n131\nTable 5-1. Summary of the potency (EC50) and efficacy (Emax, where the Emax of either serotonin\nor LSD is set to 100%) values of all the tested compounds in the \u03b2arrestin2 assay, calculated using\neither the full 120 min activation profiles (upper half), or the first 30 min (lower half of the table).\nBoth serotonin and LSD are highlighted in grey to indicate that they are set to 100% in each of the\nexperiments. The structures of the compounds are provided in Figure 1. Data are from 3\nindependent experiments. CI: 95% confidence interval. N.D.: confidence interval not determined.\n120 min activation profiles\nCompound\nReference agonist LSD Reference agonist serotonin\nEC50 (nM, CI) Emax (%, CI) EC50 (nM, CI) Emax (%, CI)\nLSD 7.43 (3.54 - 12.9) 100 (91 - 109) 7.29 (3.50 - 12.7) 87.1 (79.4 - 95.4)\nSerotonin 7.62 (4.43 - 13.2) 116 (107 - 126) 7.24 (4.43 - 11.9) 100 (93.9 - 108)\n23H-NBOMe 33.6 (19.8 - 57.3) 123 (115 - 131) 33.7 (19.7 - 57.9) 115 (107 - 123)\n24H-NBOMe 3.88 (2.33 - 6.37) 145 (136 - 154) 3.89 (2.30 - 6.45) 136 (127 - 145)\n25H-NBOMe 11.4 (6.36 - 20.4) 164 (151 - 180) 11.0 (5.60 - 21.5) 134 (121 - 148)\n26H-NBOMe 8.70 (5.81 - 12.5) 156 (147 - 165) 8.74 (5.91 - 12.4) 146 (138 - 154)\n34H-NBOMe 248 (111 - 646) 147 (129 - 182) 238 (101 - 691) 120 (104 - 152)\n35H-NBOMe 343 (187 - 645) 118 (107 - 135) 310 (165 - 593) 94.1 (83.8 - 108)\n30 min activation profiles\nCompound\nReference agonist LSD Reference agonist serotonin\nEC50 (nM, CI) Emax (%, CI) EC50 (nM, CI) Emax (%, CI)\nLSD 24.3 (N.D.) 100 (91 - 110) 23.8 (N.D.)", "start_char_idx": 165097, "end_char_idx": 167454, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "109f01df-e60b-472a-8ba4-9e653eb78d8b": {"__data__": {"id_": "109f01df-e60b-472a-8ba4-9e653eb78d8b", "embedding": null, "metadata": {"file_path": "data/brandt-no-intro.txt", "file_name": "brandt-no-intro.txt", "file_type": "text/plain", "file_size": 239829, "creation_date": "2023-12-31", "last_modified_date": "2023-12-31", "last_accessed_date": "2023-12-31"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "a0eaa9a5-aece-426b-8f20-580de8fb9f35", "node_type": "4", "metadata": {"file_path": "data/brandt-no-intro.txt", "file_name": "brandt-no-intro.txt", "file_type": "text/plain", "file_size": 239829, "creation_date": "2023-12-31", "last_modified_date": "2023-12-31", "last_accessed_date": "2023-12-31"}, "hash": "76e194b2637b440a1b1cdf5698cae061524bb4d7a3b73dfc2ba71d268a3f7019", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "af979550-506c-4f5c-a4a2-eea50dccb977", "node_type": "1", "metadata": {"file_path": "data/brandt-no-intro.txt", "file_name": "brandt-no-intro.txt", "file_type": "text/plain", "file_size": 239829, "creation_date": "2023-12-31", "last_modified_date": "2023-12-31", "last_accessed_date": "2023-12-31"}, "hash": "c0cde2f3c02f577cfd1b9579dd5c87be2a8fbd793ef1f058a6dd7b8e41ceab96", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "25b00e9f-371e-4fc4-ac25-0c8c1a74f1bc", "node_type": "1", "metadata": {}, "hash": "471848ddfae8017e49133dd8d89a272b6a5455807fd95ffbcb4eabb5fb720260", "class_name": "RelatedNodeInfo"}}, "hash": "3ee7163c064292c1e47131b03642dcd6191817646e297480a461bbf1868f7c86", "text": "100 (91 - 110) 23.8 (N.D.) 79.4 (72.0 - 87.3)\nSerotonin 11.5 (7.13 - 18.9) 128 (119 - 139) 10.9 (7.60 - 15.8) 100 (94.8 - 106)\n23H-NBOMe 74.4 (55.8 - 95.9) 133 (128 - 139) 74.5 (53.9 - 98.8) 114 (109 - 119)\n24H-NBOMe 8.34 (6.11 - 11.1) 154 (147 - 161) 8.32 (5.85 - 11.5) 132 (125 - 139)\n25H-NBOMe 24.3 (13.4 - 45.0) 179 (163 - 199) 22.9 (12.8 - 41.8) 130 (118 - 143)\n26H-NBOMe 16.3 (13.0 - 20.8) 165 (159 - 172) 16.4 (12.4 - 22.0) 142 (135 - 149)\n34H-NBOMe 488 (226 - 1707) 162 (142 - 218) 458 (191 - 2287) 118 (101 - 171)\n35H-NBOMe 678 (385 - 1295) 137 (123 - 162) 625 (353 - 1148) 98.5 (88.8 - 115)\n132\nTable 5-2. Summary of the potency (EC50) and efficacy (Emax, where the Emax of either serotonin\nor LSD is set to 100%) values of all the tested compounds in the miniGq recruitment assay,\ncalculated using either the full 120 min activation profiles (upper half), or the first 30 min (lower\nhalf of the table). Both serotonin and LSD are highlighted in grey to indicate that they are set to\n100% in each of the experiments. Data are from 3 independent experiments. CI: 95% confidence\ninterval. N.D.: Confidence interval not determined.\n120 min activation profiles\nCompound\nReference agonist LSD Reference agonist serotonin\nEC50 (nM, CI) Emax (%, CI) EC50 (nM, CI) Emax (%, CI)\nLSD 7.40 (1.82 - 17.7) 100 (84 - 115) 7.23 (1.73 - 17.5) 39.6 (33.7 - 46.0)\nSerotonin 66.4 (35.5 - 151) 256 (230 - 301) 63.5 (33.9 - 143) 103 (92.5 - 121)\n23H-NBOMe 147 (71.8 - 436) 81.2 (70 - 102) 146 (73.8 - 408) 31.9 (27.5 - 39.6)\n24H-NBOMe 22.1 (12.1 - 42.1) 144 (129 - 161) 22.2 (12.4 - 41.6) 56.9 (51.2 - 63.4)\n25H-NBOMe 49.6 (27.2 - 84.8) 141 (128 - 155) 49.2 (26.6 - 85.4) 58.8 (53.3 - 64.9)\n26H-NBOMe 40.9 (23.7 - 68.2) 136 (124 - 148) 40.9 (23.9 - 67.7) 53.3 (48.8 - 58.2)\n34H-NBOMe 974 (N.D.) 134 (N.D.) 947 (N.D.) 55.3 (45.6 - 297)\n35H-NBOMe 1097 (N.D.) 89.1 (74 - 219) 1087 (N.D.)", "start_char_idx": 167428, "end_char_idx": 169301, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "25b00e9f-371e-4fc4-ac25-0c8c1a74f1bc": {"__data__": {"id_": "25b00e9f-371e-4fc4-ac25-0c8c1a74f1bc", "embedding": null, "metadata": {"file_path": "data/brandt-no-intro.txt", "file_name": "brandt-no-intro.txt", "file_type": "text/plain", "file_size": 239829, "creation_date": "2023-12-31", "last_modified_date": "2023-12-31", "last_accessed_date": "2023-12-31"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "a0eaa9a5-aece-426b-8f20-580de8fb9f35", "node_type": "4", "metadata": {"file_path": "data/brandt-no-intro.txt", "file_name": "brandt-no-intro.txt", "file_type": "text/plain", "file_size": 239829, "creation_date": "2023-12-31", "last_modified_date": "2023-12-31", "last_accessed_date": "2023-12-31"}, "hash": "76e194b2637b440a1b1cdf5698cae061524bb4d7a3b73dfc2ba71d268a3f7019", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "109f01df-e60b-472a-8ba4-9e653eb78d8b", "node_type": "1", "metadata": {"file_path": "data/brandt-no-intro.txt", "file_name": "brandt-no-intro.txt", "file_type": "text/plain", "file_size": 239829, "creation_date": "2023-12-31", "last_modified_date": "2023-12-31", "last_accessed_date": "2023-12-31"}, "hash": "3ee7163c064292c1e47131b03642dcd6191817646e297480a461bbf1868f7c86", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "684feb52-2005-46b1-ab17-653cf3ab6268", "node_type": "1", "metadata": {}, "hash": "54949d8906617e93f348ff6258da940b604cce72aaf3a996d0645ecf5e150f93", "class_name": "RelatedNodeInfo"}}, "hash": "471848ddfae8017e49133dd8d89a272b6a5455807fd95ffbcb4eabb5fb720260", "text": "134 (N.D.) 947 (N.D.) 55.3 (45.6 - 297)\n35H-NBOMe 1097 (N.D.) 89.1 (74 - 219) 1087 (N.D.) 37.1 (30.5 - 112)\n30 min activation profiles\nCompound\nReference agonist LSD Reference agonist serotonin\nEC50 (nM, CI) Emax (%, CI) EC50 (nM, CI) Emax (%, CI)\nLSD 17.7 (10.1 - 38.6) 98.2 (85 - 114) 16.3 (8.59 - 38.7) 31.9 (27.4 - 37.2)\nSerotonin 88.5 (46.1 - 213) 305 (272 - 365) 62.2 (22.5 - 269) 87.9 (74.4 - 121)\n23H-NBOMe 236 (N.D.) 89.6 (75 - 112) 191 (N.D.) 27.1 (22.6 - 33.3)\n24H-NBOMe 37.4 (20.6 - 66.4) 171 (155 - 189) 35.1 (17.5 - 68.7) 54.3 (48.5 - 61.2)\n25H-NBOMe 86.2 (57.0 - 124) 181 (167 - 196) 129 (69.2 - 263) 74.8 (65.6 - 88.8)\n26H-NBOMe 68.0 (38.6 - 115) 162 (147 - 181) 68.3 (34.0 - 129) 51.9 (46.0 - 59.4)\n34H-NBOMe 1321 (629-33780) 156 (130 - 340) 1334 (N.D.) 51.8 (N.D.)\n35H-NBOMe 1393 (N.D.) 107 (94 - 163) 1296 (683\u201310760) 48.3 (41.0 - 83.6)\n133\n\n5.3.3 NBOMe compounds display biased agonism towards \u03b2arrestin2 over Gq Pathway\nPrevious research has shown that the N-benzyl substituted 25H analogues 25H-NBF, 25H-NBMD\nand 25H-NBOH show a preference towards the recruitment of \u03b2arrestin2 over Gq over the\nreference compound LSD.\n155 LSD does not preferentially activate recruitment of \u03b2arrestin2 (EC50\n= 6.43 nM) over Gq (7.40 nM) as seen in Table 5-1 and Table 5-2. Because the potencies at both\nthese pathways are not statistically different this is suggestive of non-biased agonism (Figure 5-3).\nConversely, serotonin displayed biased agonism towards recruitment of \u03b2arrestin2 (EC50 = 7.62\nnM) over Gq (EC50 = 66.4 nM) (Figure 5-3). In fact, all of the NBOMe isomers display \u03b2arrestin2\nbiased agonism at 5-HT2AR (Figure 5-3). While 24H-NBOMe displays the greatest biased\nagonism towards \u03b2arrestin2 35H-NBOMe displays the least. However, there does not seem to be\na clear distinction of how isomerization of the methoxy group affects biased agonism. \n134\nFigure 5-3. Concentration-response data were fit to the operational model of Black and Leff\n(1983) (GraphPad v. 9.0). Data are mean with 95% CI. *p < 0.05 compared to 0 as determined\nby non-overlapping 95% CI; n = 4 \u2013 6. Agonist bias from the 2-hour time point data [\u2206\u2206logR\n(\u03b2arrestin2 \u2013 Gq)] between \u03b2arrestin2 recruitment and Gq. \n135\n\n5.3.4 Molecular Docking\n\nAttempting to provide an explanation for the differences in potencies/efficacies observed for the isomers, molecular docking was performed, with a model based on adaptations of the recently published cryo-EM structure of the 5-HT2AR in complex with 25CN-NBOH (PDB:6WHA).", "start_char_idx": 169212, "end_char_idx": 171714, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "684feb52-2005-46b1-ab17-653cf3ab6268": {"__data__": {"id_": "684feb52-2005-46b1-ab17-653cf3ab6268", "embedding": null, "metadata": {"file_path": "data/brandt-no-intro.txt", "file_name": "brandt-no-intro.txt", "file_type": "text/plain", "file_size": 239829, "creation_date": "2023-12-31", "last_modified_date": "2023-12-31", "last_accessed_date": "2023-12-31"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "a0eaa9a5-aece-426b-8f20-580de8fb9f35", "node_type": "4", "metadata": {"file_path": "data/brandt-no-intro.txt", "file_name": "brandt-no-intro.txt", "file_type": "text/plain", "file_size": 239829, "creation_date": "2023-12-31", "last_modified_date": "2023-12-31", "last_accessed_date": "2023-12-31"}, "hash": "76e194b2637b440a1b1cdf5698cae061524bb4d7a3b73dfc2ba71d268a3f7019", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "25b00e9f-371e-4fc4-ac25-0c8c1a74f1bc", "node_type": "1", "metadata": {"file_path": "data/brandt-no-intro.txt", "file_name": "brandt-no-intro.txt", "file_type": "text/plain", "file_size": 239829, "creation_date": "2023-12-31", "last_modified_date": "2023-12-31", "last_accessed_date": "2023-12-31"}, "hash": "471848ddfae8017e49133dd8d89a272b6a5455807fd95ffbcb4eabb5fb720260", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "eb0f1fa7-cbb5-40fd-a88f-d527d7597b79", "node_type": "1", "metadata": {}, "hash": "959b84a3c77e1161ba2842d88f4851b36da03ad49f79b7a2c18f6daadf6076fb", "class_name": "RelatedNodeInfo"}}, "hash": "54949d8906617e93f348ff6258da940b604cce72aaf3a996d0645ecf5e150f93", "text": "134\nFigure 5-3. Concentration-response data were fit to the operational model of Black and Leff\n(1983) (GraphPad v. 9.0). Data are mean with 95% CI. *p < 0.05 compared to 0 as determined\nby non-overlapping 95% CI; n = 4 \u2013 6. Agonist bias from the 2-hour time point data [\u2206\u2206logR\n(\u03b2arrestin2 \u2013 Gq)] between \u03b2arrestin2 recruitment and Gq. \n135\n\n5.3.4 Molecular Docking\n\nAttempting to provide an explanation for the differences in potencies/efficacies observed for the isomers, molecular docking was performed, with a model based on adaptations of the recently published cryo-EM structure of the 5-HT2AR in complex with 25CN-NBOH (PDB:6WHA).  29 Figure 5-4a shows the position of 24H-NBOMe in the orthosteric binding pocket of the receptor, in which all of the isomers bind. Figure 5-4c \u2013 h focuses on the specific interactions of the isomers, (and 25CN-NBOH in panel H) with the amino acid residues of the receptor, providing insight into the modeled interaction of specific residues with the methoxy groups. The model showed that all NBOMe isomers can be docked in the same binding pocket as 25CN-NBOH, despite the change of the hydroxyl group on the N-benzyl moiety into a methoxy group. This latter group specifically stabilizes the molecule through an H-bond with S1593.36, and through hydrophobic interaction with S1593.36, W3366.48 and S3737.46. The nitrogen atom is observed to form a salt bridge with D1553.32 , which has been previously defined as critical for receptor interaction, and the strength is emphasized by the interaction energies in Table 5-3.  71,29 The N-benzyl moiety is stabilized in the binding pocket by hydrophobic interactions with W3366.48 and F3396.51, and both the N-benzyl moiety and the phenyl group of the phenethylamine function are stabilized by interaction with F3406.52 (Table 5-3). The reference compound LSD interacts with S2425.46 stronger than NBOMe compounds due to an H-bond between the indole on LSD and S2425.46, which NBOMes cannot participate in (Table 5-4).  136 Figure 5-4. Visual representations of the NBOMe isomers and 25CN-NBOH docked into the binding pocket of the 5-HT2AR (based on PDB: 6WHA).  29 A) 24H-NBOMe, as seen from the perspective of the N-benzyl moiety; B-H) substances bound to the 5-HT2AR looking from the perspective of the phenyl group, with specific mentioning of the residues interacting with the methoxy groups on the phenethylamine moiety. B) 24H-NBOMe, C) 23H-NBOMe, D) 25HNBOMe, E) 26H-NBOMe, F) 34H-NBOMe, G) 35H-NBOMe, and H) 25CN-NBOH.  137 Figure 5-5. Visual representations of the NBOMe isomers docked into the binding pocket of the 5-HT2AR with helices shown (based on PDB: 6WHA). (A) 24H-NBOMe, as seen from the perspective of the N-benzyl moiety; (B) 24H-NBOMe and (C) 35H-NBOMe bound to the 5- HT2AR looking from the perspective of the phenyl group, with specific mentioning of the residues proposed to interact with the methoxy groups on the phenethylamine moiety.  138 Because of the ability of the utilized model to predict to a reasonable extent the interactions of LSD and 25CN-NBOH with the 5-HT2AR, as described by Kim et al.29 , it was additionally used to assess the interactions with the methoxy groups of the phenethylamine moiety of the panel of NBOMe positional isomers. Table 5-4 specifically focuses on the modeled interactions with these methoxy groups.", "start_char_idx": 171077, "end_char_idx": 174430, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "eb0f1fa7-cbb5-40fd-a88f-d527d7597b79": {"__data__": {"id_": "eb0f1fa7-cbb5-40fd-a88f-d527d7597b79", "embedding": null, "metadata": {"file_path": "data/brandt-no-intro.txt", "file_name": "brandt-no-intro.txt", "file_type": "text/plain", "file_size": 239829, "creation_date": "2023-12-31", "last_modified_date": "2023-12-31", "last_accessed_date": "2023-12-31"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "a0eaa9a5-aece-426b-8f20-580de8fb9f35", "node_type": "4", "metadata": {"file_path": "data/brandt-no-intro.txt", "file_name": "brandt-no-intro.txt", "file_type": "text/plain", "file_size": 239829, "creation_date": "2023-12-31", "last_modified_date": "2023-12-31", "last_accessed_date": "2023-12-31"}, "hash": "76e194b2637b440a1b1cdf5698cae061524bb4d7a3b73dfc2ba71d268a3f7019", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "684feb52-2005-46b1-ab17-653cf3ab6268", "node_type": "1", "metadata": {"file_path": "data/brandt-no-intro.txt", "file_name": "brandt-no-intro.txt", "file_type": "text/plain", "file_size": 239829, "creation_date": "2023-12-31", "last_modified_date": "2023-12-31", "last_accessed_date": "2023-12-31"}, "hash": "54949d8906617e93f348ff6258da940b604cce72aaf3a996d0645ecf5e150f93", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ea28b0ec-98c0-4b8b-8896-b4245d50a8f1", "node_type": "1", "metadata": {}, "hash": "458317861f5d0b07454803550f14faf8bf4ba09cd2573d54e1cf5721aecebefc", "class_name": "RelatedNodeInfo"}}, "hash": "959b84a3c77e1161ba2842d88f4851b36da03ad49f79b7a2c18f6daadf6076fb", "text": "(A) 24H-NBOMe, as seen from the perspective of the N-benzyl moiety; (B) 24H-NBOMe and (C) 35H-NBOMe bound to the 5- HT2AR looking from the perspective of the phenyl group, with specific mentioning of the residues proposed to interact with the methoxy groups on the phenethylamine moiety.  138 Because of the ability of the utilized model to predict to a reasonable extent the interactions of LSD and 25CN-NBOH with the 5-HT2AR, as described by Kim et al.29 , it was additionally used to assess the interactions with the methoxy groups of the phenethylamine moiety of the panel of NBOMe positional isomers. Table 5-4 specifically focuses on the modeled interactions with these methoxy groups. A methoxy group on position 2 of the phenyl ring of the phenethylamine moiety (as is the case in 23H-, 24H-, 25H-, and 26H-NBOMe) hydrophobically interacts with T1603.37 , S1593.36 and V1563.33, as reflected by the weaker interaction (higher interaction energies) for substances without a methoxy group at this position. The model also proposes interactions between G2385.42 and S2425.46 and a methoxy group at position 3, as reflected by a weaker interaction of these residues with substances lacking a 3-methoxy group. For 25CN-NBOH, G2385.42 interacts with the cyano group rather than with a methoxy group. The occurrence of a methoxy group at position 4 appears to be linked to a stronger interaction (lower interaction energies) with residues S2395.43 and V2355.39. Overall, substances containing a 5-methoxy group show a stronger interaction with residues N3436.55 and L229ECL2 than substances lacking that group, with the exception of 24H-NBOMe, where the 4-methoxy group may also interact with N3436.55. However, the obtained values indicate substantially weaker interactions with these residues than those observed for LSD. Lastly, a methoxy group at position 6 contributes to the already strong interaction with V1563.33 and D1553.32, and weakly interacts with L229ECL2. Based on the interactions proposed here, it is clear that there is no trivial or \u2018single-residue\u2019 explanation for the observed lower potencies and efficacies of 23H-, 34H- and 35H-NBOMe, suggesting a concerted impact of the interaction with several residues. Steric effects have to be considered as well when interpreting the position of the ligand in the binding pocket, as is particularly relevant for the NBOMe isomers with methoxy groups on adjacent positions (23H- and 34H-NBOMe). It must 139 also be taken into consideration that this model was adapted from a miniGq bound 5-HT2AR structure, and that the presence of \u03b2arrestin2 could differentially impact ligand interaction. Within the context of this study, it was not possible to generate binding data, however, such data may help to explain some of the observed differences in receptor activation by different positional isomers.  Table 5-3. Summary of the interaction energies (kcal/mol) between compounds and the 5-HT2AR.", "start_char_idx": 173739, "end_char_idx": 176695, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ea28b0ec-98c0-4b8b-8896-b4245d50a8f1": {"__data__": {"id_": "ea28b0ec-98c0-4b8b-8896-b4245d50a8f1", "embedding": null, "metadata": {"file_path": "data/brandt-no-intro.txt", "file_name": "brandt-no-intro.txt", "file_type": "text/plain", "file_size": 239829, "creation_date": "2023-12-31", "last_modified_date": "2023-12-31", "last_accessed_date": "2023-12-31"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "a0eaa9a5-aece-426b-8f20-580de8fb9f35", "node_type": "4", "metadata": {"file_path": "data/brandt-no-intro.txt", "file_name": "brandt-no-intro.txt", "file_type": "text/plain", "file_size": 239829, "creation_date": "2023-12-31", "last_modified_date": "2023-12-31", "last_accessed_date": "2023-12-31"}, "hash": "76e194b2637b440a1b1cdf5698cae061524bb4d7a3b73dfc2ba71d268a3f7019", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "eb0f1fa7-cbb5-40fd-a88f-d527d7597b79", "node_type": "1", "metadata": {"file_path": "data/brandt-no-intro.txt", "file_name": "brandt-no-intro.txt", "file_type": "text/plain", "file_size": 239829, "creation_date": "2023-12-31", "last_modified_date": "2023-12-31", "last_accessed_date": "2023-12-31"}, "hash": "959b84a3c77e1161ba2842d88f4851b36da03ad49f79b7a2c18f6daadf6076fb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d5138923-b7e6-4b97-9a17-dfada78d923d", "node_type": "1", "metadata": {}, "hash": "af23ddf86a7d742e20fd227085076a1d604948e6c5ad74ba6a206bd0b22fff23", "class_name": "RelatedNodeInfo"}}, "hash": "458317861f5d0b07454803550f14faf8bf4ba09cd2573d54e1cf5721aecebefc", "text": "Steric effects have to be considered as well when interpreting the position of the ligand in the binding pocket, as is particularly relevant for the NBOMe isomers with methoxy groups on adjacent positions (23H- and 34H-NBOMe). It must 139 also be taken into consideration that this model was adapted from a miniGq bound 5-HT2AR structure, and that the presence of \u03b2arrestin2 could differentially impact ligand interaction. Within the context of this study, it was not possible to generate binding data, however, such data may help to explain some of the observed differences in receptor activation by different positional isomers.  Table 5-3. Summary of the interaction energies (kcal/mol) between compounds and the 5-HT2AR.  as seen from the perspective of the N-benzyl moiety shown in Figure 5-4a Compound S1593.36 D1553.32 V1563.33 W3366.48 F3396.51 F3406.52 LSD -3.50 -18.5 -13.5 -2.30 -10.49 -6.39 25CN-NBOH -9.34 -18.3 -10.7 -7.30 -8.76 -7.73 23H-NBOMe -11.5 -19.8 -11.3 -9.06 -9.41 -8.72 24H-NBOMe -9.86 -19.5 -11.2 -8.66 -9.35 -8.36 25H-NBOMe -9.90 -19.3 -11.0 -8.58 -9.01 -7.54 26H-NBOMe -9.77 -20.7 -12.9 -8.70 -9.16 -7.89 34H-NBOMe -8.59 -20.7 -10.6 -8.62 -9.30 -8.39 35H-NBOMe -8.72 -20.49 -10.1 -8.54 -10.27 -7.25 Table 5-4. Summary of the interaction energies (kcal/mol) involved in the interaction between the methoxy groups on the phenyl ring and nearby amino acid residues on the 5-HT2AR.  Compound T1603.37 S1593.36 G2385.42 S2425.46 S2395.43 V2355.39 N3436.55 L229ECL2 LSD -1.25 -3.50 -1.54 -6.46 -4.01 -2.28 -5.02 -9.91 25CN-NBOH -2.38 -9.34 -3.07 -1.90 -2.13 -0.68 -1.69 -2.98 23H-NBOMe -2.77 -11.5 -2.04 -4.86 -1.29 -0.57 -0.99 -0.56 24H-NBOMe -2.14 -9.86 -1.07 -1.74 -2.18 -3.38 -2.25 -1.13 25H-NBOMe -2.43 -9.9 -0.82 -1.81 -0.59 -0.93 -1.61 -2.25 26H-NBOMe -2.51 -9.77 -0.93 -1.70 -0.60 -0.58 -0.73 -1.76 34H-NBOMe -0.47 -8.59 -2.69 -3.23 -2.29 -3.35 -0.95 -1.09 35H-NBOMe -0.21 -8.72 -2.26 -2.57 -1.46 -1.60 -3.18 -2.46 140 5.4 Conclusion In conclusion, we report on the functional characterization of a set of positional isomers of 25HNBOMe, in which the methoxy groups are placed in different positions of the phenethylamine moiety. More specifically, the impact of the structural changes on the ability of the activated 5- HT2AR to recruit cytosolic proteins was assessed. To this end, bioassays monitoring the recruitment of either \u03b2arrestin2 or miniGq to the 5-HT2AR were employed. The results show clear differences in the EC50 (as a measure of potency) and Emax (as a measure of efficacy) values of the differentially substituted isomers.", "start_char_idx": 175971, "end_char_idx": 178541, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d5138923-b7e6-4b97-9a17-dfada78d923d": {"__data__": {"id_": "d5138923-b7e6-4b97-9a17-dfada78d923d", "embedding": null, "metadata": {"file_path": "data/brandt-no-intro.txt", "file_name": "brandt-no-intro.txt", "file_type": "text/plain", "file_size": 239829, "creation_date": "2023-12-31", "last_modified_date": "2023-12-31", "last_accessed_date": "2023-12-31"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "a0eaa9a5-aece-426b-8f20-580de8fb9f35", "node_type": "4", "metadata": {"file_path": "data/brandt-no-intro.txt", "file_name": "brandt-no-intro.txt", "file_type": "text/plain", "file_size": 239829, "creation_date": "2023-12-31", "last_modified_date": "2023-12-31", "last_accessed_date": "2023-12-31"}, "hash": "76e194b2637b440a1b1cdf5698cae061524bb4d7a3b73dfc2ba71d268a3f7019", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ea28b0ec-98c0-4b8b-8896-b4245d50a8f1", "node_type": "1", "metadata": {"file_path": "data/brandt-no-intro.txt", "file_name": "brandt-no-intro.txt", "file_type": "text/plain", "file_size": 239829, "creation_date": "2023-12-31", "last_modified_date": "2023-12-31", "last_accessed_date": "2023-12-31"}, "hash": "458317861f5d0b07454803550f14faf8bf4ba09cd2573d54e1cf5721aecebefc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6f4d0be6-8ef0-4edf-95cb-b194c64934c9", "node_type": "1", "metadata": {}, "hash": "73f0f52b61f1ffe49b96a3e3e2307b9c0bff6c65e15a523c39b25cde9518ea42", "class_name": "RelatedNodeInfo"}}, "hash": "af23ddf86a7d742e20fd227085076a1d604948e6c5ad74ba6a206bd0b22fff23", "text": "More specifically, the impact of the structural changes on the ability of the activated 5- HT2AR to recruit cytosolic proteins was assessed. To this end, bioassays monitoring the recruitment of either \u03b2arrestin2 or miniGq to the 5-HT2AR were employed. The results show clear differences in the EC50 (as a measure of potency) and Emax (as a measure of efficacy) values of the differentially substituted isomers. Overall, the isomers with a methoxy group on position 2 were more potent than those that did not have this substituent, with 24H-NBOMe being the most potent substance tested, and 23H-NBOMe being slightly less potent than 25- and 26H-NBOMe. The two isomers lacking the 2-methoxy group, 34- and 35H-NBOMe, were substantially less potent than the others. In terms of efficacy, the differences are less apparent, with 23H- and 35H-NBOMe showing less efficacy than all other isomers, although they showed similar efficacy as LSD. The results showed that the reference agonist, the assay employed, and the method of analysis did not influence these findings. Data obtained from molecular docking of these substances into a 5- HT2AR model suggest specific residues that interact with the specific methoxy groups on the phenyl moiety of the phenethylamine part of the molecule, result in the observed differential receptor activation potential of the differently-substituted isomers. As for biased agonism in general isomers with methoxy groups at the 2 positions tend to display greater ligand bias towards \u03b2arrestin2 than compounds with a methoxy in the 3 position. This is likely related to the stronger interaction between a methoxy in the 2 position and T1603.37 whereas this interaction between the methoxy in the 3 position is significatly weaker (Table 5-4). When research is more conclusive which pathway is desirable for psychedelics it is studies like these that will aid in ligand design 141 for potential therapeutics. While the methoxy pattern on the phenylalkylamine moiety has been described extensively for N-unsubstituted psychedelics, this is the first report comparatively assessing the functional effects of this isomerization in their NBOMe counterparts.  142\n\nCHAPTER 6\nDiscussion\n\n6.1 Objectives Of This Research\n\nThe overall objective of this research was to use in silico computer modelling to help explain in vitro SAR of compounds that bind to the GPCRs CB1R, CB2R, and 5-HT2AR. The research was designed to bridge the gap between in silico modelling and in vitro pharmacology. Specifically, this work demonstrates (1) how isolated enantiomers of GAT compounds display vastly different pharmacology at CB1R that may relate to their sites of binding; (2) how isomers of GAT compounds display different binding affinity at CB1R based on their chemical functional groups; (3) the relationship between functional groups of synthetic cannabinoid receptor agonists and their affinity and ligand bias at CB1R and CB2R; and (4) the relationship between functional groups of synthetic NBOMe 5-HT2AR agonists and their signaling activity at 5-HT2AR. Consequently, this research was successful in using in silico-based modelling in concert with in vitro pharmacological approaches to understand the activity of ligands at three GPCRs.\n\n6.2 Summary of Research\n\n6.2.1 GAT Compound Enantiomers and Isomers Show a Difference in Activity at CB1R GAT591 and GAT593 were separated into their respective enantiomers GAT1664, GAT1665, GAT1666 and GAT1667. Previous research has shown that the racemic mixtures GAT591 and GAT593 displayed ago-PAM properties and thus the goal of this study was to show which enantiomer was responsible for the agonist properties and PAM properties at CB1R. In this study it was discovered that the R-enantiomers (GAT1665 and GAT1667) acted as ago-PAM\u2019s while the S-enantiomers (GAT1664 and GAT1666) showed little to no activity at CB1R. This is due to the R-enantiomers binding to the ago-PAM site of CB1R near the intracellular space of the receptor on the plasma membrane whereas the S-enantiomers bound to a PAM site on CB1R near the extracellular space.", "start_char_idx": 178131, "end_char_idx": 182232, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6f4d0be6-8ef0-4edf-95cb-b194c64934c9": {"__data__": {"id_": "6f4d0be6-8ef0-4edf-95cb-b194c64934c9", "embedding": null, "metadata": {"file_path": "data/brandt-no-intro.txt", "file_name": "brandt-no-intro.txt", "file_type": "text/plain", "file_size": 239829, "creation_date": "2023-12-31", "last_modified_date": "2023-12-31", "last_accessed_date": "2023-12-31"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "a0eaa9a5-aece-426b-8f20-580de8fb9f35", "node_type": "4", "metadata": {"file_path": "data/brandt-no-intro.txt", "file_name": "brandt-no-intro.txt", "file_type": "text/plain", "file_size": 239829, "creation_date": "2023-12-31", "last_modified_date": "2023-12-31", "last_accessed_date": "2023-12-31"}, "hash": "76e194b2637b440a1b1cdf5698cae061524bb4d7a3b73dfc2ba71d268a3f7019", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d5138923-b7e6-4b97-9a17-dfada78d923d", "node_type": "1", "metadata": {"file_path": "data/brandt-no-intro.txt", "file_name": "brandt-no-intro.txt", "file_type": "text/plain", "file_size": 239829, "creation_date": "2023-12-31", "last_modified_date": "2023-12-31", "last_accessed_date": "2023-12-31"}, "hash": "af23ddf86a7d742e20fd227085076a1d604948e6c5ad74ba6a206bd0b22fff23", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d3f2e237-5c5e-4a3b-b615-fed7b7af1e7c", "node_type": "1", "metadata": {}, "hash": "ab6f7d1e88a1a8cad08a6a4ce84c8c50565e77d21929b4954510bd71e46abc51", "class_name": "RelatedNodeInfo"}}, "hash": "73f0f52b61f1ffe49b96a3e3e2307b9c0bff6c65e15a523c39b25cde9518ea42", "text": "Previous research has shown that the racemic mixtures GAT591 and GAT593 displayed ago-PAM properties and thus the goal of this study was to show which enantiomer was responsible for the agonist properties and PAM properties at CB1R. In this study it was discovered that the R-enantiomers (GAT1665 and GAT1667) acted as ago-PAM\u2019s while the S-enantiomers (GAT1664 and GAT1666) showed little to no activity at CB1R. This is due to the R-enantiomers binding to the ago-PAM site of CB1R near the intracellular space of the receptor on the plasma membrane whereas the S-enantiomers bound to a PAM site on CB1R near the extracellular space. In the radioligand binding experiments it was observed that all GAT 144 compounds enhanced the binding of [ 3H]CP55,940, which is consistent with expected PAM activity at GPCRs in the majority of cases published to date. From these experiments it was further observed that GAT1667 had the greatest affinity (KD = 28 [15 \u2013 52] nM). From a computational perspective this makes sense as \u2206G (kcal/mol) for GAT1667 (\u2206G = -64.55) is more negative than its isomers that binds to the same site GAT1665 (\u2206G = -60.77). It was even found that this research was translatable to in vivo models as we found that while GAT1664 and GAT1666 showed no notable in vivo effects, GAT1665 and GAT1667 displayed significant cataleptic, hypothermic, and anti-nociceptive effects at 3 and 10 mg/kg i.p. compared to vehicle. GAT1664, GAT1665, GAT1666, and GAT1667 do not alter physiology in normal, otherwise healthy adult mice as agonists, but GAT1665 and GAT1667 are able to augment THC\u2019s effects as PAMs when administered once. Overall, this research shows that separated enantiomers bind distinct sites on CB1R which produce unique ligand profiles. Research such as this will help when there is a clear distinction as to which bias profile is useful for specific indications.\n\n6.2.2 In silico Methods Can Be Used to Optimize Existing Compounds\n\nIn chapter 3 it was discussed how in silico methods can be used to improve the affinity and physiochemical characteristics of existing compounds. In the first part of the study, the effect on binding free energy (\u2206G) as a function of halogen substitution on three sites (referred to as X, Y and Z) of the GAT228 was assessed for a total of 144 compounds (Figure 3-1a). Without any halogens the \u2206G was computed to be -65.24kcal/mol for the control compound GAT228. For the fluorinated compounds a significant increase in \u2206G was only observed for GAT1667 (\u2206G GAT1667 = -70.88 kcal/mol) when compared to GAT228, but not GAT1665 (\u2206G GAT1665 = - 65.74 kcal/mol). For the chlorine derivatives a substantial decrease in \u2206G was observed indicating an increase in relative binding affinity. For example, the chlorinated derivative of GAT1667 145 showed a \u2206G of -78.19 kcal/mol which is 7.31 kcal/mol more stable than GAT1667. For both the bromine and iodine equivalent of GAT1667 the compounds did not dock to CB1R in the correct pose as shown in Figure 3-1b,c. This is likely due to these halogens having large atomic radii and bond lengths, making them unsuitable as ligands for this CB1R binding site.  Next, the effect of adding a NO2 to site \u2018Y\u2019 of the GAT228 scaffold was explored because there exists an arginine residue (R4.39) on CB1R close to site Y which would be expected to H-bond with the NO2 group. It was observed that a NO2 placed at position 2 of site Y did show a decrease in \u2206G by 6.46 kcal/mol when compared to GAT228 due to the presence of a H-bond.  Unfortunately, however, when the chlorines were added there was not as much space in the binding pocket which led to unfavorable steric clashing and an increase in \u2206G. Thus, overall adding a NO2 at this position was not beneficial.", "start_char_idx": 181599, "end_char_idx": 185351, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d3f2e237-5c5e-4a3b-b615-fed7b7af1e7c": {"__data__": {"id_": "d3f2e237-5c5e-4a3b-b615-fed7b7af1e7c", "embedding": null, "metadata": {"file_path": "data/brandt-no-intro.txt", "file_name": "brandt-no-intro.txt", "file_type": "text/plain", "file_size": 239829, "creation_date": "2023-12-31", "last_modified_date": "2023-12-31", "last_accessed_date": "2023-12-31"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "a0eaa9a5-aece-426b-8f20-580de8fb9f35", "node_type": "4", "metadata": {"file_path": "data/brandt-no-intro.txt", "file_name": "brandt-no-intro.txt", "file_type": "text/plain", "file_size": 239829, "creation_date": "2023-12-31", "last_modified_date": "2023-12-31", "last_accessed_date": "2023-12-31"}, "hash": "76e194b2637b440a1b1cdf5698cae061524bb4d7a3b73dfc2ba71d268a3f7019", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6f4d0be6-8ef0-4edf-95cb-b194c64934c9", "node_type": "1", "metadata": {"file_path": "data/brandt-no-intro.txt", "file_name": "brandt-no-intro.txt", "file_type": "text/plain", "file_size": 239829, "creation_date": "2023-12-31", "last_modified_date": "2023-12-31", "last_accessed_date": "2023-12-31"}, "hash": "73f0f52b61f1ffe49b96a3e3e2307b9c0bff6c65e15a523c39b25cde9518ea42", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "902ad6b6-bb31-488f-b9ee-8301e9847041", "node_type": "1", "metadata": {}, "hash": "7e0107a1039befd06ab1cc107f21ea142bb0566fe8465245a6aa749ee9dc0afd", "class_name": "RelatedNodeInfo"}}, "hash": "ab6f7d1e88a1a8cad08a6a4ce84c8c50565e77d21929b4954510bd71e46abc51", "text": "This is likely due to these halogens having large atomic radii and bond lengths, making them unsuitable as ligands for this CB1R binding site.  Next, the effect of adding a NO2 to site \u2018Y\u2019 of the GAT228 scaffold was explored because there exists an arginine residue (R4.39) on CB1R close to site Y which would be expected to H-bond with the NO2 group. It was observed that a NO2 placed at position 2 of site Y did show a decrease in \u2206G by 6.46 kcal/mol when compared to GAT228 due to the presence of a H-bond.  Unfortunately, however, when the chlorines were added there was not as much space in the binding pocket which led to unfavorable steric clashing and an increase in \u2206G. Thus, overall adding a NO2 at this position was not beneficial. The effect of replacing the ring at site \u2018X\u2019 with a series of pyridine derivatives was also assessed and showed that the optimal position for a nitrogen in the pyridine ring was para to the R substituent Figure 3-4a. This substitution was 2.25 kcal/mol morestable than the fluorinated GAT228 control (GAT1665). Although this being the case there was not a drastic effect in terms of relative bonding affinity in changing site \u2018X\u2019 or \u2018Z\u2019 to a heterocyclic functional group.  The physiochemical properties of each compound were also assessed. Fluorinated and chlorinated GAT228 compounds broke 1 Lipinski rule while brominated and iodinated compounds broke 2.  For compounds with a NO2 group at position 2 of site \u2018Y\u2019 the predicted bioavailability became worse and thus this substitution was omitted. The only compound among those tested that did not break any Lipinski rules were those in which heterocycles were incorporated into the benzene rings. Because of this observation heterocycle analogs of GAT228 were considered lead compounds Figure 3-5. A major limitation of this research is that in vitro assays would need to be 146 performed in order to prove the validity of this research as this was all conducted in silico. Recent studies have also shown that the binding site docked to in this study overlaps with n-butyldiphenylcarboxamies which act as NAMs at CB1R 165. This unfortunately only further complicates this research as it suggests that PAM and NAMs of CB1R do not have distinct binding sites.\n\n6.2.3 In silico methods can be used to discriminate G protein from \u03b2arrestin2 biased compounds\n\nWhile much of chapter 4 focused on the SAR of SCRA\u2019s at CB1R and CB2R the novel finding was that in silico methods accurately differentiated the most G protein-biased compound (JWH 018 2'-naphthyl-N-(3-methylbutyl) isomer) from the most \u03b2arrestin2-biased compound (4FMDMB-BINACA). The most G protein-biased compound (JWH 018 2'-naphthyl-N-(3- methylbutyl) isomer) shows a more negative interaction energy with the G protein bound which makes sense as this compound is G protein biased. In fact, JWH 018 2'-naphthyl-N-(3- methylbutyl) isomer is 3.78 kcal/mol more stable with the G protein-biased bound than without the G protein bound. The most \u03b2arrestin2-biased compound (4F-MDMB-BINACA) was found to be 10.56 kcal/mol more stable than 4F-MDMB-BINACA with the G protein bound.  In a general sense it was found that the most conserved interaction was a H-bond with S3837.39 on CB1R while for CB2R S2857.39 . The data indicate this H-bond must be present in order for activity to exist at CB1R/CB2R as discussed previously. In terms of ligand bias it was observed that \u2206 9\n-\nTHC, meta-AB-FUBINACA, 5-fluoro NPB-22, 5-fluoro MPP-PICA were unbiased, AB-PINACA N-(2-fluoropentyl) isomer, 3-chloro AB-PINACA, 4-Fluoro MDMB-BINACA were \u03b2arrestin2- biased and FDU-NNEI, JWH 145, EG018 were cAMP biased.", "start_char_idx": 184609, "end_char_idx": 188254, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "902ad6b6-bb31-488f-b9ee-8301e9847041": {"__data__": {"id_": "902ad6b6-bb31-488f-b9ee-8301e9847041", "embedding": null, "metadata": {"file_path": "data/brandt-no-intro.txt", "file_name": "brandt-no-intro.txt", "file_type": "text/plain", "file_size": 239829, "creation_date": "2023-12-31", "last_modified_date": "2023-12-31", "last_accessed_date": "2023-12-31"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "a0eaa9a5-aece-426b-8f20-580de8fb9f35", "node_type": "4", "metadata": {"file_path": "data/brandt-no-intro.txt", "file_name": "brandt-no-intro.txt", "file_type": "text/plain", "file_size": 239829, "creation_date": "2023-12-31", "last_modified_date": "2023-12-31", "last_accessed_date": "2023-12-31"}, "hash": "76e194b2637b440a1b1cdf5698cae061524bb4d7a3b73dfc2ba71d268a3f7019", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d3f2e237-5c5e-4a3b-b615-fed7b7af1e7c", "node_type": "1", "metadata": {"file_path": "data/brandt-no-intro.txt", "file_name": "brandt-no-intro.txt", "file_type": "text/plain", "file_size": 239829, "creation_date": "2023-12-31", "last_modified_date": "2023-12-31", "last_accessed_date": "2023-12-31"}, "hash": "ab6f7d1e88a1a8cad08a6a4ce84c8c50565e77d21929b4954510bd71e46abc51", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "aa520e95-55a5-413b-a75d-c5d2011df863", "node_type": "1", "metadata": {}, "hash": "ec8b016a00b006483d58fd280834e5613f614b74361eeac3772d2551262ed107", "class_name": "RelatedNodeInfo"}}, "hash": "7e0107a1039befd06ab1cc107f21ea142bb0566fe8465245a6aa749ee9dc0afd", "text": "In a general sense it was found that the most conserved interaction was a H-bond with S3837.39 on CB1R while for CB2R S2857.39 . The data indicate this H-bond must be present in order for activity to exist at CB1R/CB2R as discussed previously. In terms of ligand bias it was observed that \u2206 9\n-\nTHC, meta-AB-FUBINACA, 5-fluoro NPB-22, 5-fluoro MPP-PICA were unbiased, AB-PINACA N-(2-fluoropentyl) isomer, 3-chloro AB-PINACA, 4-Fluoro MDMB-BINACA were \u03b2arrestin2- biased and FDU-NNEI, JWH 145, EG018 were cAMP biased. However, it is not clear what structural features lead to ligand bias at the orthosteric site of CB1R and CB2R. The reason that many of these studies do not provide insights into ligand bias is because this is not the best method 147 of studying ligand bias. In order to expand our knowledge of ligand bias it is imperative that we begin to design studies which look at protein-protein interaction between the G protein and the intracellular helices of the GPCR where this interaction occurs and separately also looking at how the \u03b2arrestin signalling molecule interacts with CB1R.\n\n6.2.4 2-Methoxy NBOMe Compounds are more Potent than 3-Methoxy NBOMe Compounds\n\n25H-NBOMe yielded a low nM potency (EC50 = 11.4nM) in the 5-HT2AR \u03b2arrestin2 recruitment assay and a higher efficacy than LSD (Emax 164% relative to LSD). Only one of the isomers is slightly more potent than 25H-NBOMe: 24H-NBOMe yielded an EC50 value of 3.88 nM. The potency of 26H-NBOMe (8.70 nM) is similar to that of 25H-NBOMe. The highest EC50 value (33.6 nM) of all isomers with a 2-methoxy substituent, and hence the lowest potency, was observed for 23H-NBOMe. The least potent substances in the \u03b2arrestin2 recruitment assay appeared to be 34H-NBOMe and 35H-NBOMe, both lacking the 2-methoxy substituent. This change in the position of one of the methoxy groups drastically reduced in vitro potency yielding EC50 values in the higher nM range (248 nM and 343 nM). In regard to the efficacy although 25H-NBOMe has the highest efficacy (164%) the 95% confidence intervals of 24H-, 26H-, and 34H-NBOMe (145%, 156% and 147%) all overlap with 25H-NBOMe. Although the efficacies obtained for 23HNBOMe (123%) and 35H-NBOMe (118%) were lower than that of 25H-NBOMe they both were still more efficacious than LSD and serotonin.  In Table 5-2 serotonin showed the greatest efficacy (Emax = 305% relative to LSD). For the NBOMe isomers although 25H-NBOMe displayed the greatest efficacy the 95% confidence intervals of 24H-, 26H-, 34H- (171%, 162%, 156%) all overlap with 25H-NBOMe. While 23HNBOMe was the only compound that showed less efficacy than LSD (89.6%), 35H-NBOMe\u2019s efficacy (107%) was only slightly greater than LSD (98.2%). In terms of potency as measured by 148 EC50 LSD displayed the greatest potency (EC50 = 17.7 nM). For the NBOMe isomers 24HNBOMe displayed the greatest potency (EC50 = 37.4 nM) but the 95% confidence intervals of 25H- (EC50 = 86.2 nM) and 26H-NBOMe (EC50 = 68.0 nM) did overlap with 24H-NBOMe. 23HNBOMe (EC50 = 236 nM) displayed the weakest potency of the 2-methoxy substituted NBOMe isomers.", "start_char_idx": 187738, "end_char_idx": 190840, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "aa520e95-55a5-413b-a75d-c5d2011df863": {"__data__": {"id_": "aa520e95-55a5-413b-a75d-c5d2011df863", "embedding": null, "metadata": {"file_path": "data/brandt-no-intro.txt", "file_name": "brandt-no-intro.txt", "file_type": "text/plain", "file_size": 239829, "creation_date": "2023-12-31", "last_modified_date": "2023-12-31", "last_accessed_date": "2023-12-31"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "a0eaa9a5-aece-426b-8f20-580de8fb9f35", "node_type": "4", "metadata": {"file_path": "data/brandt-no-intro.txt", "file_name": "brandt-no-intro.txt", "file_type": "text/plain", "file_size": 239829, "creation_date": "2023-12-31", "last_modified_date": "2023-12-31", "last_accessed_date": "2023-12-31"}, "hash": "76e194b2637b440a1b1cdf5698cae061524bb4d7a3b73dfc2ba71d268a3f7019", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "902ad6b6-bb31-488f-b9ee-8301e9847041", "node_type": "1", "metadata": {"file_path": "data/brandt-no-intro.txt", "file_name": "brandt-no-intro.txt", "file_type": "text/plain", "file_size": 239829, "creation_date": "2023-12-31", "last_modified_date": "2023-12-31", "last_accessed_date": "2023-12-31"}, "hash": "7e0107a1039befd06ab1cc107f21ea142bb0566fe8465245a6aa749ee9dc0afd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a88a84be-4fa2-45da-887a-60818c78c939", "node_type": "1", "metadata": {}, "hash": "607d23530ebbfa8ededf01dcbdc87dfc8d4f09166d2e63877cbe09de70aa8e2b", "class_name": "RelatedNodeInfo"}}, "hash": "ec8b016a00b006483d58fd280834e5613f614b74361eeac3772d2551262ed107", "text": "While 23HNBOMe was the only compound that showed less efficacy than LSD (89.6%), 35H-NBOMe\u2019s efficacy (107%) was only slightly greater than LSD (98.2%). In terms of potency as measured by 148 EC50 LSD displayed the greatest potency (EC50 = 17.7 nM). For the NBOMe isomers 24HNBOMe displayed the greatest potency (EC50 = 37.4 nM) but the 95% confidence intervals of 25H- (EC50 = 86.2 nM) and 26H-NBOMe (EC50 = 68.0 nM) did overlap with 24H-NBOMe. 23HNBOMe (EC50 = 236 nM) displayed the weakest potency of the 2-methoxy substituted NBOMe isomers. Similarly with the \u03b2arrestin2 recruitment assay in the miniGq experiment 34H- (EC50 = 1321 nM) and 35H-NBOMe (EC50 = 1393 nM) displayed the weakest potency in terms of all the NBOMe isomers in the study.  In terms of in silico molecular modelling a methoxy group on position 2 of the phenyl ring of the phenethylamine moiety (as is the case in 23H-, 24H-, 25H-, and 26H-NBOMe) hydrophobically interacts with T1603.37, S1593.36 and V1563.33, as reflected by the weaker interaction (higher interaction energies) for substances without a methoxy group at this position. The model also proposes interactions between G2385.42 and S2425.46 and a methoxy group at position 3, as reflected by a weaker interaction of these residues with substances lacking a 3-methoxy group. This work is imperative in the psychedelic drug discovery field as it provides a framework for future compounds that will be design for specific indications. It suggests that all methoxy isomers on the phenethylamine moiety still lead to \u03b2arrestin2-biased ligands although the most \u03b2arrestin2-biased compound contains a methoxy in the 2 position. As more data accumulate as to which ligand profiles are desired for specific indications this work will aid in rational ligand design that will meet these indications.\n\n6.3 Philosophical Considerations Surrounding this Research\n\n6.3.1 Ambiguity of full vs partial agonist/antagonist\n\nBy definition a full agonist is a compound that induces a conformational change in the shape of the receptor it binds leading to a maximum in the measured outcome whereas a partial agonist 149 activates the receptor to an extent less than its maximal effect.  166 For learning purposes this definition serves its purpose but in the higher level of pharmacology the definition falls apart. The maximal effect in pharmacology is an arbitrary term that refers to the strongest measured cellular signaling outcome that has been observed to date for a given receptor and endpoint.  167 For example, if a new receptor is discovered and 20 compounds are tested at the receptor, the compound that produces the strongest effect is designated as the full agonist and anything that produces weaker effects greater than baseline are designated as partial agonists. If then a new compound is discovered that produces a stronger maximal effect, then the new compound becomes the full agonist while the one designated in the previous as a full agonist becomes a partial agonist.  The terminology of partial or full only serves as a point of arbitrary point of reference, but in recent literature is often misused as an absolute. For this reason it is critically important that research published on novel agonists, allosteric ligands, and receptor systems thoroughly describe the model systems, time points, endpoints, and calculations used to arrive at determinations of affinity, potency, efficacy, and bias.  168\n\n6.3.2 Pharmacology in a Multidimensional System\n\nIn many branches of basic sciences including pharmacology, we measure systems as 2 dimensions.  For example, we often look at dose versus response such as how different doses of a compound induce Ca2+ flux following GPCR activation. When a compound engages a biological system it interacts with many different systems in addition to the one being measured in an in experimental model. The measured endpoint data only provides a small representation of the compounds global effects in the biological system. This unidimensional understanding of a compounds effect may give rise to unanticipated side effects at later stages of the drug discovery process.  Polypharmacological approaches have begun to bridge this gap as researchers are beginning to 150 screen individual compounds and multiple GPCRs to look for off target effects once the primary compounds mechanism of action has been deduced.", "start_char_idx": 190296, "end_char_idx": 194684, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a88a84be-4fa2-45da-887a-60818c78c939": {"__data__": {"id_": "a88a84be-4fa2-45da-887a-60818c78c939", "embedding": null, "metadata": {"file_path": "data/brandt-no-intro.txt", "file_name": "brandt-no-intro.txt", "file_type": "text/plain", "file_size": 239829, "creation_date": "2023-12-31", "last_modified_date": "2023-12-31", "last_accessed_date": "2023-12-31"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "a0eaa9a5-aece-426b-8f20-580de8fb9f35", "node_type": "4", "metadata": {"file_path": "data/brandt-no-intro.txt", "file_name": "brandt-no-intro.txt", "file_type": "text/plain", "file_size": 239829, "creation_date": "2023-12-31", "last_modified_date": "2023-12-31", "last_accessed_date": "2023-12-31"}, "hash": "76e194b2637b440a1b1cdf5698cae061524bb4d7a3b73dfc2ba71d268a3f7019", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "aa520e95-55a5-413b-a75d-c5d2011df863", "node_type": "1", "metadata": {"file_path": "data/brandt-no-intro.txt", "file_name": "brandt-no-intro.txt", "file_type": "text/plain", "file_size": 239829, "creation_date": "2023-12-31", "last_modified_date": "2023-12-31", "last_accessed_date": "2023-12-31"}, "hash": "ec8b016a00b006483d58fd280834e5613f614b74361eeac3772d2551262ed107", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fed6bb5f-8768-43d5-be0c-a1b4ff5f0d21", "node_type": "1", "metadata": {}, "hash": "bf0b2228c80056989a0f03bcd476d09a0950267c8ed6015ae441415657a03324", "class_name": "RelatedNodeInfo"}}, "hash": "607d23530ebbfa8ededf01dcbdc87dfc8d4f09166d2e63877cbe09de70aa8e2b", "text": "168\n\n6.3.2 Pharmacology in a Multidimensional System\n\nIn many branches of basic sciences including pharmacology, we measure systems as 2 dimensions.  For example, we often look at dose versus response such as how different doses of a compound induce Ca2+ flux following GPCR activation. When a compound engages a biological system it interacts with many different systems in addition to the one being measured in an in experimental model. The measured endpoint data only provides a small representation of the compounds global effects in the biological system. This unidimensional understanding of a compounds effect may give rise to unanticipated side effects at later stages of the drug discovery process.  Polypharmacological approaches have begun to bridge this gap as researchers are beginning to 150 screen individual compounds and multiple GPCRs to look for off target effects once the primary compounds mechanism of action has been deduced.  169,170,171 Looking ahead, what will push this field forward is the use of artificial intelligence to provide predictions for many of the unknown and off-target effects of a compound via machine learning.\n\n6.3.3 SAR relationship is not straight forward in measuring agonism\n\nSARs are the connection between a compounds structure and how the compound affects the measured signaling outcome. Historically, GPCR research has focused on G protein activity (e.g.  an intracellular change in cAMP) or a change in \u03b2arrestin. In reality, GPCR-dependent effects are much more complicated. When a compound binds to a GPCR both the shape of the compound as well as the shape of the GPCR change. An outcome of this change in GPCR shape is the change of intracellular helical bundles on the GPCR. This change in intracellular helical bundles will cause the G protein to bind with higher or lower affinity to the intraceullar helices of the GPCR as well as changes to GPCR phosphorylation and consequent \u03b2arrestin recruitment. The unique GPCR conformation that is stabilized upon agonist binding will determine which GPCR-protein complex is best-stabilized and consequently which pathway is most-likely to be activated. From this perspective, a ligand-receptor SARs provide a limited understanding of this complex picture. A more comprehensive understanding would also incorporate how this shape change effects the affintiy of the G protein(s) and/or \u03b2arrestin to the intracellular helical bundle. The current best in silico approach to this is to utilize protein modelling and molecular dynamics simulations to assess conformational changes in the intracellular helices observed upon ligand docking. Using such an approach, one could dock the binding region of the interacting protein to the intracellular surface of the GPCR in the presence of a given compound to see if binding energy increases or decreases.  However, this approach is limited by the current power of GPU/CPUs and the ability to accuratley predict protein-protein interactions and folding with experimental validity.  The ongoing development of artificial intelligence and quantum computation may help resolve these issues. In vitro, multidimensional and time-sensitive reporter assays that allow for the visualization of more than 2 protein-protein interactions using multiple fluorescent-tagged proteins and/or fluorescent ligands may aid in our understanding of pluridimensional GPCR signaling and bias.  However, these assays are reliant upon heterelogous overexpression systems that may not translate to endogenous biological significance during drug development.\n\n6.3.4 5-HT2AR Receptor agonists Psychedelics issue\n\nThe prevailing theory on psychedelics for quite some time now is that they elicit their effects by binding to 5-HT2AR and acting as agonists. This was supported by work from Dr. Nichols\u2019 group that found ketanserin (5-HT2AR antagonist) administered prior to a 5-HT2AR agonist blocks the subjective effects of psychedelic compounds.  177 Independently, other research has found that following the administration of a psychedelic, glutamate levels in the medial prefrontal cortex increase, while glutamate levels in the hippocampus decrease.  178 While one could suppose that this proves 5HT2AR is the psychedelic receptor, it is important to ask why do exogenous 5-HT2AR agonists cause perceptual changes in reality? This is a particularly important question given that serotonin itself does not alter perception and exogeneous hallucinogenic and dissociative agents vary in their effects on perception. There are theories that attempt to explain this of which Dr.  Harris\u2019 entropic brain model is the most widely accepted.  179 Put simply, the entropic brain model represents different brain regions as hubs in a network. Each hub can connect to a few other hubs but not all hubs are directly connected.", "start_char_idx": 193736, "end_char_idx": 198567, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fed6bb5f-8768-43d5-be0c-a1b4ff5f0d21": {"__data__": {"id_": "fed6bb5f-8768-43d5-be0c-a1b4ff5f0d21", "embedding": null, "metadata": {"file_path": "data/brandt-no-intro.txt", "file_name": "brandt-no-intro.txt", "file_type": "text/plain", "file_size": 239829, "creation_date": "2023-12-31", "last_modified_date": "2023-12-31", "last_accessed_date": "2023-12-31"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "a0eaa9a5-aece-426b-8f20-580de8fb9f35", "node_type": "4", "metadata": {"file_path": "data/brandt-no-intro.txt", "file_name": "brandt-no-intro.txt", "file_type": "text/plain", "file_size": 239829, "creation_date": "2023-12-31", "last_modified_date": "2023-12-31", "last_accessed_date": "2023-12-31"}, "hash": "76e194b2637b440a1b1cdf5698cae061524bb4d7a3b73dfc2ba71d268a3f7019", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a88a84be-4fa2-45da-887a-60818c78c939", "node_type": "1", "metadata": {"file_path": "data/brandt-no-intro.txt", "file_name": "brandt-no-intro.txt", "file_type": "text/plain", "file_size": 239829, "creation_date": "2023-12-31", "last_modified_date": "2023-12-31", "last_accessed_date": "2023-12-31"}, "hash": "607d23530ebbfa8ededf01dcbdc87dfc8d4f09166d2e63877cbe09de70aa8e2b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5b103750-f08c-4e09-b77a-3c205676bf1c", "node_type": "1", "metadata": {}, "hash": "4cd1a5413a9cfc4a3a38ca733809c4772af578528671adb88ebdc17924c2da00", "class_name": "RelatedNodeInfo"}}, "hash": "bf0b2228c80056989a0f03bcd476d09a0950267c8ed6015ae441415657a03324", "text": "177 Independently, other research has found that following the administration of a psychedelic, glutamate levels in the medial prefrontal cortex increase, while glutamate levels in the hippocampus decrease.  178 While one could suppose that this proves 5HT2AR is the psychedelic receptor, it is important to ask why do exogenous 5-HT2AR agonists cause perceptual changes in reality? This is a particularly important question given that serotonin itself does not alter perception and exogeneous hallucinogenic and dissociative agents vary in their effects on perception. There are theories that attempt to explain this of which Dr.  Harris\u2019 entropic brain model is the most widely accepted.  179 Put simply, the entropic brain model represents different brain regions as hubs in a network. Each hub can connect to a few other hubs but not all hubs are directly connected. Under the influence of a psychedelic, there seems to be a higher degree of interconnectivity between hubs which leads to an overall higher degree of entropy in the brain. This increased degree of entropy in human subjects is measured with fMRI.  180 A 152 question that could help unify the theory for how psychedelics work is how does a 5-HT2AR agonist lead to the interconnectedness of these hubs? Answering such a question would be difficult as one would have to understand how to connect the dots from a compound binding to 5-HT2AR (a topic in molecular pharmacology) to interconnectedness of these hubs (a topic in psychiatry).  Historically, researchers are adept at taking the reductionist approach and answering a limited and specific question with strong evidence, but we often fail to answer questions that require interdisciplinary and integration and translation of data across models.\n\n6.3.5 Will computational methods replace experimental pharmacology?\n\nMoore\u2019s Law states that the number of transistors on a microchip doubles approximately every 2 years, though the cost of computers is halved. In the past 20 years the discipline of pharmacology has seen a widespread and growing adoption of in silico techniques to support in vitro and in vivo data 181 . With in this dissertation in silico computational modelling was able to accurately predict relative binding affinity and bias for CB1R, CB2R, and 5-HT2AR. The utilization of in silico analysis is a product of high-resolution x-ray/cryo-EM crystal structures of GPCRs coupled with the increasing power of central processing units (CPU)/graphics processing units (GPU\u2019s). In 2020 the artificial intelligence (AI) algorithm AlphaFold v2.0 was launched. AlphaFold v2.0 uses AI to predict protein structures. While many researchers, including myself, can spot obvious issues with the predicted structures of which can be contrasted to experimentally determined structures on the protein data bank, it does bring about a future where in silico computational modelling is showing higher accuracy over time. Will we eventually get to a point in time where experimental pharmacology is replaced by in silico computational methods? Currently this is not a reality as we still need experimental pharmacology to prove the vast complex nature of in vitro and in vivo systems.\n\nReferences\n\n1. Brandt AL. Computer modeling of allosteric modulators at G protein-coupled receptors.\nAllosteric Modul G Protein-Coupled Recept. Published online 2022:31-46.  doi:10.1016/b978-0-12-819771-4.00007-5\n\n2. Goddard AD, Watts A. Regulation of G protein-coupled receptors by palmitoylation and\ncholesterol. BMC Biol. 2012;10:2-4. doi:10.1186/1741-7007-10-27\n\n3. Alhosaini K, Azhar A, Alonazi A, Al-Zoghaibi F. GPCRs: The most promiscuous druggable\nreceptor of the mankind. Saudi Pharm J. 2021;29(6):539-551.\ndoi:10.1016/j.jsps.2021.04.015\n\n4. Yang D, Zhou Q, Labroska V, et al. G protein-coupled receptors: structure- and functionbased drug discovery. Signal Transduct Target Ther. 2021;6(1). doi:10.1038/s41392-020-\n00435-w\n\n5. Hauser AS, Attwood MM, Rask-andersen M, Schi\u00f6th HB, Gloriam DE. Trends in GPCR\ndrug discovery\u202f: new agents , targets and indications. Nat Publ Gr.", "start_char_idx": 197697, "end_char_idx": 201787, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5b103750-f08c-4e09-b77a-3c205676bf1c": {"__data__": {"id_": "5b103750-f08c-4e09-b77a-3c205676bf1c", "embedding": null, "metadata": {"file_path": "data/brandt-no-intro.txt", "file_name": "brandt-no-intro.txt", "file_type": "text/plain", "file_size": 239829, "creation_date": "2023-12-31", "last_modified_date": "2023-12-31", "last_accessed_date": "2023-12-31"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "a0eaa9a5-aece-426b-8f20-580de8fb9f35", "node_type": "4", "metadata": {"file_path": "data/brandt-no-intro.txt", "file_name": "brandt-no-intro.txt", "file_type": "text/plain", "file_size": 239829, "creation_date": "2023-12-31", "last_modified_date": "2023-12-31", "last_accessed_date": "2023-12-31"}, "hash": "76e194b2637b440a1b1cdf5698cae061524bb4d7a3b73dfc2ba71d268a3f7019", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fed6bb5f-8768-43d5-be0c-a1b4ff5f0d21", "node_type": "1", "metadata": {"file_path": "data/brandt-no-intro.txt", "file_name": "brandt-no-intro.txt", "file_type": "text/plain", "file_size": 239829, "creation_date": "2023-12-31", "last_modified_date": "2023-12-31", "last_accessed_date": "2023-12-31"}, "hash": "bf0b2228c80056989a0f03bcd476d09a0950267c8ed6015ae441415657a03324", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "319bb8d7-acc6-405c-bc48-df8265a7bb86", "node_type": "1", "metadata": {}, "hash": "80002a8b4379ff9aeaa0906eaf8620ad6c93eaf51daefe714e93a042887e5118", "class_name": "RelatedNodeInfo"}}, "hash": "4cd1a5413a9cfc4a3a38ca733809c4772af578528671adb88ebdc17924c2da00", "text": "Alhosaini K, Azhar A, Alonazi A, Al-Zoghaibi F. GPCRs: The most promiscuous druggable\nreceptor of the mankind. Saudi Pharm J. 2021;29(6):539-551.\ndoi:10.1016/j.jsps.2021.04.015\n\n4. Yang D, Zhou Q, Labroska V, et al. G protein-coupled receptors: structure- and functionbased drug discovery. Signal Transduct Target Ther. 2021;6(1). doi:10.1038/s41392-020-\n00435-w\n\n5. Hauser AS, Attwood MM, Rask-andersen M, Schi\u00f6th HB, Gloriam DE. Trends in GPCR\ndrug discovery\u202f: new agents , targets and indications. Nat Publ Gr. 2017;16(12):829-842.\ndoi:10.1038/nrd.2017.178\n\n6. Sriram K, Insel PA. G Protein-Coupled Receptors as Targets for Approved Drugs\u202f: How\nMany Targets and How Many Drugs? 2018;(April):251-258. doi:10.1124/mol.117.111062\n\n7. Dziedzic A, Miller E, Saluk-Bijak J, Bijak M. The gpr17 receptor\u2014a promising goal for\ntherapy and a potential marker of the neurodegenerative process in multiple sclerosis. Int J\nMol Sci. 2020;21(5). doi:10.3390/ijms21051852\n\n8. Wheatley M, Wootten D, Conner MT, et al. Lifting the lid on GPCRs: The role of \n154\nextracellular loops. Br J Pharmacol. 2012;165(6):1688-1703. doi:10.1111/j.1476-\n5381.2011.01629.x\n\n9. Hilger D, Masureel M, Kobilka BK, Struct N, Biol M. Structure and dynamics of GPCR\nsignaling complexes HHS Public Access Author manuscript. Nat Struct Mol Biol.\n2018;25(1):4-12. doi:10.1038/s41594-017-0011-7.Structure\n\n10. Blakeney JS, Reid RC, Le GT, Fairlie DP. Nonpeptidic ligands for peptide-activated G\nprotein-coupled receptors. Chem Rev. 2007;107(7):2960-3041. doi:10.1021/cr050984g\n\n11. Caron A, Reynolds RP, Castorena CM, et al. Adipocyte Gs but not Gi signaling regulates\nwhole-body glucose homeostasis. Mol Metab. 2019;27(June):11-21.\ndoi:10.1016/j.molmet.2019.06.019\n\n12. Lazar AM, Irannejad R, Baldwin TA, et al. G protein-regulated endocytic trafficking of\nadenylyl cyclase type 9. Elife. 2020;9:1-24. doi:10.7554/eLife.58039\n\n13. Taussig R, Tang WJ, Hepler JR, Gilman AG. Distinct patterns of bidirectional regulation\nof mammalian adenylyl cyclases. J Biol Chem. 1994;269(8):6093-6100.\ndoi:10.1016/s0021-9258(17)37574-9\n\n14. Khrenova MG, Kulakova AM, Nemukhin A V. Light-Induced Change of Arginine\nConformation Modulates the Rate of Adenosine Triphosphate to Cyclic Adenosine\nMonophosphate Conversion in the Optogenetic System Containing Photoactivated\nAdenylyl Cyclase. J Chem Inf Model. 2021;61(3):1215-1225.\ndoi:10.1021/acs.jcim.0c01308\n\n15. Cheng X, Ma Y, Moore M, Hemmings BA, Taylor SS. Phosphorylation and activation of \n155\ncAMP-dependent protein kinase by phosphoinositide-dependent protein kinase. Proc Natl\nAcad Sci U S A. 1998;95(17):9849-9854. doi:10.1073/pnas.95.17.9849\n\n16.", "start_char_idx": 201274, "end_char_idx": 203927, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "319bb8d7-acc6-405c-bc48-df8265a7bb86": {"__data__": {"id_": "319bb8d7-acc6-405c-bc48-df8265a7bb86", "embedding": null, "metadata": {"file_path": "data/brandt-no-intro.txt", "file_name": "brandt-no-intro.txt", "file_type": "text/plain", "file_size": 239829, "creation_date": "2023-12-31", "last_modified_date": "2023-12-31", "last_accessed_date": "2023-12-31"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "a0eaa9a5-aece-426b-8f20-580de8fb9f35", "node_type": "4", "metadata": {"file_path": "data/brandt-no-intro.txt", "file_name": "brandt-no-intro.txt", "file_type": "text/plain", "file_size": 239829, "creation_date": "2023-12-31", "last_modified_date": "2023-12-31", "last_accessed_date": "2023-12-31"}, "hash": "76e194b2637b440a1b1cdf5698cae061524bb4d7a3b73dfc2ba71d268a3f7019", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5b103750-f08c-4e09-b77a-3c205676bf1c", "node_type": "1", "metadata": {"file_path": "data/brandt-no-intro.txt", "file_name": "brandt-no-intro.txt", "file_type": "text/plain", "file_size": 239829, "creation_date": "2023-12-31", "last_modified_date": "2023-12-31", "last_accessed_date": "2023-12-31"}, "hash": "4cd1a5413a9cfc4a3a38ca733809c4772af578528671adb88ebdc17924c2da00", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "103b97df-d755-4b63-be76-6840ec16cfa1", "node_type": "1", "metadata": {}, "hash": "97fc20a5f71a1f202dc83b428922d087684cfe6ed6fbc6c7195ccbda685023a0", "class_name": "RelatedNodeInfo"}}, "hash": "80002a8b4379ff9aeaa0906eaf8620ad6c93eaf51daefe714e93a042887e5118", "text": "Khrenova MG, Kulakova AM, Nemukhin A V. Light-Induced Change of Arginine\nConformation Modulates the Rate of Adenosine Triphosphate to Cyclic Adenosine\nMonophosphate Conversion in the Optogenetic System Containing Photoactivated\nAdenylyl Cyclase. J Chem Inf Model. 2021;61(3):1215-1225.\ndoi:10.1021/acs.jcim.0c01308\n\n15. Cheng X, Ma Y, Moore M, Hemmings BA, Taylor SS. Phosphorylation and activation of \n155\ncAMP-dependent protein kinase by phosphoinositide-dependent protein kinase. Proc Natl\nAcad Sci U S A. 1998;95(17):9849-9854. doi:10.1073/pnas.95.17.9849\n\n16. Litosch I. Novel mechanisms for feedback regulation of phospholipase C-\u03b2 activity. IUBMB\nLife. 2002;54(5):253-260. doi:10.1080/15216540215673\n\n17. Sternweis PC, Smrcka A V. Regulation of phospholipase C by G proteins. Trends Biochem\nSci. 1992;17(12):502-506. doi:10.1016/0968-0004(92)90340-F\n\n18. Kadamur G, Ross EM. Mammalian phospholipase C. Annu Rev Physiol. 2013;75:127-154.\ndoi:10.1146/annurev-physiol-030212-183750\n\n19. Hanson CJ, Bootman MD, Roderick HL. Cell signalling: IP3 receptors channel calcium into\ncell death. Curr Biol. 2004;14(21):933-935. doi:10.1016/j.cub.2004.10.019\n\n20. Prole DL, Taylor CW. Structure and function of ip3 receptors. Cold Spring Harb Perspect\nBiol. 2019;11(4). doi:10.1101/cshperspect.a035063\n\n21. Zayzafoon M. Calcium/calmodulin signaling controls osteoblast growth and differentiation.\nJ Cell Biochem. 2006;97(1):56-70. doi:10.1002/jcb.20675\n\n22. Receptor O, Proteins I. Opioid receptor interacting proteins and the control of opioid\nsignaling. 2019;19(42):734-763. doi:10.2174/138161281942140105160625.Opioid\n\n23. Fong TM. Measurement of Inverse Agonism of the Cannabinoid Receptors. Vol 485.\nElsevier Inc.; 2010. doi:10.1016/B978-0-12-381296-4.00008-7\n\n24. Dunn HA, Stephen Ferguson SS. Regulation of CRFR1 and 5-HT2AR by PDZ DomainContaining Proteins SAP97 and PSD-95 Recommended Citation. Published online 2014.\nhttps://ir.lib.uwo.ca/etd\n156\n\n25. Vi\u00f1als X, Moreno E, Lanfumey L, et al. Cognitive impairment induced by delta9-\ntetrahydrocannabinol occurs through heteromers between cannabinoid CB1 and serotonin 5-HT2A receptors. PLoS Biol. 2015;13(7):1-40. doi:10.1371/journal.pbio.1002194\n\n26. Hauser MA, Legler DF. Common and biased signaling pathways of the chemokine receptor\nCCR7 elicited by its ligands CCL19 and CCL21 in leukocytes. J Leukoc Biol.  2016;99(6):869-882. doi:10.1189/jlb.2mr0815-380r\n\n27. Piekielna-Ciesielska J, Artali R, Azzam AAH, et al. Pharmacological characterization of \u00b5opioid receptor agonists with biased g protein or \u03b2-arrestin signaling, and computational\nstudy of conformational changes during receptor activation. Molecules. 2021;26(1).  doi:10.3390/MOLECULES26010013\n\n28. Kolb P, Kenakin T, Alexander SPH, et al. Community Guidelines for GPCR Ligand Bias:\nIUPHAR Review XX. Br J Pharmacol.", "start_char_idx": 203363, "end_char_idx": 206197, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "103b97df-d755-4b63-be76-6840ec16cfa1": {"__data__": {"id_": "103b97df-d755-4b63-be76-6840ec16cfa1", "embedding": null, "metadata": {"file_path": "data/brandt-no-intro.txt", "file_name": "brandt-no-intro.txt", "file_type": "text/plain", "file_size": 239829, "creation_date": "2023-12-31", "last_modified_date": "2023-12-31", "last_accessed_date": "2023-12-31"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "a0eaa9a5-aece-426b-8f20-580de8fb9f35", "node_type": "4", "metadata": {"file_path": "data/brandt-no-intro.txt", "file_name": "brandt-no-intro.txt", "file_type": "text/plain", "file_size": 239829, "creation_date": "2023-12-31", "last_modified_date": "2023-12-31", "last_accessed_date": "2023-12-31"}, "hash": "76e194b2637b440a1b1cdf5698cae061524bb4d7a3b73dfc2ba71d268a3f7019", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "319bb8d7-acc6-405c-bc48-df8265a7bb86", "node_type": "1", "metadata": {"file_path": "data/brandt-no-intro.txt", "file_name": "brandt-no-intro.txt", "file_type": "text/plain", "file_size": 239829, "creation_date": "2023-12-31", "last_modified_date": "2023-12-31", "last_accessed_date": "2023-12-31"}, "hash": "80002a8b4379ff9aeaa0906eaf8620ad6c93eaf51daefe714e93a042887e5118", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1b2c36f0-72ab-459a-9055-d5d7c9a274ce", "node_type": "1", "metadata": {}, "hash": "b3a065ddbb3beafd99aa9ffd8903ffcfe16e10f3145bd68f196a73e1d68f8fc3", "class_name": "RelatedNodeInfo"}}, "hash": "97fc20a5f71a1f202dc83b428922d087684cfe6ed6fbc6c7195ccbda685023a0", "text": "J Leukoc Biol.  2016;99(6):869-882. doi:10.1189/jlb.2mr0815-380r\n\n27. Piekielna-Ciesielska J, Artali R, Azzam AAH, et al. Pharmacological characterization of \u00b5opioid receptor agonists with biased g protein or \u03b2-arrestin signaling, and computational\nstudy of conformational changes during receptor activation. Molecules. 2021;26(1).  doi:10.3390/MOLECULES26010013\n\n28. Kolb P, Kenakin T, Alexander SPH, et al. Community Guidelines for GPCR Ligand Bias:\nIUPHAR Review XX. Br J Pharmacol. 2022;(August 2021):1-24. doi:10.1111/bph.15811\n\n29. Kim K, Che T, Panova O, et al. Structure of a Hallucinogen-Activated Gq-Coupled 5-HT2A\nSerotonin Receptor. Cell. 2020;182(6):1574-1588.e19. doi:10.1016/j.cell.2020.08.024\n\n30. Burford NT, Traynor JR, Alt A. Positive allosteric modulators of the \u03bc-opioid receptor: A\nnovel approach for future pain medications. Br J Pharmacol. 2015;172(2):277-286.  doi:10.1111/bph.12599\n\n31. Christopoulos A. Allosteric binding sites on cell-surface receptors: Novel targets for drug\ndiscovery. Nat Rev Drug Discov. 2002;1(3):198-210. doi:10.1038/nrd746\n\n32. van Aalst E, Wylie BJ. Cholesterol Is a Dose-Dependent Positive Allosteric Modulator of\nCCR3 Ligand Affinity and G Protein Coupling. Front Mol Biosci. 2021;8(August):1-14. \n157\ndoi:10.3389/fmolb.2021.724603\n\n33. Chen Y, Nong Y, Goudet C, et al. Interaction of novel positive allosteric modulators of\nmetabotropic glutamate receptor 5 with the negative allosteric antagonist site is required for\npotentiation of receptor responses. Mol Pharmacol. 2007;71(5):1389-1398.\ndoi:10.1124/mol.106.032425\n\n34. Koole C, Wootten D, Simms J, et al. Allosteric ligands of the glucagon-like peptide 1\nreceptor (GLP-1R) differentially modulate endogenous and exogenous peptide responses in\na pathway-selective manner: Implications for drug screening. Mol Pharmacol.\n2010;78(3):456-465. doi:10.1124/mol.110.065664\n\n35. Abdel-Magid AF. Allosteric Modulators: An Emerging Concept in Drug Discovery. ACS\nMed Chem Lett. 2015;6(2):104-107. doi:10.1021/ml5005365\n\n36. Wood MR, Hopkins CR, Brogan JT, Je P, Lindsley CW. \u201c Molecular Switches \u201d on mGluR\nAllosteric Ligands That Modulate Modes of Pharmacology. Published online 2011:2403-\n2410. doi:10.1021/bi200129s\n\n37. L\u00f3pez-Rodr\u00edguez ML, Benham\u00fa B, V\u00e1zquez-Villa H. Allosteric Modulators Targeting\nGPCRs.; 2019. doi:10.1016/B978-0-12-816228-6.00011-8\n\n38. Han Y, Shang Y, Herbst JJ, Connell JO. Positive Allosteric Modulators of the \u03b4 -Opioid\nReceptor. J Med Chem. 2016;58(10):4220-4229.\ndoi:10.1021/acs.jmedchem.5b00007.Notes\n\n39. Kenakin T, Strachan RT. PAM-Antagonists: A Better Way to Block Pathological Receptor\nSignaling? Trends Pharmacol Sci. 2018;39(8):748-765. doi:10.1016/j.tips.2018.05.001\n158\n\n40.", "start_char_idx": 205712, "end_char_idx": 208428, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1b2c36f0-72ab-459a-9055-d5d7c9a274ce": {"__data__": {"id_": "1b2c36f0-72ab-459a-9055-d5d7c9a274ce", "embedding": null, "metadata": {"file_path": "data/brandt-no-intro.txt", "file_name": "brandt-no-intro.txt", "file_type": "text/plain", "file_size": 239829, "creation_date": "2023-12-31", "last_modified_date": "2023-12-31", "last_accessed_date": "2023-12-31"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "a0eaa9a5-aece-426b-8f20-580de8fb9f35", "node_type": "4", "metadata": {"file_path": "data/brandt-no-intro.txt", "file_name": "brandt-no-intro.txt", "file_type": "text/plain", "file_size": 239829, "creation_date": "2023-12-31", "last_modified_date": "2023-12-31", "last_accessed_date": "2023-12-31"}, "hash": "76e194b2637b440a1b1cdf5698cae061524bb4d7a3b73dfc2ba71d268a3f7019", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "103b97df-d755-4b63-be76-6840ec16cfa1", "node_type": "1", "metadata": {"file_path": "data/brandt-no-intro.txt", "file_name": "brandt-no-intro.txt", "file_type": "text/plain", "file_size": 239829, "creation_date": "2023-12-31", "last_modified_date": "2023-12-31", "last_accessed_date": "2023-12-31"}, "hash": "97fc20a5f71a1f202dc83b428922d087684cfe6ed6fbc6c7195ccbda685023a0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "35200c13-4f4a-497c-bee7-7d7d8d9589c5", "node_type": "1", "metadata": {}, "hash": "69937b3deb10ee3b8873f92d283162b344f0f4e28c1c7d78f9f5774b94e13d92", "class_name": "RelatedNodeInfo"}}, "hash": "b3a065ddbb3beafd99aa9ffd8903ffcfe16e10f3145bd68f196a73e1d68f8fc3", "text": "; 2019. doi:10.1016/B978-0-12-816228-6.00011-8\n\n38. Han Y, Shang Y, Herbst JJ, Connell JO. Positive Allosteric Modulators of the \u03b4 -Opioid\nReceptor. J Med Chem. 2016;58(10):4220-4229.\ndoi:10.1021/acs.jmedchem.5b00007.Notes\n\n39. Kenakin T, Strachan RT. PAM-Antagonists: A Better Way to Block Pathological Receptor\nSignaling? Trends Pharmacol Sci. 2018;39(8):748-765. doi:10.1016/j.tips.2018.05.001\n158\n\n40. Wu Y, Tong J, Ding K, Zhou Q, Zhao S. GPCR Allosteric Modulator Discovery. Vol 1163.;\n2019. doi:10.1007/978-981-13-8719-7_10\n\n41. Zou S, Kumar U. Cannabinoid receptors and the endocannabinoid system: Signaling and\nfunction in the central nervous system. Int J Mol Sci. 2018;19(3).\ndoi:10.3390/ijms19030833\n\n42. Kim J, Alger BE. Reduction in endocannabinoid tone is a homeostatic mechanism for\nspecific inhibitory synapses. Nat Neurosci. 2010;13(5):592-600. doi:10.1038/nn.2517\n\n43. Navarrete F, Garc\u00eda-Guti\u00e9rrez MS, Jurado-Barba R, et al. Endocannabinoid System\nComponents as Potential Biomarkers in Psychiatry. Front Psychiatry. 2020;11(April):1-30.\ndoi:10.3389/fpsyt.2020.00315\n\n44. Trexler KR, Trexler KR, Virginia W. Acute and Repeated Effects of Synthetic Cannabinoid\nAgonism and Cannabinoid Receptor 1 Positive Allosteric Modulation and Cannabinoid\nReceptor 1 Positive Allosteric Modulation Department of Psychology. Published online\n2019.\n\n45. Volkow ND, Hampson AJ, Baler RD. Don\u2019t Worry, Be Happy: Endocannabinoids and\nCannabis at the Intersection of Stress and Reward. Annu Rev Pharmacol Toxicol.\n2017;57(June 2016):285-308. doi:10.1146/annurev-pharmtox-010716-104615\n\n46. Wang X, Liu D, Shen L, et al. A Genetically Encoded F-19 NMR Probe Reveals the\nAllosteric Modulation Mechanism of Cannabinoid Receptor 1. J Am Chem Soc.\n2021;143(40):16320-16325. doi:10.1021/jacs.1c06847\n\n47. Shao Z, Yan W, Chapman K, et al. Structure of an allosteric modulator bound to the CB1 \n159\ncannabinoid receptor. Nat Chem Biol. 2019;15(12):1199-1205. doi:10.1038/s41589-019-\n0387-2\n\n48. Hua T, Vemuri K, Nikas SP, et al. Crystal structures of agonist-bound human cannabinoid\nreceptor CB 1. Nature. 2017;547(7664):468-471. doi:10.1038/nature23272\n\n49. Shao Z, Yin J, Chapman K, et al. High-resolution crystal structure of the human CB1\ncannabinoid receptor. Nature. 2016;540(7634):602-606. doi:10.1038/nature20613\n\n50. Hua T, Li X, Wu L, et al. Activation and Signaling Mechanism Revealed by Cannabinoid\nReceptor-Gi Complex Structures. Cell. 2020;180(4):655-665.e18.\ndoi:10.1016/j.cell.2020.01.008\n\n51. Krishna Kumar K, Shalev-Benami M, Robertson MJ, et al. Structure of a Signaling\nCannabinoid Receptor 1-G Protein Complex. Cell. 2019;176(3):448-458.e12.\ndoi:10.1016/j.cell.2018.11.040\n\n52.", "start_char_idx": 208023, "end_char_idx": 210712, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "35200c13-4f4a-497c-bee7-7d7d8d9589c5": {"__data__": {"id_": "35200c13-4f4a-497c-bee7-7d7d8d9589c5", "embedding": null, "metadata": {"file_path": "data/brandt-no-intro.txt", "file_name": "brandt-no-intro.txt", "file_type": "text/plain", "file_size": 239829, "creation_date": "2023-12-31", "last_modified_date": "2023-12-31", "last_accessed_date": "2023-12-31"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "a0eaa9a5-aece-426b-8f20-580de8fb9f35", "node_type": "4", "metadata": {"file_path": "data/brandt-no-intro.txt", "file_name": "brandt-no-intro.txt", "file_type": "text/plain", "file_size": 239829, "creation_date": "2023-12-31", "last_modified_date": "2023-12-31", "last_accessed_date": "2023-12-31"}, "hash": "76e194b2637b440a1b1cdf5698cae061524bb4d7a3b73dfc2ba71d268a3f7019", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1b2c36f0-72ab-459a-9055-d5d7c9a274ce", "node_type": "1", "metadata": {"file_path": "data/brandt-no-intro.txt", "file_name": "brandt-no-intro.txt", "file_type": "text/plain", "file_size": 239829, "creation_date": "2023-12-31", "last_modified_date": "2023-12-31", "last_accessed_date": "2023-12-31"}, "hash": "b3a065ddbb3beafd99aa9ffd8903ffcfe16e10f3145bd68f196a73e1d68f8fc3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "33c809d4-e77c-4603-bbd3-66a70bc6bf47", "node_type": "1", "metadata": {}, "hash": "b3fc0d3077f054a8c91d83944762512ae57542865b93f8992e008f951963c5c5", "class_name": "RelatedNodeInfo"}}, "hash": "69937b3deb10ee3b8873f92d283162b344f0f4e28c1c7d78f9f5774b94e13d92", "text": "High-resolution crystal structure of the human CB1\ncannabinoid receptor. Nature. 2016;540(7634):602-606. doi:10.1038/nature20613\n\n50. Hua T, Li X, Wu L, et al. Activation and Signaling Mechanism Revealed by Cannabinoid\nReceptor-Gi Complex Structures. Cell. 2020;180(4):655-665.e18.\ndoi:10.1016/j.cell.2020.01.008\n\n51. Krishna Kumar K, Shalev-Benami M, Robertson MJ, et al. Structure of a Signaling\nCannabinoid Receptor 1-G Protein Complex. Cell. 2019;176(3):448-458.e12.\ndoi:10.1016/j.cell.2018.11.040\n\n52. Andrzejewska A, Staszak K, Kaczmarek-Ry\u015b M, S\u0142omski R, Hryhorowicz S.\nUnderstanding cannabinoid receptors: structure and function. Folia Biol Oecologica.\n2018;14:1-13. doi:10.1515/fobio-2017-0004\n\n53. Nebane NM, Kellie B, Song ZH. The effects of charge-neutralizing mutation D6.30N on\nthe functions of CB1 and CB2 cannabinoid receptors. FEBS Lett. 2006;580(22):5392-5398.\ndoi:10.1016/j.febslet.2006.09.001\n\n54. Kapur A, Hurst DP, Fleischer D, et al. Mutation studies of Ser7.39 and Ser2.60 in the human\nCB1 cannabinoid receptor: Evidence for a serine-induced bend in CB1 transmembrane helix\n7. Mol Pharmacol. 2007;71(6):1512-1524. doi:10.1124/mol.107.034645\n160\n\n55. Lafaye G, Karila L, Blecha L, Benyamina A. Cannabis, cannabinoids, and health. Dialogues\nClin Neurosci. 2017;19(3):309-316. doi:10.31887/dcns.2017.19.3/glafaye\n\n56. Marcu J, Console-Bram L, Abood ME. Current cannabinoid receptor nomenclature and\npharmacological principles. Endocannabinoid Regul Monoamines Psychiatr Neurol\nDisord. Published online 2013:25-54. doi:10.1007/978-1-4614-7940-6_3\n\n57. Brutlag A, Hommerding H. Toxicology of Marijuana, Synthetic Cannabinoids, and\nCannabidiol in Dogs and Cats. Vet Clin North Am - Small Anim Pract. 2018;48(6):1087-\n1102. doi:10.1016/j.cvsm.2018.07.008\n\n58. Yu H, Liu X, Chen B, et al. The neuroprotective effects of the cb2 agonist gw842166x in\nthe 6-ohda mouse model of parkinson\u2019s disease. Cells. 2021;10(12):1-17.\ndoi:10.3390/cells10123548\n\n59. Xing C, Zhuang Y, Xu TH, et al. Cryo-EM Structure of the Human Cannabinoid Receptor\nCB2-Gi Signaling Complex. Cell. 2020;180(4):645-654.e13.\ndoi:10.1016/j.cell.2020.01.007\n\n60. Cabral GA, Griffin-Thomas LT. Emerging role of the cannabinoid receptor CB 2 in immune\nregulation: Therapeutic prospects for neuroinflammation. Expert Rev Mol Med.\n2009;11(804):1-31. doi:10.1017/S1462399409000957\n\n61. Li X, Hua T, Vemuri K, et al. Crystal Structure of the Human Cannabinoid Receptor CB2.\nCell. 2019;176(3):459-467.e13. doi:10.1016/j.cell.2018.12.011\n\n62. Millan MJ, Marin P, Bockaert J, Mannoury la Cour C. Signaling at G-protein-coupled\nserotonin receptors: recent advances and future research directions. Trends Pharmacol Sci.", "start_char_idx": 210206, "end_char_idx": 212896, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "33c809d4-e77c-4603-bbd3-66a70bc6bf47": {"__data__": {"id_": "33c809d4-e77c-4603-bbd3-66a70bc6bf47", "embedding": null, "metadata": {"file_path": "data/brandt-no-intro.txt", "file_name": "brandt-no-intro.txt", "file_type": "text/plain", "file_size": 239829, "creation_date": "2023-12-31", "last_modified_date": "2023-12-31", "last_accessed_date": "2023-12-31"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "a0eaa9a5-aece-426b-8f20-580de8fb9f35", "node_type": "4", "metadata": {"file_path": "data/brandt-no-intro.txt", "file_name": "brandt-no-intro.txt", "file_type": "text/plain", "file_size": 239829, "creation_date": "2023-12-31", "last_modified_date": "2023-12-31", "last_accessed_date": "2023-12-31"}, "hash": "76e194b2637b440a1b1cdf5698cae061524bb4d7a3b73dfc2ba71d268a3f7019", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "35200c13-4f4a-497c-bee7-7d7d8d9589c5", "node_type": "1", "metadata": {"file_path": "data/brandt-no-intro.txt", "file_name": "brandt-no-intro.txt", "file_type": "text/plain", "file_size": 239829, "creation_date": "2023-12-31", "last_modified_date": "2023-12-31", "last_accessed_date": "2023-12-31"}, "hash": "69937b3deb10ee3b8873f92d283162b344f0f4e28c1c7d78f9f5774b94e13d92", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a9ca6388-e41e-42cb-ad1c-999e850932ab", "node_type": "1", "metadata": {}, "hash": "1187b11ee427428b7fe01266d4b8cbc0d04013a2a0bba4e228605435ac4774e5", "class_name": "RelatedNodeInfo"}}, "hash": "b3fc0d3077f054a8c91d83944762512ae57542865b93f8992e008f951963c5c5", "text": "Cabral GA, Griffin-Thomas LT. Emerging role of the cannabinoid receptor CB 2 in immune\nregulation: Therapeutic prospects for neuroinflammation. Expert Rev Mol Med.\n2009;11(804):1-31. doi:10.1017/S1462399409000957\n\n61. Li X, Hua T, Vemuri K, et al. Crystal Structure of the Human Cannabinoid Receptor CB2.\nCell. 2019;176(3):459-467.e13. doi:10.1016/j.cell.2018.12.011\n\n62. Millan MJ, Marin P, Bockaert J, Mannoury la Cour C. Signaling at G-protein-coupled\nserotonin receptors: recent advances and future research directions. Trends Pharmacol Sci. \n161\n2008;29(9):454-464. doi:10.1016/j.tips.2008.06.007\n\n63. Chi T, Gold JA. A review of emerging therapeutic potential of psychedelic drugs in the\ntreatment of psychiatric illnesses. J Neurol Sci. 2020;411(November 2019):116715.\ndoi:10.1016/j.jns.2020.116715\n\n64. Kelmendi B, Kaye AP, Pittenger C, Kwan AC. Psychedelics. Curr Biol. 2022;32(2):R63-\nR67. doi:10.1016/j.cub.2021.12.009\n\n65. Pompeiano M, Palacios JM, Mengod G. Distribution of the serotonin 5-HT2 receptor family\nmRNAs: comparison between 5-HT2A and 5-HT2C receptors. Mol Brain Res. 1994;23(1-\n2):163-178. doi:10.1016/0169-328X(94)90223-2\n\n66. Vollenweider FX, Vollenweider-Scherpenhuyzen MFI, B\u00e4bler A, Vogel H, Hell D.\nPsilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action.\nNeuroreport. 1998;9(17):3897-3902. doi:10.1097/00001756-199812010-00024\n\n67. Halberstadt AL, Nichols DE, Vollenweider FX. Behavioral Neurobiology of Psychedelic\nDrugs. Vol 2.; 2017. http://www.springer.com/series/7854\n\n68. Braden MR, Nichols DE. Assessment of the roles of serines 5.43(239) and 5.46(242) for\nbinding and potency of agonist ligands at the human serotonin 5-HT2A receptor. Mol\nPharmacol. 2007;72(5):1200-1209. doi:10.1124/mol.107.039255\n\n69. Dong C, Ly C, Dunlap LE, et al. Psychedelic-inspired drug discovery using an engineered\nbiosensor. Cell. 2021;184(10):2779-2792.e18. doi:10.1016/j.cell.2021.03.043\n\n70. Cao D, Yu J, Wang H, et al. Structure-based discovery of nonhallucinogenic psychedelic\nanalogs. Science (80- ). 2022;375(6579):403-411. doi:10.1126/science.abl8615\n162\n\n71. Wacker D, Wang S, McCorvy JD, et al. Crystal Structure of an LSD-Bound Human\nSerotonin Receptor. Cell. 2017;168(3):377-389.e12. doi:10.1016/j.cell.2016.12.033\n\n72. Sliwoski G, Kothiwale S, Meiler J, Lowe EW. Computational methods in drug discovery.\nPharmacol Rev. 2014;66(1):334-395. doi:10.1124/pr.112.007336\n\n73. Rasmussen SGF, Choi HJ, Rosenbaum DM, et al. Crystal structure of the human \u03b22\nadrenergic G-protein-coupled receptor. Nature. 2007;450(7168):383-387.\ndoi:10.1038/nature06325\n\n74. Palczewski K, Kumasaka T, Hori T, et al.", "start_char_idx": 212351, "end_char_idx": 215007, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a9ca6388-e41e-42cb-ad1c-999e850932ab": {"__data__": {"id_": "a9ca6388-e41e-42cb-ad1c-999e850932ab", "embedding": null, "metadata": {"file_path": "data/brandt-no-intro.txt", "file_name": "brandt-no-intro.txt", "file_type": "text/plain", "file_size": 239829, "creation_date": "2023-12-31", "last_modified_date": "2023-12-31", "last_accessed_date": "2023-12-31"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "a0eaa9a5-aece-426b-8f20-580de8fb9f35", "node_type": "4", "metadata": {"file_path": "data/brandt-no-intro.txt", "file_name": "brandt-no-intro.txt", "file_type": "text/plain", "file_size": 239829, "creation_date": "2023-12-31", "last_modified_date": "2023-12-31", "last_accessed_date": "2023-12-31"}, "hash": "76e194b2637b440a1b1cdf5698cae061524bb4d7a3b73dfc2ba71d268a3f7019", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "33c809d4-e77c-4603-bbd3-66a70bc6bf47", "node_type": "1", "metadata": {"file_path": "data/brandt-no-intro.txt", "file_name": "brandt-no-intro.txt", "file_type": "text/plain", "file_size": 239829, "creation_date": "2023-12-31", "last_modified_date": "2023-12-31", "last_accessed_date": "2023-12-31"}, "hash": "b3fc0d3077f054a8c91d83944762512ae57542865b93f8992e008f951963c5c5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d6246a73-1943-481a-ab8e-2b9661c18fb2", "node_type": "1", "metadata": {}, "hash": "02138b2110fb2d295ad8b249707f3d9eba31f8b34e6ce7994b927da475c49494", "class_name": "RelatedNodeInfo"}}, "hash": "1187b11ee427428b7fe01266d4b8cbc0d04013a2a0bba4e228605435ac4774e5", "text": "Crystal Structure of an LSD-Bound Human\nSerotonin Receptor. Cell. 2017;168(3):377-389.e12. doi:10.1016/j.cell.2016.12.033\n\n72. Sliwoski G, Kothiwale S, Meiler J, Lowe EW. Computational methods in drug discovery.\nPharmacol Rev. 2014;66(1):334-395. doi:10.1124/pr.112.007336\n\n73. Rasmussen SGF, Choi HJ, Rosenbaum DM, et al. Crystal structure of the human \u03b22\nadrenergic G-protein-coupled receptor. Nature. 2007;450(7168):383-387.\ndoi:10.1038/nature06325\n\n74. Palczewski K, Kumasaka T, Hori T, et al. Crystal structure of rhodopsin: A G proteincoupled receptor. Science (80- ). 2000;289(5480):739-745.\ndoi:10.1126/science.289.5480.739\n\n75. Singh KD, Karnik SS. Current Trends in GPCR Allostery. J Membr Biol. 2021;254(3):293-\n300. doi:10.1007/s00232-020-00167-6\n\n76. Lu D, Immadi SS, Wu Z, Kendall DA. Translational potential of allosteric modulators\ntargeting the cannabinoid CB 1 receptor. Acta Pharmacol Sin. 2019;40(3):324-335.\ndoi:10.1038/s41401-018-0164-x\n\n77. Alaverdashvili M, Laprairie RB, Alaverdashvili M, Laprairie RB. The future of type 1\ncannabinoid receptor allosteric ligands. Drug Metab Rev. 2018;0(0):14-25.\ndoi:10.1080/03602532.2018.1428341\n\n78. Ahn KH, Mahmoud MM, Kendall DA. Allosteric modulator ORG27569 induces CB1\ncannabinoid receptor high affinity agonist binding state, receptor internalization, and Gi\nprotein-independent ERK1/2 kinase activation. J Biol Chem. 2012;287(15):12070-12082. \n163\ndoi:10.1074/jbc.M111.316463\n\n79. Robert B. Laprairie, Abhijit R. Kulkarni, Pushkar M. Kulkarni, Dow P. Hurst, Diane Lynch,\nPatricia H. Reggio, David R. Janero, Roger G. Pertwee LA, Stevenson, Melanie E. M.\nKelly, Eileen M. Denovan-Wrigh and GAT. Mapping Cannabinoid 1 Receptor Allosteric\nSite(s): Critical Molecular Determinant and Signaling Profile of GAT100, a Novel, Potent,\nand Irreversibly Binding Probe. Vol 176.; 2016.\ndoi:10.1021/acschemneuro.6b00041.Mapping\n\n80. Weichert D, Gmeiner P. Covalent Molecular Probes for Class A G Protein-Coupled\nReceptors: Advances and Applications. ACS Chem Biol. 2015;10(6):1376-1386.\ndoi:10.1021/acschembio.5b00070\n\n81. Laprairie RB, Bagher AM, Rourke JL, et al. Positive allosteric modulation of the type 1\ncannabinoid receptor reduces the signs and symptoms of Huntington\u2019s disease in the R6/2\nmouse model. Neuropharmacology. 2019;151(May 2018):1-12.\ndoi:10.1016/j.neuropharm.2019.03.033\n\n82. Laprairie RB, Kulkarni PM, Deschamps JR, et al. Enantiospecific Allosteric Modulation of\nCannabinoid 1 Receptor. ACS Chem Neurosci. 2017;8(6):1188-1203.\ndoi:10.1021/acschemneuro.6b00310\n\n83. Hurst DP, Garai S, Kulkarni PM, Schaffer PC, Reggio PH, Thakur GA. Identification of\ncb1 receptor allosteric sites using force-biased mmc simulated annealing and validation by\nstructure-activity relationship studies.", "start_char_idx": 214510, "end_char_idx": 217271, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d6246a73-1943-481a-ab8e-2b9661c18fb2": {"__data__": {"id_": "d6246a73-1943-481a-ab8e-2b9661c18fb2", "embedding": null, "metadata": {"file_path": "data/brandt-no-intro.txt", "file_name": "brandt-no-intro.txt", "file_type": "text/plain", "file_size": 239829, "creation_date": "2023-12-31", "last_modified_date": "2023-12-31", "last_accessed_date": "2023-12-31"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "a0eaa9a5-aece-426b-8f20-580de8fb9f35", "node_type": "4", "metadata": {"file_path": "data/brandt-no-intro.txt", "file_name": "brandt-no-intro.txt", "file_type": "text/plain", "file_size": 239829, "creation_date": "2023-12-31", "last_modified_date": "2023-12-31", "last_accessed_date": "2023-12-31"}, "hash": "76e194b2637b440a1b1cdf5698cae061524bb4d7a3b73dfc2ba71d268a3f7019", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a9ca6388-e41e-42cb-ad1c-999e850932ab", "node_type": "1", "metadata": {"file_path": "data/brandt-no-intro.txt", "file_name": "brandt-no-intro.txt", "file_type": "text/plain", "file_size": 239829, "creation_date": "2023-12-31", "last_modified_date": "2023-12-31", "last_accessed_date": "2023-12-31"}, "hash": "1187b11ee427428b7fe01266d4b8cbc0d04013a2a0bba4e228605435ac4774e5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3204607e-e603-476d-8c50-1aae82cb447c", "node_type": "1", "metadata": {}, "hash": "41d7d72e1730d13762d4349509a21adbcf2b87781f647d5d271e6d7f5ab1d966", "class_name": "RelatedNodeInfo"}}, "hash": "02138b2110fb2d295ad8b249707f3d9eba31f8b34e6ce7994b927da475c49494", "text": "Neuropharmacology. 2019;151(May 2018):1-12.\ndoi:10.1016/j.neuropharm.2019.03.033\n\n82. Laprairie RB, Kulkarni PM, Deschamps JR, et al. Enantiospecific Allosteric Modulation of\nCannabinoid 1 Receptor. ACS Chem Neurosci. 2017;8(6):1188-1203.\ndoi:10.1021/acschemneuro.6b00310\n\n83. Hurst DP, Garai S, Kulkarni PM, Schaffer PC, Reggio PH, Thakur GA. Identification of\ncb1 receptor allosteric sites using force-biased mmc simulated annealing and validation by\nstructure-activity relationship studies. ACS Med Chem Lett. 2019;10(8):1216-1221.\ndoi:10.1021/acsmedchemlett.9b00256\n\n84. Mouslech Z, Valla V. Endocannabinoid system: An overview of its potential in current \n164\nmedical practice. Neuroendocrinol Lett. 2009;30(2):153-179.\n\n85. Of S, Neurobiological THE, Involved M, The IN, Eating DOF, Disorders A. Study of the\nneurobiological mechanisms involved in the development of eating and addictive disorders.\nPublished online 2017.\n86. Sallaberry CA, Astern L. The Endocannabinoid System, Our Universal Regulator. J Young\nInvestig. 2018;34(6):48-55. doi:10.22186/jyi.34.5.48-55\n87. Bissantz C, Logean A, Rognan D. High-throughput modeling of human g-protein coupled\nreceptors: Amino acid sequence alignment, three-dimensional model building, and receptor\nlibrary screening. J Chem Inf Comput Sci. 2004;44(3):1162-1176. doi:10.1021/ci034181a\n88. Kruk-Slomka M, Banaszkiewicz I, Biala G. The Impact of CB2 Receptor Ligands on the\nMK-801-Induced Hyperactivity in Mice. Neurotox Res. 2017;31(3):410-420.\ndoi:10.1007/s12640-017-9702-4\n89. Hillard CJ. Circulating Endocannabinoids: From Whence Do They Come and Where are\nThey Going? Neuropsychopharmacology. 2018;43(1):155-172. doi:10.1038/npp.2017.130\n90. McDougle DR, Kambalyal A, Meling DD, Das A. Endocannabinoids anandamide and 2-\narachidonoylglycerol are substrates for human CYP2J2 epoxygenase. J Pharmacol Exp\nTher. 2014;351(3):616-627. doi:10.1124/jpet.114.216598\n91. Scotter EL, Abood ME, Glass M. The endocannabinoid system as a target for the treatment\nof neurodegenerative disease. Br J Pharmacol. 2010;160(3):480-498. doi:10.1111/j.1476-\n5381.2010.00735.x\n92. Kulkarni AR, Garai S, Janero DR, Thakur GA. Design and Synthesis of Cannabinoid 1 \n165\nReceptor ( CB1R ) Allosteric Modulators\u202f: Drug Discovery Applications. Vol 593. 1st ed.\nElsevier Inc.; 2017. doi:10.1016/bs.mie.2017.06.018\n93. Greig IR, Baillie GL, Abdelrahman M, Trembleau L, Ross RA. Bioorganic & Medicinal\nChemistry Letters Development of indole sulfonamides as cannabinoid receptor negative\nallosteric modulators. Bioorg Med Chem Lett. 2016;26(18):4403-4407.\ndoi:10.1016/j.bmcl.2016.08.018\n94. Garai S, Kulkarni PM, Schaffer PC, et al.", "start_char_idx": 216778, "end_char_idx": 219435, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3204607e-e603-476d-8c50-1aae82cb447c": {"__data__": {"id_": "3204607e-e603-476d-8c50-1aae82cb447c", "embedding": null, "metadata": {"file_path": "data/brandt-no-intro.txt", "file_name": "brandt-no-intro.txt", "file_type": "text/plain", "file_size": 239829, "creation_date": "2023-12-31", "last_modified_date": "2023-12-31", "last_accessed_date": "2023-12-31"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "a0eaa9a5-aece-426b-8f20-580de8fb9f35", "node_type": "4", "metadata": {"file_path": "data/brandt-no-intro.txt", "file_name": "brandt-no-intro.txt", "file_type": "text/plain", "file_size": 239829, "creation_date": "2023-12-31", "last_modified_date": "2023-12-31", "last_accessed_date": "2023-12-31"}, "hash": "76e194b2637b440a1b1cdf5698cae061524bb4d7a3b73dfc2ba71d268a3f7019", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d6246a73-1943-481a-ab8e-2b9661c18fb2", "node_type": "1", "metadata": {"file_path": "data/brandt-no-intro.txt", "file_name": "brandt-no-intro.txt", "file_type": "text/plain", "file_size": 239829, "creation_date": "2023-12-31", "last_modified_date": "2023-12-31", "last_accessed_date": "2023-12-31"}, "hash": "02138b2110fb2d295ad8b249707f3d9eba31f8b34e6ce7994b927da475c49494", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c69f5e0b-ea37-4df0-a15e-cd12c78a34da", "node_type": "1", "metadata": {}, "hash": "a5f9cfdb662a017f22b4bb57c86680bce900f1290288e8ca9f94306fbe1047fb", "class_name": "RelatedNodeInfo"}}, "hash": "41d7d72e1730d13762d4349509a21adbcf2b87781f647d5d271e6d7f5ab1d966", "text": "Design and Synthesis of Cannabinoid 1 \n165\nReceptor ( CB1R ) Allosteric Modulators\u202f: Drug Discovery Applications. Vol 593. 1st ed.\nElsevier Inc.; 2017. doi:10.1016/bs.mie.2017.06.018\n93. Greig IR, Baillie GL, Abdelrahman M, Trembleau L, Ross RA. Bioorganic & Medicinal\nChemistry Letters Development of indole sulfonamides as cannabinoid receptor negative\nallosteric modulators. Bioorg Med Chem Lett. 2016;26(18):4403-4407.\ndoi:10.1016/j.bmcl.2016.08.018\n94. Garai S, Kulkarni PM, Schaffer PC, et al. Application of Fluorine- And Nitrogen-Walk\nApproaches: Defining the Structural and Functional Diversity of 2-Phenylindole Class of\nCannabinoid 1 Receptor Positive Allosteric Modulators. J Med Chem. 2020;63(2):542-568.\ndoi:10.1021/acs.jmedchem.9b01142\n95. Garai S, Kulkarni PM, Schaffer PC, et al. Application of Fluorine- And Nitrogen-Walk\nApproaches: Defining the Structural and Functional Diversity of 2-Phenylindole Class of\nCannabinoid 1 Receptor Positive Allosteric Modulators. J Med Chem. 2020;63(2).\ndoi:10.1021/acs.jmedchem.9b01142\n96. Roebuck AJ, Greba Q, Smolyakova AM, et al. Positive allosteric modulation of type 1\ncannabinoid receptors reduces spike-and-wave discharges in Genetic Absence Epilepsy\nRats from Strasbourg. Neuropharmacology. 2021;190(January):108553.\ndoi:10.1016/j.neuropharm.2021.108553\n97. Roebuck AJ, Greba Q, Onofrychuk TJ, et al. Dissociable changes in spike and wave\ndischarges following exposure to injected cannabinoids and smoked cannabis in Genetic\nAbsence Epilepsy Rats from Strasbourg. Eur J Neurosci. 2020;(December 2020):1-16.\ndoi:10.1111/ejn.15096\n166\n98. Price MR, Baillie GL, Thomas A, et al. Allosteric modulation of the Cannabinoid CB1\nreceptor. Mol Pharmacol. 2005;68(5):1484-1495. doi:10.1124/mol.105.016162\n99. Vigolo A, Ossato A, Trapella C, et al. Novel halogenated derivates of JWH-018: Behavioral\nand binding studies in mice. Neuropharmacology. 2015;95:68-82.\ndoi:10.1016/j.neuropharm.2015.02.008\n100. Kilkenny C, Browne WJ, Cuthill IC, Emerson M, Altman DG. Improving bioscience\nresearch reporting: The arrive guidelines for reporting animal research. PLoS Biol.\n2010;8(6):6-10. doi:10.1371/journal.pbio.1000412\n101. Spartan\u201918 Parallel Suite. Published online 2018.\n102. Schr\u00f6dinger Release 2018. Published online 2018.\n103. Shim JY, Bertalovitz AC, Kendall DA. Identification of essential cannabinoid-binding\ndomains: Structural insights into early dynamic events in receptor activation. J Biol Chem.\n2011;286(38):33422-33435. doi:10.1074/jbc.M111.261651\n104. Fiser A, Sali A. ModLoop: Automated modeling of loops in protein structures.\nBioinformatics. 2003;19(18):2500-2501. doi:10.1093/bioinformatics/btg362\n105. Marcu J, Shore DM, Kapur A, et al. Novel insights into CB1 cannabinoid receptor signaling:\nA key interaction identified between the extracellular-3 loop and transmembrane helix 2. J\nPharmacol Exp Ther.", "start_char_idx": 218936, "end_char_idx": 221809, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c69f5e0b-ea37-4df0-a15e-cd12c78a34da": {"__data__": {"id_": "c69f5e0b-ea37-4df0-a15e-cd12c78a34da", "embedding": null, "metadata": {"file_path": "data/brandt-no-intro.txt", "file_name": "brandt-no-intro.txt", "file_type": "text/plain", "file_size": 239829, "creation_date": "2023-12-31", "last_modified_date": "2023-12-31", "last_accessed_date": "2023-12-31"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "a0eaa9a5-aece-426b-8f20-580de8fb9f35", "node_type": "4", "metadata": {"file_path": "data/brandt-no-intro.txt", "file_name": "brandt-no-intro.txt", "file_type": "text/plain", "file_size": 239829, "creation_date": "2023-12-31", "last_modified_date": "2023-12-31", "last_accessed_date": "2023-12-31"}, "hash": "76e194b2637b440a1b1cdf5698cae061524bb4d7a3b73dfc2ba71d268a3f7019", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3204607e-e603-476d-8c50-1aae82cb447c", "node_type": "1", "metadata": {"file_path": "data/brandt-no-intro.txt", "file_name": "brandt-no-intro.txt", "file_type": "text/plain", "file_size": 239829, "creation_date": "2023-12-31", "last_modified_date": "2023-12-31", "last_accessed_date": "2023-12-31"}, "hash": "41d7d72e1730d13762d4349509a21adbcf2b87781f647d5d271e6d7f5ab1d966", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "13e0d659-a453-41be-a5b9-0ba7ffe4dae8", "node_type": "1", "metadata": {}, "hash": "b2c0d54fc9d7465ff513c16c6adb0098c9227a452f9cd33024362fc7e86b0fc5", "class_name": "RelatedNodeInfo"}}, "hash": "a5f9cfdb662a017f22b4bb57c86680bce900f1290288e8ca9f94306fbe1047fb", "text": "102. Schr\u00f6dinger Release 2018. Published online 2018.\n103. Shim JY, Bertalovitz AC, Kendall DA. Identification of essential cannabinoid-binding\ndomains: Structural insights into early dynamic events in receptor activation. J Biol Chem.\n2011;286(38):33422-33435. doi:10.1074/jbc.M111.261651\n104. Fiser A, Sali A. ModLoop: Automated modeling of loops in protein structures.\nBioinformatics. 2003;19(18):2500-2501. doi:10.1093/bioinformatics/btg362\n105. Marcu J, Shore DM, Kapur A, et al. Novel insights into CB1 cannabinoid receptor signaling:\nA key interaction identified between the extracellular-3 loop and transmembrane helix 2. J\nPharmacol Exp Ther. 2013;345(2):189-197. doi:10.1124/jpet.112.201046\n106. Fay JF, Farrens DL. The membrane proximal region of the cannabinoid receptor CB1 Nterminus can allosterically modulate ligand affinity. Biochemistry. 2013;52(46):8286-8294.\ndoi:10.1021/bi400842k\n167\n107. Fay JF, Farrens DL. Structural dynamics and energetics underlying allosteric inactivation\nof the cannabinoid receptor CB1. Proc Natl Acad Sci U S A. 2015;112(27):8469-8474.\ndoi:10.1073/pnas.1500895112\n108. Garai S, Leo LM, Szczesniak AM, et al. Discovery of a Biased Allosteric Modulator for\nCannabinoid 1 Receptor: Preclinical Anti-Glaucoma Efficacy (). J Med Chem.\n2021;64(12):8104-8126. doi:10.1021/acs.jmedchem.1c00040\n109. Song ZH, Bonner TI. A lysine residue of the cannabinoid receptor is critical for receptor\nrecognition by several agonists but not WIN55212-2. Mol Pharmacol. 1996;49(5):891-896.\n110. Stahl EL, Zhou L, Ehlert FJ, Bohn LM. A novel method for analyzing extremely biased\nagonism at G protein-coupled receptors. Mol Pharmacol. 2015;87(5):866-877.\ndoi:10.1124/mol.114.096503\n111. Article C. An operational model of pharmacological agonism\u202f: the effect of E /[ A ] curve\nshape on agonist dissociation constant estimation. 2010;160. doi:10.1111/j.1476-\n5381.2010.00855.x\n112. Kenakin T, Watson C, Muniz-Medina V, Christopoulos A, Novick S. A simple method for\nquantifying functional selectivity and agonist bias. ACS Chem Neurosci. 2012;3(3):193-\n203. doi:10.1021/cn200111m\n113. Hryhorowicz S, Kaczmarek-Ry\u015b M, Andrzejewska A, et al. Allosteric modulation of\ncannabinoid receptor 1\u2014 current challenges and future opportunities. Int J Mol Sci.\n2019;20(23):1-19. doi:10.3390/ijms20235874\n114. Hillard CJ. Biochemistry and pharmacology of the endocannabinoids \n168\narachidonylethanolamide and 2-arachidonylglycerol \u0afe. 2000;61:3-18.\n115. Janero DR, Thakur GA. Expert Opinion on Drug Discovery Leveraging allostery to improve\nG protein- coupled receptor ( GPCR ) -directed therapeutics\u202f: cannabinoid receptor 1 as\ndiscovery target. Expert Opin Drug Discov. 2016;11(12):1223-1237.\ndoi:10.1080/17460441.2016.1245289\n116. Slivicki RA, Xu Z, Mali SS, Hohmann AG.", "start_char_idx": 221158, "end_char_idx": 223940, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "13e0d659-a453-41be-a5b9-0ba7ffe4dae8": {"__data__": {"id_": "13e0d659-a453-41be-a5b9-0ba7ffe4dae8", "embedding": null, "metadata": {"file_path": "data/brandt-no-intro.txt", "file_name": "brandt-no-intro.txt", "file_type": "text/plain", "file_size": 239829, "creation_date": "2023-12-31", "last_modified_date": "2023-12-31", "last_accessed_date": "2023-12-31"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "a0eaa9a5-aece-426b-8f20-580de8fb9f35", "node_type": "4", "metadata": {"file_path": "data/brandt-no-intro.txt", "file_name": "brandt-no-intro.txt", "file_type": "text/plain", "file_size": 239829, "creation_date": "2023-12-31", "last_modified_date": "2023-12-31", "last_accessed_date": "2023-12-31"}, "hash": "76e194b2637b440a1b1cdf5698cae061524bb4d7a3b73dfc2ba71d268a3f7019", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c69f5e0b-ea37-4df0-a15e-cd12c78a34da", "node_type": "1", "metadata": {"file_path": "data/brandt-no-intro.txt", "file_name": "brandt-no-intro.txt", "file_type": "text/plain", "file_size": 239829, "creation_date": "2023-12-31", "last_modified_date": "2023-12-31", "last_accessed_date": "2023-12-31"}, "hash": "a5f9cfdb662a017f22b4bb57c86680bce900f1290288e8ca9f94306fbe1047fb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fba4bc5e-619c-4d9b-9b08-ebc769f3550c", "node_type": "1", "metadata": {}, "hash": "f421912c7e2c515ef601d2962fda3bf7f151eddba4cbdef131741d8f37f87062", "class_name": "RelatedNodeInfo"}}, "hash": "b2c0d54fc9d7465ff513c16c6adb0098c9227a452f9cd33024362fc7e86b0fc5", "text": "Int J Mol Sci.\n2019;20(23):1-19. doi:10.3390/ijms20235874\n114. Hillard CJ. Biochemistry and pharmacology of the endocannabinoids \n168\narachidonylethanolamide and 2-arachidonylglycerol \u0afe. 2000;61:3-18.\n115. Janero DR, Thakur GA. Expert Opinion on Drug Discovery Leveraging allostery to improve\nG protein- coupled receptor ( GPCR ) -directed therapeutics\u202f: cannabinoid receptor 1 as\ndiscovery target. Expert Opin Drug Discov. 2016;11(12):1223-1237.\ndoi:10.1080/17460441.2016.1245289\n116. Slivicki RA, Xu Z, Mali SS, Hohmann AG. Brain permeant and impermeant inhibitors of\nfatty-acid amide hydrolase suppress the development and maintenance of paclitaxelinduced neuropathic pain without producing tolerance or physical dependence in vivo and\nsynergize with paclitaxel to reduce tumor. Pharmacol Res. 2019;142(August 2018):267-\n282. doi:10.1016/j.phrs.2019.02.002\n117. Slivicki RA, Mali SS, Hohmann AG. Voluntary exercise reduces both chemotherapyinduced neuropathic nociception and deficits in hippocampal cellular proliferation in a\nmouse model of paclitaxel-induced peripheral neuropathy. Neurobiol Pain.\n2019;6(May):100035. doi:10.1016/j.ynpai.2019.100035\n118. Janero DR, Thakur GA. Leveraging allostery to improve G protein-coupled receptor\n(GPCR)-directed therapeutics: cannabinoid receptor 1 as discovery target. Expert Opin\nDrug Discov. 2016;11(12):1223-1237. doi:10.1080/17460441.2016.1245289\n119. Schwartz TW, Holst B. Allosteric enhancers , allosteric agonists and ago-allosteric\nmodulators\u202f: where do they bind and how do they act\u202f? 2007;28(8).\ndoi:10.1016/j.tips.2007.06.008\n120. Saleh N, Hucke O, Kramer G, et al. Multiple Binding Sites Contribute to the Mechanism of\nMixed Agonistic and Positive Allosteric Modulators of the Cannabinoid CB1 Receptor. \n169\nAngew Chemie. 2018;130(10):2610-2615. doi:10.1002/ange.201708764\n121. Garai S, Schaffer PC, Laprairie RB, et al. Design, synthesis, and pharmacological profiling\nof cannabinoid 1 receptor allosteric modulators: Preclinical efficacy of C2-group GAT211\ncongeners for reducing intraocular pressure. Bioorganic Med Chem. 2021;50(July):116421.\ndoi:10.1016/j.bmc.2021.116421\n122. Zhang X, Wong SE, Lightstone FC. Toward fully automated high performance computing\ndrug discovery: A massively parallel virtual screening pipeline for docking and molecular\nmechanics/generalized born surface area rescoring to improve enrichment. J Chem Inf\nModel. 2014;54(1):324-337. doi:10.1021/ci4005145\n123. Ballesteros JA, Weinstein H. Integrated methods for the construction of three-dimensional\nmodels and computational probing of structure-function relations in G protein-coupled\nreceptors. Methods Neurosci. 1995;25(C):366-428. doi:10.1016/S1043-9471(05)80049-7\n124. Katritch V, Fenalti G, Abola EE, Roth BL, Cherezov V, Stevens RC. Allosteric sodium in\nclass A GPCR signaling. Trends Biochem Sci. 2014;39(5):233-244.\ndoi:10.1016/j.tibs.2014.03.002\n125. Pattar SV, Adhoni SA, Kamanavalli CM, Kumbar SS.", "start_char_idx": 223415, "end_char_idx": 226366, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fba4bc5e-619c-4d9b-9b08-ebc769f3550c": {"__data__": {"id_": "fba4bc5e-619c-4d9b-9b08-ebc769f3550c", "embedding": null, "metadata": {"file_path": "data/brandt-no-intro.txt", "file_name": "brandt-no-intro.txt", "file_type": "text/plain", "file_size": 239829, "creation_date": "2023-12-31", "last_modified_date": "2023-12-31", "last_accessed_date": "2023-12-31"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "a0eaa9a5-aece-426b-8f20-580de8fb9f35", "node_type": "4", "metadata": {"file_path": "data/brandt-no-intro.txt", "file_name": "brandt-no-intro.txt", "file_type": "text/plain", "file_size": 239829, "creation_date": "2023-12-31", "last_modified_date": "2023-12-31", "last_accessed_date": "2023-12-31"}, "hash": "76e194b2637b440a1b1cdf5698cae061524bb4d7a3b73dfc2ba71d268a3f7019", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "13e0d659-a453-41be-a5b9-0ba7ffe4dae8", "node_type": "1", "metadata": {"file_path": "data/brandt-no-intro.txt", "file_name": "brandt-no-intro.txt", "file_type": "text/plain", "file_size": 239829, "creation_date": "2023-12-31", "last_modified_date": "2023-12-31", "last_accessed_date": "2023-12-31"}, "hash": "b2c0d54fc9d7465ff513c16c6adb0098c9227a452f9cd33024362fc7e86b0fc5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b0319540-80fa-471c-843e-0730841cdd81", "node_type": "1", "metadata": {}, "hash": "be37a542e37ccc6a21acbecba5334ff9d067560e741d906982fa9feb04051471", "class_name": "RelatedNodeInfo"}}, "hash": "f421912c7e2c515ef601d2962fda3bf7f151eddba4cbdef131741d8f37f87062", "text": "2014;54(1):324-337. doi:10.1021/ci4005145\n123. Ballesteros JA, Weinstein H. Integrated methods for the construction of three-dimensional\nmodels and computational probing of structure-function relations in G protein-coupled\nreceptors. Methods Neurosci. 1995;25(C):366-428. doi:10.1016/S1043-9471(05)80049-7\n124. Katritch V, Fenalti G, Abola EE, Roth BL, Cherezov V, Stevens RC. Allosteric sodium in\nclass A GPCR signaling. Trends Biochem Sci. 2014;39(5):233-244.\ndoi:10.1016/j.tibs.2014.03.002\n125. Pattar SV, Adhoni SA, Kamanavalli CM, Kumbar SS. In silico molecular docking studies\nand MM/GBSA analysis of coumarin-carbonodithioate hybrid derivatives divulge the\nanticancer potential against breast cancer. Beni-Suef Univ J Basic Appl Sci. 2020;9(1).\ndoi:10.1186/s43088-020-00059-7\n126. Briegleb G. Electron Affinity of Organic Molecules. Angew Chemie Int Ed English.\n1964;3(9):617-632. doi:10.1002/anie.196406171\n170\n127. Paladini AC, Marder M, Viola H, Wolfman C, Wasowski C, Medina JH. Flavonoids and\nthe Central Nervous System: from Forgotten Factors to Potent Anxiolytic Compounds. J\nPharm Pharmacol. 2010;51(5):519-526. doi:10.1211/0022357991772790\n128. Vijayarani KR, Govindarajulu M, Ramesh S, et al. Enhanced Bioavailability of Boswellic\nAcid by Piper longum: A Computational and Pharmacokinetic Study. Front Pharmacol.\n2020;11(December):1-8. doi:10.3389/fphar.2020.551911\n129. Webb NE, Wood DM, Greene SL, et al. Change in the new psychoactive substances\nassociated with Emergency Department acute toxicity presentations associated with the\nintroduction of the UK 2016 Psychoactive Substances Act. Clin Toxicol. 2019;57(1):36-41.\ndoi:10.1080/15563650.2018.1494277\n130. Sankhla MS, Sharma A, Kumar R. Abuse of Synthetic Cannabinoids in the World of\nForensic Science. 2018;2(June):1-8.\n131. White CM. The Pharmacologic and Clinical Effects of Illicit Synthetic Cannabinoids. J Clin\nPharmacol. 2017;57(3):297-304. doi:10.1002/jcph.827\n132. Spaderna M, Addy PH, D\u2019Souza DC. Spicing things up: Synthetic cannabinoids.\nPsychopharmacology (Berl). 2013;228(4):525-540. doi:10.1007/s00213-013-3188-4\n133. Rachman T. Pathology, Toxicogenetics, and Criminalistics of Drug Abuse.; 2018.\n134. Sholler DJ, Huestis MA, Amendolara B, Vandrey R, Cooper ZD. Pharmacology ,\nBiochemistry and Behavior Therapeutic potential and safety considerations for the clinical\nuse of synthetic cannabinoids. Pharmacol Biochem Behav. 2020;199(May):173059.\ndoi:10.1016/j.pbb.2020.173059\n171\n135. Zuccarini G, Atri ID, Cottone E, Mackie K, Shainer I. Interference with the Cannabinoid\nReceptor CB1R Results in Miswiring of GnRH3 and AgRP1 Axons in Zebrafish Embryos.\n:1-23.\n136. Andersen HK, Andersen HK. Scholar Commons A Comparative Study of Cannabinoids &\nCB1 Receptor GI Signaling by. Published online 2020.\n137. Wang W, Bian J, Sun Y, Li Z. Pharmacology & Therapeutics The new fate of internalized\nmembrane receptors\u202f: Internalized activation. Pharmacol Ther.", "start_char_idx": 225820, "end_char_idx": 228761, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b0319540-80fa-471c-843e-0730841cdd81": {"__data__": {"id_": "b0319540-80fa-471c-843e-0730841cdd81", "embedding": null, "metadata": {"file_path": "data/brandt-no-intro.txt", "file_name": "brandt-no-intro.txt", "file_type": "text/plain", "file_size": 239829, "creation_date": "2023-12-31", "last_modified_date": "2023-12-31", "last_accessed_date": "2023-12-31"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "a0eaa9a5-aece-426b-8f20-580de8fb9f35", "node_type": "4", "metadata": {"file_path": "data/brandt-no-intro.txt", "file_name": "brandt-no-intro.txt", "file_type": "text/plain", "file_size": 239829, "creation_date": "2023-12-31", "last_modified_date": "2023-12-31", "last_accessed_date": "2023-12-31"}, "hash": "76e194b2637b440a1b1cdf5698cae061524bb4d7a3b73dfc2ba71d268a3f7019", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fba4bc5e-619c-4d9b-9b08-ebc769f3550c", "node_type": "1", "metadata": {"file_path": "data/brandt-no-intro.txt", "file_name": "brandt-no-intro.txt", "file_type": "text/plain", "file_size": 239829, "creation_date": "2023-12-31", "last_modified_date": "2023-12-31", "last_accessed_date": "2023-12-31"}, "hash": "f421912c7e2c515ef601d2962fda3bf7f151eddba4cbdef131741d8f37f87062", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "84fe4345-b40d-42a8-a74c-dee60c5ed80d", "node_type": "1", "metadata": {}, "hash": "52adfa08b805629992fb51e9c8374584807b511d541c87ff0e2f96940019c73a", "class_name": "RelatedNodeInfo"}}, "hash": "be37a542e37ccc6a21acbecba5334ff9d067560e741d906982fa9feb04051471", "text": "Pharmacol Biochem Behav. 2020;199(May):173059.\ndoi:10.1016/j.pbb.2020.173059\n171\n135. Zuccarini G, Atri ID, Cottone E, Mackie K, Shainer I. Interference with the Cannabinoid\nReceptor CB1R Results in Miswiring of GnRH3 and AgRP1 Axons in Zebrafish Embryos.\n:1-23.\n136. Andersen HK, Andersen HK. Scholar Commons A Comparative Study of Cannabinoids &\nCB1 Receptor GI Signaling by. Published online 2020.\n137. Wang W, Bian J, Sun Y, Li Z. Pharmacology & Therapeutics The new fate of internalized\nmembrane receptors\u202f: Internalized activation. Pharmacol Ther. 2022;233(49):108018.\ndoi:10.1016/j.pharmthera.2021.108018\n138. Bouvier M, Bouvier M, Bouvier M, et al. Quantification of Ligand Bias for Clinically\nRelevant 2-Adrenergic Receptor Ligands\u202f: Implications for Drug Taxo . Related papers\nQuantification of Ligand Bias for Clinically Relevant Drug Taxonomy s.\n139. Zagzoog A, Mohamed KA, Kim HJJ, et al. In vitro and in vivo pharmacological activity of\nminor cannabinoids isolated from Cannabis sativa. Sci Rep. 2020;10(1):1-13.\ndoi:10.1038/s41598-020-77175-y\n140. Bolognini D, Cascio MG, Parolaro D, Pertwee RG. AM630 behaves as a protean ligand at\nthe human cannabinoid CB 2 receptor. Br J Pharmacol. 2012;165(8):2561-2574.\ndoi:10.1111/j.1476-5381.2011.01503.x\n141. Miller EB, Murphy RB, Sindhikara D, et al. Reliable and Accurate Solution to the Induced\nFit Docking Problem for Protein-Ligand Binding. J Chem Theory Comput.\n2021;17(4):2630-2639. doi:10.1021/acs.jctc.1c00136\n142. Black JW, Leff P. Operational models of pharmacological agonism. Proc R Soc London -\n172\nBiol Sci. 1983;220(1219):141-162. doi:10.1098/rspb.1983.0093\n143. Laprairie RB, Bagher AM, Kelly MEM, Denovan-wright EM. Biased Type 1 Cannabinoid\nReceptor Signaling Influences Neuronal Viability in a Cell Culture Model of Huntington\nDisease s. Published online 2016:364-375.\n144. Zhang X, Perez-Sanchez H, C. Lightstone F. A Comprehensive Docking and MM/GBSA\nRescoring Study of Ligand Recognition upon Binding Antithrombin. Curr Top Med Chem.\n2017;17(14):1631-1639. doi:10.2174/1568026616666161117112604\n145. Weiss DR, Karpiak J, Huang XP, et al. Selectivity Challenges in Docking Screens for GPCR\nTargets and Antitargets. J Med Chem. 2018;61(15):6830-6845.\ndoi:10.1021/acs.jmedchem.8b00718\n146. Antonides LH, Cannaert A, Norman C, et al. Enantiospecific synthesis, chiral separation,\nand biological activity of four indazole-3-carboxamide-type synthetic cannabinoid receptor\nagonists and their detection in seized drug samples. Front Chem. 2019;7(MAY).\ndoi:10.3389/fchem.2019.00321\n147. Patel M, Manning JJ, Finlay DB, et al. Signalling profiles of a structurally diverse panel of\nsynthetic cannabinoid receptor agonists. Biochem Pharmacol. 2020;175(December\n2019):113871. doi:10.1016/j.bcp.2020.113871\n148. Hartogsohn I. Constructing drug effects: A history of set and setting. Drug Sci Policy Law.\n2017;3:205032451668332. doi:10.1177/2050324516683325\n149.", "start_char_idx": 228208, "end_char_idx": 231137, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "84fe4345-b40d-42a8-a74c-dee60c5ed80d": {"__data__": {"id_": "84fe4345-b40d-42a8-a74c-dee60c5ed80d", "embedding": null, "metadata": {"file_path": "data/brandt-no-intro.txt", "file_name": "brandt-no-intro.txt", "file_type": "text/plain", "file_size": 239829, "creation_date": "2023-12-31", "last_modified_date": "2023-12-31", "last_accessed_date": "2023-12-31"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "a0eaa9a5-aece-426b-8f20-580de8fb9f35", "node_type": "4", "metadata": {"file_path": "data/brandt-no-intro.txt", "file_name": "brandt-no-intro.txt", "file_type": "text/plain", "file_size": 239829, "creation_date": "2023-12-31", "last_modified_date": "2023-12-31", "last_accessed_date": "2023-12-31"}, "hash": "76e194b2637b440a1b1cdf5698cae061524bb4d7a3b73dfc2ba71d268a3f7019", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b0319540-80fa-471c-843e-0730841cdd81", "node_type": "1", "metadata": {"file_path": "data/brandt-no-intro.txt", "file_name": "brandt-no-intro.txt", "file_type": "text/plain", "file_size": 239829, "creation_date": "2023-12-31", "last_modified_date": "2023-12-31", "last_accessed_date": "2023-12-31"}, "hash": "be37a542e37ccc6a21acbecba5334ff9d067560e741d906982fa9feb04051471", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a22344f3-2e99-4e4a-af67-c45508d4cf5f", "node_type": "1", "metadata": {}, "hash": "af4e1a034ccc61b1a52202017edb09742166512b8970e6d815dea1ed6e8795f0", "class_name": "RelatedNodeInfo"}}, "hash": "52adfa08b805629992fb51e9c8374584807b511d541c87ff0e2f96940019c73a", "text": "Enantiospecific synthesis, chiral separation,\nand biological activity of four indazole-3-carboxamide-type synthetic cannabinoid receptor\nagonists and their detection in seized drug samples. Front Chem. 2019;7(MAY).\ndoi:10.3389/fchem.2019.00321\n147. Patel M, Manning JJ, Finlay DB, et al. Signalling profiles of a structurally diverse panel of\nsynthetic cannabinoid receptor agonists. Biochem Pharmacol. 2020;175(December\n2019):113871. doi:10.1016/j.bcp.2020.113871\n148. Hartogsohn I. Constructing drug effects: A history of set and setting. Drug Sci Policy Law.\n2017;3:205032451668332. doi:10.1177/2050324516683325\n149. Obreshkova D, Kandilarov I, Angelova VT, Iliev YT. PHARMACO - TOXICOLOGICAL\nASPECTS AND ANALYSIS OF PHENYLALKYLAMINE AND \n173\nINDOLYLALKYLAMINE. 2017;(March).\n150. Dean BV, Stellpflug SJ, Burnett AM, Engebretsen KM. 2C or Not 2C: Phenethylamine\nDesigner Drug Review. J Med Toxicol. 2013;9(2):172-178. doi:10.1007/s13181-013-0295-\nx\n151. Chambers SA, Desousa JM, Huseman ED, Townsend SD. The DARK Side of Total\nSynthesis: Strategies and Tactics in Psychoactive Drug Production. ACS Chem Neurosci.\n2018;9(10):2307-2330. doi:10.1021/acschemneuro.7b00528\n152. Breeksema JJ, Niemeijer AR, Krediet E, Vermetten E, Schoevers RA. Psychedelic\nTreatments for Psychiatric Disorders: A Systematic Review and Thematic Synthesis of\nPatient Experiences in Qualitative Studies. CNS Drugs. 2020;34(9):925-946.\ndoi:10.1007/s40263-020-00748-y\n153. de Barros WA, Nunes C da S, Souza JA da CR, et al. The new psychoactive substances\n25H-NBOMe and 25H-NBOH induce abnormal development in the zebrafish embryo and\ninteract in the DNA major groove. Curr Res Toxicol. 2021;2(November):386-398.\ndoi:10.1016/j.crtox.2021.11.002\n154. Pottie E, Cannaert A, Van Uytfanghe K, Stove CP. Setup of a Serotonin 2A Receptor (5-\nHT2AR) Bioassay: Demonstration of Its Applicability to Functionally Characterize\nHallucinogenic New Psychoactive Substances and an Explanation Why 5-HT2AR\nBioassays Are Not Suited for Universal Activity-Based Screening . Anal Chem.\n2019;91(24):15444-15452. doi:10.1021/acs.analchem.9b03104\n155. Pottie E, Dedecker P, Stove CP. Identification of psychedelic new psychoactive substances\n(NPS) showing biased agonism at the 5-HT2AR through simultaneous use of \u03b2-arrestin 2 \n174\nand miniG\u03b1q bioassays. Biochem Pharmacol. 2020;182(September).\ndoi:10.1016/j.bcp.2020.114251\n156. Fuxe K, Tarakanov A, Romero Fernandez W, et al. Diversity and bias through receptorreceptor interactions in GPCR heteroreceptor complexes. Focus on examples from\ndopamine D2 receptor heteromerization. Front Endocrinol (Lausanne). 2014;5(MAY):1-\n11. doi:10.3389/fendo.2014.00071\n157. S\u00e1nchez-Fern\u00e1ndez G, Cabezudo S, Garc\u00eda-Hoz C, Tobin AB, Mayor F, Ribas C. ERK5\nactivation by Gq-coupled muscarinic receptors is independent of receptor internalization\nand \u03b2-arrestin recruitment. PLoS One. 2013;8(12):1-8. doi:10.1371/journal.pone.0084174\n158. Zhang G, Stackman RW.", "start_char_idx": 230518, "end_char_idx": 233468, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a22344f3-2e99-4e4a-af67-c45508d4cf5f": {"__data__": {"id_": "a22344f3-2e99-4e4a-af67-c45508d4cf5f", "embedding": null, "metadata": {"file_path": "data/brandt-no-intro.txt", "file_name": "brandt-no-intro.txt", "file_type": "text/plain", "file_size": 239829, "creation_date": "2023-12-31", "last_modified_date": "2023-12-31", "last_accessed_date": "2023-12-31"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "a0eaa9a5-aece-426b-8f20-580de8fb9f35", "node_type": "4", "metadata": {"file_path": "data/brandt-no-intro.txt", "file_name": "brandt-no-intro.txt", "file_type": "text/plain", "file_size": 239829, "creation_date": "2023-12-31", "last_modified_date": "2023-12-31", "last_accessed_date": "2023-12-31"}, "hash": "76e194b2637b440a1b1cdf5698cae061524bb4d7a3b73dfc2ba71d268a3f7019", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "84fe4345-b40d-42a8-a74c-dee60c5ed80d", "node_type": "1", "metadata": {"file_path": "data/brandt-no-intro.txt", "file_name": "brandt-no-intro.txt", "file_type": "text/plain", "file_size": 239829, "creation_date": "2023-12-31", "last_modified_date": "2023-12-31", "last_accessed_date": "2023-12-31"}, "hash": "52adfa08b805629992fb51e9c8374584807b511d541c87ff0e2f96940019c73a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "28386f62-f721-484b-be83-2620373773d5", "node_type": "1", "metadata": {}, "hash": "09b47bbb7f337818a03d08a8b5b380e6fe219f147f786fdfc46d0129458caf2e", "class_name": "RelatedNodeInfo"}}, "hash": "af4e1a034ccc61b1a52202017edb09742166512b8970e6d815dea1ed6e8795f0", "text": "Fuxe K, Tarakanov A, Romero Fernandez W, et al. Diversity and bias through receptorreceptor interactions in GPCR heteroreceptor complexes. Focus on examples from\ndopamine D2 receptor heteromerization. Front Endocrinol (Lausanne). 2014;5(MAY):1-\n11. doi:10.3389/fendo.2014.00071\n157. S\u00e1nchez-Fern\u00e1ndez G, Cabezudo S, Garc\u00eda-Hoz C, Tobin AB, Mayor F, Ribas C. ERK5\nactivation by Gq-coupled muscarinic receptors is independent of receptor internalization\nand \u03b2-arrestin recruitment. PLoS One. 2013;8(12):1-8. doi:10.1371/journal.pone.0084174\n158. Zhang G, Stackman RW. The role of serotonin 5-HT2A receptors in memory and cognition.\nFront Pharmacol. 2015;6(OCT):1-17. doi:10.3389/fphar.2015.00225\n159. McClure-Begley TD, Roth BL. The promises and perils of psychedelic pharmacology for\npsychiatry. Nat Rev Drug Discov. Published online 2022. doi:10.1038/s41573-022-00421-\n7\n160. Marder SR, Roth B, Sullivan PF, et al. Advancing drug discovery for schizophrenia. Ann N\nY Acad Sci. 2011;1236(1):30-43. doi:10.1111/j.1749-6632.2011.06216.x\n161. Pottie E, Kupriyanova O V., Brandt AL, Laprairie RB, Shevyrin VA, Stove CP. Serotonin\n2A Receptor (5-HT2AR) Activation by 25H-NBOMe Positional Isomers: In Vitro\nFunctional Evaluation and Molecular Docking. ACS Pharmacol Transl Sci. 2021;4(2):479-\n487. doi:10.1021/acsptsci.0c00189\n162. Clark CR. Forensic Chemistry of Substituted N-Benzylmethoxy (N-BOMe) \n175\nPhenethylamines: Isomeric Designer Drugs Related to 25I-N-BOMe. Published online\n2020.\n163. Pottie E, Tosh DK, Gao ZG, Jacobson KA, Stove CP. Assessment of biased agonism at the\nA3 adenosine receptor using \u03b2-arrestin and miniG\u03b1i recruitment assays. Biochem\nPharmacol. 2020;177(March):113934. doi:10.1016/j.bcp.2020.113934\n164. Dixon AS, Schwinn MK, Hall MP, et al. NanoLuc Complementation Reporter Optimized\nfor Accurate Measurement of Protein Interactions in Cells. ACS Chem Biol.\n2016;11(2):400-408. doi:10.1021/acschembio.5b00753\n165. Gado F, Ceni C, Ferrisi R, et al. CB1 receptor binding sites for NAM and PAM: A first\napproach for studying, new n\u2011butyl\u2011diphenylcarboxamides as allosteric modulators. Eur J\nPharm Sci. 2022;169(September 2021):106088. doi:10.1016/j.ejps.2021.106088\n166. Inanobe A, Furukawa H, Gouaux E. Mechanism of partial agonist action at the NR1 subunit\nof NMDA receptors. Neuron. 2005;47(1):71-84. doi:10.1016/j.neuron.2005.05.022\n167. Kenakin T. Drug efficacy at G protein-coupled receptors. Annu Rev Pharmacol Toxicol.\n2002;42(February 2002):349-379. doi:10.1146/annurev.pharmtox.42.091401.113012\n168. Aghazadeh Tabrizi M, Baraldi PG, Borea PA, Varani K. Medicinal Chemistry,\nPharmacology, and Potential Therapeutic Benefits of Cannabinoid CB2Receptor Agonists.\nChem Rev. 2016;116(2):519-560. doi:10.1021/acs.chemrev.5b00411\n169.", "start_char_idx": 232903, "end_char_idx": 235660, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "28386f62-f721-484b-be83-2620373773d5": {"__data__": {"id_": "28386f62-f721-484b-be83-2620373773d5", "embedding": null, "metadata": {"file_path": "data/brandt-no-intro.txt", "file_name": "brandt-no-intro.txt", "file_type": "text/plain", "file_size": 239829, "creation_date": "2023-12-31", "last_modified_date": "2023-12-31", "last_accessed_date": "2023-12-31"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "a0eaa9a5-aece-426b-8f20-580de8fb9f35", "node_type": "4", "metadata": {"file_path": "data/brandt-no-intro.txt", "file_name": "brandt-no-intro.txt", "file_type": "text/plain", "file_size": 239829, "creation_date": "2023-12-31", "last_modified_date": "2023-12-31", "last_accessed_date": "2023-12-31"}, "hash": "76e194b2637b440a1b1cdf5698cae061524bb4d7a3b73dfc2ba71d268a3f7019", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a22344f3-2e99-4e4a-af67-c45508d4cf5f", "node_type": "1", "metadata": {"file_path": "data/brandt-no-intro.txt", "file_name": "brandt-no-intro.txt", "file_type": "text/plain", "file_size": 239829, "creation_date": "2023-12-31", "last_modified_date": "2023-12-31", "last_accessed_date": "2023-12-31"}, "hash": "af4e1a034ccc61b1a52202017edb09742166512b8970e6d815dea1ed6e8795f0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bf9d4c1d-b7f5-4be0-a883-5f14e75b093c", "node_type": "1", "metadata": {}, "hash": "ad9bdff9e6d36083683e1594cdacd3ec375926963a3797d9cc33eb60c163d215", "class_name": "RelatedNodeInfo"}}, "hash": "09b47bbb7f337818a03d08a8b5b380e6fe219f147f786fdfc46d0129458caf2e", "text": "Neuron. 2005;47(1):71-84. doi:10.1016/j.neuron.2005.05.022\n167. Kenakin T. Drug efficacy at G protein-coupled receptors. Annu Rev Pharmacol Toxicol.\n2002;42(February 2002):349-379. doi:10.1146/annurev.pharmtox.42.091401.113012\n168. Aghazadeh Tabrizi M, Baraldi PG, Borea PA, Varani K. Medicinal Chemistry,\nPharmacology, and Potential Therapeutic Benefits of Cannabinoid CB2Receptor Agonists.\nChem Rev. 2016;116(2):519-560. doi:10.1021/acs.chemrev.5b00411\n169. Reddy AS, Zhang S. Polypharmacology: Drug discovery for the future. Expert Rev Clin\nPharmacol. 2013;6(1):41-47. doi:10.1586/ecp.12.74\n170. Peng Y, McCorvy JD, Harps\u00f8e K, et al. 5-HT2C Receptor Structures Reveal the Structural \n176\nBasis of GPCR Polypharmacology. Cell. 2018;172(4):719-730.e14.\ndoi:10.1016/j.cell.2018.01.001\n171. Mccorvy JD, Butler K V, Kelly B, et al. Structure-inspired design of \u03b2-arrestin-biased\nligands for aminergic GPCRs HHS Public Access Author manuscript. Nat Chem Biol.\n2018;14(2):126-134. doi:10.1038/nchembio.2527.Structure-inspired\n172. Jumper J, Evans R, Pritzel A, et al. Highly accurate protein structure prediction with\nAlphaFold. Nature. 2021;596(7873):583-589. doi:10.1038/s41586-021-03819-2\n173. Bryant P, Pozzati G, Elofsson A. Improved prediction of protein-protein interactions using\nAlphaFold2. Nat Commun. 2022;13(1):1-11. doi:10.1038/s41467-022-28865-w\n174. Wang L, Wang HF, Liu SR, Yan X, Song KJ. Predicting Protein-Protein Interactions from\nMatrix-Based Protein Sequence Using Convolution Neural Network and Feature-Selective\nRotation Forest. Sci Rep. 2019;9(1):1-12. doi:10.1038/s41598-019-46369-4\n175. Namkung Y, Le Gouill C, Lukashova V, et al. Monitoring G protein-coupled receptor and\n\u03b2-arrestin trafficking in live cells using enhanced bystander BRET. Nat Commun. 2016;7.\ndoi:10.1038/ncomms12178\n176. Zimmerman B, Beautrait A, Aguila B, et al. Differential \u03b2-arrestin - Dependent\nconformational signaling and cellular responses revealed by angiotensin analogs. Sci Signal.\n2012;5(221). doi:10.1126/scisignal.2002522\n177. Nichols DE, Lloyd DH, Johnson MP, Hoffman AJ. Synthesis and Serotonin Receptor\nAffinities of a Series of Enantiomers of \u03b1-Methyltryptamines: Evidence for the Binding\nConformation of Tryptamines at Serotonin 5-HT1B Receptors. J Med Chem. \n177\n1988;31(7):1406-1412. doi:10.1021/jm00402a026\n178. Mason NL, Kuypers KPC, M\u00fcller F, et al. Me, myself, bye: regional alterations in glutamate\nand the experience of ego dissolution with psilocybin. Neuropsychopharmacology.\n2020;45(12):2003-2011. doi:10.1038/s41386-020-0718-8\n179. G. Petri, P. Expert, F. Turkheimer, R. Carhart-Harris, D. Nutt PJH and FV. Homological\nscaffolds of brain functional networks. J R Soc Interface. 2014;10(4):312.\ndoi:10.1038/nrn2618\n180.", "start_char_idx": 235201, "end_char_idx": 237942, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bf9d4c1d-b7f5-4be0-a883-5f14e75b093c": {"__data__": {"id_": "bf9d4c1d-b7f5-4be0-a883-5f14e75b093c", "embedding": null, "metadata": {"file_path": "data/brandt-no-intro.txt", "file_name": "brandt-no-intro.txt", "file_type": "text/plain", "file_size": 239829, "creation_date": "2023-12-31", "last_modified_date": "2023-12-31", "last_accessed_date": "2023-12-31"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "a0eaa9a5-aece-426b-8f20-580de8fb9f35", "node_type": "4", "metadata": {"file_path": "data/brandt-no-intro.txt", "file_name": "brandt-no-intro.txt", "file_type": "text/plain", "file_size": 239829, "creation_date": "2023-12-31", "last_modified_date": "2023-12-31", "last_accessed_date": "2023-12-31"}, "hash": "76e194b2637b440a1b1cdf5698cae061524bb4d7a3b73dfc2ba71d268a3f7019", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "28386f62-f721-484b-be83-2620373773d5", "node_type": "1", "metadata": {"file_path": "data/brandt-no-intro.txt", "file_name": "brandt-no-intro.txt", "file_type": "text/plain", "file_size": 239829, "creation_date": "2023-12-31", "last_modified_date": "2023-12-31", "last_accessed_date": "2023-12-31"}, "hash": "09b47bbb7f337818a03d08a8b5b380e6fe219f147f786fdfc46d0129458caf2e", "class_name": "RelatedNodeInfo"}}, "hash": "ad9bdff9e6d36083683e1594cdacd3ec375926963a3797d9cc33eb60c163d215", "text": "J Med Chem. \n177\n1988;31(7):1406-1412. doi:10.1021/jm00402a026\n178. Mason NL, Kuypers KPC, M\u00fcller F, et al. Me, myself, bye: regional alterations in glutamate\nand the experience of ego dissolution with psilocybin. Neuropsychopharmacology.\n2020;45(12):2003-2011. doi:10.1038/s41386-020-0718-8\n179. G. Petri, P. Expert, F. Turkheimer, R. Carhart-Harris, D. Nutt PJH and FV. Homological\nscaffolds of brain functional networks. J R Soc Interface. 2014;10(4):312.\ndoi:10.1038/nrn2618\n180. Atasoy S, Roseman L, Kaelen M, Kringelbach ML, Deco G, Carhart-Harris RL.\nConnectome-harmonic decomposition of human brain activity reveals dynamical repertoire\nre-organization under LSD. Sci Rep. 2017;7(1):1-18. doi:10.1038/s41598-017-17546-0\n181. Campbell IB, Macdonald SJF, Procopiou PA. Medicinal chemistry in drug discovery in big\npharma: past, present and future. Drug Discov Today. 2018;23(2):219-234.\ndoi:10.1016/j.drudis.2017.10.007", "start_char_idx": 237459, "end_char_idx": 238384, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}}, "docstore/ref_doc_info": {"a0eaa9a5-aece-426b-8f20-580de8fb9f35": {"node_ids": ["bbd4baa4-ae84-4508-bfed-a7c2cb433d1a", "f8f153ef-0f33-40c9-b07a-1edb5ddeacdc", "8e69c8bc-27ca-4263-a3b9-21a66520c4bd", "c837b524-37dd-4a8d-80f5-04f501ea5d94", "69becf14-6c0c-4e2c-962b-19f81cb59e48", "e9751117-56d0-4930-95a8-de8a758fcec7", "34e6b0a0-591f-4efa-997a-a1923c8fad58", "ed0262b0-e314-429f-8eff-5b23a68c375a", "82d970d1-55ff-47b1-991a-424227d2a819", "7fb4cb7f-3756-4de5-83f4-4c46edf5db68", "13098646-5b47-4002-8d99-d0f177e3eff8", "dd1adc35-aa10-418c-a564-07dd8f0ff28f", "424f8406-2074-4a46-b943-c95f9a7d79e3", "4a52ea30-c9bb-420f-a744-059010702fa2", "e1a669e6-7a0a-4bff-bf8a-09398503f04c", "08d2fdaf-e724-4186-85cb-bcb1d36bc6d6", "701d2f9e-cdd0-4984-9ee1-dc83c5eb2357", "267009fd-b62c-49da-ad26-725119870165", "370b0028-229f-4784-9254-d7c7919356f1", "b7857807-c303-450e-a91d-a1063c15668b", "37406ad9-817c-43d4-aa71-f5cf3a6c0830", "79f04175-06e1-4be6-a6a5-87fe45e0a8d0", "7cf6ad74-5796-4e7b-a5db-a597641b605f", "58f038fc-7646-4ea8-87ee-f3887467d710", "582ec677-6038-48f8-a30d-e6aabc38349f", "4f999dc1-d2a8-4733-8bcb-ef262464e754", "58989e49-3b5b-4716-acfe-9a5da6396e33", "554de318-ec6f-4de0-9960-864394ddca79", "0e49efe3-ce03-45d0-b299-a67d33696a72", "be4131a0-7c74-4a94-92be-2724d1b79033", "d21131fc-9ed9-4e4a-89b4-b38aac3891fb", "b15a7c26-e188-4c10-9c6c-4fdb6456b8e9", "ab536b16-72a5-40ed-8fdb-ca39960ca097", "cdd30fbc-84ba-473b-8550-cf8b4a337bbf", "49e2bc8b-9caa-44af-84c7-1c6db1b3a2f3", "6ec1c67f-ffb0-48b0-8508-3da256b4dd95", "0a77778e-2844-4b0d-8977-0a1f423024a6", "1b8b41ec-e48c-4c71-bede-c100b46a35d8", "27b59cff-59a9-41ae-8eb9-03a5f6b63cb9", "0310fae1-be20-417b-ad3d-62575f97ad54", "297306db-ae99-4e76-9307-c0c6f93626eb", "81d39c1d-2db8-4c5c-bb81-0777c471a97a", "87f9eb02-5f85-43be-aea7-96d9e24360a0", "2171d15e-6952-45a9-b0db-a0a936392c88", "6ad0dfb9-91d9-4725-9594-6c934d992a0b", "ce62f0de-1c59-49cd-90fe-685d0a9a0fa7", "e4fc6a8f-870a-443a-b60a-769f1be7989b", "859081fc-ba7a-4fc5-bac0-1fd78811d3e3", "1d011d49-3a0b-4261-862c-0db78c3a0e6a", "c816406c-8e25-4267-bf1b-650fd0bd6443", "78ac8d9c-e602-4601-b572-e35eae44b23b", "aef4c23e-97ef-4287-8abf-9fe19b4d1087", "8e38df85-cd95-414c-b128-e45742367fe7", "e6beed53-e696-489c-b0a5-5cc306840b34", "17bb3a56-9359-47fc-8076-168c7382cf39", "8f75f1ce-66c0-4c43-b4ea-c6c3eab01b6b", "f1878e25-c289-47e5-b7f7-ac50745103a2", "725e92db-cd38-43d4-a732-287851a65b5a", "44c45d08-35c9-41b3-ad60-cbeeef4660be", "6c46b555-ed9e-4776-8373-6fc61d504f7c", "5af7a950-8c25-4e11-a3f1-0734210c6a1d", "586c219f-ff5c-476e-bf1b-15e5523ecf10", "0d912877-f1cf-4853-9f04-536ce46c0030", "e49f75dc-b4d8-4a71-bc43-d3eceb669e53", "a63ff3d8-c46e-4a3a-ae38-c46a1d44c433", "f3e24b75-a027-4fcc-8b32-8a01a861e485", "523d3edc-48a4-455a-9084-ddb27f0a9a95", "c6cd3ca0-4a12-4748-bbc6-4127b39f5344", "af979550-506c-4f5c-a4a2-eea50dccb977", "109f01df-e60b-472a-8ba4-9e653eb78d8b", "25b00e9f-371e-4fc4-ac25-0c8c1a74f1bc", "684feb52-2005-46b1-ab17-653cf3ab6268", "eb0f1fa7-cbb5-40fd-a88f-d527d7597b79", "ea28b0ec-98c0-4b8b-8896-b4245d50a8f1", "d5138923-b7e6-4b97-9a17-dfada78d923d", "6f4d0be6-8ef0-4edf-95cb-b194c64934c9", "d3f2e237-5c5e-4a3b-b615-fed7b7af1e7c", "902ad6b6-bb31-488f-b9ee-8301e9847041", "aa520e95-55a5-413b-a75d-c5d2011df863", "a88a84be-4fa2-45da-887a-60818c78c939", "fed6bb5f-8768-43d5-be0c-a1b4ff5f0d21", "5b103750-f08c-4e09-b77a-3c205676bf1c", "319bb8d7-acc6-405c-bc48-df8265a7bb86", "103b97df-d755-4b63-be76-6840ec16cfa1", "1b2c36f0-72ab-459a-9055-d5d7c9a274ce", "35200c13-4f4a-497c-bee7-7d7d8d9589c5", "33c809d4-e77c-4603-bbd3-66a70bc6bf47", "a9ca6388-e41e-42cb-ad1c-999e850932ab", "d6246a73-1943-481a-ab8e-2b9661c18fb2", "3204607e-e603-476d-8c50-1aae82cb447c", "c69f5e0b-ea37-4df0-a15e-cd12c78a34da", "13e0d659-a453-41be-a5b9-0ba7ffe4dae8", "fba4bc5e-619c-4d9b-9b08-ebc769f3550c", "b0319540-80fa-471c-843e-0730841cdd81", "84fe4345-b40d-42a8-a74c-dee60c5ed80d", "a22344f3-2e99-4e4a-af67-c45508d4cf5f", "28386f62-f721-484b-be83-2620373773d5", "bf9d4c1d-b7f5-4be0-a883-5f14e75b093c"], "metadata": {"file_path": "data/brandt-no-intro.txt", "file_name": "brandt-no-intro.txt", "file_type": "text/plain", "file_size": 239829, "creation_date": "2023-12-31", "last_modified_date": "2023-12-31", "last_accessed_date": "2023-12-31"}}}}